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Abstract 
Background 
Body weight and composition change after treatment for breast cancer are important considerations 
when investigating factors affecting risk of disease-free survival. Concurrent loss of lean body mass 
(LBM) and increase in body fat is common after treatment for breast cancer and are related to the 
development of metabolic disease.  Shorter observational studies have reported significant 
associations between body composition changes, inflammation, cardiac death and increased risk of 
metabolic syndrome. Thus, studies that aim to increase the understanding of how body composition 
change affects outcomes in this population are required. Numerous studies have investigated the 
mechanisms and quantity of body fat change, however, quantity and causes of LBM loss after 
treatment are not fully understood.  
Exercise interventions have been shown to improve body composition (LBM and body fat%), waist 
girth, aerobic fitness and other risk factors for metabolic syndrome without reducing body weight. 
Nutrition interventions have been shown to reduce body weight and body fat% that is accompanied 
with an improvement in metabolic health. However, the reduction in weight includes potentially 
detrimental reductions in LBM and significantly increased risk of sarcopenia. The combination of 
nutrition plus exercise seems to maintain LBM and elicit concurrent body fat and/or body weight 
reductions. Long chain omega-3 fatty acids (LCn-3) have been associated with improved cardio-
metabolic health, have a theoretical yet inconsistent effect on adiposity, are associated with 
decreased inflammation, and more recently have been shown to improve the response of LBM to an 
anabolic stimulus. Thus, they present as a relevant clinical option for this population, yet no 
evidence currently exists after treatment for breast cancer.  
Therefore, this PhD research had two aims: the primary aim was to examine the independent and 
combined effects of an exercise and nutrition program and LCn-3 supplementation on LBM change, 
QOL and chronic inflammation soon after completion of treatment for breast cancer. This was done 
by conducting a 6-month 3-arm randomised controlled trial that compared three conditions: 1) LCn-
3 supplementation only (N-3); 2) LCn-3 supplementation plus a 12-week group exercise and 
nutrition lifestyle program (Ex+N-3); and, 3) the lifestyle program plus placebo - olive oil 
(Ex+OO). The secondary aim was to explore baseline cross-sectional associations between body 
composition (in particular LBM) and LCn-3 intake, treatment, demographical and lifestyle factors 
after completion of treatment for breast cancer. For the scope of this PhD thesis, the investigation 
targeted women who had completed treatment of breast cancer within the last 12 months, and were 
considered ‘disease free’ at entry to the trial. The thesis is presented as both unpublished work, and 
a series of published and submitted manuscripts.  
I
 Due to slower than expected recruitment, 49 participants were included in the trial, and were 
generally representative of women who have been diagnosed with breast cancer in Australia. 
In the six month randomised controlled trial, all three groups experienced maintenance of LBM, 
with no significant differences between groups after 24 weeks. Compared to women who consumed 
LCn-3 supplements or participated in the lifestyle program separately, those exposed to  both 
interventions were more likely to experience a greater amount of body weight and waist and hip 
girth reduction. Quality of life (QOL) improved for all groups, while C-reactive protein (CRP) 
levels did not change throughout the intervention. Secondary analyses indicated that LCn-3 
supplementation was associated with improved physical function and maintenance of grip strength 
independent of exercise and nutrition. Limitations of the intervention were lower than expected 
recruitment rate, and the effectiveness of the resistance training program may have been reduced as 
a result of the use of elastic resistance equipment.   
In terms of the secondary aim (cross-section at baseline), after adjusting for weight and age, the 
major determinants of LBM after treatment were higher levels of aerobic fitness and the ability to 
perform a greater number of push ups. Erythrocyte levels of LCn-3, energy and protein intake, CRP 
and treatment related variables were not associated with body composition after treatment for breast 
cancer.    
This thesis provides new insight into the synergy of LCn-3 and an exercise and nutrition lifestyle 
program in a population of women who have been treated for breast cancer. Combining LCn-3 
supplementation with best practice nutrition and exercise advice is a consideration for clinicians 
aiming to prevent and improve adverse body composition change after treatment. Longer-term 
research investigating the preventive effect of LCn-3 and exercise on development of metabolic 
syndrome and breast cancer related morbidity and mortality should be undertaken. Finally, our 
novel findings indicate that muscle function is strongly associated with weight adjusted LBM after 
treatment, and its use as a measure of health warrants further investigation in determining the 
overall health of breast cancer survivors. 
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 Chapter(1(–(Introduction((
Breast cancer is the most common cancer diagnosis for women, with it’s global incidence totaling 
1.38 million in 2008 (Ferlay et al. 2010). In Australia alone, annual incidence has increased from 
5310 to 13 567 over the last 2.5 decades (Australian Institute of Health and Welfare & Cancer 
Australia 2012). Fortunately, due to improved diagnostic, surgical and adjuvant (chemotherapy and 
radiotherapy) treatments for breast cancer, 5-yr survival rates have increased to 89.3% (Australian 
Institute of Health and Welfare & Cancer Australia 2012). However, all women with breast cancer 
are at equal, if not greater, risk of dying from heart disease as they are from breast cancer itself 
(Hanrahan et al. 2007), and treatment may be a factor that elevates this cardiovascular disease 
(CVD) risk (Rock and Demark-Wahnefried 2002). 
 
After treatment for breast cancer, presence of higher BMI, abdominal obesity, increased 
inflammation and/or hyperglycaemia are strongly linked to an increased risk of mortality and 
recurrence (Protani et al 2010, Pierce, Ballard-Barbash et al 2009) and metabolic disease (Healy et 
al. 2010). However, after treatment total body weight gains commonly range up to 5kg in the one to 
three years following treatment (Demark-Wahnefried, Campbell, and Hayes 2012), with the 
greatest rate of change occurring within the first six to 12 months following treatment (Makari-
Judson et al 2007). A combination of epidemiological and intervention studies have indicated that, 
compared to body weight increase or substantial decrease (>3kg change), weight stability (Nichols 
et al 2009, Caan et al 2008) or moderate body weight loss (<3kg change) (Ligibel 2012, 
Chlebowski et al 2006) are related to improved survival. Currently for early stage breast cancer, a 
vast majority of women are more likely to gain total body weight than to experience weight loss 
after treatment (Demark-Wahnefried et al 2012). However unlike weight gain in healthy 
populations that typically consist of lean and fat mass increases, breast cancer survivors commonly 
experience loss of lean body mass (LBM) and concurrent increases in visceral (Cheney, Mahloch, 
and Freeny 1994) and general fat mass (Rooney and Wald 2007, Harvie 2010).  
 
Increases in adipose tissue have been shown to increase levels of C-reactive protein (CRP) and 
serum amyloid A (SAA) (Dee et al. 2012), which have in turn been associated with increased risk 
of all cause and cardiovascular (CVD) mortality in breast cancer survivors (Pierce, Ballard-
Barbash, et al. 2009). A limited number of studies have partly explained mechanisms underpinning 
loss of LBM after treatment for breast cancer. However, chemotherapy (Sheean, Hoskins, and 
Stolley 2012), a reduction in physical inactivity (Irwin et al. 2005), and chronic inflammation 
(Mourtzakis and Bedbrook 2009) have been proposed as potential causes. Also, intentional weight 
1
 loss through dietary energy restriction may promote a greater rate of LBM loss. In contrast, 
treatment with aromatase inhibitors may positively influence LBM (van Londen et al. 2011). 
Overall, there is limited research describing modifiable risk factors for LBM and general body 
composition change in this population.  
 
Physical activity is an important consideration when assessing changes in general health and LBM 
after a diagnosis of breast cancer. A growing evidence base indicates that contraction of skeletal 
LBM through exercise has numerous positive effects on immune and hormonal function (Pedersen 
and Febbraio 2012). Observational data indicates that increased levels of physical activity (brisk 
walking 3 hours/day) have been associated with improved mortality and reduced recurrence after a 
diagnosis of breast cancer (Ibrahim and Al-Homaidh 2010). While physical inactivity is known to 
contribute to systemic pathophysiological changes such as insulin resistance, cardiovascular 
disease, colon cancer and osteoporosis (Hamilton, Hamilton, and Zderic 2007). Thus, considering 
the greater risk of mortality and metabolic syndrome in this population, assessment of physical 
activity and inactivity is important for ongoing morbidity and mortality. 
 
Physical activity interventions have been shown to be effective in maintaining volume and function 
of LBM in breast cancer survivors (Schmitz et al. 2010). In addition, formal physical activity after 
breast cancer treatment has been shown to reduce risk factors for metabolic syndrome such as 
aerobic capacity (Courneya et al 2007), waist girth (Guinan et al 2013; Fernandez et al, 2013), and 
improve both overall, breast, psychosocial and physical function subscales of quality of life (QOL) 
following treatment (Herrero et al, 2006; Fernandez-Lao et al, 2013; Courneya et al, 2007; 
Matthews et al, 2007; Ohira et al, 2006).  Therefore, prescribed exercise may be important in 
improving not only survival and morbidity, but enhancing QOL and body composition as well.  
 
Dietary interventions in women who have completed treatment for breast cancer have shown that 
moderate weight loss through a low fat diet (2.7kg) may improve survival over 4 years (Chlebowski 
et al 2006). A shorter study (<12 months in length) has shown that greater weight loss (>5kg) may 
improve risk factors for metabolic disease (Thomson et al 2010), yet this occurred at the expense of 
an increased incidence of sarcopenia. Thus, if future trials are to explore the potential metabolic 
benefits of body weight loss in this population, strategies to ameliorate LBM loss are important 
considerations. 
 
In both healthy and cancer populations, resistance exercise training (RET) is associated with 
increased LBM volume and function (Schmitz et al 2005, Courneya et al 2007), while some 
2
 evidence indicates aerobic exercise may also prevent loss of LBM in breast cancer survivors (Irwin 
et al 2009). Furthermore,  specific nutrients such as LCn-3 (McDonald, Bauer, and Capra 2013) and 
branched chain amino acids (BCAAs)(Breen and Phillips 2013) have been shown to provide 
additional benefit to LBM accretion alone or in combination with exercise training. However, 
neither LCn-3s nor BCAAs have been investigated alone or in conjunction with exercise training in 
a population of women who have completed treatment for breast cancer. 
 
LCn-3s have a well-established role in decreasing inflammation in healthy (Calder 2012) and 
cancer populations (Murphy et al 2012). There is growing evidence that indicates improved breast 
cancer related outcomes after higher intake of LCn-3 (Patterson et al 2013, de Lorgeril 2014). In 
addition, they may also enhance body composition improvements through improvements in 
adiposity (Kabir et al, 2007; Hill et al, 2007), LBM accretion (Smith et al, 2011) and functional 
change (Rodacki et al, 2012). Furthermore, LCn-3 supplements are readily available, safe and 
widely consumed, thus they are an excellent candidate for further investigation in this population.  
 
Therefore, the primary aim of this thesis was to examine the independent and combined effects of 
an exercise and nutrition program and LCn-3 supplementation on LBM change, QOL and chronic 
inflammation up to 12 months after completion of treatment for breast cancer.  
The secondary aim was to explore associations between body composition (in particular LBM) and 
LCn-3 intake, treatment, demographical and lifestyle factors after completion of treatment for 
breast cancer. .  
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 Overview(of(the(thesis(
Chapter 2 
Review of the literature inclusive of two review publications: 
The unpublished literature review includes: @ A detailed summary of the current literature surrounding body composition changes and 
their sequelae after treatment for breast cancer. @ A comprehensive literature review of exercise interventions, dietary interventions and 
combined exercise dietary interventions and their effect on body composition change. 
Published reviews: 
1. McDonald, Bauer, Capra (2011) Body composition and breast cancer – a role for lean body mass. 
Cancer Forum 35 (2).  
This manuscript explains the importance of lean body mass for those at risk and diagnosed with 
breast cancer, and briefly outlines the current literature and potential interventions to reduce or 
prevent adverse LBM changes after treatment.  
2. McDonald, Bauer, Capra, Cole (2012) Omega-3 fatty acids and changes in LBM-alone or in 
synergy for better muscle health? Can. J. Physiol. Pharmacol. 91: 459–468 (2013) 
dx.doi.org/10.1139/cjpp-2012-0304 
This manuscript addresses the current literature for the effects of LCn-3 on LBM change, and how 
these effects may be augmented through addition of concurrent anabolic interventions. In addition, 
the review aimed to determine the appropriate dosage of LCn-3 required to effectively test its 
efficacy in LBM change 
Chapter 3 - Methods 
Methods – inclusive of one published manuscript 3, and an extended description of additional 
measures not included in the publication. 
 
McDonald, CK., Bauer, J., Capra, S., Cole, J.  The Muscle mass, Omega-3, Diet, Exercise and 
Lifestyle (MODEL) study protocol – a randomised controlled trial for women who have completed 
breast cancer treatment. BMC Cancer (2014) 14 (1): 264. Journal Impact Factor: 3.33 
Chapter 4 – Baseline Results 
Cross sectional results from baseline assessment – inclusive of one published manuscript. In 
addition, extended unpublished results and their respective discussions are included after the paper 
to provide results for measures not included the published manuscript. 
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 McDonald C, Bauer J, Capra S, Waterhouse M (2013) Muscle function and omega-3 fatty acids in 
the prediction of lean body mass after breast cancer treatment. SpringerPlus (2013), 2: 681 doi: 
10.1186/2193-1801-2-681.  
This cross-sectional analysis of the data set at baseline addresses the secondary aim of the thesis. 
There are currently no studies that have linked muscle strength or function to body composition 
outcomes in breast cancer survivors. This paper contributes novel evidence in this area. 
Chapter 5 – Intervention Results 
Reporting of results from the randomised controlled trial. This chapter includes one manuscript 
under review, and results and discussion from exploratory analyses that were not included in the 
manuscript.  
The Muscle mass, Omega-3, Diet, Exercise and Lifestyle (MODEL) Study – a randomised 
controlled trial in women who have completed treatment for breast cancer – Submitted for review – 
Breast Cancer Research & Treatment  
This paper addresses the primary aim of the thesis. 
Chapter 6 – Discussion and Conclusions 
Discussion, Limitations and strengths, Conclusions and Future Directions 
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Chapter 2 - Literature review 
2.0$Overview$
This chapter begins with an unpublished review of the literature that describes the influence of body 
composition on breast cancer risk, and prognosis following treatment. The focus of this chapter is to 
elucidate the following: what is considered to be the recommended body composition outcome for 
breast cancer survivors when considering overall mortality and morbidity. The second part of this 
chapter is a published review that summarises these findings and collates information from non-
breast cancer populations to suggest potential nutritional aids that could be utilized to better 
maintain LBM after treatment for breast cancer. 
Following this the second published manuscript describes the considerations for use of LCn-3 as an 
adjunct to exercise and nutrition interventions. The paper describes detail on appropriate dosing, 
and the need for LCn-3 to be combined with an anabolic stimulus in order to have an effect on 
LBM. 
2.0.1 Literature search method 
A literature search was carried out using MEDLINE and Pubmed databases. Selected studies and 
review articles were hand-searched for additional relevant references, with forward citation 
searching completed through Google Scholar and within journal databases.  
Quality assessment 
Studies were assessed for quality (relevance and validity) according to the guidelines set out in the 
Evidence Analysis Manual published by the Academy of Nutrition and Dietetics, 2010 (Academy 
of Nutrition and Dietetics 2010). High quality studies are assigned a (+); Studies of neutral quality 
are assigned (0); studies of poor quality were assigned a (-). 
In addition, articles were assigned a level of evidence according to the National Health & Medical 
Research Council (NH&MRC) evidence based clinical practice guidelines. 
ADA and NH&MRC guidelines can be found in Appendix 5. Full details of the search terms used 
in the literature review can be found in Appendix 5. 
Quality of Body Composition Assessment Tools 
Various instruments for measurement of body composition are reported in the literature. Within the 
literature review, the term ‘high quality measure’ is used when referring to the use of dual energy x-
ray absorptiometry (DEXA), air displacement plethysmography (ADP), magnetic resonance 
imagery (MRI), computed-tomography scans (CT scans) and under-water-weighing (UWW) to 
measures body composition. For the purposes of this review, lower quality measures in determining 
approximate fat and muscle content of the body are considered to be skinfold assessment, bio-
electrical impedance, and simple girth (waist and hip) measures. While we consider that ‘high 
quality’ instruments produce more reliable, all results generated from body composition analysis 
will have certain error due to indirect measurement and assumptions made. 
  
Recent analyses and investigation into reliability of DEXA indicate that results can vary 
considerably depending on the technicians’ and participants’ preparation and performance during 
the measurement. Considerations such as food and fluid consumption before the test, and specific 
limb position/rotation can create significant variance in serial measures (Nana et al 2014). All of the 
studies in the review below were performed before 2014, and as a result have not consistently 
reported or considered these factors, which decreases the reliability of results reported (Nana et al 
2014). Similarly, ADP and UWW use the assumption of thoracic volume in the calculation of its 
body composition result. Due to biological variation this will contribute to inaccuracies in one-off 
measures (Fields et al 2002). However considering the small changes in lung volume over one to 
six months, this may not affect the reliability of serial measures. In contrast, length of hair and 
volume of the hair under the cap can influence the total body volume particularly for ADP (Fields et 
al 2002). Reliability of MRI and CT scans is related to technical precision, i.e. how effectively 
muscle and fat is demarcated by the technician. Weaknesses of MRI and CT scans in determining 
body composition are related to their estimate of volume of fat tissue, and their inability to separate 
adipose tissue and the actual fat within the tissue. However, MRI is an excellent instrument to 
measure abdominal adipose tissue (Wells et al 2006).  
 
Granted the presence of these known errors, these measures are still considered to be more accurate 
and reliable in determining muscle and fat compartments than skinfold measures and bio-electrical 
impedance, thus have been considered as higher quality (Wells et al 2006).  
2.1$Body$composition$and$breast$cancer:$risk,$prognosis$and$survival$
Understanding the effects of body composition change on breast cancer and overall health outcomes 
is important to the development of a safe treatment protocol. This review aims to discuss what is 
currently considered the optimal body composition before and after treatment for breast cancer.  
2.1.1$Body$mass$and$composition$and$breast$cancer$risk$
BMI and breast cancer risk 
Collectively, studies investigating the association between body composition and risk of breast 
cancer have only used total body weight/body mass index (BMI), waist and hip girth, and/or waist- 
 to-hip ratio as the measures of body size. Changes in these measures have been associated with risk 
of breast cancer, however the literature indicates differences in relationships for pre- and post-
menopausal women.  
A meta-analysis of 345 studies with a total of 31039 women indicated that for European and North 
American women, each 5kg/m2 increase in BMI was related to a decreased risk of premenopausal 
breast cancer (Hazard ratios (HRs) 0.92; 95% CI: 0.88, 0.97), while the same increment in change 
was related to a higher risk of post-menopausal breast cancer (HRs 1.12; 95%CI 1.08, 1.16) 
(Renehan et al. 2008). On the other hand, a higher BMI was correlated to an increased risk of breast 
cancer in Asian-Pacific populations for both pre- and postmenopausal women (Renehan et al. 
2008). 
Waist and Waist-to-hip ratio 
Menopausal status also seems to influence the effect of waist and waist-to-hip ratio (WHR) on 
breast cancer risk. A systematic review (Harvie, Hooper, and Howell 2003) and one meta-analysis 
(Connolly et al. 2002) both reported that compared to those in the lowest quartiles of waist girth 
(Harvie, Hooper, and Howell 2003) and waist-to-hip ratio (WHR) (Harvie, Hooper, and Howell 
2003, Connolly et al. 2002), respectively, those in the highest quartile experienced the greatest risk 
of pre- and postmenopausal breast cancer risk. After controlling for BMI, Connolly et al (2002) 
reported that the relationship was maintained in postmenopausal women, however Harvie et al 
(Harvie, Hooper, and Howell 2003) found that the association disappeared in premenopausal 
women after controlling for BMI. Thus, it is this author’s (the candidate’s) suggestion that 
abdominal obesity measured by waist girth or WHR, but not BMI, may be related to premenopausal 
breast cancer, while general obesity may be the more powerful measure of body composition in 
predicting postmenopausal breast cancer risk. 
Lean body mass and body fat% 
Two prospective cohort studies (Mellemkjaer et al. 2006, MacInnis et al. 2004), one repeated 
measure time series study (Lahmann et al. 2003), and one case control study(Ronco et al. 2009) 
have evaluated the effect of body fat% and LBM on breast cancer incidence. The results of the first 
three trials were limited to postmenopausal women measured with BIA. In contrast, Ronco et al 
(Ronco et al. 2009) included women in pre- and postmenopausal states and used skinfold plus 
additional anthropometric measures such as, femoral condyle and bistiloid diameters for body 
composition assessment.  
 
Two of four studies reported that a higher LBM is positively associated with incidence of breast 
cancer (Mellemkjaer et al. 2006, MacInnis et al. 2004), while three of four studies have indicated an 
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 increased risk for those in the highest quartile for body fat% (MacInnis et al. 2004, Lahmann et al. 
2003, Ronco et al. 2009). However, it is possible the association of LBM and increased risk of 
breast cancer may not be as strong as indicated in the 2 studies finding a positive result. A higher 
total LBM will typically be found secondary to both higher body weight and BMI, as 20-40% of 
normal weight gains are attributed to LBM increases (Forbes et al. 1996). Therefore, women with a 
higher BMI are more likely to also have a higher absolute lean mass along with higher absolute fat 
tissue. Therefore the increased risk may be related to a higher BMI than measure of LBM. 
Supporting this, Ronco et al (2009) reported that less appendicular LBM, and a greater fat-to-
muscle were associated with an increased risk of breast cancer (Ronco et al. 2009). However, the 
study  was conducted in a Uruguayan population of very low socioeconomic status. Furthermore 
the body composition calculation used had not been validated in published literature, thus it’s 
generalisability to Western populations may be limited (Ronco et al. 2009). However, relationships 
between muscle and fat, rather than individual measures of either compartment warrant further 
investigation. 
 
Taking these data together, a higher total body weight, which is likely to result in higher waist girth, 
body fat% and absolute LBM are likely to increase the risk of breast cancer in western 
postmenopausal populations. However, lower total body weight and higher abdominal obesity are 
related to higher incidence of breast cancer in women who are premenopause. Measures of body 
composition that include a measure of body weight adjusted LBM may reveal different 
relationships, however confirmation studies are needed. 
2.1.2(Body(composition(at(breast(cancer(diagnosis((
Higher BMI after a diagnosis of breast cancer is related to an increased risk of mortality and 
recurrence regardless of menopausal status. Two recent meta-analyses of epidemiological studies 
indicated that compared to women who were non-obese, women who were obese at the time of 
diagnosis had a 25(Niraula et al. 2012) to 33%(Protani, Coory, and Martin 2010) increased risk of 
overall mortality. Similar results were noted for breast cancer specific mortality (Protani, Coory, 
and Martin 2010, Niraula et al. 2012). These results were unchanged when women were stratified 
by menopausal status (Niraula et al. 2012), oestrogen receptor status (Niraula et al. 2012, Protani, 
Coory, and Martin 2010), HER-2 receptor status(Protani, Coory, and Martin 2010), or if WHR was 
used as the measure of body composition (Protani, Coory, and Martin 2010). In terms of breast 
cancer recurrence, a 10-year follow up of a large Danish cohort (N=18 967) indicated the risk of 
developing distant metastases was 46% greater for obese (BMI >30kg.m-2) versus non-obese 
women (Ewertz et al. 2011). Of note, both chemotherapy and endocrine therapy seemed to be less 
effective after 10-years in obese women (Ewertz et al. 2011). 
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Potential reasons for the relationship of a higher BMI to poorer prognosis have been proposed but 
not yet rigorously tested. Niraula et al reported that compared to women of normal weight, women 
who are obese tend to present with larger tumours, have more advanced disease, may experience 
under-dosing of chemotherapy or enhanced toxicity which reduces compliance (Niraula et al. 
2012). Direct mechanisms for breast cancer development include obesity related insulin resistance 
and the obesity-associated increase in pro-inflammatory cytokine production (Pierce, Ballard-
Barbash, et al. 2009). Non-diabetic women diagnosed with breast cancer who’s insulin 
measurements were in the highest quartile, compared to those in the lowest quartile, had a 2-fold 
increased risk of recurrence and 3-fold increased risk of mortality (Goodwin et al. 2002). Insulin 
and inflammatory mediators have been associated with increased breast cancer cell growth and 
proliferation and increased adverse sex hormone levels (Rose, Komninou, and Stephenson 2004). 
Furthermore, obese individuals typically have a greater fat mass. Fat mass is a key site for 
aromatase enzyme activity which contributes to adverse/carcinogenic hormonal profiles through the 
conversion of androgens to oestrogens (Niraula et al. 2012). Excessive oestrogen production 
through this pathway is an established risk factor, and breast cancer mortality and morbidity are 
improved when this enzyme is inhibited. 
 
Thus, the majority of evidence indicates that obesity and it’s related metabolic and clinical 
implications is a significant risk factor for poorer prognosis in women who have been diagnosed 
with breast cancer. The next section of this chapter aims to discuss the implications of weight 
change after treatment, and how that may influence disease free and overall survival. 
2.1.3(Change(in(body(weight(and(BMI(after(a(breast(cancer(diagnosis(
Research from the last two decades has shown a consistent trend of body weight gain occurring in 
50 to 100% of women who are completing or have completed adjuvant treatment for breast cancer; 
reviewed here (Rooney and Wald 2007, Harvie 2010). Earlier studies indicated gains of up to 11kg 
during and soon after chemotherapy (Camoriano et al. 1990). However, more recent studies indicate 
this figure has diminished, with 5kg gains still common during the same time frame (Irwin et al. 
2005, Ingram and Brown 2004, Harvie et al. 2004, Demark-Wahnefried, Campbell, and Hayes 
2012). This decrease in weight gain may be related to increased awareness of the importance of a 
healthy lifestyle post treatment amongst oncologists and patients alike (Demark-Wahnefried, 
Campbell, and Hayes 2012).  It was also noted that the probability of re-attaining the pre-diagnosis 
weight was inversely associated with initial post-treatment weight gains (Nichols et al. 2009). This 
suggests that early strategies to prevent weight gain are critical to long term management of the 
issue. 
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Body weight change, recurrence and survival after breast cancer treatment 
A number of studies in large populations (range of n=111 to12915) (Chen et al. 2010, Caan et al. 
2012, Nichols et al. 2009, Kroenke et al. 2005, Zhang et al. 1995, Daling et al. 2001, Thivat et al. 
2011) have shown inconsistent associations between body mass change and breast cancer disease 
free survival. However, large lifestyle intervention trials conducted over the last decade indicate 
that intentional weight loss through appropriate nutrition and exercise habits may elicit survival 
benefit for survivors of breast cancer (Ligibel and Goodwin 2012, Demark-Wahnefried, Campbell, 
and Hayes 2012). A large (n=693) 4-year long randomised controlled trial is currently underway in 
the USA to better understand this (the ENERGY trial: Exercise and Nutrition to Enhance Recovery 
and Good Health in You). This study is investigating the efficacy and feasibility of achieving 
sustained weight loss through group based cognitive-behavioural therapy in women who have been 
diagnosed with breast cancer in the last 5 years. Its aim is to examine the impact of weight loss on 
recurrence, disease free survival, quality of life and co-morbidities (Rock et al 2013). 
Four large prospective cohort studies (Kroenke et al. 2005, Caan et al. 2006, Chen et al. 2010, 
Nichols et al. 2009) and a project combining four large data sets (Caan et al. 2012), have revealed 
an increasingly consistent U-shaped trend for body weight change and mortality in women after 
completion of treatment for breast cancer. Kroenke et al (2005) reported findings from the Nurses’ 
Health Study data set (N=5204), which indicated that non-smoking women of normal weight at 
diagnosis (<25kg/m2) who had an increase in BMI of more than 2kg/m2 after diagnosis experienced 
increased risk of total mortality, breast cancer recurrence and mortality (Kroenke et al. 2005). In 
addition, for those who experienced a change in BMI of 0.5 to <2kg/m2, a significant increase in 
total mortality and breast cancer recurrence was noted, while a positive trend was seen for breast 
cancer mortality (Kroenke et al. 2005). Relationships were not significant for women who smoked, 
and were weaker for postmenopausal as opposed to premenopausal women (Kroenke et al. 2005). 
 
In contrast to these findings, Caan et al (2006) reported findings from the Life After Cancer 
Epidemiology (LACE)(Caan et al. 2008) data set (N=1692), which were previously combined with 
the control group of the Women’s Healthy Eating and Lifestyle (WHEL) study (N=3215)(Caan et 
al. 2006). Compared to those who maintained weight, total mortality and recurrence for those who 
gained weight of any magnitude, or those who experienced moderate weight loss were not 
significantly different. Of note, there were no significant differences found between smokers and 
non-smokers. However, compared to women who maintained weight, those who lost more than 
10% of their pre-diagnosis body weight experienced a significant increased risk of breast cancer 
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 recurrence (HR = 1.7, 95% CI: 1.0 to 2.6) and death due to any cause (HR = 2.1, 95% CI: 1.3 to 
3.4) (Caan et al. 2006). 
 
Nichols et al (2009) (Nichols et al. 2009).(N=3993), Chen et al(Chen et al. 2010) (N=5042) and 
‘The After Breast Cancer Pooling Project’ (N=12 915) (Caan et al. 2012), which combined four 
large prospective data sets (Chen et al. 2010, Kroenke et al. 2005, Caan et al. 2008, Pierce et al. 
2002), have reported that the lowest mortality risk is found in those who maintained their weight 
within 2-10% of their body weight taken at diagnosis.  
 
Nichols et al (Nichols et al. 2009) reported that compared to those women who maintained their 
weight (a change of +2kg), women who gained >10kg from the time of diagnosis experienced a 
70% increased risk of mortality. In addition, an increased risk of mortality was also reported for 
those who lost 2.1 to 10kg (HR = 1.39, 95% CI: 1.04 to 1.86), and greater risk again for those who 
lost more than 10kg (HR = 2.66, 95% CI: 1.73 to 4.07)(Nichols et al. 2009).  Similar results were 
found in a Chinese population, where a body weight loss of >1kg was seen to increase the risk of 
mortality (HR: 2.41; 95% CI: 1.62–3.58) (Chen et al. 2010). 
 
A recent collation of four large prospective data sets including North American and Chinese studies 
indicated a non-significant increase in death following weight gain after treatment, yet confirmed a 
40% increased risk of death for US populations who lost >10% of their pre-diagnosis weight in the 
18 to 48 (median: 25) months following (Caan et al. 2012). Of note, in those who lost >10% of their 
weight, overall mortality risk for the Shanghai cohort was more than two-fold the risk seen in the 
US population (Shanghai: HR, 3.25; 95% CI, 2.24–4.73 versus US: HR: 1.41; 95%CI, 1.14–1.75).  
Importantly, non-breast cancer mortality was increased with those who lost weight (HR: 1.62; 95% 
CI, 1.21–2.19) in US populations only, however for Shanghai, 86% of the deaths were due to breast 
cancer related events, and HR for total and breast cancer mortality were of similar magnitude (HR, 
3.60; 95% CI, 2.39–5.42). 
 
Additionally, sequelae of body weight change after treatment extend past breast cancer related 
events. Increasing gains and losses in body weight have been associated with increased risk of CVD 
(Nichols et al. 2009), and arthralgias secondary to aromatase inhibitors (Demark-Wahnefried, 
Campbell, and Hayes 2012). Weight gain alone has been associated with increased surgical 
complications, lymphoedema risk, fatigue & menopausal symptoms, while weight loss alone has 
been associated with poorer bone health and fracture risk (Demark-Wahnefried, Campbell, and 
Hayes 2012). 
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 Vast differences in timing of recruitment, assessment of weight (self-report and clinician measured) 
and definition of breast cancer recurrence may account for the differences in results between these 
large studies.  
 
Summary of body weight and breast cancer survival 
The weight of evidence currently indicates that maintenance of body weight following treatment is 
associated with the lowest risk of mortality, recurrence and co-morbidities. Significant loss of body 
weight is strongly associated with poorer mortality outcomes in prospective trials, while 
inconsistencies have been noted for body weight gain. A limitation of these studies is that none 
have accounted for the influence of body fat% or LBM change. Individual and combined changes in 
these different body compartments are likely to have a large influence on metabolic health, and 
therefore may be one reason as to why inconsistencies have been noted in cohorts to date. 
 
2.1.4(Fat(mass(and(LBM(change(and(outcomes(after(breast(cancer(treatment(
LBM growth typically accounts for 20-40% of total weight gains in disease free populations 
(Forbes et al. 1996). Simultaneous fat mass gain and loss of LBM is common after treatment for 
breast cancer (Rooney and Wald 2007). Studies of breast cancer survivors have shown that after 
chemotherapy, total fat mass gains of 2.4kg (Demark-Wahnefried et al. 2001) to 6.7kg (Harvie et al. 
2004) were accompanied by LBM losses of -0.4kg to -1.7kg, respectively. Women who seemingly 
maintain their weight in the years after treatment still undergo these adverse changes, such that the 
loss LBM matches the increase in adipose tissue (Kutynec et al. 1999). Factors that are linked with 
greater increases in fat and LBM loss include premenopausal as opposed to postmenopausal status 
at diagnosis (Demark-Wahnefried et al. 2001), experiencing treatment related menopause (Goodwin 
et al. 1999), receiving chemotherapy compared to no chemotherapy (Harvie 2010), a lower BMI at 
diagnosis, and those who are least physically active after treatment (Irwin et al. 2003). Finally, the 
loss of LBM is still prevalent, albeit of smaller magnitude in postmenopausal compared to 
premenopausal breast cancer populations (Aslani et al. 1999, Harvie et al. 2004).   
 
The most notable changes in body composition are seen during adjuvant chemotherapy and in the 6 
to 12 months following this (Harvie et al. 2004, Demark-Wahnefried et al. 2001, Aslani et al. 1999, 
Battaglini et al. 2007), while increases in total weight still occur after this point (Nichols et al. 
2009). It has been suggested that longer regimes of chemotherapy have resulted in greater weight 
increases. However, there are no studies that have reported weight change comparing the same 
agent at different durations (Gadéa et al 2011). Furthermore, smaller studies have indicated an 
increase in weight after longer (~6 month duration) cyclophosphamide, methotrexate, and 5-
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 flurouracil (CMF) regimens, but no weight change after shorter (~3 month duration) Adriamycin 
and cyclophosphamide (AC)  (Gadéa et al 2011) regimens. On the other hand, larger trials have 
indicated significant weight gain irrespective of chemotherapy agent (Goodwin et al 1999; Saquib 
et al 2007; Makari-Judson et al 2007). 
 
Loss of LBM with concurrent fat and total weight gains are associated with metabolic dysfunction 
including impaired glucose metabolism (Healy et al. 2010), high triglyceride levels (Hamilton, 
Hamilton, and Zderic 2007), and chronic inflammation in breast cancer populations (Mourtzakis 
and Bedbrook 2009). Cheney et al (Cheney, Mahloch, and Freeny 1994) noted that of those women 
who gained fat mass after chemotherapy, all experienced an increase in visceral adipose tissue 
measured by CT scan. Visceral adipose tissue is known to increase risk of metabolic syndrome 
related diseases though an increase in chronic inflammation (Lee et al. 2009). While it has been 
established that fat tissue is a very active endocrine and immune regulating tissue, skeletal muscle 
tissue may also have independent and/or complimentary influence on these regulatory pathways 
(Mourtzakis and Bedbrook 2009, Flynn, McFarlin, and Markofski 2007, Pedersen and Febbraio 
2012). Thus a decrease in LBM could be an important marker of, and/or exacerbate the metabolic 
dysfunction associated with visceral adipose tissue deposition. 
Additional considerations for measurement of body composition in breast cancer populations 
Fluid accumulation as a result of lymphedema is an important consideration for measuring body 
composition in breast cancer survivors. Up to 33% of women who have completed treatment for 
breast cancer have an increased risk of developing treatment related lymphedema in the arm (Hayes 
et al 2008). Compared to women who are treated surgically with a lumpectomy, those who have 
undergone axillary lymph node dissection experienced significantly higher rates of lymphoedema 
(DiSipio et al 2013). In addition, greater risk is also associated with an increasing extent of axillary 
node dissection, and treatment with radiotherapy. 
 
A recent review discusses strengths and weaknesses of common body composition measurement 
devices, and their suitability in a cancer survivor setting (Di Sebastiano and Mourtzakis 2012).   
The measures discussed included bioelectrical impedance analysis (BIA), skinfolds, dual energy X-
ray absorptiometry, magnetic resonance imaging (MRI), computed-tomography scans (CT scans), 
under-water-weighing (UWW) and air displacement plethysmography (ADP).  
 
BIA is strongly influenced by fluid changes in the body, thus its measure of LBM and fat mass may 
be confounded by lymphedema status (Di Sebastiano and Mourtzakis 2012). Similarly, skinfold 
assessment may be significantly affected by upper limb swelling, particularly the triceps and biceps 
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 measures. Accumulation of fluid may acutely alter the thickness of a skinfold, which would 
significantly reduce the reliability of the measure. DEXA, magnetic resonance imaging (MRI) and 
computed-tomography scans (CT scans) allow segregation of body compartments, including those 
with increased swelling. However, unlike DEXA which allows specific assessment of limbs and 
trunk, MRI and CT scans normally measure body composition from a single picture, or ‘slice’, 
typically at the level of the lumbar spine, and not allow interpretation of body composition for the 
upper limb (Di Sebastiano and Mourtzakis 2012). Measurement via UWW and ADP, which utilise 
the principles densitometry, may be altered as arm volume increases as a result of fluid retention. 
ADP & UWW calculates body composition by using established densities of LBM and fat mass, 
thus a change in density due to water retention may make the measure less reliable. For 
measurement using ADP, a previous study has shown that consumption of over 1000ml of water 
has the effect of increasing the value for fat mass without altering the LBM result (Vukovich and 
Peters 2003). However, the same study indicated that fluid retention as a result of creatine loading 
was reflected by an increase in LBM. A later study indicated that consumption of a small amount of 
food or water (cereal and milk or 350ml of Gatorade, respectively) resulted in no significant change 
to body composition when measured by BIA, DEXA or ADP (Heiss et al 2008). Therefore, a 
change in arm volume of 1000ml as a result of swelling may influence body composition analysis, 
and it may be less likely to affect LBM results. Alternatively, the gradual accumulation of fluid in 
the interstitial space may be interpreted like creatine-induced water retention. The effect that 
lymphoedema-related swelling has on body composition measurement is currently not known and 
should be accounted for in studies using densitometry.  
2.1.5(Mechanisms(of(body(composition(changes(after(treatment(for(breast(cancer(
Even with detailed assessments of energy balance (physical activity, total energy intake, resting 
energy expenditure), the body weight increases seen in breast cancer survivors are above those 
predicted in the energy balance equations. Two studies have noted that weight gain has been of 
significantly greater magnitude compared to predicted weight changes (Demark-Wahnefried et al. 
1997, Harvie et al. 2004). In fact, one study reported body weight gain when the population 
reported lifestyle parameters predictive of a negative energy balance (Demark-Wahnefried et al. 
1997). Physical activity levels after treatment have been better associated with body composition 
changes after treatment. Breast cancer survivors have repeatedly reported stable (Harvie et al. 2004, 
Kutynec et al. 1999, Irwin et al. 2003) or lower levels of physical activity during and after 
treatment, and these reductions have been correlated to increases in weight (Irwin et al. 2005, 
Demark-Wahnefried et al. 2001, Goodwin et al. 1999, Kumar et al. 2004). However, limited data is 
available to explain the loss of LBM (Demark-Wahnefried et al. 1997).  
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 Drawing from other populations, chemotherapy induced myotoxicity (Fanin et al. 2000) and 
increased systemic inflammation (Mourtzakis and Bedbrook 2009) after treatment may be two 
factors that explain LBM loss in breast cancer populations. Both of these factors require further 
investigation in future studies. Currently, it is thought that loss of LBM is greater in those who have 
completed chemotherapy (Sheean, Hoskins, and Stolley 2012), while gains in LBM have been 
noted in post-menopausal women prescribed aromatase inhibitors (AIs), due to a greater androgenic 
hormonal profile (van Londen et al. 2011). 
2.1.6(Summary(of(body(composition(and(breast(cancer(
Collectively, the current literature indicates that greater waist girth or WHR is associated with 
premenopausal breast cancer risk, while postmenopausal risk is associated with a higher BMI. 
Regardless of menopausal state, greater BMI or waist girth at diagnosis are equally associated with 
increased risk of breast cancer related morbidity and mortality. For both lines of investigation, no 
definitive studies have indicated a role for LBM in breast cancer risk or prognosis. 
 
After diagnosis, a large literature base indicates that weight stability and/or moderate weight loss 
(<3kg) is associated with the lowest risk of morbidity and mortality from any cause, while both 
body weight gain and significant body weight loss are associated with poorer outcomes. 
 
More detailed analyses of change in LBM and fat mass following treatment for breast cancer may 
provide a better understanding of how body weight change relates to mortality and morbidity 
outcomes. Gain in general and abdominal fat mass is associated with greater inflammation 
(Mourtzakis and Bedbrook 2009, Dee 2010), greater risk of cardiovascular disease (Pierce, Ballard-
Barbash, et al. 2009), and risk of metabolic syndrome (Healy et al. 2010). There is a dearth of long 
term evidence in regards to modifiable factors that predict LBM after treatment, however a 
significant number of shorter exercise and nutrition interventions (see next section) indicate longer 
term data is warranted. 
(
2.2(Exercise(and(dietary(interventions(and(their(effect(on(body(
composition(in(breast(cancer(survivors(
2.2.1(Controlled(trials(evaluating(the(effect(of(exercise(alone(
Exercise training and body composition has been extensively researched in breast cancer 
populations. An outcome of body composition change has been reported in 31 controlled exercise 
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 trials. Of these, five (n=612; range: 20-242) have been conducted during adjuvant chemotherapy 
(Battaglini et al. 2007, Winningham et al. 1989, Segal et al. 2001, Courneya et al. 2007, Mutrie et 
al. 2007), two (n=130; range: 30-100) have spanned both adjuvant chemotherapy and after 
completion of treatment (DeNysschen et al. 2011, Nikander et al. 2007), and 24 (n=2389; range 16-
573) have been conducted after completion of adjuvant therapies excluding endocrine therapy 
(Ligibel et al. 2008, Daley et al. 2007, Mustian, Katula, and Zhao 2006, Schmitz et al. 2009, Irwin, 
Alvarez-Reeves, et al. 2009, Matthews et al. 2007, Schmitz, Ahmed, et al. 2005, Herrero et al. 
2006, Burnham and Wilcox 2002, Pinto et al. 2005, Rogers et al. 2009, Courneya, Mackey, et al. 
2003, Courneya, Friedenreich, et al. 2003, Vallance et al. 2007, Basen-Engquist et al. 2006, Saarto 
et al. 2011 , Twiss et al. 2009, Winters-Stone et al. 2011, Fernández-Lao et al. 2013, Mulero Portela 
et al. 2008, Nicole Culos-Reed et al. 2006, Guinan et al. 2013, Pinto et al. 2003, Nuri et al. 2012). 
Change in total body weight and/or BMI was reported in 29 studies, a measure of body fat 
(percentage or fat mass) was reported in 18 studies, two studies reported change in sum of skinfolds 
without conversion to body fat%, while LBM was reported in 14 studies. DEXA was used in 8 
studies, BIA was used in five studies, sum of three skinfolds was reported in five studies, and sum 
of five skinfolds was reported in 3 studies. Studies reporting a measure of LBM are summarized in 
Table 2.1 
Body composition changes in controlled exercise interventions 
Description of studies 
Of the 29 studies that reported total weight changes as a result of an exercise intervention, 27 found 
no change in total body weight. In contrast to the minimal changes seen in overall body weight, 
nine (Courneya, Friedenreich, et al. 2003, Herrero et al. 2006, Burnham and Wilcox 2002, Schmitz, 
Ahmed, et al. 2005, Irwin, Alvarez-Reeves, et al. 2009, Fernández-Lao et al. 2013, Battaglini et al. 
2007, Winningham et al. 1989, Courneya et al. 2007) of 17 indicated a reduction in body fat%. In 
addition,  two (Guinan et al. 2013, Fernández-Lao et al. 2013) of four of studies reported a 
reduction in waist girth when compared to control. Seven of the 13 studies that reported body 
composition as a primary measure reported a significant improvement in body fat% favouring the 
exercise groups (Herrero et al. 2006, Burnham and Wilcox 2002, Irwin, Alvarez-Reeves, et al. 
2009, Battaglini et al. 2007, Schmitz, Holtzman, et al. 2005, Winningham et al. 1989, Fernández-
Lao et al. 2013), with one showing a trend for benefit (Courneya et al. 2007) the five remaining 
studies reported no differences in body fat% change between groups (Matthews et al. 2007, Nuri et 
al. 2012, Guinan et al. 2013, DeNysschen et al. 2011, Winters-Stone et al. 2011) 
In regards to studies that reported change in LBM, six of 10 (N=798, range: 16-242) studies 
reported a significant improvement in LBM for exercise groups compared to control (Herrero et al. 
2006, Battaglini et al. 2007, Schmitz, Ahmed, et al. 2005, Courneya et al. 2007, Irwin, Alvarez-
17
 Reeves, et al. 2009, Fernández-Lao et al. 2013). Of the four studies that have reported LBM change 
using DEXA, ADP and UWW three studies reported greater gains in LBM for the exercise group 
(Courneya et al. 2007, Schmitz, Ahmed, et al. 2005, Irwin, Alvarez-Reeves, et al. 2009), while one 
study indicated no effect for exercise (Matthews et al. 2007).  A more detailed explanation of why 
these differences occurred can be found in the following sections. 
 
Timing of exercise, i.e. during/after treatment, and type of exercise training aerobic or resistance 
exercise and supervised or home based, are important mediators in body composition changes and 
therefore require a more in-depth investigation, discussed below. Studies reporting LBM as a 
primary outcome and/or used a high quality measure for body composition will be the focus of this 
review. See Table 2.1 for a summary of these trials reporting high quality body composition data.
Effects of exercise on body composition during chemotherapy 
The majority of studies evaluating the effects of exercise on body composition during 
chemotherapy have shown a benefit for both LBM and BF%. One trial has indicated no change 
(DeNysschen et al. 2011) compared to controls. However, the majority of studies investigating the 
effects of exercise training during chemotherapy have reported increases in LBM(Courneya et al. 
2007, Winningham et al. 1989, Battaglini et al. 2007) and attenuated gains in body fat% (Courneya 
et al. 2007, Winningham et al. 1989, Battaglini et al. 2007). While current literature in healthy 
populations would indicate better LBM maintenance to be associated with resistance training, both 
aerobic and resistance training interventions have had mixed results during chemotherapy. 
Aerobic exercise alone 
Aerobic exercise prescription during chemotherapy has had mixed effects on LBM and other 
markers of body composition. Denysschen et al (DeNysschen et al. 2011) found no effect for 
aerobic exercise on body composition during chemotherapy. However, the study was confounded 
by their control group, who performed the same amount of exercise as both intervention groups. 
Similarly, a high quality study by Courneya et al (Courneya et al. 2007) using DEXA noted aerobic 
exercise training alone tended to decrease body fat% gains, while having no significant effect on 
LBM. However, further analyses in the study by Courneya et al (2007) revealed that compared to 
control, significant decreases in body fat% and increases in LBM were noted for exercisers with 
later stage disease (IIB/IIIA), while no effect was found for earlier stage disease (I/IIA). The reason 
for differing results in those with later stage disease is currently unknown, however a potential 
explanation may be related to treatment associated inflammation (Mills et al. 2008). Those with 
later stage disease undergo more intensive treatments, which in turn are related to higher levels of 
inflammation and myotoxicity (Mills et al. 2008). Higher levels of inflammation are known to 
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 induce proteolysis through up regulation of the ATP-ubiquitin-proteasome pathway (Debigare, 
Cote, and Maltais 2001).  
 
Since loss of LBM may be higher in those with later stage disease, an intervention that reverses 
LBM loss may create a greater ‘control versus intervention’ difference than if the effect of 
intervention is compared to those with a smaller loss of LBM. For example, those diagnosed with 
earlier stage disease experience less intensive treatment and less inflammation (Mourtzakis et al 
2009), therefore they may experience a smaller LBM loss, thus creating a smaller disparity between 
control and intervention groups. In addition, baseline levels of fat and total body mass may 
influence the effect of the intervention, i.e those with a higher body fat may experience a greater 
loss of body fat than leaner individuals. Unfortunately, raw data on absolute LBM and fat mass 
values were not given (Irwin et al 2009) so it is not able to be determined if the changes reported 
were due to differences at baseline. 
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 TABLE&2.1&CONTROLLED&EXERCISE&TRIALS&EVALUATING&LBM&CHANGES&IN&BREAST&CANCER&SURVIVORS&
Author,(Yr,(
Design,((
Country(
Rank,(Quality,(
Primary(
outcome(
Population( Intervention( Body(composition(and(adherence(outcomes( Comments(
Exercise interventions during chemotherapy 
Winningham, 
1989 
RCT – 2 arm 
USA 
NHMRC: II 
Quality: + 
Body 
composition 
N=34 initial; N=24 follow 
up;  
Post Sx; Age: 45.6yrs 
(32-66yrs); Menopausal 
status: 42% 
postmenopausal 
No significant differences 
between groups 
10-week intervention during CTx 
INT: 3 sessions/wk, aerobic exercise: 20-
30min/session, 60-85% of highest HR. 
Measures: skinfolds (3 sites): Supra-iliac, 
anterior thigh, triceps. Weight, Height. 
Max VO2, Obesity defined: >30% fat as 
per fold measures. 
No significant changes in body weight (kg) 
INT: +0.88kg, CON: +1.99kg (F=1.86, p=1.888) 
Significant ↓ in body fat% 
INT: -0.51%, CON +2.19%; F=5.26, p=0.033 
Trend for ↑ in LBM (kg) 
INT: +2.04kg, CON: -1.26kg, P=0.066 
INT: Stabilised body fat%; CON: ↑body fat%. 
Obese individuals increased body fat% 2-fold 
compared to non-obese 
Initial fat loss occurred in upper body. 
Limitations: Small sample size, 
prednisone use, no dietary control. 
Obese individuals in CON gained more 
weight  
 
Limited demographical information 
Battaglini, 2007 
RCT, 2-arm  
USA, Brazil  
 
NHMRC II 
Quality: +/O 
Body 
composition 
N=20; Age: 57yrs;  Wt: 
82.2kg (SD 25kg); Fat 
mass: 30.1% (SD 4.2) 
 
No other demographical 
results reported 
Sig diff between groups 
not reported 
Duration:&15&weeks;&INT:&6&wks&postGSx.&&INT:&2/wk&for&60mins.&48G84hrs&apart.&&40G60%&of&both&AET&and&RET.&6G12min&cardio,&15G30min&RET&(6G12&reps)&&CON:&instructed&not&to&engage&in&exercise&
Measures: skinfolds (3 sites): triceps, supra 
iliac, abdomen. Fat and lean mass 
VO2, Muscle strength (est. 1-RM) through a 
series of machine tests 
Body&weight&not&reported&Significant&↓&in&body&fat%&between&groups&INT:&G3.1%,&CON:&+1.1%,&P=0.004&&Significant&↑&in&%LBM&between&groups&INT:&+3.1%,&CON:&G0.2%,&P=0.004&between&groups&(NS&within&groups&for&either&LBM%&or&Body&fat&%)&Adherence:&100%&
As treatment progressed, group 
differences increased.  
 
Results made significant by the 
deterioration in control group and 
improvements in INT group. 
 
Minimal demographical information 
Courneya 2007 
RCT, 3-arm 
Canada 
 
NHMRC: II 
Quality: + 
 
Body 
composition  &
N=242, Age: 49yrs; Stage 
I-IIIA, 100% during 
chemotherapy; 
Menopausal status: 33% 
postmenopausal; Taxane 
CTx: 34.1% 
 
No sig diff between 
groups across any 
parameters &
Mean&duration:&17&weeks&(duration&of&CTx)&AET:&3&sessions/wk&on&cycle,&treadmill&or&elliptical&aerobic&exercise&@60%&to&80%&of&VO2mac.&15&increased&to&45&minutes&by&end&of&INT.&RET:&3&sessions/wk,&2&sets&of&8G12&reps&@&60G70%&of&est.&1GRM.&9&exercises&CON:&Asked&not&to&initiate&an&exercise&program&for&the&duration&Measures:&Wt,&Ht,&DEXA,&Arm&water&displacement,&&QOL,&VO2max&(treadmill)&
Strength: 8-RM bench and leg extension 
No&significant&change&in&body&weight&&AET:&+1.0,&RET:&+1.6,&CON:&+1.2,&P=0.698&Trend&for&↓&body&fat%&for&AET&vs.&CON*&AET:&+0.2,&RET:&+0.3,&CON:&+1.0,&P=0.076*&&Significant&↑&in&LBM&(kg)&for&RET&vs.&CON&AET:&+0.5,&RET:&+1.0,&CON:&+0.2kg,&P=0.015&(b/w&RET& &UC)&Body&comp&when&assessing&only&Stage&IIB/IIIA.&Significant&↑&in&LBM&(kg)&for&RET& &AET&AET:&+1.3,&RET:&+2.6,&CON&G0.3,&RET>AET>CON&&(all&significant&P<0.007);&&Significant&↓&in&body&fat%&for&AET& &RET&AET:&G1.0,&RET:&G1.4,&CON:&+1&RET&vs.&CON,&P=0.019.&AET&vs.&CON,&P=0.034&
No significant changes for Stage I/IIA for LBM or 
body fat%. 
RET more effective for LBM increases in 
all populations. AET more effective 
overall for body fat% loss. 
Any exercise is beneficial for body fat% 
in later stage disease. RET is more 
effective for LBM in those with later 
stage disease 
 
AET improves VO2max compared to RET 
& UC 
RET improves strength compared to AET 
& UC 
 
 
 &
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Exercise interventions during and after treatment 
Denysschen, 
2011 
RCT 3-arm 
USA 
 
NHMRC: II 
Quality: O 
 
Body 
composition 
 
  
N=100 (BrCa, Female 
100%); Age: mean for 
groups 48.7yrs to 51.6yrs; 
Stage I-III; BMI: 25.2 
(5.5); Menopausal status: 
34 to 44% 
premenopausal;  
During CTx: 100% 
Differences at baseline: 
LBM higher in non-
exercising control group; 
More smokers in control 
group &
Duration: During treatment (During): 4-6 
months; Post-treatment (Post): 4-6 months; 
Home based with phone calls. Ppt choice of 
aerobic exercise; 3-5 sessions/wk. 20-30 
min @ >12-14 RPE. Goal: 1200 to 
1500kcal/wk expenditure 
Intervention groups: 
EE: Exercise during and after treatment 
CE: Exercise after treatment only 
CC: No exercise (control) 
Measures: DEXA, Wt, Ht 
Max VO2 – treadmill, Karnofsky, Nutrition 
symptoms checklist 
No significant change in body weight (all values 
are net change from baseline value) 
During: EE: -1.1kg, CE: +2kg, CC: -2.1kg 
Post: EE: -0.6kg, CE: +2kg, CC: +2.7kg 
No significant change in LBM (CC had higher 
LBM at baseline than EE) 
During: EE: +1.8kg, CE: +1.3kg, CC: -0.8kg 
Post: EE: +0.3kg, CE: +0.6kg, CC: -0.6kg 
No significant changes in body fat%  
During: EE: +0.5%, CE: +1.2%, CC: +1.5% 
Post: EE: +1%, CE: +1.5%, CC: +2.8% 
Adherence: EE group: 74% @ end of CTx, 78% @ 
end of Study; CE group: 86% at end of study. 
Trend for more fat gains in CC group.  
Did not measure control group activity 
and exercise prior to study was measured 
by self-report.  
CC group was shown to exert the same 
MET-hrs each week as CE and EE. 
Dietary intake not measured. 
Significant differences in baseline LBM 
(EE vs. CC) &
Aerobic Exercise interventions after surgery, radiation therapy and chemotherapy 
Irwin 2009 
RCT 2-arm 
USA 
 
NHMRC II 
Quality: + 
 
Primary 
outcome (body 
composition) 
N=75, Age: 56.5yrs; Time 
since Dx: 3.3yrs; Stage 0-
IIIA.  
Menopausal: 100% 
postmenopausal. 
Sedentary 
Excl: Smokers, T2DM 
and previous cancer  
 
No sig differences in 
baseline parameters 
 &
Duration: 6 month (subset 12 months, 
n=48) 
INT: 150min/wk aerobic exercise, 5 x 
30min sessions/week. 3 supervised, 2 
unsupervised. 60-80% of HRmax. Any 
aerobic apparatus. Any resistance 
training/yoga did not count toward PA 
goals. 
CON: Allowed to exercise but received 
no support until after trial. 
Measures: DEXA, Ht, Wt, Waist, Hip 
7-Day Physical Activity Log, FFQ for 
dietary intake 
No significant changes in body  
6 months: INT: -0.55kg, UC: +0.1kg, P=0.39.  
12 mth: INT: -0.2 vs. UC: +0.6, P=0.61 
Significant ↓ in body fat% @ 6 & 12mth 
6 mths: INT: -0.79%, CON: +0.42%, P=0.0022 12mths:&G1.19%.&G0.03%,&P=0.043&&
Significant ↑ in LBM @ 6 but not 12 mth 
6 mth: INT: +0.34kg, CON: -0.35kg, P=0.047 12mths:&INT:&+1.7,&CON:&+0.2,&P=0.25&
No change in waist (cm) 
INT: -1.5, CON: -0.8, p=0.57 
No change in hip girth (cm) 
INT: -0.8, CON: +0.6, p=0.21 
Significant LBM changes for those <56yrs. 
Significant body fat% ↓ for: >56yrs, Later stage, BMI 
<30. Increased exercise related to increased change.  
Supervised exercise may increase LBM 
and ↓ body fat%, with larger effects in 
certain demographics. 
 
Greater adherence to exercise is 
correlated to increased body fat% 
changes.  
Matthews 2007  
RCT, 2-arm, 
Multicentre 
USA 
 
NHMRC: II 
Quality: + 
 
Body 
composition 
N=34; Age: 51.3 to 56yrs 
(means of groups); Stage 
I-III; Time since Dx: 
0.7yrs; Menopausal 
status: 100% 
postmenopausal, BMI 
>25,  
 
No sig diff between 
groups @ baseline 
Duration: 12 week  
INT: Home based, ↑ walking from 3 x 
20-30min session, to 5 x 30-40min 
sessions. RPE 11-13. Pedometers given 
out. Contact: 1x 30min home face-to-
face. 5 follow up phone calls. 
CON: Continue normal activities 
Measures: DEXA, BIA, Wt, Ht; 
Physical Activity: CHAMPS 
questionnaire + Accelerometers 
Dietary intake: DHQ and NCI F&V  
No&significant&change&in&body&weight&(kg)&&INT:&0.04&vs.&0.01,&P=1.00&Trend&for&↓&in&body&fat&%&&INT:&G0.2;&CON:&+0.4,&P=0.15&No&significant&change&in&LBM&(kg):(INT:&&+0.21,&CON:&G0.3,&P=0.27&Volume&of&exercise&and&fruit&and&vegetable&consumption&had&no&bearing&on&change&Walking&increased:&4.9&to&16.8METGhrs/wk,&compared&to&5&to&6.6&in&control&group.&Adherence:&97%&at&6&weeks;&71%&at&12&weeks&
Physical activity was increased. Trends 
for body composition changes were 
present. 
Longer duration study may show results 
RPE used to determine aerobic work. 
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Burnham, 2002,  
3-arm RCT 
NHMRC 
IIQuality  
+ 
Primary (body 
composition) 
N=18 (BrCa n=15) All 
groups contained BrCa 
(n=5) and Colon Ca (n=1) 
Age: means 50 to 56yrs; 
Time post Rx: 9 to 
10.3mths  
 
No sig differences for 
bline variables 
10-week intervention 
3 sessions/wk, mixed aerobic 
modalities; Duration: 14min week 1 to 
32min at wk 10. 
ModINT: Initial 40-50% of HRR, final 
60% of HRR 
LowINT: Initial 25-35% of HRR, final 
40% of HRR. 
Measures: body fat% from skinfolds (3 
sites), Wt, VO2 Peak (treadmill); QOL; 
Flexibility 
Exercise groups combined for final analysis 
No significant change for body weight 
INT: -0.2%, CON: -0.6%, P>0.05 
Significant ↓ in body fat % 
INT: -2.4%, CON: 0.1%, P<0.05 
 
Exercisers had significant increase in absolute and 
relative VO2 peak compared to controls, P<0.05 
Attendance for exercise: 95% 
Both low and moderate intensity exercise 
offers benefit in a number of 
physiological and psychological areas. 
 
Limited by small numbers, and short 
duration and somewhat heterogeneous 
sample. 
Guinan, 2013 
2-arm RCT 
NHMRC II 
Quality: 0 
Primary 
anthropometric
s and blood 
biomarkers for 
metabolic 
syndrome 
N=26, Age: 48.12yrs, 
30.8% postmenopausal, 
96.2% Caucasian, Time 
since CTx: 3.74 months, 
Stage I/II/III: 
26.9/50/23.1%; 
Tamoxifen: 57.6%, AI: 
19.2%. 
No diff between groups 
8-week intervention, 2 supervised 
sessions/wk, building from 1 to 5 home 
sessions/wk. 
AET: 35-65% HRmax (lower range for 
those with lower initial fitness). HR 
monitor for adherence in gym and at 
home. 5% increase in aerobic intensity 
each 2 weeks. 
CON: Education session on exercise 
Measures: 0, 8 & 12 weeks 
Body composition: BIA & waist 
PA: GT3X accelerometer 
Bloods: CRP, TChol, HDL, LDL, TG, 
BGLs, Insulin, HOMA-IR, HbA1c 
ITT analysis: No change in weight, BF%, LBM or 
Waist at 8 or 12 weeks 
Confidence intervals for waist indicated change, but 
were not significant between groups. 
Per protocol analysis (>90% of exercise class attended) 
No reported change in weight, BF% or LBM 
Significant reduction in Waist girth at 3 months 
INT: -4.63 95% CI: -5.7 to -3.6;   CON: -0.3 (-2.3 to 
1.7), p=0.05. 
CRP: Within group reductions for INT, but no 
differences between groups at 8 weeks (p=0.07) and 12 
weeks (p=0.69) 
Accelerometer did not show change in activity for per 
protocol or ITT.  
Godin activity questionnaire indicated an increase in 
‘total weekly exercise’ for adherers (p=0.005) 
Differences only found in those who 
adhered to the protocol >90%. &
Resistance exercise interventions after treatment 
Schmitz, 2009,  
RCT, 2 arm 
Multicentre 
Quality: + 
NHMRC: II 
Secondary 
outcome (body 
composition) 
N=141 @ baseline, 
N=130 final Past or 
current diagnosis of stable 
lymphoedema. Age: 
56yrs, Time since Dx: 
6.5yrs (1 to 15 yrs); 
Stage: I/II/III: 46%, 1%, 
and 31%. (n/a: 21%).  
Menopausal status: not 
reported. Sedentary. 
Baseline differences in 
tamoxifen (p=0.008). No 
other differences between 
groups 
During: 12 months.   
INT: Progressive resistance training – 2 
sessions/wk (90min per session) – 9-10 
resistance exercises. Building 1 to 3 sets per 
exercise for 10 repetitions. 13 weeks 
supervised. 39 weeks unsupervised. No 
limit to weight increase. 
Lymphoedema flare up resulted in return to 
lowest available weight for upper body 
resistance. 
CON: Continue normal activity 
Measures: DEXA – LBM and Body fat % 
Wt, Ht, Arm volume. PA (MET min/wk); 
Diet 
No significant changes in body weight 
INT: -1%; CON: -0.4%, P=0.47. 
No significant changes in body fat%  
INT: -0.3%; CON: -0.1%, P=0.19.  
No significant changes in LBM 
INT -1%; CON: -1.1%, P=0.67. 
 
No sig differences in lymphoedema status 
1-RM Strength increased for INT group 
Bench press: INT: +29.4%, CON: +4.1%, P<0.001; 
Leg press: INT: +32.5%, +7.6%, P<0.001  
Attendance at 3 monthly intervals: 96%, 88%, 81% 
75%. 
Weight lifting is safe in breast cancer 
populations: INT had ↓ severity of arm 
and hand symptoms, ↓ no. of 
exacerbations; ↑ muscular strength. 
Lymphoedema may have reduced 
expected strength gains. 
 &
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Schmitz, 2005 
+ O’Hira, 2006 
RCT, 2 arm 
Wait list 
control 
USA 
 
Quality: + 
NHMRC: II 
 
Safety of RET 
& Body 
composition &
N=85,&Age:&53.3yrs,&Time&since&Dx:&1.7&to&2.01yrs,&Time&since&last&Rx:&1.1&to&1.2yrs,&BMI&<40kg/m2;&Stage&0GIIIA;&Menopausal&status:&85%&post.&Sedentary&&&No&significant&differences&between&groups&&
Duration:&6&months&INT:&13&weeks;&2/wk&resistance&training.&Supervised,&then&13&weeks&not&supervised.&&8G10&reps,&2G3&sets&per&exercise,&9&exercises&for&upper&and&lower&combined&No&changes&to&aerobic&CON:&Wait&list&control,&performed&INT&from&6G12&mths&Measures:&DEXA,&Wt,&Ht,&Waist&Bloods:&IGFGaxis,&Insulin,&HOMA&&DHQ,&PARGQ,&1GRM,&QOL:&CARESGSF&Injury,&Depression:&CESGD&&
No&significant&change&in&body&weight&(kg)&INT:&&+0.3,&CON:&+0.2,&P=0.84&Significant&decrease&in&body&fat%&b/w&groups&&INT:&G1.14,&CON:&+0.25,&P=0.03&Significant&increase&in&LBM&(kg)&b/w&groups&INT:&+0.88,&CON&+0.02,&P=0.008&
No significant change in waist girth 
INT: -1.1%, CON: +0.22, p=0.08 
No sig differences in lymphoedema status 
1-RM Strength increased for INT group 
Bench press: INT: +63%, CON: +12%, P<0.001; Leg 
press: INT: +38%, +9%, P<0.001  
Biochemical: No change for: Glucose, Insulin, 
HOMA, IGF-I, IGFBP-1, 2; Adherence: 0-6 mths: 
Mean 92%; Median: 96%; 6-12mths: Mean: 66%; 
Median: 77% 
Resistance&training&may&decrease&body&fat%&and&increase&LBM.&Strength&gains&much&higher&than&tissue&growth.&&Correlations&for&LBM&and&QOL:&r=0.26,&P<0.05;&and&Bench&press&and&QOL:&r=0.53,&P<0.01.&
  
Winters-Stone, 
2011,  
RCT, 2-arm, 
USA 
 
Quality: + 
NHMRC: II 
 
Primary 
outcome: LBM, 
Fat mass, Bone 
mass, BMD 
INT, CON 
N=52, 54; 
Postmenopausal: 100%; 
Age: 62.3, 62.2yrs (1.7); 
BMI: 29.5 (5.8); Time 
since Dx: 4.75yrs, 
5.25yrs; Stage: O/I/II/IIIa: 
7.7%/ 
38.5%/48.1%/1.9%; 
3.7%/40.7%/35.2%/9.3% 
Recevied CTx: 61.5%, 
59.3%; RTx: 92.3%, 
83.3%; AI: 42.3%, 
40.7%;  
No diff b/w groups 
INT:  Supervised 2/wk Home based 1/wk 
for 1 year.  
Supervised: Free/machine/body weights 1-3 
sets, 8-12 reps 3-4 upper body & 3-4 lower 
body exercises + 1-2 sets of 10 reps: 2 
footed jumps 30cm in height.  
Home: Same as above with therabands 
CON: Whole body stretching – seated or 
lying 
Measures: 0, 6, 12 months  
DEXA: LBM, Fat mass, BMD 
Bloods/Urine: Osteocalcin, & urinary 
deoxypyrodinoline cross-links.  
Physical Activity: CHAMPS PA 
quesionairre 
Dietary intake: Energy + Calcium - Block 
FFQ 
All&b/w&group&differences&No&significant&%&change&in&body&weight&(kg)&&INT:&&+1.19%,&CON:&+0.27%,&P=0.55&No&significant&%&change&in&bone&free&LBM&(kg)&ITT&INT:&+1.38%,&CON:&+1.12%,&p=0.91&INT&group&taking&AIs&had&a&greater&LBM&increase&than&those&in&INT&group&not&taking&AI.&No&effect&for&AI&vs.&NonGAI&in&CON&group.&&No&significant&%&change&in&body&fat%&INT:&0.00%,&CON:&G0.52%,&P=0.50&
No change in energy intake 
Exercise adherence: Total, Supervised & Home 
INT: 57%, 76%, 23%; CON: 62%, 72%, 44% 
  
Greater increases in LBM for AI takers 
than non-takers in POWIR group. Small 
decrease in non-AI users in FLEX, vs. 
no change in AI takers. 
 
Resistance and jumping maintained 
spine BMD. Whereas CON group 
experienced decreased BMD. 
 
 &
Combined aerobic and resistance training after treatment 
Herrero 2006,  
RCT 2 arm 
Spain 
 
NHMRC: II 
Quality: + 
 
Body 
composition 
N=16; Age: 50.5yrs; 
Time since Dx: 24-58 
mths (range); Menopausal 
status: 100%; Stage I-II  &No&differences&across&groups&for&any&variables&&
Duration: 8 weeks; INT: 3/wk x 90min: 11 
resistance exercises 3 sets for large and 2 
for small groups. Progressive o/load; 
Aerobic: 20min 70%HRR, to 30min 80% 
HRR (or split: 2x10min). 
CON: Asked to not exercise. Measures:&skinfolds&(3&sites),&Wt,&Ht.&Max&VO2,&100G110%&BM&lift;&Endurance,&EORTC,&SitGstand&
No&significant&change&in&body&weight&(kg)&INT:&G1.1kg,&CON:&G0.4,&95%CI:&G2.93&to&1.38&Significant&↓&in&body&fat&%&&INT:&G2,&CON:&0;&95%CI:&G3&to&G3.8,&p<0.05&Significant&increase&in&LBM&(kg)&INT:&+0.7,&CON:&&G0.3,&95%CI:&0.25&to&1.86&&
Significant ↑ in sit-to-stand, leg press and VO2max 
for INT, P<0.05; Trend for bench press: P=0.08 
Adherence to training: 91% 
Relative ↑ in LBM and ↓ body fat% in a 
short time period.  
INT was 270 minutes/wk over 3 sessions. 
Increased volume may explain changes. 
Significant improvement in VO2mac, lower 
body function and strength. 
Small sample size, skinfolds and limited 
demographical information given 
23
 RCT: Randomised controlled trial; Ca: Cancer; Sx: Surgery, CTx: Chemotherapy; RTx: Radiotherapy; AIs: Aromatase Inhibitors; Rx: Treatment 
HR: Heart rate; AET: Aerobic exercise training; RET: Resistance exercise training; 1-RM: 1 repetition max; 8-RM: 8 repetition max; Wt: Weight; Ht: Height; LBM: Lean body 
mass; BMD: Bone mineral density; DEXA: Dual energy X-ray absorptiometry; QOL: Quality of life; HRR: Heart rate reserve; RPE: Relative perceived exertion; FFQ: Food 
frequency questionnaire; PA: Physical activity; CV: Cardiovascular; Time since Dx: time since diagnosis; IGF: Insulin like growth factor; HOMA: Homeostasis Model Assessment; 
DHQ: Diet History Questionnaire; PAR-Q: Physical Activity Readiness Questionnaire; CARES-SF: Cancer rehabilitation evaluation system – short form; T2DM: Type 2 Diabetes 
Mellitus; NCI F&V: National Cancer Institute Fruit and vegetable screen 
INT: Intervention group; CON: Control group; ITT: Intention to treat; mths: Months;  
Fernandez-Lao, 
2012 
3 arm –wait list 
control 
Spain 
Quality: O 
NHMRC: III-1 
Pseudo-
randomised 
 
 &
N=96, Age: 48, Time post 
Rx: 75% <12 mths since; 
Stage: I-IIIA: Tamoxifen: 
39, AI: 39, None: 8 &
Land-based intervention (Land) 
60min, 3/wk 8 weeks 
AET: 40-50% of session <60% HRmax 
RET: 2-3 sets, 8-12 repetitions 
DVD of exercises provided after the 
program 
Water based intervention (Water) 
Same as above with water related 
restrictions on exercise 
CON – given reading material for breast 
cancer related exercise and nutrition. 
No caloric restriction 
Measures 
8-point BIA, Wt, perometry of arm, waist, 
QOL (EORTC-QLQ-BR23) 
Group x time interaction for LBM: F=3.566; 
p=0.008 
Land had greater increases than Water (p<0.001) & 
CON (p=0.009) 
Group x time interaction for body fat%:  F=3.376; 
p=0.011. 
Land had greater decreases than Water (p<0.001) 
CON (0.002) 
Group x time interaction for waist girth: F=4.553, 
p=0.002. CON had greater increases than Land 
(p<0.001) or Water (p-0.003) 
Group x time interaction for breast symptoms: 
F=9.048; p<0.001. Water greater increases than 
Land (p<0.01) or CON (p<0.05). 
Adherence: Land: 84.8%  vs 91.9% water 
Those who exercised maintained body 
weight, while those who did not exercise 
gained weight. 
Difficult to control resistance and 
consistency in the water. &
Saarto 2011 
2-arm RCT 
Finland 
 
NHMRC: II 
Quality: + 
 
Bone loss 
 
 &
N=573; Age: 35 to 68. 
Invasive breast cancer; 
Time since end of adj. 
RTx or CTx or started 
endocrine Rx <4mths 
earlier. 
12 months, 1 supervised + 2-3 home 
sessions 
Aerobic step class: 150 to 180 jumps (10cm 
to 15 then 20cm benches after 8 mths) 
Circuit training:  
Aerobics –  
Circuit class: 150 to 180, with only 100 
more demanding jumps in later stages 
Classes aimed at 14-16 RPE 
Home sessions: 100 leaps + Nordic 
walking/walking 
CON: Normal activity with no formalised 
supervised or home sessions 
Measures: 
Body comp: DEXA, Wt, Ht 
CV fitness: 2km walk test; Dynamic 
strength: figure 8 test 
Leisure time PA – 2-wk prospective 
exercise diary 
No significant difference in weight change. 
Premenopausal: Body weight increase 1.4 to 1.9% 
with no training effect 
Postmen: No change in weight 
No significant effect for LBM 
Premenopausal 
INT: 43.7 ! +0.3kg (0.077 to 0.617) NS 
CON: 44 ! +0.268 (-0.041 to 0.0577) 
Post Menopausal 
INT: 44.6 ! +0.34kg (-0.005 to 0.694) p=0.13 
CON: 43.2 ! -0.011 (-0.288 to 0.266) 
No significant change in fat mass between groups 
Premenopausal 
3.4-3.8% increase for both groups 
Post menopausal 
1.8-2% increase for both groups 
Adherence: Premenopausal: 58%, Postmenopausal: 
63% &
Effect on BMD only for premenopausal. 
AIs were a strong predictor of bone loss 
Improvements in physical performance: 
Figure-8 running, compared to control. 
2km walk time improved in 
premenopausal trainees more than control. 
No difference for post menopausal. 
Change in control group activity was large 
and positive. No dose-response seen for 
exercise and bone &
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 Resistance exercise training protocols during chemotherapy 
One high quality controlled trial, has assessed the effect of resistance training on LBM changes 
during chemotherapy. Courneya et al reported a significant increase in LBM with no effect on body 
fat%(Courneya et al. 2007). Those with later stage disease experienced significantly greater gains in 
LBM compared to control or aerobic exercise, while decreases in body fat% was on par with 
aerobic exercise (Courneya et al. 2007). Of note, those who completed the resistance training 
protocol were also more likely to complete their chemotherapy regimen. This is an important 
consideration for those undergoing treatment, in that exercise may improve primary treatment, not 
just improve outcomes in relation to metabolic health and physical function. 
Combined resistance and aerobic exercise training protocols during chemotherapy 
Combined aerobic and resistance training may reduce body fat% when compared to usual 
care(Battaglini et al. 2007, Winningham et al. 1989), and may increase LBM simultaneously 
(Battaglini et al. 2007, Winningham et al. 1989). While findings are encouraging and consistent, 
caution should be exercised in interpreting these results as both studies utilised skinfolds, which 
may have reduced precision particularly in overweight/obese women (Kuczmarski, Fanelli, and 
Koch 1987) 
 
A number of limitations are found within the exercise intervention literature. Exercise training has 
not been shown to reduce body weight in those diagnosed with breast cancer. It is considered that 
300 minutes/week of moderate intensity exercise is required for significant weight loss without 
dietary intervention (Jakicic and Otto 2005). So far, no studies performed in breast cancer 
populations have aimed for more than 270 minutes of weekly exercise, which may partly explain 
this lack of body weight change. All exercise interventions during chemotherapy failed to control 
for dietary energy intake. On the other hand, previous observational studies have found no 
consistent relationships between dietary energy intake and body composition changes (Demark-
Wahnefried et al. 2001, Harvie et al. 2004, Goodwin et al. 1999). All exercise interventions ranged 
from 90 – 150min of prescribed exercise each week, although significant findings were only found 
in those programs that included objectively measured and supervised exercise (Battaglini et al. 
2007, Winningham et al. 1989, Courneya et al. 2007) as opposed to home-based exercise 
(DeNysschen et al. 2011). Considering these limitations, interventions that combine nutrition and 
exercise prescription should be conducted to better control for energy intake. Furthermore, 
clinicians should be aware that both supervision and objective monitoring of exercise interventions 
are important to best achieve desired outcomes of body composition change.  
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 Current findings from one high quality study indicate that in those completing treatment, aerobic 
exercise training alone may be effective in reducing body fat%, while resistance training may be 
effective in increasing LBM, and importantly, these changes can occur during chemotherapy 
(Courneya et al. 2007). Combined aerobic and resistance training may confer benefits for both 
LBM and body fat% simultaneously (Battaglini et al. 2007, Winningham et al. 1989).  
Of interest, the greatest relative improvements in body composition during treatment have been 
found in those with later stage disease (Stage IIB/IIA) (Courneya et al. 2007). These preliminary 
findings indicate that further investigation in this area is warranted (Irwin et al. 2003). 
Exercise interventions and body composition after treatment 
Of the eight studies that assessed LBM changes, four studies noted a significant increase for the 
individuals within exercising groups (Irwin, Alvarez-Reeves, et al. 2009, Schmitz, Ahmed, et al. 
2005, Herrero et al. 2006, Fernández-Lao et al. 2013), while one additional study indicated a benefit 
only for exercisers being treated with aromatase inhibitors (AIs) (Winters-Stone et al. 2011). Three 
studies indicated no significant difference for the exercisers compared to control (Matthews et al. 
2007, Schmitz et al. 2009, Saarto et al. 2011).  Controlled exercise trials after adjuvant treatment 
were typically designed using conventional aerobic and resistance training, however Tai 
Chi(Mustian et al. 2004) and water-based resistance training protocols (Fernández-Lao et al. 2013) 
were also conducted.  
 
Of the 17 controlled trials published, exercisers experienced significantly greater decreases in body 
fat% or skinfold measures in six studies (Fernández-Lao et al. 2013, Schmitz, Ahmed, et al. 2005, 
Irwin, Alvarez-Reeves, et al. 2009, Herrero et al. 2006, Burnham and Wilcox 2002, Courneya, 
Friedenreich, et al. 2003). Two studies indicated the same but statistically non-significant trend 
(p<0.15) (Matthews et al. 2007, Courneya, Mackey, et al. 2003) (only studies reporting LBM are 
summarized in Table 2.1). Compared to non-exercise groups, exercisers experienced a greater 
decrease in waist girth in one study (Guinan et al. 2013), better maintenance, i.e. stability instead of 
loss, in one study (Fernández-Lao et al. 2013), and no change in two studies (Irwin, Alvarez-
Reeves, et al. 2009, Schmitz, Ahmed, et al. 2005). 
 
Overall, individuals who participated in supervised exercise interventions were more likely to 
experience a significant increase in LBM compared to control groups. All studies reporting a 
significant change in LBM and five of the six studies that reported a significant change in body 
fat% utilised supervised exercise protocols (Schmitz, Ahmed, et al. 2005, Fernández-Lao et al. 
2013, Irwin, Alvarez-Reeves, et al. 2009, Herrero et al. 2006, Burnham and Wilcox 2002). Only 
one home-based protocol reported a significant reduction in body fat%(Courneya, Friedenreich, et 
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 al. 2003), however a number of studies prescribing supervised exercise reported no differences 
between groups (Daley et al. 2004, Guinan et al. 2013, Mustian et al. 2004, Ligibel et al. 2008, 
Winters-Stone et al. 2011, Saarto et al. 2011, Schmitz et al. 2009, Courneya, Mackey, et al. 2003). 
Menopausal status, length of intervention, nor sample size was seen to influence changes in body 
composition.  
Aerobic training and body composition after treatment 
Results from aerobic training studies alone have been mixed in regard to body composition change. 
Typically, protocols have prescribed three to five sessions per week, with duration ranging from 30 
to 45 minutes and intensity from 55 to 75% of estimated HRmax. Of the three studies that used a 
high quality body composition measure (DEXA), Irwin et al (Irwin, Alvarez-Reeves, et al. 2009) 
was the only study to be employ a supervised (three supervised, two unsupervised each week) and 
objectively monitored exercise protocol (Heart Rate (HR) monitors). Furthermore, it was the only 
study to report significant increase in LBM and decrease in body fat% in favour of the exercise 
group. However, no significant change was seen in waist girth (mean differences: LBM +0.69kg, 
BF%: -3.0%)(Irwin, Alvarez-Reeves, et al. 2009).  Matthews et al (Matthews et al. 2007) and 
Denysschen et al (DeNysschen et al. 2011) both utilised subjective prescription of exercise intensity 
(Borg Scale), unsupervised aerobic exercise programs, and did not report statistically significant 
differences between groups for LBM or body fat%. Both of these interventions set objective targets 
for volume of exercise to perform that were measured through self-report, and both supported 
participants through phone counselling. In studies that have objectively prescribed and monitored 
aerobic exercise intensity with heart rate monitors or tailored treadmill workloads, exercisers have 
experienced significantly greater reductions in body fat%, albeit using lower quality measures of 
body composition (BIA and skinfolds)(Courneya, Friedenreich, et al. 2003, Irwin, Alvarez-Reeves, 
et al. 2009, Burnham and Wilcox 2002). This may indicate that exercise prescription based on 
subjectivity (Borg scale) and performed at home leads to a lower level (volume and intensity) of 
activity being performed, and thus a lesser effect when compared to non-exercising control groups. 
 
Further sub-group analysis by Irwin et al (2009) indicated that compared to non-exercise groups, 
those younger than 56yrs, or with a BMI of more than 30kg/m2 experienced significantly greater 
increases in LBM (Irwin, Varma, et al. 2009). In contrast, benefits related to body fat% were 
significantly higher for women who were over 56yrs of age, were non-obese, had later stage disease 
(II-IIIA versus 0-I); or were taking any endocrine therapy versus none (Irwin, Alvarez-Reeves, et al. 
2009). The authors proposed that younger individuals are more likely to experience chemotherapy-
induced menopause and lose more LBM post-diagnosis. Due to this greater LBM loss experienced 
by these women, an intervention that reverses or even halts the changes will make the loss in a 
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 control group more pronounced. Thus those at the highest risk of adverse change may receive a 
greater net benefit from exercise than women who experienced natural menopause and are not as 
prone to the LBM loss (Irwin, Alvarez-Reeves, et al. 2009). 
Resistance training and body composition after treatment 
Resistance training alone may increase LBM and decrease body fat%. Of the three well-designed 
RCTs (Schmitz, Ahmed, et al. 2005, Schmitz et al. 2009, Winters-Stone et al. 2011), two noted a 
significant benefit for the exercise group (Schmitz, Ahmed, et al. 2005, Winters-Stone et al. 2011), 
while the other found no difference between groups(Schmitz et al. 2009).  
Winters-Stone et al (Winters-Stone et al. 2011) did not find whole group differences between 
exercise and control (DEXA - mean difference: +0.26%, p=0.91). However, exercisers taking AIs 
experienced statistically significant increases in LBM, while those in the control group did not 
experience any change in LBM regardless of treatment with AIs (group x AI on slope of time; t(95) 
= -2.51, p=0.01) (Winters-Stone et al. 2011). This extends findings that AIs had previously been 
reported in observational studies as having an independent and anabolic effect on LBM thought to 
be due to their androgenic properties (van Londen et al. 2011, Montagnani, Gonnelli, et al. 2008, 
Francini et al. 2006). 
 
The three resistance exercise trials used supervised progressive training twice-weekly, while 
Winters-Stone et al (2011) also prescribed a jumping program consisting of 20-60 jumps per 
session, and an additional home theraband strength session once per week. Schmitz et al 
(2005)(Schmitz, Ahmed, et al. 2005), and Schmitz et al (2009)(Schmitz et al. 2009) both prescribed 
progressive resistance training, however differences in frequency and intensity existed between 
protocols. The 2005 study reported a +0.86kg mean difference in change of LBM in favour of the 
training group (Schmitz, Ahmed, et al. 2005), while no effect was reported in 2009 (Schmitz et al. 
2009). Differences in primary outcome, population selection and training regimes may explain 
these inconsistencies. The 2009 study was designed to assess safety of resistance training for 
women with lymphoedema (Schmitz et al. 2009) as opposed to the 2005 study, which aimed to 
assess general safety and efficacy of resistance training in body composition change (Schmitz, 
Ahmed, et al. 2005). The 2005 study also recruited participants who were more recently diagnosed 
with breast cancer (mean of 1.8 years, versus 6.5 years post-diagnosis).  
Typically, the greatest body composition changes occur in the first six to 12 months following 
treatment and may continue for three to four years, albeit more slowly (Makari-Judson, Judson, and 
Mertens 2007, Harvie 2010). Resistance training sooner after treatment may therefore create a 
greater disparity in anabolic status when compared to an extended time post-treatment. In addition, 
the 2009 study recruited only those with past or current clinically diagnosed lymphoedema, while 
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 these individuals were excluded from the 2005 trial. Participants with lymphoedema may have been 
more cautious with their weight progression, which may have reduced their potential gains. 
Supporting this, the 2005 study noted a 63% improvement in 1-RM bench press, compared to a 
29% improvement in the 2009 study.  
Three supervised sessions per week may have elicited a greater change than twice weekly(Schmitz, 
Ahmed, et al. 2005, Schmitz et al. 2009) or twice weekly plus one unsupervised session (Winters-
Stone et al. 2011) as the study during chemotherapy by Courneya et al (2007) noted significant 
LBM changes for the resistance exercise group at this frequency (Courneya et al. 2007). Similarly, 
studies from healthy populations would indicate that LBM gains may increase with a higher weekly 
dose of resistance exercise (Rhea et al. 2003), while more recent literature indicates that lifting to 
temporary failure is an important key to maximal muscle protein synthesis (Breen et al 2011). 
 
Further research needs to investigate the mediating effects of later stage disease, earlier intervention 
(immediately post treatment) and changes in function as a result of training, however resistance 
training can be considered safe for all breast cancer survivors with or without lymphoedema. One 
trial assessing safety of exercise reported a 10% injury rate related to the intervention itself, with 
only one injury being severe enough to stop participation in the intervention (Schmitz et al 2005). 
Of note, lower back injuries were the most common accounting for 50% of all intervention related 
injuries reported. Schmitz et al (2009) noted a significantly lower rate of exacerbations of 
lymphedema was reported as a result of resistance training when compared to the control group. 
Finally, adherence over 12 months of both trials was reported to be ~80%.  
Combined aerobic and resistance training and body composition after treatment  
Exercise interventions that have combined both resistance and exercise training have had positive 
effects on LBM, however the data is currently limited by the use of lower quality measures of body 
composition.   
The two studies reporting LBM change noted a significant increase in LBM after land-based 
training (Herrero et al. 2006, Fernández-Lao et al. 2013). Herrero et al reported a significant 
increase in LBM in favour of the exercise group (mean difference: +1.0kg 95%CI: 0.25 to 1.86) 
after eight weeks of training measured by skinfold assessment (Herrero et al. 2006). In addition, 
Fernandez-Lao (2013) reported a significant group x time interaction for the land-based resistance 
and aerobic training over water-based training and control using BIA. (p=0.008) (Fernández-Lao et 
al. 2013). Both studies prescribed combined training three times per week, with a total weekly 
duration ranging from 180(Fernández-Lao et al. 2013) to 270mins (Herrero et al. 2006) per week, 
both employed progressive overload for both resistance and aerobic protocols and supervised all 
sessions in gym environments using free and body weights.  Markers of strength and 
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 cardiorespiratory fitness were reported by Herrero et al, and compared to non-exercising controls, 
the exercisers experienced greater improvements in lower body strength, power and VO2max 
(Herrero et al. 2006). However, Herrero et al (2006) had a small sample size (N=16) and ideally 
larger trials are needed for more conclusive data. 
 
Body fat% decreased significantly in two studies (Ligibel et al 2008, Fernández-Lao et al. 2013), 
while one reported waist girth maintenance in the exercise groups compared to a significant 
increase in the non-exercise control group (Fernández-Lao et al. 2013). In the second study, Ligibel 
et al (2008) found that 200 minutes of combined training resulted in a decrease in hip girth for the 
exercise group, however no change was reported for body fat%. 
Functional change after exercise training 
Despite there being a less consistent effect of exercise training on body composition change, 
exercise trials have consistently shown significant increases physical function. Resistance training 
programs have reported increases in 1-Repetition max (1-RM) strength from 30-60% after 12 
months of training (Schmitz et al 2005, 2009). In addition, aerobic exercise after treatment has 
resulted in 18.6% improvements in VO2max (Burnham et al 2002) compared to no change in the 
control group. However, during chemotherapy, aerobic training maintained VO2max, while control 
and resistance training groups experienced a decline over the course of treatment. (Courneya et al 
2007)  
LBM function and strength has been shown to be more predictive than absolute values of LBM or 
fat mass (Ruiz et al 2008, Newman et al 2006). Thus, future research aiming to assess the effects of 
an intervention on body composition should also assess the effect on physical function. 
Conclusions for controlled exercise trials conducted after treatment 
Compared to resistance training alone, supervised and/or objectively monitored aerobic exercise 
training is indicated as the preferred protocol to reduce body fat% and measures of girth. As 
expected, compared to aerobic exercise training, resistance training is more likely to increase LBM. 
Thus, combined resistance and aerobic exercise training may simultaneously improve LBM and 
body fat%, and be the preferred prescription. However future studies should prescribe training three 
times per week in order to determine benefit of a given protocol.  
A major limitation in the literature stems from the lack of premenopausal participants included in 
completed studies. All studies conducted so far have included primarily postmenopausal 
populations. Considering premenopausal women experience adverse body composition changes of 
larger magnitude than postmenopausal women following treatment (Vance et al. 2011), future 
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 studies should include this population to make the information more generalisable to all breast 
cancer survivors. 
 
Aiming for LBM maintenance or growth with a reduction in body fat% and/or waist girth is a 
clinically relevant goal for breast cancer survivors participating in an exercise program alone 
without specific dietary prescription. 
Summary of the effects of exercise training on measures of body composition 
During chemotherapy and after treatment completion, progressive resistance training with a 
frequency of at least twice per week is likely to elicit the greatest LBM gains, while aerobic and 
combined resistance and aerobic training protocols are more likely to positively affect body fat% 
and waist girth compared to non-exercising control groups. 
The greatest difference in LBM change reported between groups is 1kg (Herrero et al. 2006). 
Reasons for this low magnitude change may be due to a number of reasons. Firstly, breast cancer 
survivors are predisposed to LBM loss (Harvie 2010), thus maintenance or small increments may 
be considered a clinically significant outcome. Secondly, dietary intake has been inadequately 
assessed in the current studies. The lack of focus on supportive anabolic nutrients in breast cancer 
trials may have confounded changes in LBM or general body composition. Finally, volume of 
exercise protocols may have been too low to achieve a greater magnitude of change, i.e. > 3 
sessions/week may have produced more consistent results (Rhea et al. 2003). However, lower 
volumes of resistance exercise (120min/week of resistance training)(Schmitz, Ahmed, et al. 2005) 
have been shown to elicit desirable body composition changes, i.e. a decrease in body fat% and 
increase in LBM.  
 
In breast cancer survivors, body fat% has been most effectively reduced by supervised and/or 
objectively monitored aerobic exercise both during and after chemotherapy. Resistance training 
alone and combined aerobic and resistance training may increase LBM and reduce body fat% 
simultaneously, which is considered the optimal outcome for these individuals.  
 
Preliminary findings have shown that exercise training may positively affect treatment with AIs as 
they modify hormonal profiles to be more androgenic (Winters-Stone et al. 2011). Greater 
reductions in body fat% as a result of exercise training may  occur in those: with later stage both 
(during and after treatment)(Courneya et al. 2007, Irwin, Alvarez-Reeves, et al. 2009); older than 
56yrs; non-obese; and those on endocrine therapy(Irwin, Alvarez-Reeves, et al. 2009)..  
Limitations of the current literature are the lack of premenopausal women included in trials, and for 
those with differing disease stages and ages. In addition, studies should be focused both during and 
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 immediately after treatment as this may be the time where most effect can be created (Makari-
Judson, Judson, and Mertens 2007). 
 
Finally, and more practically, women are more likely to have greater relative gains in strength than 
increases in LBM cross-sectional area (Hubal et al. 2005). Cardiorespiratory and muscle function 
(strength/endurance) can increase by up to 18-20% and 60%, respectively, post intervention. 
Improvements in cardio-respiratory fitness, independent of body weight change, are associated with 
better quality of life (Ingram, Courneya, and Kingston 2006) in breast cancer survivors, and reduced 
risk of cardiovascular disease and diabetes in non-breast cancer populations (Arsenault et al. 2009, 
Gau et al. 2010). Increased strength is associated with greater quality of life in breast (Herrero et al. 
2006) and non-breast cancer survivor populations (Dale et al. 2013, Heesch et al. 2012, Beniamini 
et al. 1997). 
Therefore, the key outcome measure considerations when determining the efficacy of an exercise 
training intervention should include:  1. Body'composition'change:'LBM'maintenance'or'growth'with'moderate'decreases'of'body'fat%'and/or'waist'girth.'2. Functional'change:'improvements'in'strength'and'or'cardiorespiratory'fitness.'
2.2.2#Body#composition#changes#after#dietary#intervention#alone#
Numerous dietary interventions exist in breast cancer populations. Similar to exercise, a vast 
majority of the interventions have been focused on or include a measure of body weight change. 
Observational studies have indicated an inconsistent relationship between body weight and fat mass 
gains and dietary energy intake (Demark-Wahnefried, 2001, Harvie et al 2004). In one study, 
weight increase was reported in the presence of a dietary energy deficit. Interventions focusing on 
energy restriction or diet quality have revealed more predictable findings in regard to weight, with 
potentially adverse effects on body composition. 
Dietary energy restriction results in total body weight loss, however it may be at the expense of 
LBM (Thompson et al 2010). Interventions focused on healthy changes to improve diet quality 
without energy restriction often achieve body weight losses of 0.5kg to 3kg (Chlebowski et al 2006, 
Saquib et al 2008, Villarini et al 2012, Hebert et al 2001), however LBM has not been reported in 
these trials. An intervention focusing on anabolic nutrients is required to better investigate LBM 
during weight loss in breast cancer populations. Nutrients with anabolic properties have not yet 
been used in a population of women who have been treated for breast cancer, and present as an 
important consideration in diet only trials. 
In all, 10 controlled trials that have assessed an element of prescribed dietary alteration and reported 
at least one outcome of body composition (Table 2.2). Six of these studies aimed for body weight 
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 loss through dietary energy restriction (N=306)(Shaw, Mortimer, and Judd 2007a, Shaw, Mortimer, 
and Judd 2007b, Djuric et al. 2002, de Waard et al. 1993, Thomson et al. 2010, Flynn and Reinert 
2010), and four studies, producing multiple articles, have evaluated the effect of micronutrient or 
food quality alteration on without prescribing energy restriction (N=5327)(Chlebowski et al. 2006, 
Saquib et al. 2008, Thomson et al. 2005, Villarini et al. 2012). Generally, studies performed after 
2003 were of high quality (Thomson et al. 2005, Chlebowski et al. 2006, Thomson et al. 2010, 
Shaw, Mortimer, and Judd 2007a, Shaw, Mortimer, and Judd 2007b, Villarini et al. 2012), and one 
was ranked as neutral quality (Flynn and Reinert 2010). Earlier studies were limited by poor 
demographic/disease selection or description (de Waard et al. 1993, Hebert et al. 2001), or lack of 
equal groups at baseline (Djuric et al. 2002).  
 
Body mass was reported in all 10 studies, body fat% as measured by DEXA or BIA was reported in 
six studies(Shaw, Mortimer, and Judd 2007b, Thomson et al. 2010, Thomson et al. 2005, Jen et al. 
2004, Flynn and Reinert 2010, Villarini et al. 2012), skin fold thickness was reported in two studies 
(Shaw, Mortimer, and Judd 2007a, Villarini et al. 2012). LBM was reported in four studies, one 
using a high quality measure (DEXA)(Thomson et al. 2010), and three others used BIA (Thomson 
et al. 2005, Villarini et al. 2012, Flynn and Reinert 2010). 
Eight of ten studies reported more postmenopausal participants (range: 64% to 100%), in addition, 
participants had completed treatment for breast cancer more than one year before trial entry in all 
but three studies (Chlebowski et al. 2006, Hebert et al. 2001, Villarini et al. 2012). Considering both 
premenopausal status (Goodwin et al. 1999, Harvie et al. 2004) and a shorter duration since 
completing therapy (Makari-Judson, Judson, and Mertens 2007) are associated with larger changes 
in body composition, studies are currently lacking to describe changes for these populations.  
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 TABLE&2.2&CONTROLLED&TRIALS&EVALUATING&DIETARY&INTERVENTIONS&ON&BODY&COMPOSITION&IN&BREAST&CANCER&SURVIVORS&
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Author,(
Year,(
Design,(
Country,(
Quality,(
Primary(
outcome!
Population! Intervention! Body(composition(and(other(outcomes! Comments!
Interventions&using&dietary&energy&restriction&(N=262)&&&de&Ward,&1993&&RCT&2&arm&Netherlands&(Ned)& &Poland&(Pol)&Multicentre&NHMRC:&II&Quality:&T&Body&composition&
N=102&(initial)&Pol:&n=48;&Ned:&n=54&Intervention:&n=59&Control:&n=43&Age:&50T69yrs&Postmeno:&100%,&&&BMI&>27kg/m2&Stage:&Not&defined&&
Duration:&3&years&follow&up&Follow&up:&3yrs&Ned,&1&yr&Pol&INT:&Dietitian&delivered&(unspecified&no.&of&sessions);&1500kCal&intake,&with&further&reduction&to&1000kCal&if&weight&loss&not&being&achieved.&CON:&Usual&care.&Had&access&to&weight&loss&advice&on&request.&Measures:&Body&weight&
Results&after&1&year&Significant&↓&in&body&weight&Overall:&INT:&T6kg,&CON:&+1kg,&P<0.001&Ned:&Weight&loss&at&3&years&was&correlated&to&weight&loss&after&1&year,&r=0.91.&
Weight&loss&at&1&year&reflected&loss&at&3&years&No&details&of&demographics.&Limited&information&re:&intervention&intensity.&No&body&composition&breakdown&60%&follow&up&at&3&years&
Djuric,&2002,&Jen,&2004&USA&&RCT&4Tarm&Quality:&O&&Body&composition&
N=48;&Age:&52.1yrs&(8.4);&Weight:&94.5&(13&SD);&Postmeno:&75%;&CTx:&63%&Current&tamoxifen:&63%;&Diagnosed&within&last&4&yrs;&coTmorbidities.&Differences&in&metabolic&biomarkers,&similar&BMI&and&weight.&&
Duration:&12&mths&WW:&Weight&watchers,&&DC:&Dietary&counsellingT2100T4200kJ&deficit&+&30min&PA/day&&WW+DC:&Weight&watchers&and&dietary&counselling&+&recommendation&to&increase&exercise&&Contact:&WW&–&weekly;&DC:&Weekly&for&12&weeks,&biTweekly&for&12&weeks&CON&:&Healthy&Eating&for&Cancer&Measures:&BIA:&Tetra&polar&Wt,&Ht,&3TDay&food&records&FACTTAn&
Significant&↓&in&body&weight&(kg)&WW:&T2.7,&DC:&T8,&WW+DC:&T9.5,&CON:&+1.1;&WW+DC>DC>WW>CON,&All&significant&to&P<0.05.&Significant&↓&body&fat%&WW:&T0.99,&DC:&T3.17,&WW+DC:&T3.65,&CON:&+0.23;&WW+DC=DC>WW=CON&WW+DC&only&group&with&significant&within&group&change.&Greater&attendance&associated&with&greater&loss;&Caloric&intake&did&not&correlate&to&results;&Benefits&for&weight&loss&and&improvements&in&TChol,&HDL;&WW+DC&↓&leptin&
Study&showing&Wt&loss&achievable&and&will&come&with&good&changes&in&CVD&markers&Time&intensive&education&to&achieve&results.&Body&fat%&change&indicate&significant&loss&of&LBM&by&deduction&PA&measure&lacking&sensitivity&
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  Shaw,&2007&&RCT,&2Tarm&UK&Quality:&+&NHMRC:&II&&Arm&volume&
N=21;&Age:60yrs&(median);&BMI:&32&(mean);&Time&since&Dx:&>1yr;&BMI&>25&&No&differences&between&groups&&
Duration:&12&weeks&INT:&Dietitian&delivered.&4200kJ&deficit&from&habitual&diet,&all&diets&>4200kJ/d.&↓&refined&CHO&and&↓&high&fat&foods.&CON:&Healthy&eating&guidelines&Exercise&not&discussed&Contact:&Monthly&Measures:&skinfolds&(4Tsite),&Wt,&Ht,&7Tday&food&diary,&Arm&volume,&&Waist,&Hip&Bloods:&TG,&TChol,&Carotenoids,&Insulin&3Tday&food&diaries&&
Significant&↓&in&body&weight&(kg)&INT:&T3.3,&CON:&0.0,&P=0.02&No&significant&change&in&skinfolds&(mm)&INT:&T5,&CON:&2.5,&P=0.426&Arm&volume&(ml)T&affected&arm:&T350&vs.&T11,&P=0.003&Correlation&of&weight&loss&and&change&in&arm&volume:&R=0.513,&P=0.017&
Weight&reduction&was&effective,&without&a&significant&reduction&in&skinfolds.&No&record&of&LBM&change.&Weight&reduction&was&correlated&to&reductions&in&arm&volume.&No&record&of&PA&or&encouragement&Generalisable&to&without&lymphoedema?&Long&enough&for&an&effect&&
Shaw,&2007&&RCT,&3Tarm&UK&&Quality:&+&NHMRC:&II&&Arm&volume&
N=51&Age:&69yrs:Lymphoedema:&100%;&Diff&in&arm&volume:&44%&BMI:&29&(mean)&Time&since&Rx:&>12mth,&+/T&hormonal&Rx&&&
Duration:&6&months&INTTWeight&Reduction&(WR):&Dietitian&delivered.&4200T5050kJ&energy&deficit&INTTLow&Fat&(LF):&<20%&of&energy&from&fat&CON:&Continue&eating&habits&Exercise&not&discussed&or&measured&Contact:&Unknown&Measures:&skinfolds&(4Tsite),&Ht,&Wt,&7Tday&food&diary,&Girth&of&swollen&limb& &Perometry&&
Significant&↓&in&body&weight&(kg)&INTTWR:&T4,&INTTLF:&T2.6,&CON:&T0.6&Diff&between&groups,&P=0.006&Significant&↓&in&body&fat%&INTTWR:&&T2.8,&INTTLF:&T1.4,&CON:&T0.4,&Diff&between&groups,&P=0.017&No&significant&difference&in&change&of&excess&arm&volume&Weight&reduction&had&a&significant&effect&on&reduction&of&swollen&arm&(irrespective&of&dietary&group)&Spearman&rank&0.423,&P=0.002&
Skinfolds&in&overweight/obese.&Weight&loss&successful&for&↓&in&refined&CHO&and&high&fat&foods.&Adherence&to&diet:&42%&and&59%&for&weight&loss&and&low&fat.&All&but&1&lost&weight&in&weight&loss&group.&Intention&to&treat&analysis.&
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Interventions aiming for weight stability and macro/micronutrient alteration (N=5327) 
Chlebowski, 
2006 RCT 2-arm 
USA 
Quality: +  
NHMRC: II 
BrCa survival 
 
N=2437; INT: 975, 
CON: 1462. Data for 
BMI @ Baseline: 
N=2381 Yr 1: N=1985; 
Yr 3: N=1581; Yr 5: 
N=847 
Final; White: 84.75, 
time since Dx: <1yr, 
Menopausal: N/A; 
Stage I-IIIA; CTx: 
52.4%; T2DM: 5%; 
BMI>26: 54.1% 
Follow up 5 years INT: 
Reduce fat to 15%. Individual 
fat gram goal 8 x 1hr Dietitian 
sessions, plus f/up every 3 
months. Isoenergetic intake 
with less fat CON: General 
healthy eating, nutritional 
adequacy of vitamins and 
minerals only Measures: Wt, 
Ht 
Significant  in weight for INT Mean 
difference b/w INT & CON: Yr 1: -
2.3kg, p<0.05; Yr 3: -1.8kg, P<0.05; Yr 
5: -2.7kg, P<0.05. INT:  Relapse free 
survival, 24%, P<0.05 Recurrence 
free survival, 29%, P<0.05  Disease 
free survival, 19%. P<0.05 No 
difference in survival 
 
Weight loss not an aim, saw significant 
reduction in weight at 1, 3, 5yrs. Significant 
attrition. Results strongest for ER-ve status 
WHEL 
Saquib, 2008 
Thomson, 2005 RCT 
2-arm Multicentre 
USA 
Quality: +  
NHMRC: II 
BrCa Survival 
 
N=2718 53.4yrs (26-
74) BMI: 27.3kg/m2 
(57% OW); Race: 85% 
white; Stage III: 4,2% 
Thomson (subset) N=52 
– means of groups 
Age: 55.9 & 52.3yrs, 
Race: 100 % 90% 
white; Menopause: Pre: 
9.5, Peri: 14.3, Post: 
76.2; time since Dx: 
<4yrs 
No sig diff b/w groups 
4 yrs ongoing INT: 5 
vegetable serves, 450ml 
vegetable juice, 3 fruit serves, 
30g fibre, and 15-20% energy 
from fat. Telephone 
counselling, cooking classes 
and newsletters. CON: print 
materials with general healthy 
eating tips (Source: US Dept 
Agriculture) Common 
Measures: Wt, Dietary: 4 x 
24hr dietary recalls, PAQ 
Thomson: BIA, Waist, Hip 
(6, 12, 48mths) 
Significant  body weight (kg) at 1-yr 
1-year: INT: -0.05, CON: 0.71, 
p<0.0001 4-yr: INT: +1.77, CON: 
+1.43, NS Thomson (N=52) Trend for 
 body weight @ 48mths 
(RMANOVA) INT: +0.73kg, CON: 
+1.93kg, P=0.1 No sig diff among time 
points, P=0.32 Significantly lower body 
fat% over time (baseline, 6mth, 
12mth) INT: Bline: 31.6%, 6m: -1.5, 
12m: +1.04 CON: Bline: 31.1%, 6m: -
0.1, 12m: +2.27 Sig diff among time 
points, P=0.04 Significantly  LBM 
(kg) for INT group Mean change: INT: 
-0.62kg, CON: +0.64kg P=0.048 No 
difference in body fat% or waist girth 
change at 48 months between groups 
Body fat% was lower in INT after 6mth, but not 
after 48mths. Mean change in LBM over 
48mths was reduced in INT group. 
Changes are within limits for BIA. Different 
mean weight changes compared to larger 
population. 
Total energy intake did not decrease, despite 
energy density decreasing 
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Hebert, 2001 
 RCT 3 arm  
Quality: O   
NHMRC: II  
Body  composition  
 
N=172, N=157 final;   
Postmeno: 63.1%,  
Time since Dx:  
<12mth: 61.2%.  Stage 
I-II   20-65yrs; CTx: 
Ever:  61.2% (During:  
14%)  
No difference  between 
groups  
Duration: 4mth, 12mth f/up  
SRC: Mindfulness stress 
reduction.   NEP: 2 
individuals + 14 x 150 minute 
group  sessions + 1 full-day 
(5.5 hr) workshop. Diet 
contained: 20% fat, high  
fibre - education and support. 
Weight  loss not a priority.  
CON: given free choice   
Measures: 7Day diet recall- 
FFQ, Beck Anxiety  Index, 
BDI, Self-esteem, Symptom 
checklist  
Significant ↓ in body weight @ 4 mth  
NEP: -2.4kg, SRC: 0kg,CON: +0.2kg, 
P<0.05 NEP vs SRC & CON  No 
significant change @ 12mth  NEP: 
+0.1kg, SRC: +0.4kg, +0.5kg, P>0.05  
Those with higher expectation of NEP  
outcomes performed better than those 
with  low outcomes.  
Class attendance did not affect weight 
loss  
Healthy eating with no weight loss goal  
reduced weight over 4 mths but not 12  months.  
Expectation of randomisation did not affect  
outcomes  
Villarini,  2012   
RCT 2 arm  Milan, 
Italy  
NHMRC: II   
Quality: +ve  
Body  composition  
  
Invasive BrCa,  
Scheduled for CTx,  no 
metastases,  Milan, 
n=96  INT: Age: 52.7  
(10.8), Ht: 1.61  (0.07), 
Wt: 63.8  (11.8); BMI: 
24.7  (4.5); BP: 128, 
DBP:  82.4  CON: Age: 
48.4 , Ht:  1.63, Wt: 
64.7, BMI:  24.7, SBP: 
131, DBP:  85.6  
Start to finish of adjuvant 
chemotherapy   
INT: Cooking classes and 
common meals twice  per 
week  Macrobiotic diet – rice, 
millet, spelt, barley,  corn, 
pulses, vegetables, fermented 
soy, tofu,  seaweeds, fish and 
sugar/fat free desserts,  fruit, 
wine, cheese, yoghurt, eggs 
and meat   
CON: Given baseline 
education from INT group,  
and information on reducing 
side effects of  cancer  
Measures: Time point (TP) 1-
Bline, TP2-end of  1st cycle 
and TP3-end of CTx  Waist 
and hip, weight  BIA, 
skinfolds (4-site); 39-item 
food frequency  
Significant decrease in weight for INT 
group compared to control   
Weight    
TP1 to TP2: INT: -2.7kg, CON: -1.4kg, 
p=0.06   
TP1 to TP3: INT: -2.9kg, CON: -0.1kg, 
p=0.00   
LBM   TP1 to TP2: INT: -0.8kg, CON: 
-0.7kg, p=0.45   
TP1 to TP3: INT: -0.7kg, CON: +0.1kg, 
p=0.01   
Fat mass TP1 to TP2: INT: -2.6kg, 
CON: -1.4kg, p=0.32   
TP1 to TP3: INT: -2.3kg, CON: -0.7kg, 
p=0.03   
Waist: TP1 to TP2: INT: -2.7cm, CON: 
-1.5cm, p=0.05   
TP1 to TP3: INT: -3cm, CON: -0.1cm, 
p=0.01   
Hip: TP1 to TP2: INT: -1.4cm, CON: -
1.5cm, p=0.23   
TP1 to TP3: INT: -1.7cm, CON: 
+0.1cm, p=0.03  
Healthy diet information to both groups  may 
have influenced results, as CON  decreased 
weight and fat mass.  Extremely high retention 
rates.Weight gain is minimal on anthracyclines,  
but most notable on CMF, where the  weight 
gain was only seen in non-dietary  arm.  Some 
LBM lost, ~30% of total weight lost.  
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Flynn, 2010 
Cross-over RCT 2-
arm 
USA 
NHMRC: II 
Quality: O 
 
Different effects of 
diet 
N=44 (20 completed 6 
months); 59.2yrs (52-
73); BMI: 
27.9+2.8kg/m2, Body 
fat%: 41.6+4.6, LBM: 
58.6+5.1% 
No data given on other 
demographic 
categories. No ITT 
 
8 week interventions for each 
diet – order randomised. 
Diet 1: Plant based Olive oil 
(PBOO) 1500cal; unlimited 
veg; 3 tbsp of olive oil/day, 3 
servings of fruit, 6oz/week 
poultry, 8oz/week seafood. 
Mainly vegetarian meals. 
National Cancer Institute 
(NCI) diet: 25-50g fat; 
unlimited F&V minimum (5 
serves/day); 7oz of meat, 
Canola oil provided for 
cooking. 
Measures: Ht, Wt, BIA, waist 
hip girth.Bloods: TG, Chol, 
Carotenoids, Insulin, 3-d food 
diary 
Significant ↓ body weight (kg) for 
PBOO vs NCI: PBOO: -3.6kg vs -
2.7kg, p=0.05,  
No significant difference in %LBM 
change 
PBOO: +1.9% vs NCI: +1.1%, p=0.12 
No significant difference in body fat% 
change: PBOO: -1.9% vs NCI: 1.4%, 
p=0.28 
No significant change in waist girth: 
PBOO: -3.4 vs NCI: -2.6, p=0.25 
 
PBOO diet was more efficacious for weight loss 
than a standard low fat diet despite energy intake 
being greater for the PBOO diet.  
The PBOO was more palatable, more likely to 
be chosen for the 6 month follow up. 
 
No absolute value of LBM was given making 
body composition change difficult to interpret 
 
Limited demographical information given. 
 
 
Wt: Weight; Ht: Height; BMI: Body mass index; LBM: Lean body mass; aLBM: appendicular LBM; OW: Overweight; BIA: Bioelectrical impedance; Postmeno: 
Postmenopausal; CRP: C-reactive protein; HOMA: Homeostasis Assessment Model; TChol: Total Cholesterol; PA: Physical activity; PAQ: Physical activity 
questionnaire; RER: Respiratory Exchange Ratio; CHO: Carbohydrates; FACT-An: Functional Assessment of Cancer Therapy-Anaemia subscale; CTx: 
Chemotherapy; PBOO: Plant based olive oil diet; TP: Time point; INT: intervention group; CON: Control group; BrCa: Breast Cancer
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 Dietary interventions evaluating the effects of dietary energy restriction on body composition 
All six studies that prescribed a dietary energy restriction have reported statistically and clinically 
significant reductions in body weight for intervention groups. Significant reductions in body fat% 
were generally consistent within studies when they were reported. Prescribed daily energy deficits 
ranged from 2100kJ to 5050kJ in five studies (Shaw, Mortimer, and Judd 2007a, Shaw, Mortimer, 
and Judd 2007b, Djuric et al. 2002, de Waard et al. 1993, Thomson et al. 2010), while one delivered 
a standard 6250kJ (1500Cal) per day (Flynn and Reinert 2010). To date, no trials have targeted 
specific nutrients that may preserve LBM, the major focus of published studies thus far have been 
on total body weight loss. 
 
After a body weight loss of ~6kg (5.9kg and 6.3kg for the two intervention groups, respectively), 
LBM was significantly reduced after 6 months energy restriction in one high quality study 
(Thomson et al. 2010), while a neutral quality study reported no change in LBM after 8 weeks of 
energy restriction, however no data was shown (Flynn and Reinert 2010). The high quality study by 
Thomson et al (2010) reported that prevalence of myopenia, defined by an appendicular LBM 
(aLBM) measurement of <5.67kg/m2, increased from 8% to 18% for the entire study population 
(both groups on energy restricted diets) (Thomson et al. 2010). Considering the predisposition for 
loss of LBM in this population, exacerbation of this loss is not considered an optimal result. In a 
healthy population of postmenopausal women, higher dietary protein was correlated with reduced 
losses of LBM and appendicular (aLBM) even after controlling for exercise (Easter et al. 2008), 
however associations between protein intake and LBM change were not reported for this study due 
to inadequate power (Thomson et al. 2010). 
 
 
Over the six studies, reductions in body weight ranged from 2.6kg to 9.5kg, and were achieved over 
a range of 8 to 52 weeks. Longer studies with follow up of 6 months or more were those that found 
the greatest losses in body weight >6kg (Thomson et al. 2010, de Waard et al. 1993, Djuric et al. 
2002).  Individuals within intervention groups were typically contacted weekly for the first 8 to 12 
weeks, with a decrease in contact over time. Regularity of contact had little influence on magnitude 
of weight loss, however Jen et al (2004) identified that participants exposed to dietitian-led dietary 
education and a Weight Watchers program, those participants lost significantly more weight than 
the dietitian-only group, which in turn was better than the weight watchers program alone (Jen et al. 
2004). Considering Weight Watchers was continued weekly for the duration of the study, and the 
dietitian-led education was reduced after the first 12 weeks, there may be an advantage to more 
regular contact throughout the dietary change process. 
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Two studies compared groups exposed to identical energy restrictions that differed in macronutrient 
profile with differing findings. Thomson et al (2010) reported comparable results for low 
carbohydrate versus a low fat dietary prescription over 6 months (i.e. 5.9kg and 6.3kg, respectively) 
(Thomson et al. 2010). Flynn et al (2010) reported a significantly greater reduction in body weight 
for those allocated to a Mediterranean dietary pattern that was higher in fat, and lower in protein 
and carbohydrate diet (PBOO) than one based on the National Cancer Institute guidelines (NCI) 
(Flynn and Reinert 2010). The greater weight loss in the PBOO group occurred even though dietary 
recalls indicated a lower daily energy intake in the NCI group (~6100kJ and 4773kJ, respectively). 
Unstructured subjective data indicated the PBOO diet provided greater palatability, satiety and ease 
of preparation, meaning greater reductions in body weight may have been a result of better 
adherence to the diet, rather than macronutrient profile.  
 
As expected in trials that elicited significant reductions in total body weight, a significant decrease 
in measures of body fat% was found in three studies that reported a measure of adiposity (Thomson 
et al. 2010, Jen et al. 2004, Shaw, Mortimer, and Judd 2007b), while one reported no difference 
compared to control (Shaw, Mortimer, and Judd 2007a). Change in waist girth was clinically and 
statistically significantly reduced in the one trial that reported it (Thomson et al. 2010) 
Limitations in studies reporting body composition change after dietary intervention stem from the 
lack of high quality body composition measures, plus four studies lacked appropriate control for 
physical activity to determine it’s role in body composition change (Shaw, Mortimer, and Judd 
2007a, Shaw, Mortimer, and Judd 2007b, Jen et al. 2004, de Waard et al. 1993).  
 
Cardiovascular and metabolic syndrome related outcomes after dietary intervention 
While body weight loss may result in LBM loss, biomarkers of cardiovascular and metabolic health 
were improved. Thompson et al (2010) noted a trend for reduced CRP after weight loss and 
improvements in HbA1c and triglyceride levels in the low carbohydrate group. Shaw et al (2007a & 
2007b)(Shaw, Mortimer, and Judd 2007a, Shaw, Mortimer, and Judd 2007b) noted a correlation for 
weight loss and reduction in arm volume in a population with lymphoedema, and Jen et al (2004) 
reported significant improvements in total cholesterol, HDL cholesterol and leptin levels after 
weight loss (Jen et al. 2004). 
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 Summary of findings from dietary energy restriction interventions 
It is evident from current knowledge that body weight loss and reductions in body fat% are 
achievable in breast cancer survivor populations after dietary energy restriction. This is important, 
as prospective data has indicated a limited role for dietary intake in treatment related weight gain 
(Demark-Wahnefried et al. 2002). However, body weight loss may occur at the cost of clinically 
significant and detrimental losses of LBM (Thomson et al. 2010). Further studies are needed to 
confirm changes in LBM after diet-induced weight loss, and to determine if the resulting improved 
metabolic profile in breast cancer survivors is more beneficial than the potential detriment of 
significant LBM loss. Successful studies have involved frequent contact with a dietitian as 
individuals or groups, with potentially better results to come from continued frequent contact. 
Dietary interventions prescribing a change in dietary pattern without energy restriction 
Change in diet quality, or an increase in specific nutrients may be of benefit to mortality and 
morbidity following treatment for breast cancer. The following dietary interventions have aimed to 
modify dietary quality as opposed to overall energy consumption. These studies have typically 
elicited small albeit clinically relevant changes in weight. 
Dietary interventions that have focused on altering dietary quality or dietary pattern without energy 
restriction have resulted in a trend to decrease body weight  (0.5kg to -3kg) over time. There are 
two distinct categories of controlled trials that have prescribed dietary pattern changes without 
energy restriction: survival studies (Chlebowski et al. 2006, Saquib et al. 2008) and short duration 
dietary interventions (Hebert et al. 2001, Villarini et al. 2012).  
The WINS (N=2437)(Chlebowski et al. 2006), and WHEL (N=2718)(Saquib et al. 2008) studies 
prescribed a reduced total dietary fat (15% of total energy intake), and reduced total dietary fat (15-
20% total energy intake) and increased vegetable intake (>10 serves per day), respectively. Both 
studies aimed to assess the impact of diet on breast cancer survival. The studies ran for five and four 
years, respectively, and compared to control groups, both noted a small yet significantly lower body 
weight  (-2.7kg, p<0.05 & -0.05kg, p<0.001, respectively) for intervention groups after one year 
follow up. However, only the WINS study reported long-term maintenance of this difference (5-
year follow up). The WINS study resulted in a significant reduction in total energy intake, which 
explained the sustained weight loss for the intervention group (Chlebowski et al. 2006). In contrast, 
findings from the WHEL study indicated that overall energy density was reduced but the energy 
content of the greater intake of fruits and vegetables compensated in the intervention group 
compensated for this and may explain the lack of clinically significant weight change (i.e. -0.05kg) 
throughout follow up (Saquib et al. 2008). 
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 Thomson et al (2005) reported change in LBM and body fat%, as measured by BIA, in a subset 
(N=52) of the WHEL study population (Thomson et al. 2005). Compared to control, LBM was seen 
to significantly decline in the intervention group (+0.64kg vs -0.62kg, p=0.048) over 48 months of 
follow up. Body fat% gains were attenuated in the intervention compared to control after 6 months, 
but not 48 months. No such measure was taken in the WINS study. Of note, the WINS study 
reported benefit in the intervention group for relapse and disease free survival reporting a 65% 
attrition rate over 5 years. The study indicated a benefit for relapse, recurrence and disease free 
survival in the intervention group, and this was thought to be a result of the difference in weight 
change as opposed to the total fat restriction (Chlebowski et al. 2006). 
 
In contrast to the two large trials of long duration, Villarini et al(Villarini et al. 2012) and Hebert et 
al(Hebert et al. 2001) conducted shorter term dietary interventions (three & four months, 
respectively) with smaller sample sizes, which differed in dietary prescription. However both 
reported significant short term reductions in body weight for intervention groups (-2.7kg vs -
1.4kg(Villarini et al. 2012); & -2.7kg vs +0.2kg(Hebert et al. 2001). Herbert et al (2001)(Hebert et 
al. 2001) compared the effect of a dietitian-led nutrition program (NEP), with a mindfulness based 
stress reduction clinic program and a usual care control after completion of treatment. Villarini et al 
(2012) prescribed a diet based on Mediterranean and macrobiotic diet principles through 
chemotherapy with ongoing cooking classes, compared to a baseline cooking class for the control 
group. Only Villarini et al (Villarini et al. 2012) reported a significant a difference between groups 
after longer follow up, -2.9kg vs 0.01kg & +0.1 vs +0.5kg, respectively.  
 
Compared to control, Villarini et al (2012) reported a significant loss of LBM (mean difference: -
0.8kg, p<0.01) and body fat% (mean difference: -1.6%, p=0.03) for the intervention group at the 
final time point (Villarini et al. 2012). 
Change in energy intake reported by Hebert et al (2001) (-280kJ/day) only explained 40% of the 
total weight loss over 3 months, and did not differ from control groups. On the other hand, while 
Villarini et al (2012) did not report energy intake, a previous study using the same dietary protocol 
indicated a reduction in energy intake of 1000kJ per day as a result of the reduced energy density 
created. This may explain the 2.7kg weight loss over 4 months (Berrino et al. 2001) The small but 
significant loss of LBM found in intervention groups that reported significant weight 
loss(Chlebowski et al. 2006) is noteworthy due to the heightened propensity for LBM loss in breast 
cancer survivors (Thomson et al. 2010).  
 
42
 Dietary interventions that have aimed for dietary pattern change without energy restriction have 
reported an initial weight loss with mixed results in regards to long term follow up. The magnitude 
of the weight loss was <3kg amongst all studies at all time points. In contrast, for the two studies 
that reported LBM change, both reported reductions in LBM as part of the weight lost. However, 
these findings are limited by the use of BIA as body composition measurement. Considering that 
LBM loss and cancer related muscle wasting is not a good outcome for women after treatment 
(Thompson et al 2010), interventions should focus on anabolism of LBM and concurrent fat mass 
reduction, through either anabolic nutrients like increased and specific protein intake, or the 
addition of exercise.  
Summary of controlled trials evaluating the effects of diet on body composition 
LBM losses are common in non-cancer populations during diet-induced weight loss, the specific 
population of breast cancer survivors may be more adversely affected due to their pre-existing 
propensity to lose LBM in the absence of overall weight loss (Harvie 2010, Demark-Wahnefried et 
al. 2001) Compared to control groups, both energy restricted dietary prescription, and diets 
prescribing specific foods without energy restriction, result in body weight losses of >6kg, and 0.05 
to 2.9kg, respectively. Interventions targeting weight loss through energy restriction elicited greater 
change than those that only looked to alter dietary pattern without restriction.  
 
Interventions aimed at maintaining LBM should be considered in breast cancer populations. 
Anabolic adjuncts to energy restriction should be a consideration to limit the amount of LBM loss. 
Finally, limitations to the current data are the under-representation of premenopausal populations, 
and to date no study has attempted to delineate differences between the responses of pre- and 
postmenopausal women. Considering premenopausal women are often at higher risk of weight gain 
after treatment, including them in future studies would be valuable for overall breast cancer 
management. 
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 2.2.3$Controlled$trials$assessing$the$effect$of$combined$exercise$and$dietary$
interventions$on$body$composition$$
The combination of exercise and dietary prescription may be the most effective intervention to elicit 
body weight and body fat reduction while concurrently maintaining or increasing LBM. The 
previous sections have indicated that: exercise alone contributes to LBM gains and body fat 
reduction, and this occurs in the absence of body weight change; and, dietary energy restriction is 
related to significant reductions in body weight, however, the concurrent loss of LBM places 
women at greater risk of myopenia. The following review focuses on studies that have evaluated the 
effect of concurrent nutrition and exercise prescription. All studies that included a measure of LBM 
have reported maintenance (see Table 2.3), and compared to control, a reduction in body fat% and 
body weight have been observed (Djuric 2011, Demark-Wahnefried et al. 2008, Mefferd et al. 
2007).  
 
Of the eight published studies that combined nutrition and exercise prescription in populations with 
cancer, six have investigated the effects solely in breast cancer survivors (Demark-Wahnefried et al. 
2008, Mefferd et al. 2007, Harris et al. 2012, Pakiz et al. 2011, Scott et al. 2013, Djuric 2011); one 
of which reported but was not powered to detect change in body composition (Djuric 2011); and 
two studies reported weight and BMI changes in survivors of mixed cancer diagnoses (Morey et al. 
2009, Demark-Wahnefried et al. 2007). The mixed cancer population studies did not separate 
results for breast cancer populations. In addition, body composition data was limited to body weight 
and BMI only, thus this review will focus on the six controlled trials exclusively focused on breast 
cancer populations. These studies are comprised of three high quality (Demark-Wahnefried et al. 
2008, Harris et al. 2012, Pakiz et al. 2011), and three neutral quality studies (Mefferd et al. 2007, 
Scott et al. 2013, Djuric 2011) (Table 2.3).  
 
For those studies that included a measure of LBM, no differences were seen in LBM change within 
or between groups, regardless of total body weight change (Mefferd et al. 2007, Demark-
Wahnefried et al. 2008, Djuric 2011). Mefferd et al (2007) reported no change in LBM in both 
groups measured by DEXA, while the intervention group lost total body weight (-5.7kg) and body 
fat (-5.5%) (Mefferd et al. 2007). Demark-Wahnefried et al (2008) reported no change in LBM for 
any group, however the exercise plus high fruit and veg/low fat diet group gained significantly less 
body fat% than the exercise alone and control groups (Demark-Wahnefried et al. 2008). Djuric et al 
(2011) indicated a non-significant trend for LBM increase, and body fat% decrease for the 
intervention group (Djuric 2011). However the study was not powered to detect body composition 
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 changes. Furthermore, the exercise training protocols in all studies were focused on aerobic exercise 
and very light weight resistance training, thus LBM increases were not expected.  
 
Differences in study design may explain these discrepancies in body fat% and body weight changes. 
Firstly, Mefferd et al (2007) coupled a 2000-4000kJ dietary energy restriction with home-based 
aerobic and supervised resistance exercise training (Mefferd et al. 2007). In contrast, Demark-
Wahnefried et al (2008) did not prescribe an energy restriction and exercises were performed 
unsupervised. As seen in exercise-only controlled trials, supervised exercise interventions are more 
likely to be successful in creating body composition change. Mefferd et al (2007) included mainly 
postmenopausal women who finished treatment 3.5 years previous, while Demark-Wahnefried et al 
(2008) included only pre-menopausal women going through chemotherapy. Compared to 
postmenopausal women, premenopausal women who have been treated for breast cancer tend to 
gain more weight (Goodwin et al. 1999). In addition, chemotherapy has been shown to be 
associated with a reduction in sport related exercise (Irwin et al. 2005).. However, Courneya et al 
(2007) reported that exercise can elicit significant body composition changes during chemotherapy 
with supervised progressive resistance training. 
 
Thompson et al (2010) reported clinically significant loss of LBM after dietary energy restriction 
alone. That Mefferd et al (2007) and Djuric et al (2011) observed concurrent body fat reduction and 
LBM maintenance indicates that the addition of exercise training to a dietary energy deficit is an 
important clinical consideration for optimal body composition outcomes.  
 
For studies prescribing an energy deficit through diet, the magnitude of differences in body weight 
loss between intervention and control groups ranged from -0.85kg to -5.5kg (Mefferd et al. 2007, 
Pakiz et al. 2011, Scott et al. 2013, Harris et al. 2012). Differences between studies seem to be 
related to the amount of exercise that was prescribed. A greater magnitude of weight loss was 
reported in trials that prescribed >300min/week (-5.5kg) (Mefferd et al. 2007, Pakiz et al. 2011), 
compared to 150min/week (-3.3 to -4kg) (Harris et al. 2012), which in turn was greater than those 
that prescribed 120-135min/week (-1.09kg) (Scott et al. 2013). In contrast, Demark-Wahnefried et 
al (2008) who prescribed a high fruit and vegetable low-fat diet without energy restriction did not 
report any significant weight loss between groups. A lack of body weight loss for these intervention 
groups could be explained by a lower amount of exercise prescribed (>30min of AET, >3 
times/week plus RET with therabands every other day), and adhered to (adherence: 43% and 26% 
for calcium plus exercise and high fruit and vegetable intake, and calcium plus exercise alone, 
respectively) (Demark-Wahnefried et al. 2008).  
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 Djuric et al (2011) specifically prescribed a tailored a weight maintenance diet and therefore the 
<1kg change in 12 months would suggest adequate adherence to this prescription. However, the 
intervention group experienced a substantial within group decrease in waist girth at 6 months (-
7.6cm), which was attenuated slightly at 12 months (-3.5cm) (Djuric 2011). The two other studies 
that reported waist girth change, compared to the control group, both reported statistically 
significant reductions for the intervention group (Scott et al. 2013, Harris et al. 2012, Djuric 2011). 
Scott et al (2013) reported a significant reduction in body weight and waist girth in the absence of 
body fat% change; while Djuric et al (2011) noted this but only for weight change within the 
intervention group. Therefore, it could be speculated that exercise preferentially targets abdominal 
fat, and the effect on the body is to increase muscle while fat is reduced. This effect makes physical 
activity important to interventions aiming to improve body composition. 
 
A large limitation for all of these trials was the consistent lack of detail in describing the aerobic 
and resistance exercise programs. For the aerobic protocols, no detail of target workloads and 
intensity were given other than a simple outline, e.g. moderate activity for 60 minutes per day. 
Similarly, little description of resistance training interventions were given such that frequency, 
intensity and time were not made clear in the manuscript. Finally, control group protocols differed 
with one study providing written diet and exercise education materials (Djuric 2011), three offered 
no exercise and dietary energy intake advice (Mefferd et al. 2007, Pakiz et al. 2011, Scott et al. 
2013, Demark-Wahnefried et al. 2008), one compared a telephone versus in-person group delivery 
using similar exercise and dietary recommendations (Harris et al. 2012), and one did not indicate 
any procedures for the control group (Scott et al. 2013). 
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 TABLE&2.3:&STUDIES&EVALUATING&EFFECTS&OF&DIET&AND&EXERCISE&INTERVENTION&ON&BODY&COMPOSITION&Author,&Yr,&Quality& Design& Population& Intervention& Body&composition&and&adherence&outcomes& Comments&Demark&Wahnefried,&2008,&USA&&Quality:&+&NHMRC:&II&&Secondary&outcome&
3Uarm&RCT& N=90;&Age:&41.8&(5/6)&yrs;&Time&since&Dx:&Receiving&CTx&currently&Causasion:&85%;&BMI:&25.8kg/m2;&Chemotherapy:&100%;&Premenopausal:&100%;&Taxane:&52%&
6&months,&phone&delivered;&14&x&10U30min&sessions.&From&2nd&cycle&of&chemotherapy.&CaEx:&Calcium&rich&diet&+&Exercise&&CLFEx:&Calcium&+&Low&Fat&+&high&Fruit& &Vegetable&+&Ex&&CON:&Calcium&attention&control&&Exercise:&HomeUbased:&AET&>30min,&>3/wk&(HR&monitor,&pace&tapes);&RET:&Every&other&day&–&therabands&Diet:&Low&fat:&<20%&energy&as&fat;&High&Fruit&and&veg:&>5&serves/day.&Calcium:&1200U1500mg/day;&&Measures:&&Baseline&and&6Umonths.&Wt,&DEXA,&Dietary&intake&(FFQ),&Physical&activity,&QOL,&HADS&
No&difference&in&weight&change&between&groups&CaEx:&+2.3kg,&CLFEx:&+0.3,&CON:&+1.7&–&p>0.05&&Significantly&less&body&fat%&gains&for&CLFEx.&&CaEx:&+1.7,&CLFEx:&+0.2,&CON:&+1.1,&P<0.05&(compared&to&group&1& &3,&when&trunk&fat&not&included).&No&difference&in&LBM&change&between&groups&CaEx:&U0.98,&CLFEx:&U0.29,&CON:&+0.69,&P>0.05&&Attrition:&8.8%&Adherence&to&exercise:&CLFEx:&43%,&CaEx:&26%&
Lean&body&mass&not&affected&by&intervention.&NonUtrunk&fat&mass&may&decrease&with&low&fat,&high&fruit&and&vegetable&+&exercise.&RET&may&not&have&been&hard&enough&to&elicit&change,&Calcium&may&have&protein&preserving&effect&reducing&effect&compared&to&control.&Not&initially&powered&to&detect&changes.&
Mefferd,&2007,&USA&&NHMRC:&II&Quality:&O&&Primary&outcome&
RCTU&wait&list&control& N=76;&Age:&56.3&(8.2)&yrs;&BMI:&31.0&(4.2);&Time&since&Dx:&3.5yrs&(<1U14yrs);&Caucasian:&93%;&Postmenopausal:&84%;&Stage:&IUIIIA&
16Uweek&intervention&&INT:&Weekly&inUperson&meetings&for&16&weeks&+&phone&calls.&Then&1/month&for&6&months&&&&&&&&&&&Diet:&500U1000kcal/day&energy&restriction&+&Exercise:&AET&up&to&1Uhr/day&+&a&goal&of&2U3/wk&RET&supervised&(group).&SelfUdirected&goals&and&motivation.&Measures:&Baseline&and&16&weeks&DEXA,&7Uday&PAR,&Lipids,&No&diet&history&
↑&weight&loss&for&INT&INT:&U5.7kg&(6.8);&CON:&U0.5kg&(0.6),&P<0.05&↑&loss&of&body&fat%&for&INT&INT:&U5.5&(U15),&CON:&U1.4&(U3.5),&P<0.01&No&change&in&LBM&for&either&group&INT:&+0.1kg,&CON:&0.&Leg&and&trunk&fat&decreased&in&INT&group&&>80%&attendance&to&sessions&&
Significant&fat&mass&loss&with&no&loss&of&LBM.&Population&may&not&be&experiencing&myopenia&that&long&after&treatment.&&No&data&on&adherence/&progression&of&exercise/&type&of&resistance&training&&Pakiz&Italy,&2012&&NHMRC&II&Quality:&+ve&&Primary&outcome&&&&&
2Uarm&RCT&2:1&INT:Con&& N=85&INT:&n=56&vs&CON:&n=29&Stage&IUIIIa&Dx:&within&last&14&yrs;&Age:&33U71yrs&Caucasian:94%,&&&
12&month&intervention&INT:&Exercise:&Goal&1hr/day&moderate&intensity&Diet:&500U1000kcal/day&energy&deficit&&Contact:&InUperson&group&U&weekly&for&4&mths,&1/month&followUups&from&5U12&months.&Individual&phone&calls&weekly&for&1&month,&fortnightly&(month&2U3),&monthly&from&4U12&month&CON:&WaitUlist&control&group&Measures:&0,&16& &52&weeks&Body&comp:&DEXA&7Uday&physical&activity&recall&instrument&Step&test&–&1st&15s&recovery&
↑&weight&loss&for&INT&INT:&U5.7kg&(3.5),&CON:&U0.2kg&(4.1),&p<0.0001&↑&change&in&body&fat%&for&INT&INT:&U4.5&(3.8),&CON:&U0.9&(2.3),&p<0.0001&↑&change&in&waist&for&INT&INT:&U7.1cm&(6.4),&CON:&U2.5cm&(7.7)&Improved&HR/30s&for&INT:&Step&test&Increased&PA&for&INT&group&(hrs/day&exercise)&PA:&+2.2hrs&vs&+0.3hrs&&
Intervention&improved&weight,&body&fat%&and&waist&girth,&physical&activity&and&fitness.&No&report&of&LBM&Decreases&in&TNFUa&for&both&groups,&?not&related&to&fat&tissue&Discussion&looked&to&single&out&INT&group&results,&while&disregarding&results&of&control&group&
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 Djuric&(Djuric&2011)&2&arm&RCT&&NHMRC:&II&Quality:&Neutral&&&Not&powered&for&body&comp&&
2Uarm&RCT& N=40,&>18yrs,&Stage&IUIIIA,&BMI:&26.1U28.1,&Scheduled&for&Chemo&or&within&2&weeks&of&starting.&Stable&Wt&(within&2.5kg&for&last&2&months)&&
12&month&intervention&INT:&Written&information&and&MI&telephone&counselling.&&Diet:&High&fruit&and&veg/low&fat&diet&with&weight&control.&Fat&and&Fast&Food&Counters&+&semiUtailored&meal&plan&for&weight&stability.&Exercise:&AET:&Goal&U&30min&modUvig/day&&CON:&Written&information&as&above.&No&telephone&MI&sessions&Contact:&weekly&for&2&weeks,&bi&weekly&for&5&months,&monthly&for&the&last&6&months&25%&drop&out&–&higher&in&INT&Measures:&0,&6&12mths&Body&comp:&Wt,&Ht,&DEXA,&Waist&and&hip&PAQ&from&WHI,&QOL:&FACTUB&Dietary:&Dietary&screeners&(fruit&and&veg&and&energy&from&fat&screener)&+&oneUoff&24&hour&unannounced&recall.&&Compared&to&a&modified&5Upass&recall.&HDL,&TG,&CRP,!CUpeptide,&IGFU1,&IGFBPU3&Total&carotenoids&
No&significant&change&in&body&weight&at&6&or&12&months,&compared&to&baseline&INT:&71.7kg,&+0.5kg,&U0.8kg,&CON:&71.3kg,&U0.8kg,&+0.7kg&U&NS&No&significant&change&in&LBM&after&12&months&INT:&+1.4%,&CON:&U1.2%&No&significant&changes&in&body&fat%&at&12&mths!!INT:&U1.7%,&&CON:&+1.2%&U&NS&Significant&within&group&decrease&in&waist&for&INT&at&6&months&6&month&change:&INT:&U7.6cm&(p<0.05),&CON:&U0.6cm&12&month&change&from&baseline:&INT:&U3.5cm,&CON:&+2.7cm&No&change&in&CRP,&Blood&pressure.&&
Completers&–&higher&F&V&and&higher&carotenoids&than&nonUcompleters.&CRP&higher&at&baseline&in&CON&Effect&of&had&started/not&started&chemo:&U&no&diff&in&anthro&or&bloods&U&higher&physical&scores&and&breast&cancer&specific&subset&for&nonUstarters.&Fruit&and&veg&screener&predicted&more&fruit&and&veg&than&the&recall&Increase&in&physical&activity,&QOL&and&&&
Harris&2012&&NHMRC:&IIIi&Quality:&+ve&&Primary&–&Weight&change&&
2Uarm&quasiUexperimental&& N=35;&52.8kg,&Wt:86.1,&71.4%&postmenopausal,&80%&Caucasian,&No&diff&at&baseline&&
Phase&I:&6&months;&Phase&2:&6U12&months&InUPerson&(IP)&INT:&16&sessions&(60U90min).&PA:&150min/wk&mod&exercise,&500U1000Cal&energy&deficit&(aim&0.5&to&1kg/wk&Wt&loss)&Phase&2:&Monthly&contact&by&trained&interventionist&(promote&further&loss&or&maintenance)&Phase&1:&TeleUINT&(Tele):&1/wk&contact&(15U60min&sessions)&(TrestleTree,&Inc),&similar&but&tailored&intervention&with&similar&guidelines&to&above&Phase&2:&Monthly&contact&by&TrestleTree&Measures:&0,&6,&12&months&Body&composition:&Wt,&BMI,&Waist&Bloods:&LDL,&HDL,&TChol,&TGs,&BGLs&Blinded:&assessment&and&intervention&teams&&&
Significant&weight&loss&for&both&groups&after&6&months.&No&diff&between&groups&IP:&U3.3kg,&p=0.002&Tele:&U4kg,&p=0.01&Significant&weight&regain&at&12&months&for&IP,&with&weight&maintenance&for&Tele&group.&InUperson:&+1.3kg,&p=0.009&Tele:&U1.0kg,&p=0.185&Between&groups:&p=0.056&Significant&decrease&in&waist&for&both&groups&after&6&months.&No&diff&b/w&groups.&InUPerson:&U3.4cm,&p<0.05&Tele:&U5.6:&U5.6cm,&p<0.05&Decrease&in&TG&IP&Decrease&in&LDL&for&Tele&compared&to&IP.&&&
Mode&of&delivery&did&not&have&a&bearing&on&results.&Individual&consultation&may&be&inherently&advantageous&Each&1kg&of&weight&lost&is&a&16%&reduction&in&Diabetes&risk&
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 Scott&2013&&&NHMRC:&II&Quality:&Neutral&&Primary&outcome&–&Body&weight&&&
2Uarm&RCT& N=90&(47& 43);&3U18&months&post&Rx;&Age:&55.6U55.9yrs;&&Wt:&78U83.2kg;&Caucasian:&98%;&CTx:&54U57%;&&RTx:&85U81%;&Tamoxifen:&49U51%;&AI:&30U26%;&Postmeno:&67.7%;&
24&weeks&INT&U&Sessions&3/wk&supervised&exercise&and&diet&education&sessions.&&Exercise:&30min&AET&@&65U85%&+&RET:&10U15min&resistance&bands,&hand&weights,&stability&balls.&Individualised&diet&counselling:&2500kJ&deficit&+&weekly&group&sessions&CON:&Unknown&Measures:&0&and&24wk&U&ITT&Body&composition:&BIA&–&body&fat%,&Wt,&waist,&hip&Fitness:&Estimated&Aerobic&fitness,&BP&QOL:&FACTUB&Diet:&3Uday&diet&diaries&Bloods:&Testosterone,&SHBG,&BGLs,&hsUCRP,&TChol,&HDL,&Estrone,&Estradiol,&insulin,&IGFU1,&IGFBPU1& &3,&Leptin&
80%&adherence&ITT:&Borderline&reduction&in&weight&for&INT&vs&CON&at&24&wks.&INT:&U1.09kg&(IQR:&U0.15&to&U2.9kg)&CON:&U0.4kg&(IQR:&0.7&to&U1.8kg)&P=0.07,&between&groups&When&outliers&(>3&SD&from&mean)&were&removed:&INT:&U1.25&(IQR:&U0.26&to&U2.93kg)&CON:&U0.4&(IQR:&0.73&to&U1.72kg)&P=0.03&No&change&in&BF%&was&seen&Significant&decrease&in&waist&for&INT&compared&to&CON&Adj&mean&difference:&U3.32&(95%&CI&U1.53&to&U5.11),&p=0.001&Fitness:&Improved&aerobic&fitness,&diastolic&blood&pressure&QOL:&Improved&FACTUB:&+6&(p=0.004),&Subscale:&+2&(p=0.007)&between&groups&
No&description&of&control&activity&Low&quality&body&composition&measure&No&LBM&measure&`&
INT: Intervention group; CON: Control group; ITT: Intention to treat; RCT: Randomised controlled trial; Ca: Cancer; Sx: Surgery, CTx: Chemotherapy; RTx: Radiotherapy; AIs: 
Aromatase Inhibitors; Rx: Treatment; HR: Heart rate; AET: Aerobic exercise training; RET: Resistance exercise training; Wt: Weight; Ht: Height; LBM: Lean body mass; DEXA: 
Dual energy X-ray absorptiometry; QOL: Quality of life; FFQ: Food frequency questionnaire; PA: Physical activity; CV: Cardiovascular; Time since Dx: time since diagnosis; 
IGF: Insulin like growth factor; HOMA: Homeostasis Model Assessment; INT: Intervention group; CON: Control group; ITT: Intention to treat; mths: Months; 7-Day PAR: 7-
day Physical Activity Record; FACT-B: Functional Assessment during Cancer Therapy – Breast; CRP: C-Reactive Protein; HADS: Hospital Anxiety 
and Depression Score. PAQ: Physical Activity Questionnaire; WHI: Women’s Health Initiative(Irwin et al. 2011) 
 &
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 In summary, the lack of high quality studies evaluating the combined effects of exercise and dietary 
interventions on body composition in breast cancer survivors currently precludes the ability to 
derive firm conclusions regarding optimal interventions manipulating body composition. However, 
initial findings indicate that dietary energy restriction coupled with combined aerobic and resistance 
exercise may evoke a clinically significant reduction in body weight, body fat%, or waist girth with 
concurrent LBM maintenance. Similarly, diet prescriptions aiming to maintain weight in 
conjunction with exercise may reduce body fat gains during chemotherapy. Future studies should 
include participants of similar time post diagnosis, with a specific focus on those who are 
completing, or have completed chemotherapy in the last 12 months, as this may be both the most 
teachable moment for lifestyle change (Harvie 2010), and also the most critical time to prevent 
change in weight (Makari-Judson et al 2007)  Finally, it is important to note that while attempts to 
create weight loss and LBM maintenance have been successful in these studies, the long term 
effects of this body composition change are currently unknown in this population. By observing 
other populations, reductions in body fat/waist, and LBM retention are likely to promote greater 
metabolic health. However at this point, the effect of relatively fast and substantial weight loss on 
breast cancer and overall mortality and morbidity has not been studied. Some evidence does 
indicate a benefit for moderate weight loss through diet and exercise changes in a population of 
women with breast cancer (Ligibel and Goodwin 2012). Thus a smaller reduction in body weight 
comprised mainly of body fat is the best clinical target given the current evidence. A combination 
of healthy eating without energy restriction plus exercise prescription is most likely to create this 
type of change.  
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 2.3 Published manuscript #1  
The following published manuscript was written as a brief review of the information covered above. 
The focus of the article was the influence of LBM on breast cancer, and in turn, the influence of 
breast cancer on LBM. Up until this point, the majority of breast cancer research has focused on fat 
tissue. However, evidence for muscle-fat cross talk relating to the immune and hormone regulation 
make LBM a critical consideration when discussing metabolic function and disease outcomes 
(Pedersen and Febbraio 2012, Brandt and Pedersen 2010). The manuscript gives a short overview 
of the effects of exercise and diet on LBM change, and then considers how these effects could be 
optimised through specific nutrients. Here the possible benefits of LCn-3s are introduced. These 
benefits are then discussed in detail in the following section of this chapter.
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There were 1.15 million new cases of breast cancer 
diagnosed worldwide in 2002,1 while in Australia alone, 
12,600 new cases are diagnosed each year and at the 
end of 2006 there were 144,000 breast cancer survivors 
country-wide.2 Significant advances in research have 
increased our understanding of predisposing factors and 
improved the management of breast cancer, resulting in 
a five-year survival rate of 88% and a one-year survival 
of 97%.2 
Over the last three decades, numerous studies and meta-
analyses have established a relationship between body 
composition and breast cancer aetiology and prognosis.3-6 
Postmenopausal breast cancer risk has a positive correlation 
with body mass index (BMI),3 while a lower BMI3 but high 
waist to hip ratio (WHR) is associated with an increased risk 
of premenopausal breast cancer.4,5 At the time of diagnosis, 
a higher BMI and WHR are both related to poorer prognosis, 
irrespective of menopausal status.6 
Due to the strong correlation found between BMI, WHR and 
body fat mass, investigations have focused on the function 
of fat tissue in breast cancer aetiology with specific reference 
to its influence over sex hormone balance, endocrine 
function, insulin and insulin-like growth factors and 
adipokine expression.7 More recently, better understanding 
of the function of lean body mass (LBM) indicates that it 
too exerts a powerful endocrine, immune and hormonal 
influence within the body.8 
For breast cancer survivors, simultaneous LBM loss with 
fat tissue accumulation, known as sarcopenic obesity, is 
common.9-11 The complete aetiology of LBM loss in this 
population is unclear, however it appears to be associated 
with poorer metabolic outcomes, such as earlier onset of 
cardiovascular disease and metabolic syndrome related 
diseases.8,12,13 In addition, LBM has been shown to be 
a positive predictor of survival in chronic heart failure,14 
chronic kidney disease,15 chronic obstructive pulmonary 
disease,16 and cancer cachexia.17 Evidence from these 
populations suggest that LBM loss may in part be related 
to inflammatory mediators present as a result of the disease 
state and treatment.17,18
The purpose of this review is: to provide a brief outline of 
findings related to LBM before and after breast cancer 
diagnosis; to explore the role of inflammation in LBM loss 
in breast cancer survivor populations; and review the 
established and potential roles of exercise and dietary 
intake in LBM maintenance specific to the breast cancer 
survivor population. 
Search criteria
A literature search was carried out using MEDLINE and 
Pubmed databases. Selected studies and review articles 
were hand-searched for additional relevant references. Key 
terms used included: breast cancer (breast neoplasms, 
cancer of the breast, breast cancer survivor, breast 
neoplasm risk); body composition (percentage body fat, 
muscle mass, lean body mass, skeletal muscle, body 
composition); exercise (physical activity, resistance training, 
aerobic training); diet (energy intake, omega-3 fatty acids, 
diet therapy, caloric/energy restriction). Additional search 
criteria included, subjects >18 years of age, non-metastatic 
breast cancer survivors and articles published in English. 
Included articles were those that reported body fat 
composition and/or lean body mass in relation to: breast 
cancer risk (all study designs included); time after breast 
cancer diagnosis (all prospective and retrospective cohort 
studies, case series, non-randomised and randomised 
studies); and diet and exercise, or combined interventions 
post breast cancer diagnosis (all non-randomised and 
randomised control trials). 
BODY COMPOSITION AND BREAST CANCER –  
THE ROLE OF LEAN BODY MASS
Cameron McDonald, Judith D Bauer and Sandra Capra 
University of Queensland, Queensland.  
Email: cameron.mcdonald1@uqconnect.edu.au
Abstract
Breast cancer risk and outcomes for breast cancer survivors are known to be influenced by body composition. A wealth 
of literature surrounds the function and role of fat tissue, however considerably less is known regarding lean body mass 
and its functional role in immune, hormonal and metabolic regulation in breast cancer aetiology. This review outlines 
findings relevant to lean body mass before, and following breast cancer diagnosis. A paucity of research exists regarding 
lean body mass and breast cancer risk. However, post-diagnosis lean body mass losses are commonly reported and 
a concern for ongoing co-morbidity after treatment. A comprehensive mechanism for sarcopenic obesity in breast 
cancer survivors is currently unknown. However, findings from other disease states indicate that the effects of chronic 
inflammation and/or an increase in sedentary activity may partly explain the exaggerated losses of lean body mass. 
Exercise has been a successful intervention for attenuating lean body mass losses after treatment, while weight loss 
through energy restriction may exacerbate breast cancer related sarcopenia. Combining exercise with dietary intervention 
to optimise lean body mass may be ideal; however there is insufficient evidence for this at present. Similarly, the role 
of functional food supplements, such as omega-3 fatty acids and essential amino acids, may aid lean body mass 
maintenance through anti-inflammatory action and increased muscle protein synthesis.
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LBM prior to breast cancer diagnosis
There is a lack of studies prospectively assessing LBM 
in association with breast cancer risk using sensitive 
measures such as dual-energy X-ray absorptiometry, CT 
scanning, densitometry or bioelectrical impedance. Of the 
studies that could be located, two prospective cohorts 
consisting entirely of postmenopausal women, have 
reported mixed results for the effect of LBM on breast 
cancer risk as assessed by bioelectrical impedance.19,20 
In a Dutch postmenopausal population with a median 
of six years follow-up, each 1kg/m2 increase in LBM-to-
height ratio (LBM divided by height squared) was positively 
associated with breast cancer risk, with seemingly no effect 
from body fat to height ratio.20 This differed somewhat 
to a postmenopausal Australian cohort measured at 
baseline and again after nine years.19 Each 10kg increase 
in absolute lean body and fat mass, and 10cm increase 
in waist circumference, were associated with increased 
breast cancer risk. However, when results were stratified 
for time since onset of menopause and history of hormone 
replacement therapy (HRT), a significant effect was only 
found for those who had experienced menopause more 
than 15 years before assessment, and in never-users of 
HRT.19-21 
These results are not surprising, as it is well established 
that adult weight increases and higher BMI values are 
significantly associated with postmenopausal breast 
cancer risk.3,21 Considering normal weight gain in healthy 
adult populations involves a simultaneous increase in LBM 
and fat mass,22 the association between breast cancer risk 
and absolute LBM in these studies may be secondary to 
the effects of significant long-term total body weight and 
fat mass gain during adulthood. 
In contrast to the above findings, when the ratio of fat 
to skeletal muscle mass was measured at or shortly 
following diagnosis in a Uruguayan case-control study, 
a higher value for fat-to-muscle ratio was more indicative 
of a breast cancer diagnosis.23 Compared to the lowest 
(1st) quartile of fat-to-muscle ratio, both 3rd and 4th 
quartiles had an odds risk of 4.86 and 6.09 (p<0.0001) 
independent of BMI and menopausal status. The authors 
noted that to maintain skeletal muscle mass at a level 
that was protective, regular exercise was mandatory. 
Alternatively, these results may indicate the importance 
of active lean tissue and its influence over immune 
and hormonal regulation.24 Caution in interpretation of 
these data is required. Limitations regarding the body 
composition measurement methodology used, and 
the applicability of findings to populations in developed 
countries are not clear.
To date, few meaningful relationships between LBM 
and risk of breast cancer have been uncovered. Current 
evidence suggests that the effect of LBM may be 
secondary to total weight and fat mass gains prior to 
diagnosis. More prospective studies using accurate 
and repeated measures of body composition, along 
with markers of muscle function, are required to further 
elucidate the protective or predisposing effect of LBM and 
breast cancer risk.
Pattern of LBM changes after breast cancer 
treatment
Sarcopenic weight gains are common after treatment 
for breast cancer.10 Over the five years following active 
treatment, 50-100% of survivors have been shown to 
increase total weight,10,11 with the probability of re-attaining 
their pre-diagnosis weight being inversely associated 
with initial post-treatment weight gains.12 LBM growth 
accounts for 20-40% of total weight gains in disease free 
populations.22 Studies of breast cancer survivors have 
shown that more than one year after chemotherapy, total 
fat mass gains of 2.4kg to 6.7kg were accompanied by 
LBM losses of -0.4kg to -1.7kg, respectively.9,25 Women 
who seemingly maintain their weight in the years after 
treatment still undergo these adverse changes, such that 
LBM losses match increases in adipose tissue.26 Factors 
that are linked with more exaggerated changes include 
premenopausal status at diagnosis, experiencing treatment 
related menopause,27 receiving chemotherapy compared to 
no chemotherapy, a lower BMI at diagnosis and those who 
are least physically active after treatment.28 The sarcopenic 
pattern is still prevalent, albeit of smaller magnitude in 
postmenopausal breast cancer populations.25, 29 
In regards to timing of LBM changes, the most significant 
changes are seen during adjuvant chemotherapy and in 
the 6 to 12 months following this.9,25,29,30 By observing 
control groups in large randomised trials, the rate of 
sarcopenic weight gain seems to normalise two to four 
years post diagnosis,31-34 however total weight increases 
can still occur after this point.12
LBM losses with concurrent fat and total weight gains are 
associated with metabolic dysfunction including impaired 
glucose metabolism,13 high triglyceride levels,35 and chronic 
inflammation in healthy and diseased populations.8 While 
the function of fat tissue has been a focus of previous 
interventions aimed at breast cancer survivors, LBM should 
be evaluated more closely in future, as it is known to be a 
large contributor to glucose disposal,8 triglyceride oxidation 
and, when stimulated through exercise, can exert systemic 
anti-inflammatory effects.36 
Contributors to LBM losses 
Studies assessing moderators of weight change during 
treatment (local surgery and radiotherapy, with or without 
chemotherapy) have not conclusively explained the 
reasons for the higher than expected total weight gains 
and the sarcopenic nature of the body composition 
changes.9,25,27,37,38 The role of both resting metabolic rate 
and energy intake do not fully explain the magnitude of 
weight change after treatment.9,27 It is thought that any 
increases in fat mass are sufficient to mask the resting 
metabolic rate reduction associated with LBM losses,9 
while weight gains have been observed even after a 
reduction in energy intake.27 In contrast, lower levels of 
physical activity have been associated with increased 
weight,38 however total weight gains still seem to be greater 
than predicted after accounting for the reduction in energy 
expenditure associated with decreased physical activity.25 
Therefore, auxiliary mechanisms other than those relating to 
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conventional energy balance, such as chronic inflammation 
metabolic disturbances related to sedentary activity, may 
partly explain the exaggerated changes in LBM. 
Systemic inflammation has proven to be a strong inhibitor 
of muscle protein synthesis and increased muscle protein 
degradation in ovarian, gastroesophageal and pancreatic 
cancers.39,40 A full review of these mechanisms can be 
found elsewhere.40 In brief, increased circulating levels of 
inflammatory cytokines such as tumour necrosis factor 
(TNF-)alpha and interleukin-6 (IL-6), and increased genetic 
expression of inflammatory markers through nuclear 
factor-kappa B (Nf-ƙB), stimulate muscle degradation 
while inhibiting muscle protein synthesis.40 At least 
one prospective study revealed that elevated levels of 
inflammatory markers have been positively associated with 
body mass accumulation in healthy populations.41 
Direct associations between LBM changes and inflammatory 
markers have not yet been made in breast cancer survivor 
populations. Elevated levels of acute phase inflammatory 
markers, C-reactive protein and serum amyloid A, have been 
correlated with increased fatigue,42 increased incidence of 
cardiovascular disease, insulin resistance,43 and mortality 
independent of BMI, stage of disease and race.44 Cytokines 
generated from active LBM (particularly skeletal muscle), 
known as myokines,45 contribute to the anti/inflammatory 
balance of the body.8 While the muscle-fat cytokine 
interplay has not been fully elucidated, numerous studies 
have confirmed that muscle activity has a significant anti-
inflammatory influence on the systemic cytokine milieu, and 
further research may develop mechanisms that increase the 
importance of functional LBM in healthy and breast cancer 
populations.24 
A reduction in physical activity and an increase in sedentary 
activity are common after breast cancer diagnosis.28 
Increased sedentary time, such as sitting or lying down, 
has been related to increased adiposity in breast cancer 
populations.46 This phenomenon can be explained through 
an increase in abdominal fat deposition, decreased 
insulin sensitivity,35 decreased triglyceride oxidation,35 
and an inhibition of muscle synthesis,47 following muscle 
deactivation related to physical inactivity. Decreased 
energy expenditure plus the metabolic disturbances 
associated with physical inactivity, may partially explain 
discrepancies in predicted and actual weight gains found 
in breast cancer survivors.
Inflammation and sedentary activity related changes in 
metabolism have a significant role in LBM physiology. More 
research is needed to fully elucidate exact physiological 
mechanisms even in healthy populations, however 
compelling evidence indicates that regularly stimulated as 
opposed to dormant LBM may be closely related to LBM 
changes.13, 48
Influences of exercise and diet on LBM
Diet and physical activity interventions have had a significant 
impact on body composition changes in breast cancer 
survivors despite their disappointing influence on LBM 
following treatment. 
Regular exercise in the well population has been shown to 
reduce breast cancer risk by 25-30%,49 and after diagnosis, 
total mortality by ~40%, breast cancer mortality by 34%, and 
breast cancer recurrence by 24%.50 Therefore, increased 
physical activity is recommended for healthy populations 
and breast cancer survivors alike. 
With respect to LBM, randomised control trials that 
involved resistance training have shown 0.5 to 0.88kg 
LBM increases over 8 to 26 weeks.51-53 In a population 
that typically loses muscle mass, aerobic exercise during 
and after treatment when compared to no intervention, 
has been shown to attenuate and sometimes reverse LBM 
losses.32, 33 However, a recent meta-analysis of randomised 
control trials notes only body fat percentage is consistently 
improved by aerobic exercise in this population.54 As 
well as absolute LBM growth, improvement of muscle 
function in conjunction with smaller absolute LBM growth 
is an important outcome in this population. A landmark 
randomised control trial by Schmitz et al (2009)  investigated 
the effect of year long, twice weekly resistance training on 
outcomes relating to lymphoedema. The study did not 
detect a significant change in LBM compared to control. 
However upper and lower body strength increased by 
29% and 32% respectively in the intervention group, 
compared to 4% and 8% respectively in the control.31 
Similarly, VO2 max was disproportionately improved after 
aerobic exercise training compared to the relatively small 
improvements of body composition.54,55 Considering the 
varying abilities of individuals of different body shapes 
and genetic predisposition to increasing absolute LBM, 
functional outcomes may give a more consistent insight 
into physiological improvement of LBM. Muscle strength 
has been shown to be a better predictor of mortality than 
muscle mass in ageing populations,56 VO2 max has long 
been an independent marker of mortality regardless of body 
composition in other populations,57 and evidence shows 
that exercise training and muscle contraction exerts anti-
inflammatory effects through myokine production.24 While 
the data regarding outcomes and muscle function is lacking 
in breast cancer survivors, these consistent relationships 
in otherwise not dissimilar populations are suggestive of 
similar links in breast cancer populations. 
Dietary interventions for breast cancer survivors 
have shown successful weight loss through energy 
restriction,58-61 and with mixed results after low fat and 
high fruit and vegetable consumption.62,63 Randomised 
control trials assessing weight loss through energy 
restriction in breast cancer survivors have resulted in 3.3 
to 9.5kg weight loss over 6 to 12 months.59-61 However, 
there has been little focus on lean mass maintenance 
in these studies. In otherwise healthy overweight and 
obese populations, weight loss through energy restriction 
without exercise inevitably results in losses of both 
fat and LBM.60,64,65 A recent randomised control trial 
evaluated the efficacy of low carbohydrate or low fat 
diets for weight loss in breast cancer survivors and 
their potential hazard to LBM.60 Similar weight loss 
was found for each group, however, while body fat 
percentage, metabolic markers and C-reactive protein 
decreased, a classification of sarcopenia categorised 
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by appendicular LBM (<5.67kg/m2), measured by dual-
energy X-ray absorptiometry, increased from 8% to 18% 
within the study cohort.60 Considering the known link 
between breast cancer survival and the loss of LBM after 
treatment, this study is the first in this population that 
clearly indicates the need for additional interventions to 
attenuate LBM during weight loss. 
Combining exercise and dietary restriction for breast cancer 
survivors has shown promise in attenuating LBM loss 
during total body weight loss.66 Some studies have been 
underpowered or have failed to measure LBM,67-69 leaving 
the need for more research into a model that has been useful 
in non-breast cancer populations.65 Apart from exercise, 
anti-inflammatory nutrients may have utility in this population 
when addressing LBM maintenance. Long chain omega-3 
fatty acids (LCn-3 FAs) through anti-inflammatory and 
mitochondrial influence, are associated with protein sparing 
and increased fat oxidation in overweight populations,70-72 
and LBM attenuation in cancer cachexia.39,73 In conjunction 
with exercise, LCn-3FAs supplementation has shown 
to exert more powerful effects again on fat oxidation and 
LBM growth.71 Substantial literature supports the ability 
of LCn-3FAs to reduce inflammation through many of the 
pathways associated with LBM loss.74-76 An Australian 
study is currently underway investigating these relationships 
within a breast cancer survivor cohort. Another potential 
group of nutrients that show promise in LBM preservation 
are supplemented essential amino acids. Emerging 
findings indicate that essential amino acids, when dosed 
appropriately, may independently stimulate muscle protein 
synthesis.77 Supplementation has improved LBM in both 
chronic heart failure and older female populations,78,79 and 
has a theoretical potential in breast cancer populations. 
Conclusions
Adipose tissue has long been a focus of breast cancer 
aetiology and management. While little published research 
exists, recent insights regarding the role of LBM in 
inflammatory, immune and hormonal balance indicate an 
intriguing avenue for improving breast cancer outcomes. 
Sarcopenic weight gains during and after breast cancer 
treatment are not fully understood, however inflammatory 
regulation, inactivation of muscle tissue through sedentary 
activity and muscle-fat communication via endocrine 
pathways may provide further explanation of these adverse 
changes. Regardless of the incomplete physiological 
understanding, exercise interventions during and after 
treatment are effective in attenuating and reversing 
LBM losses in breast cancer survivors. Perhaps more 
importantly, it has been shown to dramatically improve 
muscle function in breast cancer populations. In contrast, 
dietary energy restriction alone is effective in reducing 
weight, however, the concurrent loss of LBM during weight 
loss may expose survivors to more severe sarcopenic 
changes. Optimal management of body composition is 
still under investigation, however conclusions from other 
populations would indicate a combined diet and exercise 
approach is best. Finally, a potential role exists for specific 
dietary supplements that address chronic inflammation 
and inhibition of muscle protein synthesis likely present in 
breast cancer survivors.
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 2.4$Omega*3$fatty$acids$(LCn*3):$Function$and$influences$on$body$
composition$
2.4.0$Overview$of$LCn*3$in$the$context$of$inflammation$and$body$composition$change$
LBM maintenance may be partly controlled by the balance of inflammation in the body (Mitch and 
Goldberg 1996). In healthy active populations, the acute inflammatory response as a result of 
physical activity triggers a cascade of pathways that effectively remove damaged muscle tissue and 
initiate growth and repair resulting in net LBM gains. The inflammatory response is responsible for 
break down and removal of damaged tissues, and signals growth factors to the site so that growth 
can begin (Ploeger et al. 2009). However, low-grade chronic inflammation often identified by 
slightly but consistently higher than baseline levels of inflammatory cytokines (Interleukin-6 and C-
Reactive Protein)(Jensen 2008) may be responsible for greater muscle tissue breakdown with a 
dampened anabolic or growth response. This is turn may lead to inflammation related myopenia, 
which is related to numerous functional and metabolic sequelae (Fearon, Evans, and Anker 2011). 
In breast cancer populations, chronic low grade inflammation as measured by CRP and serum 
amyloid A (SAA) was predictive of survival, however the relationship of LBM change was not 
addressed (Pierce, Ballard-Barbash, et al. 2009). Apart from physical activity, certain nutrients have 
been shown to exert anti-inflammatory effects that may decrease chronic inflammation and be 
protective of LBM (Jensen 2008). LCn-3s are nutrients that have a sound theoretical, rodent and 
human literature base that support the potential in ameliorating sequelae of chronic 
inflammation(Calder 2012).  
This section will give a background of the rationale and mechanisms for the anti-inflammatory 
action of LCn-3s. The second part of this section is a published paper that explores the evidence for 
LCn-3 supplementation and it’s effect on absolute and functional LBM. In addition, the published 
paper also gives insight into dosing and tissue uptake of LCn-3s in humans that is likely to 
influence results observed in the published literature. 
2.4.1 Rationale and overview of LCn-3, inflammation and body composition 
Omega-3 FA, inflammation and body composition 
Severe acute and low-grade chronic inflammation, via the ubiquitin-proteasome pathway, can lead 
to proteolysis and net LBM loss (Mitch and Goldberg 1996). Ongoing research continues to 
confirm that LCn-3s are critical for appropriate inflammatory response and cessation (Calder 2012). 
In addition, LCn-3s are thought to influence fuel utilization in the mitochondria resulting in higher 
fat oxidation in humans (Buckley and Howe 2010). Taken together, LCn-3s present as potential 
therapeutic agents in maintaining LBM and helping to reduce body fat mass. This section details 
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 some of the proposed and known mechanisms that explain LCn-3s role in maintaining a healthy 
body composition. 
LCn-3s, inflammation and LBM 
The acute inflammatory response is necessary in order for the body to defend itself and to heal. 
However, it is generally agreed that cardiovascular disease and other conditions related to metabolic 
syndrome are largely driven by chronic low-grade inflammation (Egger and Dixon 2009). 
Similarly, in diseases such as chronic heart failure, chronic obstructive pulmonary diseases and 
cancer, prolonged higher concentration of inflammatory cytokines and signaling proteins are related 
to disease progression and certain co-morbidities, in particular myopenia, or muscle wasting 
(Fearon, Evans, and Anker 2011). A considerable amount of research has investigated the roles of 
diet and physical activity in reducing chronic inflammation. Over the past two decades LCn-3s have 
been extensively researched to determine the function and effect of their anti-inflammatory action. 
LCn-3s are thought to influence a number of pathways associated with the stimulation and 
propagation of the inflammatory response (Calder 2012). These include relationships with 
leucocyte chemotaxis, reduced adhesion molecule expression and decreased leucocyte-endothelium 
interaction, decreased AA derived eicosanoid production and AA containing endocannabinoids, 
increased production of weak EPA eicosanoids and EPA and DHA containing endocannabinoids, 
increased production of pre-resolutions resolvins and protectins, decreased production of 
inflammatory cytokines, decreased T-cell reactivity (Calder 2012). Considering the potential role of 
inflammation in LBM decline, elucidating the role of LCn-3s may enable better management of 
myopenia in populations that are susceptible. Relevant pathways to LBM protection are discussed 
below. 
LCn$3s'and'their'effects'on'inflammatory'mediators'
Overall, higher concentrations of LCn-3s in the diet are likely to promote a dampening of the pro-
inflammatory response through a number of pathways (Wada et al. 2007, Fetterman Jr and 
Zdanowicz 2009). LCn-3s competitively inhibit the production of more pro-inflammatory AA 
derived eicosanoids, and independently of eicosanoid production (Fetterman Jr and Zdanowicz 
2009). LCn-3s directly inhibit the activation of Nuclear Factor kappa B (Nf-kB) (Boutros et al. 
2010, Calder 2012) in part through agonistic ligand binding of PPAR-Gamma complexes, which in 
turn reduces transcription of TNF-a, IL-1 and IL-6 mRNAs (Flachs et al. 2009). Many of these 
effects may be due to, and/or in addition to, their emerging role in cell membrane lipid rafts (Singer 
2004, Chapkin et al. 2009). These functions become relevant to homeostasis of muscle protein, as 
all of these inflammatory pathways up-regulate the ubiquitin-proteasome pathway (UPP), which 
when activated increases proteolysis (Smith, Mukerji, and Tisdale 2005, Wyke et al. 2005, 
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 Simmons et al. 1984). Proteolysis is normal in healthy populations, however it is typically balanced 
by protein synthesis.  In acute or chronic inflammation higher rates of proteolysis are observed, and 
is amplified by an inhibition of protein synthesis (Mitch and Goldberg 1996). Taken together, LCn-
3s affect many of the pathways associated with proteolysis, and have a theoretical role in decreasing 
LBM breakdown related to increased inflammation. 
LCn$3'and'their'role'in'fat'oxidation'
LCn-3 may reduce body fat by up-regulating genes associated with fatty acid oxidation (Buckley 
and Howe 2010). A number of human trials have shown that LCn-3 supplementation resulted in 
reduction of body weight (Kabir et al. 2007), body fat (Hill et al. 2007, Noreen et al. 2010, Couet et 
al. 1997), and adipocyte diameter (Kabir et al. 2007). In addition, a small but well controlled study 
reported an increase of fatty acid oxidation after LCn-3 was increased in their meals for 3 weeks 
(Couet et al. 1997). In animal and in-vitro studies, LCn-3s have been shown to increase transfer of 
acyl groups into the mitochondria for beta-oxidation by up regulating the expression of 
mitochondrial Carnitine palmitoyl transferase I (CPT-I) in visceral/ectopic fat, but not subcutaneous 
fat (Flachs et al. 2005). Visceral/ectopic fat deposition has been shown to be more indicative of 
metabolic disease and inflammation when compared to subcutaneous fat. In addition, it is thought 
that LCn-3s up-regulate the production of uncoupling protein (UCP)-3 in skeletal muscle 
mitochondrial cell membranes (Hun Cha et al. 2001). UCP-3 causes mitochondrial proton leakage, 
which reduces ATP production and increases heat output, thus more fatty acids are needed for the 
same ATP output. In conjunction with this, LCn-3s are also thought to increase peroxisome acyl 
CoA oxidase (Acyl-CoA) (Flachs et al. 2009). Peroxisome fatty acid oxidation, which is increased 
with presence of Acyl-CoA is less efficient than mitochondrial beta-oxidation yielding 30-40% less 
ATP and 30% more heat. Taking the in-vitro findings for these three mechanisms, LCn-3s may 
increase resting fatty acid oxidation particularly in visceral/ectopic fat tissue, which could result in a 
loss of fat mass and/or a reduction in metabolic dysfunction.  
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 2.5 Published Manuscript #2  
LCn-3 and their role in body composition change 
This published review summarises previous studies that have investigated the role of LCn-3s in 
body composition change in humans. It outlines the available evidence for their efficacy in humans 
and reviews the dosage strategies required to maximize the effect of LCn-3s in trials. An important 
finding of this review relates to the effects of LCn-3 in conjunction with exercise. A number of 
trials over the last four years have investigated elements of LBM function and response, however to 
date there has been no compilation of these findings. Additionally, LCn-3 studies are notoriously 
heterogeneous when it comes to dosing and measurement of dosing adherence, thus the review 
addresses methodological considerations for this as well.
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REVIEW
Omega-3 fatty acids and changes in LBM: alone or in synergy for better
muscle health?1
Cameron McDonald, Judy Bauer, and Sandra Capra
Abstract: Myopenia or muscle wasting due to ageing, chronic disease, and various medical interventions has been associated
with increased mortality, morbidity, and poorer physical function. Attempts through nutrient and exercise interventions have
been made to prevent this deterioration. In addition, while a measure of lean body mass (LBM) is associated with health
outcomes, LBM functionmay be a better prognostic tool. Long-chain omega-3 fatty acids (LCn-3s) are nutrients thatmaymitigate
LBM losses in noncancer populations. The purpose of this review is to determine whether LCn-3s have a role in LBM sparing in
noncancer populations, to establish a minimum dose and duration of LCn-3s that will result in LBM change, and to summarise
the potential effects of LCn-3s on LBM function when combined with an anabolic stimulus. Overall, in noncancer populations,
LCn-3s have limited utility in sparing LBM during energy balance, energy restriction, or in conjunction with aerobic exercise.
Further investigations are required to determine the appropriate dose and duration of LCn-3s for optimal LBM function. Finally,
compelling evidence exists for LCn-3s in conjunction with an anabolic stimulus to improve LBM function and quality. Function-
ality of LBM tissue is an important outcome for population health, and LCn-3s show some promise, albeit pending further study.
Key words: omega-3 fatty acids, lean body mass, myopenia, sarcopenia, exercise, physical activity.
Résumé : La myopénie ou perte musculaire due au vieillissement, aux maladies chroniques et a` différentes interventions
médicales a été associée a` un accroissement de mortalité, de morbidité et a` un appauvrissement de la fonction physique. Des
tentatives d'interventions nutritionnelles et d'exercices ont été faites pour prévenir cette détérioration. En outre, alors que la
mesure de la masse maigre est associée des résultats cliniques, la fonction de la masse maigre pourrait constituer un meilleur
outil pronostique. Les acides gras oméga-3 a` longue chaine (LCn-3) sont des nutriments qui peuvent atténuer la perte musculaire
chez des populations non atteintes de cancer. Le but de cet article de synthèse est de déterminer si les LCn-3 jouent un rôle dans
la préservation de la masse maigre chez des populations non atteintes de cancer, d'établir une dose minimale de LCn-3 et une
durée de traitementminimale qui résulteraient en un changement de lamassemaigre, ainsi que de résumer les effets potentiels
des LCn-3 sur la fonction de la masse maigre lorsque combinés a` un stimulus anabolique. Dans l'ensemble, chez des populations
non atteintes de cancer, les LCn-3 ont une utilité limitée dans la préservation de la masse maigre en condition de balance
énergétique, de restriction énergétique ou en combinaison avec un exercice aérobique. Des recherches plus poussées sont
nécessaires pour déterminer la dose appropriée et la durée d'un traitement aux LCn-3 pour maintenir une fonction optimale de
la masse maigre. Finalement, il existe une preuve convaincante que les LCn-3 combinés a` un stimulus anaérobique améliorent
la fonction et la qualité de la masse maigre. Une masse maigre fonctionnelle est un résultat clinique important en santé des
populations et les LCn-3 sont prometteurs, bien que des études plus poussées soient requises. [Traduit par la Rédaction]
Mots-clés : acides gras oméga 3, masse maigre, myopénie, sarcopénie, exercice, activité physique.
Introduction
Skeletal muscle mass, commonly referred to as lean body mass
(LBM), is the major reservoir of amino acids in the body, account-
ing for 50%–60% of the body's stores (Lenk et al. 2010; Muscaritoli
et al. 2010). Its primary purposes are to provide movement,
strength, and respiration (Lenk et al. 2010), with recent evidence
indicating that skeletal muscle mass has important functions in
immunosufficiency (Castaneda et al. 1995; Roubenoff 2008). How-
ever, because of a number of behavioural and disease factors,
muscle wasting, recently described using the term myopenia
(Fearon et al. 2011a; 2011b), has become common and is becoming
established as an important prognostic marker of disease and
general health. The termmyopenia is preferred to others because
it can represent all types of muscle wasting, and it translates well
in other languages (Fearon et al. 2011a). Sarcopenia is a term that
has been primarily used to describe clinically significant muscle
wasting in the elderly, while cachexia is defined as “… a multi-
factorial syndrome defined by an ongoing loss of skeletal muscle
mass that cannot be fully reversed by conventional nutrition sup-
port …” (Fearon et al. 2011b), recognised in association with a
number of conditions. However, muscle wasting is found at the
centre of both sarcopenia and cachexia, and therefore the term
myopenia is appropriate as a general classification (Fearon et al.
2011a).
Myopenia is defined as “… a clinically relevant degree ofmuscle
wasting that is associated either with impaired functional capac-
ity and (or) with increased risk of morbidity or mortality” (Fearon
et al. 2011a). It has been estimated to affect 20% of those aged over
60 years (Taaffe 2006), and is associated with disuse, malnutrition,
acute and chronic inflammation, and cachexia (Muscaritoli et al.
2010; Fearon et al. 2011a; 2011b). Muscle wasting is directly associ-
ated with loss of strength, increased likelihood of falls, and loss of
autonomy. It is also associatedwith increasedmortality in healthy
older populations (Stenholm et al. 2008; Bunout et al. 2011; Gen-
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ton et al. 2012). Furthermore, evidence from large epidemiological
studies indicates that the loss of muscle function may be more
indicative of mortality and adverse health outcomes than one's
absolute loss of LBM (Newman et al. 2006; Ruiz et al. 2008). Myope-
nia is also associated with ectopic deposition of intramuscular
triglyceride, which has been associated with chronic inflamma-
tion, increased insulin resistance (Goodpaster et al. 2000), and
greater incidence of cardiovascular disease (Hamdy et al. 2006).
Studies that aimed to determine the mechanistic aspects of
myopenia have reported that acute and chronic inflammation are
associated with both increased muscle proteolysis and reduced
response to anabolic stimuli, also known as anabolic resistance
(Breen and Phillips 2011; Haran et al. 2012). A wealth of literature
indicates that both aerobic and resistance exercises increase LBM
function, while resistance training alone is regarded as the inter-
vention associated with the most improved strength and size of
the LBM. In young healthy, elderly, and diseased populations,
studies have investigated strategies to prevent myopenia and to
ameliorate anabolic resistance with the aim of enhancing the
muscle protein synthetic (MPS) response to an anabolic stimulus,
such as resistance exercise. Typically, the interventions of interest
have targeted antiinflammatory (Cerchietti et al. 2007; Murphy
et al. 2011a; 2011b), anabolic agents (Breen and Phillips 2011; Deutz
et al. 2011), or combinations of both (Rogers et al. 2011) in an
attempt to mitigate these changes in muscle mass and function.
Long-chain omega-3 fatty acids (LCn-3s) have been proposed to
preserve LBM through their antiinflammatory action and subse-
quent downregulation of the ubiquitin–proteasome pathway
(Calder 2009).
Over the last 2 decades, LCn-3s have become a common dietary
supplement. Initially, LCn-3s were promoted as an effective ad-
junct in secondary prevention of cardiovascular disease (Wang
et al. 2006) and over time have been used in many other condi-
tions for which there are acute and chronic inflammatory back-
grounds. One area of investigation in response to the rise in
obesity is the potential for LCn-3s to positively influence body
composition. However, recent systematic reviews addressing
some of these issues indicate that little to no evidence exists to
promote LCn-3s for body weight loss (Martínez-Victoria and Yago
2012), while some evidence exists for its use in reducing body fat
in lieu of weight change (Buckley and Howe 2009). However, from
all of the trials reviewed, themagnitude of change in body fatmay
have minimal clinical utility (Buckley and Howe 2009).
LCn-3s have been established as anti-inflammatory agents in
humans, and the mechanisms of their action have been exten-
sively reviewed elsewhere. In brief, LCn-3s offer protection from
proteolysis and subsequent muscle wasting, through altered ge-
netic expression and a variety of immunomodulatory pathways
(Babcock et al. 2003; Novak et al. 2003; Mishra et al. 2004; Singer
2004; Edwards and O'Flaherty 2008; Calder 2009; Chapkin et al.
2009). While acute inflammation is normal, the presence ofmajor
acute or low grade chronic inflammation leads to higher rates of
proteolysis, and is also seen to inhibit protein anabolism (Haran
et al. 2012). With regards to the deposition of ectopic or intramus-
cular triglyceride, LCn-3s are thought to decrease this through
enhanced mitochondrial lipid oxidation via some pathways in-
cluding upregulation of uncoupling protein-3 (Hun Cha et al.
2001; Buckley and Howe 2009) and carnitine palmitoyl transferase
(Buckley and Howe 2010). In contrast, the long-chain omega-6
fatty acid linolenic acid (LA), which is the precursor for
arachadonic acid, is typically responsible for the production of
proinflammatory eicosanoids (Calder 2009). The content of LA in
theWestern diet is much higher than LCn-3s, i.e., LCn-6:LCn-3 has
been reported as 15–20:1, and there is some evidence indicating a
negative effect of this unbalanced ratio that is thought to be op-
timal at 1–4:1 (Simopoulos 1999).
The proposed mechanisms of LBM preservation and increased
fatty acid oxidation lead to the hypothesis that LCn-3s may im-
prove body composition. On the other hand, epidemiological ev-
idence that better survival for individuals is associated with more
functional LBM, rather than higher LBM alone, suggests thatman-
agement should include a measure of muscle function to validate
an agent's efficacy (Newman et al. 2006; Ruiz et al. 2008). In re-
gards to the potential of LCn-3s to assist in maintenance or im-
provement of muscle function, little discussion has taken place in
published literature.
Therefore, the purpose of this review is to answer the following
questions: (i) Do LCn-3s have an effect on change in LBM when
taken alone or in conjunction with energy restriction or an exer-
cise program? (ii) If there is an effect, what is theminimumdose of
LCn-3s required to elicit change in LBM, or LBM protection, and
what factors influence the objective measurement of LCn-3s with
relevance to LBM change? (iii) Does the addition of LCn-3s to an
anabolic stimulus (e.g., an amino acid dose or exercise program)
have a synergistic effect on LBM or LBM function?
Materials and methods
A systematic search was carried out using the MEDLINE and
Pubmed databases. Key terms used included omega 3 fatty acids
(n-3 fatty acids, omega 3, and polyunsaturated fatty acids), body
composition (percentage body fat, musclemass, LBM, and skeletal
muscle), exercise (physical activity, resistance training, and aero-
bic training), tissue uptake (cholesterol esters, phospholipids, se-
rum lipids, erythrocytes, and adipose tissue), LBM quality, and
LBM function (muscle strength, intramuscular triglycerides, mus-
cle protein synthesis, anabolic resistance, peak torque, and mito-
chondrial expansion). With regards to LCn-3 supplementation
and LBM change, trials were included if they reported on an adult
(>18 years of age) noncancer or noncachectic population, used
fatty fish or LCn-3 supplementation as capsules, emulsion, or
other, had a concurrent control group (randomised or pseudo-
randomised), and reported on changes in LBM. Studies and
reviews of studies with the primary objective of assessing dose–
response and subsequent tissue uptake of LCn-3s were included if
they or the studies they reviewed reported an objective measure
of LCn-3 content in at least one bodily tissue before and after
supplementation taken as capsules or emulsions. Studies report-
ing the effects of LCn-3s in conjunction with an anabolic stimulus
on LBM function were included if they reported an objective
measure of LCn-3s and an objective measure of LBM function or
quality before and after supplementation with LCn-3s, were
uncontrolled or controlled trials, and included adults (>18 years of
age) from any population. The quality of the studies was assessed
using the Academy of Nutrition and Dietetics's Evidence Analysis
handbook. Assessment of the studies included grading studies by
research design (Class A through to D) and quality criteria (Posi-
tive, Neutral, and Negative), giving a study an overall rating of
high, neutral, or poor (Academy of Nutrition and Dietetics 2010).
Do LCn-3s have an effect on change in LBM when taken
alone or in conjunction with energy restriction or an
exercise program?
To date, there have been 10 controlled trials that have assessed
the effect of LCn-3s on change in LBM over time (Table 1). Three of
these studies have investigated the effects of LCn-3s alone while
maintaining energy balance through controlled energy intake or
normal intake (Couet et al. 1997; Noreen et al. 2010; Crochemore
et al. 2012), 6 studies have reported the effects of LCn-3s on LBM
during weight loss (Storlien et al. 2001; Krebs et al. 2006;
Thorsdottir et al. 2007; Abete et al. 2008; Hlavaty et al. 2008; Munro
and Garg 2012), and 1 study has combined aerobic exercise with or
without LCn-3 supplementation (Hill et al. 2007). Overall, there
was significant heterogeneity among studies in regards to LCn-3
dose, length of intervention, prescribed energy deficit, and con-
trol of LCn-3 adherence. In addition to this, the quality of the
papers have been generally less than optimal in that of the 10
460 Can. J. Physiol. Pharmacol. Vol. 91, 2013
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Table 1. Controlled trials assessing the impact of LCn-3s on lean body mass.
Reference study and
quality rating Population Measures
Dose, duration, intervention, and
measures
Reported change in
LBM Comments
Couet et al. 1997; non-
RCT cross-over time
series; quality, +ve
n = 6; young healthy adults;
mean BMI, 21.9±1.6 kg/m2;
mean body fat, 12.42%
Body composition, DEXA;
adherence, LCn-3
content of platelet
phospholipids; PA,
assessed; diet, assessed
INT, capsules (EPA, 1.1 g/day and DHA,
0.7 g/day); control, non-n3FA oil
added in; 3 weeks control diet;
10–12 week washout; and 3 weeks
intervention (FO)
INT, +0.2 kg; control,
–0.24 kg; other
body composition;
NS (p > 0.05)
Strengths: total control of diet
during intervention. High
quality measure cross-over
design. Limitations: short
duration
Noreen et al. 2010;
2-arm RCT; quality,
—
n = 44; age, 18–55 years;
healthy, no metabolic/
cardiac disease
Body composition,
BodPod (ADP);
adherence, not
reported; PA, not
measured; diet, not
measured
INT, capsules (EPA, 1.6 g/day and
DHA, 0.8 g/day); control, 4 g/day
sunflower oil; 6 weeks
supplementation + maintain
current habits
INT, +0.5 kg (95% CI
0.3–0.8); control,
–0.1 kg (95% CI –
0.6–0.4); p = 0.03
Strengths: high dose LCn-3s
and quality of assessment.
Limitations: no diet or
physical activity reported
and no adherence of pills
reported
Crochemore et al.
2012; 3-arm RCT;
Quality, –ve
n = 41; age 60.78 years;
T2DM, menopausal, and
MetX risk factors
Body composition, BIA;
adherence, pill count;
PA, not measured;
diet, not measured
INT-high, capsules (EPA, 0.55 g and
DHA, 0.35 g); INT-low (EPA, 0.32 g
and DHA, 0.21 g); and control,
gelatin + vitamin E; 30 days with no
other conditions reported
INT-high, +0.66%;
INT-low, +0.38%;
control, +1.1%; NS
within groups and
NS among groups
Limitations: low dose, short
duration, poor quality body
composition measure, no
control of diet or PA, and
no measure of pill
adherence
LCn-3s in conjunction with prescribed energy restriction
Thorsdottir et al. 2007;
4-arm RCT;
quality, +ve
n = 324¡ 278 final (no
difference in dropouts);
age, 20–40 years;
WC, >94 cm men and
>80 cm women; BMI,
27.5–32.5 kg/m2
Body composition, BIA;
adherence; diet,
assessed; PA, assessed
Total EPA/DHA content: INT, 450 g
lean fish/week (0.3 g/day); INT, 450 g
fatty fish/week (3 g/day); INT,
capsules (1.5 g/day); control, no
seafood + placebo; 8 week
intervention, tailored 30% dietary
energy restriction
No significant
change reported in
LBM for any
group. LBM values
not shown
Large sample size and
variation in LCn-3 delivery.
Significant drop out and
poor quality body
composition measurements
Abete et al. 2008;
2-arm pseudo-RCT;
unblinded;
quality, –ve
n=40; n = 32; male and
female; age, 36 years (7);
BMI, 31.6 kg/m2 (3.5);
otherwise healthy
Body composition, BIA;
adherence, not
reported; diet,
assessed; PA, assessed
INT, 3 fatty fish/week (EPA, 0.15 g and
DHA, 0.42 g); control, no fish, ALA
LCn-3 only; 8 weeks plus 30%
energy restriction (30% fat, 53%
CHO, and 17% protein)
INT, –2.4 kg; control,
–2.4 kg; p = 0.983
between groups
Controlled for diet. Low dose,
poor quality measure, and
low protein content of diet
may account for ++LBM loss
Hlavaty et al. 2008;
2-arm RCT; blinding
unknown;
quality, –ve
n = 40 (100% female); age,
N3, 55.2 years (13.2);
control, 59 years (10.2);
moderately obese; BMI,
N3, 33.1 kg/m2; control,
36.2 kg/m2
Body composition, BIA;
adherence, serum
triglycerides analysis;
diet, all food supplied;
PA, not reported
INT, yoghurt enriched with LCn-3s
(620 mg EPA+DHA, individual not
given); control, yoghurt with no
LCn-3s; phase 1, 3 days, weight
stabilisation, and inpatient; phase
2, 21 days inpatient, 2500 kJ/day
restriction + 60 min; PA/day (not
defined), controlled meal
production
INT, –0.8 kg; control,
+1.8 kg; p < 0.008
favouring control
Differences in initial weight
confounded all results. Low
dose LCn-3s used. Low
quality body composition
measure; control
significantly more obese at
bline for weight, body fat %,
fat mass (kg), and LBM (kg)
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Table 1 (concluded).
Reference study and
quality rating Population Measures
Dose, duration, intervention, and
measures
Reported change in
LBM Comments
Krebs et al. 2006;
3-arm RCT;
quality, +ve
n = 116; completed, n = 93
(100% female); age,
44.7 years (21–69); BMI,
35 kg/m2 (range:
26.2–47.6); 100% insulin
resistant
Body composition, DEXA
+ CT scan (L2–L4);
adherence, plasma
and adipose fatty
acids; diet, not
reported; PA, not
reported
INT, capsules (EPA, 1.3 g andDHA, 2.9 g);
placebo, capsules (LA, 2.8 g and
oleic acid, 1.4 g); control, none;
24 week intervention, 3.3–3.8 MJ/day
(MR) for 5 weeks, reintroduced food
7 weeks, weight maintenance
12–24 weeks; INT, LCn-3+energy
restriction; placebo, energy
restriction alone; C–control, no
LCn-3s or energy restriction
No change in LBM
for any group.
Results not shown
High dose prescribed.
Effective weight loss
program. Physical activity
not recorded. Milk-based
diet may protect lean mass
(high protein and calcium)
Storlien et al. 2001; 3-
arm RCT; open label;
quality:—
n = 52 (34 females); age:
female, 48 years and
male, 46 years; mild to
moderate HTN; obese,
130%–170% IBW
Body composition,
UWW; adherence, not
reported; diet, food
provided by study; PA,
measured, not shown
(no changes reported)
Total EPA/DHA content unknown;
phase 1, 7 day inpatient isocaloric;
phase 2, 10 week energy deficit
(males, 1800 kcal/day and females,
1200 kcal/day); with differing
polyunsaturated:saturated (P:S) fat
content; INT, P:S = 1.0 (LCn-3s 25%
of fat); n-6FAs, P:S = 1.0 (n-6FAs 25%
of fat); control, P:S = 0.25
INT, –1.23 kg; n-6FA,
–2.92 kg; control,
–2.68 kg; p > 0.05
(NS); and % body
weight lost as
LBM: INT, 14.3%;
n-6FA, 28.6%;
control, 24% (NS)
No defined levels of LCn-3.
Diet controlled and high
quality measures used.
Trend for less muscle loss
for omega-3 group. Not
sufficiently powered for a
5% change. Differences in
baseline weight between
groups
Munro and Garg 2012;
2-armRCT; quality,—
n = 40; 32 final; BMI,
33 kg/m2; otherwise
healthy
Body composition,
DEXA; adherence, RBC
fatty acids; diet,
measured; PA, not
reported
INT, capsules (EPA, 0.42 g and DHA,
1.62 g); control, sunola oil; 4 weeks
weight loss (3000 kJ/day), then 10
weeks body weight maintenance
INT, –1.36 kg;
control, –1 kg;
p > 0.05 (NS)
High DHA dose, high quality
body composition measure,
and correlation found
between fat lost and EPA
and DHA. No measure of
physical activity
Hill et al. 2007; 4-arm
RCT; double blind;
quality, +ve
n = 81; 75 final (28 men);
age, 52; body fat %, 43.9 +
at least 1 MetX RF
Body composition,
DEXA; adherence, RBC
fatty acids; diet,
measured; PA,
compliance (>85%)
LCn-3 groups, (EPA, 0.36 g and DHA,
1.56 g); placebo, sunflower oil, 6 g;
2 × 2 factorial, n–3, placebo +
exercise, no exercise; 12 weeks
exercise, run/walk, 45 min, 3
sessions/week at 75% age-predicted
maximum heart rate
Data not shown.
Stated that LBM
did not differ
between groups
High dose of DHA and high
quality body composition
measures. Good measures
of compliance
Note: LCn-3s, long-chain omega-3 fatty acids; LBM, lean body mass; RCT, randomised control trial; BMI, body mass index; DEXA, dual-energy X-ray absorptiometry; PA, physical activity; INT, intervention; EPA,
eicosapentanoic acid; DHA, docosapentanoic acid; FO, fish oil; NS, nonsignficant; ALA, !-linolenic acid; ADP, air displacement plethysmography; T2DM, type II diabetes mellitus; MetX RF, metabolic syndrome X risk
factors; BIA, bioelectrical impedance; diet, dietary intake; WC, waist circumference; BMI, body mass index; HTN, hypertension; IBW, ideal body weight; UWW, underwater weighing; n-6FAs, long-chain omega-6 fatty
acids; RBC, red blood cells; +ve, high quality;—, neutral quality; and –ve, poor quality
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studies (Table 1), only 4 were allocated a rating of high (Couet et al.
1997; Krebs et al. 2006; Hill et al. 2007; Thorsdottir et al. 2007), 3
were neutral (Storlien et al. 2001; Noreen et al. 2010 Munro and
Garg 2012), and 3 were poor (Abete et al. 2008; Hlavaty et al. 2008;
Crochemore et al. 2012).
LCn-3s alone and changes in LBM
Three studies have investigated the influence of LCn-3s on
change in LBM during energy balance, i.e., stable energy intake
aiming for weight stability, in healthy individuals. Two studies
used a high quality measure of body composition, dual-energy
X-ray absorptiometry (DEXA) (Couet et al. 1997) and air displace-
ment plethysmography (ADP) (Noreen et al. 2010), respectively,
while one used bioelectrical impedance (Crochemore et al. 2012).
Duration of the studies was not consistent, with 3 week (Couet
et al. 1997), 30 day (Crochemore et al. 2012), and 6 week (Noreen
et al. 2010) intervention periods. Similarly, LCn-3 supplementa-
tion varied from 0.53 to 2.4 g/day. Only 1 study reported an objec-
tive measure of LCn-3 tissue uptake, and the same study was the
only 1 of the 3 to appropriately account for dietary intake and
physical activity during the study period (Couet et al. 1997).
In regards to LBM change, Noreen et al. (2010) reported a statis-
tically significant increase in LBM (+0.5 ± 0.5 kg) when compared
with the control (–0.1 ± 1.2 kg) after 6 weeks of supplementation
with 1.6 g eicosapentanoic acid (EPA) and 0.8 g docosahexanoic
acid (DHA) in healthy middle-aged men and women. Couet et al.
(1997) reported a trend for LBM to increase after 3 weeks of sup-
plementation (1.1 g EPA and 0.7 g DHA); however, it did not reach
statistical significance. Crochemore et al. (2012) reported no dif-
ference in LBM change after 30 days of varying, albeit, lower daily
doses of LCn-3 (lower dose, 0.33 g EPA and 0.21 g DHA; higher dose,
0.55 g EPA and 0.35 g DHA). Taken together, these results, while
inconclusive, indicate that higher doses (>1.7 g LCn-3) for longer
durations (>6 weeks) may be required to realise benefit for LBM.
Regardless of this, even the greater change in LBM only reached
0.5 kg (Noreen et al. 2010), which may have limited clinical signif-
icance and is within the error ranges of the devices used to esti-
mate body composition.
Controlled trials of LCn-3s plus energy restriction and
changes in LBM
Of the 6 trials that reported LBM changes after energy restric-
tion with or without LCn-3 supplementation, 1 study showed a
trend for LBM retention during weight loss (Storlien et al. 2001),
while the other 5 showed no effect (Krebs et al. 2006; Thorsdottir
et al. 2007; Abete et al. 2008; Hlavaty et al. 2008; Munro and Garg
2012).
All 6 studies were designed to determine whether LCn-3s en-
hanced weight loss in conjunction with energy restriction. Again,
heterogeneity existed in regards to dosage of LCn-3, duration, type
and amount of energy restriction, andmeasurement of body com-
position. Only 2 of the studies were assessed as high quality (Krebs
et al. 2006; Thorsdottir et al. 2007), 2 were considered of neutral
quality (Storlien et al. 2001; Munro and Garg 2012), and 2 were of
poor quality (Abete et al. 2008; Hlavaty et al. 2008).
High quality measures of body composition, DEXA (Krebs et al.
2006) and underwater weighing (Storlien et al. 2001), were used in
2 studies, while bioelectrical impedance analysis (BIA) was used
for the remaining 4 (Thorsdottir et al. 2007; Abete et al. 2008;
Hlavaty et al. 2008; Munro and Garg 2012). Prescribed daily LCn-3
intake was unknown in 1 study using capsules (Storlien et al. 2001)
and ranged from 0.57 to 4.2 g/day in the remaining 5 studies. An
objective measure of adherence (tissue content of LCn-3s) was
assessed in 3 studies (Krebs et al. 2006; Hlavaty et al. 2008; Munro
and Garg 2012). Study duration ranged from 3 to 24 weeks, with 2
of the longer studies being part energy restriction and the remain-
der weight maintenance diets with continuing supplementation
(Krebs et al. 2006; Munro and Garg 2012).
Four of the 6 studies assessing energy restriction plus LCn-3s
reported no difference in LBM change between the LCn-3 groups
and the control. One study indicated a statistically nonsignificant
trend for the LCn-3 group to experience a lower loss of LBM than
the control, while total weight loss was similar (Storlien et al.
2001), and 1 study reported a significantly greater loss of LBM for
the LCn-3 groupwhen comparedwith the control; however, group
differences at baseline heavily confounded the relatively short
trial (Hlavaty et al. 2008).
Thorsdottir et al. (2007) and Abete et al. (2008) assessed the
effect of fatty fish intake included in an energy-restricted diet
compared with no seafood, while the former also compared lean
fish and LCn-3 capsules. Both studies were carried out in other-
wise healthy overweight and obese individuals for over 8 weeks.
Thorsdottir et al. (2007) reportedweight losses of 6.5 and 4.2 kg for
the men and women, respectively, for all of the groups, whereas
Abete et al. (2008) reported losses of 4.9 kg for both the fatty fish
supplemented and the non-fish-supplemented groups; however,
there was no reported effect of LCn-3 on LBM change as measured
by BIA in either study. Thorsdottir et al. (2007) reported expected
changes in RBC fatty acid analysis, whereas Abete et al. (2008) did
not report anymeasure of LCn-3 adherence. The daily dose of total
LCn-3s used by Thorsdottir et al. (2007) (1.5 g from capsules and
3 g from fatty fish) was somewhat higher than the relatively small
amount used by Abete et al. (2008) (0.15 g EPA,, 0.42 g DHA, 0.62 g
docosapentaenoic acid, and 0.5 g !-linolenic acid).
Krebs et al. (2006) (n = 93) and more recently Munro and Garg
(2012) (n = 32) assessed the effect of very low energy diets (VLED;
!800 kcal/day) !835 and 720 kcal/day, followed by prescribed
energy balance for 12 and 10weeks, respectively. Krebs et al. (2006)
prescribed 4.2 g of LCn-3s (1.3 g EPA and 2.9 g DHA) for 12 weeks of
VLED and found both groups, composed of obese women
(21–69 years), lost very little LBM (LCn-3 group, 0.4 kg; and control,
0.5 kg) compared with their total loss of !10 kg over 12 weeks,
determined using DEXA. Considering that the VLED was based
primarily on semiskimmed milk, it is possible that the high qual-
ity amino-acid intake from themilkmay have reducedmuscle loss
during the trial (Zemel et al. 2005a, 2005b). Munro and Garg (2012)
prescribed 2.04 g of LCn-3 (0.42 g EPA and 1.62 g DHA), yet found
no difference in LBM change between groups as measured by BIA.
Storlien et al. (2001) conducted a 3-arm randomised control trial
(RCT; n = 52) using individuals with mild hypertension that com-
pared diets of the same total energy (1200 kcal for the females and
1800 kcal for the males) with differing polyunsaturated:saturated
fat ratios, i.e., saturated fat (control), 0.25; high LCn-3, 1.0; and
high n-6FA, 1.0. Body composition change, as determined by un-
derwater weighing, indicated a nonsignificant tendency for the
LCn-3 group to preserve more LBM during weight loss. However,
the authors did not report prescribed LCn-3 intake and they did
not objectively measure LCn-3 tissue uptake making it difficult to
draw conclusions from their findings.
Finally, Hlavaty et al. (2008) performed a 3 week inpatient low
energy diet (2500 kJ energy restriction) with or without LCn-3
fortified yoghurt. Despite a total LCn-3 intake of 0.62 g/day and
objective LCn-3 markers indicating an increase in a number of
tissues, large differences at baseline significantly confounded all
results relating to body composition.
Studies of LCn-3s and exercise on change in LBM
To date, 1 study has reported LBM change after a controlled
intervention investigating the combined effects of LCn-3s and ex-
ercise (Hill et al. 2007). They conducted a high quality 4-arm RCT
(n = 65) in middle-aged obese sedentary individuals with at least
1 metabolic comorbidity, such that groups received either LCn-3s or
sunflower (placebo) alone or supplementation in conjunction
with cardiovascular training of three 45 min treadmill walking/
running sessions at 75% VO2max per week for 12 weeks. The LCn-3
groups received 0.36 g EPA and 1.56 g DHA daily. Body composi-
McDonald et al. 463
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tion was assessed using DEXA, and a significant time interaction
existed for fish oil and exercise for body fat mass. LBM change was
reported as nonsignificant across all groups.
Summary of LCn-3 supplementation effect on LBM change
From the results of these trials, LCn-3s do not seem to alter LBM
when taken alone or in combination with energy restriction or
aerobic exercise in generally healthy or obese chronically dis-
eased populations. Limitations in the current literature stem from
several key components of the trials completed and relate to dos-
age of LCn-3s used, length of intervention, assessment of body
composition, and the addition of an anabolic stimulus, some of
which are discussed below.
Potential limitations of the current interventions and
suggestions for the future
Is there a minimum dose required to elicit change in LBM, and
how and when should it be measured?
A number of factors are related to tissue concentration of
LCn-3s after supplementation. Very little is known regarding op-
timal LCn-3 concentrations for body composition change, if in-
deed there is one. In addition, it is not yet known which tissue is
most highly correlated to LCn-3 uptake when assessing LBM
change. Body mass index (BMI) has been shown to be negatively
correlated with tissue concentration increases (Hogg et al. 2006;
Yee et al. 2010). Also, studies indicate that higher doses of LCn-3s
result in higher maximal tissue concentrations after supplemen-
tation (Katan et al. 1997; Yee et al. 2010), while preparationmethod
of the LCn-3s has a significant influence on digestion and absorp-
tion of the LCn-3s in the gut.
In regards to BMI, Hogg et al. (2006) reported that while
participants in the treatment arm were given the same 4 g daily
dose of fish oil (1.88 g EPA and 1.48 g DHA), analysis indicated a
15-fold inter-individual difference in the plasma phospholipid
LCn-3:arachadonic acid (AA) ratio from those with the highest
and lowest body masses. Both EPA:AA and DHA:AA ratios were
significantly correlated with dose per kilogram body mass (for
EPA, r = 0.78, p < 0.001; and for DHA, r = 0.86, p < 0.001) (Hogg
et al. 2006; Yee et al. 2010).
LCn-3 uptake into a variety of tissues has been shown to be
dose-dependent. Two long-term studies have reported the effects
of increasing doses of LCn-3s taken in the form of triglycerides in
men (Katan et al. 1997) and ethyl esters in women (Yee et al. 2010),
and both indicated that higher doses resulted in more rapid and
higher absolute increases in tissue concentration of LCn-3s. Katan
et al. (1997) used LCn-3, delivered as marine-triglycerides, daily
doses of 0.97 g (0.81 g EPA and 0.16 g DHA), 1.95 g (1.62 g EPA and
0.33 g DHA), and 2.92 g (2.43 g EPA and 0.49 g DHA) for low,
middle, and high groups, respectively, in a group of male monks
for 12 months. Tissue content of EPA and DHA were significantly
higher for each increment in dose for cholesterol esters, erythro-
cytes, gluteal adipose, and abdominal adipose tissue at all time
points. More recently, Yee et al. (2010) used 4 varying daily doses of
0.84 g (0.47 g EPA and 0.37 gDHA), 2.52 g (1.4 g EPA and 1.12 g DHA),
5.04 g (2.8 g EPA and 2.24 g DHA), and 7.56 g (4.2 g EPA and
3.36 g DHA) over 6 months to determine LCn-3 differences in rate
of tissue concentration change of serum total lipids and breast
adipose tissue in individuals at high risk of breast cancer. Com-
pared with the 2 lower doses, total serum lipid EPA and DHA
concentrations were raised significantly more for the 2 higher
doses from 2 to 6 months, while no difference was seen between
the 2 higher doses. In contrast, no significant differences were
found for the 3 highest doses over 6 months; however, all were
significantly higher than the low dose, despite higher doses
leading to incrementally higher average values for breast tissue
LCn-3s.
Taken together, these long-term dose–response studies indicate
LCn-3 concentration in cholesterol esters and erythrocytes in-
creases incrementally with doses of EPA and DHA up to at least
2.95 g/day (2.43 g EPA and 0.49 g DHA) delivered as triglycerides
(Katan et al. 1997) and potentially up to 5.04 g/day (2.8 g EPA and
2.24 g DHA) provided as ethyl esters (Yee et al. 2010). While for
adipose tissue, maximal tissue content was seen to occur after
1.4 g of EPA and 1.12 g of DHA per day (Yee et al. 2010).
Rate of LCn-3 uptake in different tissues
An additional consideration in LCn-3 supplementation studies
is the measurement of LCn-3 uptake into the various body tissues
and compartments and how uptake rates can dramatically differ.
Typically, tissue content of LCn-3s is measured to determine ad-
herence of consumption, while several epidemiological studies
have indicated that LCn-3 tissue concentration may have a prog-
nostic utility for particular conditions. However, different tissues
in the body have vastly different uptake rates that need to be
considered.
Maximal tissue content of serum cholesterol ester fatty acids
has been shown to occur after 56 days of supplementation, with
the half-maximum concentration being reached after 4.8 days
(Katan et al. 1997). Another compartment commonly measured is
plasma phospholipids, which indicate a similar LCn-3 uptake rate;
however, for serum erythrocytes, maximum tissue content has
been recorded after 60 (Yee et al. 2010) to 180 (Katan et al. 1997)
days, with half-maximum levels being reached after 28 to 30 days
(Katan et al. 1997; Cao et al. 2006). Several studies consistently
indicate that plasma phospholipids (Cao et al. 2006; Harris et al.
2007) and cholesterol esters (Katan et al. 1997) have a higher rate of
uptake than erythrocytes (Katan et al. 1997; Cao et al. 2006; Harris
et al. 2007), which in turn has a higher rate than that seen in
adipose tissue (Katan et al. 1997; Yee et al. 2010). These speeds of
uptake logically seem to be related to the rate of turnover for the
respective tissues.
Delivery of LCn-3s depending on type of preparation
Limitations of the above studies in dosage and uptake come
from the varying uptake of different LCn-3 preparations. Trials
have indicated that a hierarchy of LCn-3 uptake exists for different
preparations, such that pre-emulsified LCn-3s from fish and nor-
mal krill oil are taken up more effectively than LCn-3s as re-
esterified triglycerides (marine triglycerides) (Garaiova et al. 2007;
Haug et al. 2011; Schuchardt et al. 2011; Ulven et al. 2011), which in
turn are better taken up than ethyl esters (Neubronner et al. 2011;
Schuchardt et al. 2011; Hussey et al. 2012). These studies are typi-
cally conducted over a 48 to 72 h period and good homogeneity in
results has been seen. Long-term dose–response studies have not
been performed using emulsion or krill oil; however, these forms
of delivery are likely to be useful in decreasing the required abso-
lute dose of LCn-3s rather than to improve the effect from LCn-3s
when compared with triglyceride and ethyl ester forms (Ulven
et al. 2011).
It has not been established what level of LCn-3s or even which
tissue will be most advantageous to gauge the likelihood of body
composition change. Knowing this may be useful in designing
trials that provide definitive results. What can be taken from the
existing data is that it takes at least 56 days to saturate the tissue
with the highest turnover rate (cholesterol esters) and consider-
ably longer for erythrocytes (180 days) and fat tissue (indefinite).
To appropriately determine the effect of LCn-3s a run-in period
may be required to maximise tissue concentration before other
intervention variables are applied or measured.
Finally, in relation to LBM, the authors could not locate any
studies assessing the rate of LCn-3 uptake, e.g., time to half-
maximum and (or) maximum saturation for skeletalmuscle phos-
pholipids. Some evidence from cancer populations has indicated
that LCn-3 muscle phospholipid content is positively correlated
with skeletal muscle tissue maintenance during chemotherapy
(Murphy et al. 2010); however, LCn-3 dose and time response stud-
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ies have not yet been performed in any population. Understand-
ing fatty acid turnover in this compartment is presumably an
important consideration for future studies.
How tissue uptake may have affected results from studies
assessing change in LBM
In regards to the minimum dosage of omega-3 taken from the
current literature cited above, only 3 of the trials assessing the effect
of LCn-3s on body composition change provided a dose that would
have achieved near maximal tissue uptake of DHA (>1.12 g/day)
(Krebs et al. 2006; Hill et al. 2007; Munro and Garg 2012), with only
one study providing enough of both EPA (>1.4 g/day) and DHA
(Krebs et al. 2006). None of these studies reported a statistically
significant difference in LBM change between the groups supple-
mented with LCn-3 and the control groups. On the other hand, all
of these trials were <6 months duration, and whether this time-
frame is long enough for LCn-3s to have an effect on LBM is cur-
rently unknown. Some data indicate that red blood cell (RBC)
content of LCn-3 relates to changes in fat mass (Munro and Garg
2012), but equivalent data are not yet available for LBM, and so this
is an area that requires further investigation.
Does the addition of LCn-3s to an anabolic stimulus (e.g., an
amino acid dose or exercise program) have a synergistic
effect on LBM or LBM function?
Traditionally, weight, BMI, and measures of body fat (percent
and waist circumference) have been positively correlated with
general incidence of disease andmortality. However, over the past
decade, significantly more attention has been paid to the impor-
tance of LBM and the function of that LBM to determine even
stronger relationships with disease and mortality in certain pop-
ulations (Newman et al. 2005, 2006; Taaffe 2006; Haran et al. 2012).
For this reason, measurement of not only muscle mass, but mus-
cle function may have significant clinical utility both on an indi-
vidual and population health level.
LBM function rather than absolute LBM as a prognostic
health marker
The Analysis of the Health, Ageing, and Body Composition trial
by Newman et al. (2006) indicated that muscle strength as deter-
mined by quadriceps strength and hand-grip strength were both
independently correlated tomortality risk, and remained sowhen
analyses were adjusted for sarcopenia. In addition, the strength–
mortality relationship remained statistically significant after con-
trolling for levels of inactivity, chronic disease, and race (Newman
et al. 2006). This study corroborated and added strength to previ-
ous findings as they used cross-sectional area of the thigh muscle
(CT scan) and appendicular muscle mass (DEXA) measures to con-
trol for sarcopenia. Similar findings were reported in a male co-
hort (n = 8762) followed for 18.9 years: when compared with the
lowest tertile, a statistically significant reduction in all-cause and
cancer-mortality was seen for those in the middle and highest
tertile of upper and lower body combined strength. These re-
mained significant after adjusting for relevant confounders in-
cluding cardiorespiratory fitness as measured by VO2max (Ruiz
et al. 2008). Furthermore, the accumulation of intramuscular fat,
in a non-elite athlete setting, has been associated with insulin
resistance and increased cardiovascular disease risk (Goodpaster
et al. 2000). Taken together, function and quality of the muscle is
building as an important factor in general survival and quality of
life.
Is there synergy between LCn-3s and an anabolic stimulus?
Although LCn-3s may not have a convincing role in promoting
LBM gains in the trials published to date, recent data have indi-
cated a role for LCn-3s in enhanced muscle quality (Murphy et al.
2011a; 2011b), response to resistance training, and muscle protein
synthesis in both young and healthy and older populations when
an anabolic stimulus, essential amino acid/insulin (Smith et al.
2011a, 2011b) or resistance exercise (Rodacki et al. 2012) is added to
LCn-3 supplementation (Table 2).
Smith et al. (2011a, 2011b) performed 2 small high-quality stud-
ies in young + healthy (n = 9, 1-arm pre/post-test), and older +
healthy (n = 16, 2-arm RCT) men and women to assess the effect of
8 weeks LCn-3 (1.86 g EPA/day and 1.5 g DHA/day (for both studies))
or corn oil supplementation on muscle protein synthesis during basal
postabsorptive and hyperinsulineamic–hyperaminoacidaemic clamp
conditions. Interestingly, for both groups, LCn-3 supplementation
did not increase muscle protein synthesis in the basal post-
absorptive state. However, the rates ofmuscle protein synthesis in
response to insulin and amino acid infusion were!50% and 100%
increases in young and older populations, respectively. Of note,
inflammatory markers of both populations were unaffected
through the 8 weeks, while an upregulation of anabolic signalers
mTOR and p70s6k found in the LCn-3 groups only provided a
possiblemechanism bywhich LCn-3smay have an anabolic effect.
The findings were that while LCn-3s alone did not seem to in-
crease basal protein synthesis, in conjunction with other anabolic
stimuli, i.e., amino acids and insulin, the anabolic response was
enhanced. Both of these studies contribute to the hypothesis that
LCn-3s may act as a muscle tissue anabolic primer, such that an
anabolic stimulus elicits a greater response than when there is
less LCn-3s in the muscle tissue.
Rodacki et al. (2012) investigated the neuromuscular effects of
LCn-3 supplementation in !65-year-old women (n = 45) and how
length of supplementation affected different elements of muscle
contraction. The study involved 3 groups, all received 36 sessions
of progressive lower body strength training over 12 weeks. Group
1 received resistance training alone, group 2 had resistance train-
ing and daily LCn-3 supplementation (0.36 g EPA and 0.24 g DHA)
for 12 weeks, while the group 3 received the LCn-3 dose for 60 days
leading into the study and then continued on the same dose for
the 12 weeks with resistance training. All groups experienced im-
provements in peak torque, electromechanical delay, and func-
tional capacity. Interestingly, both of the groups supplemented
with LCn-3 experienced significantly greater improvements in
peak torque, electromechanical delay, and in 1 of 4 functional
tests. However, no differences were found among the LCn-3 sup-
plemented groups themselves. While the population and dosage
were small, confounding issues due to diet and physical activity
were addressed, and the trial was of appropriate length to realise
benefit.
This trial generated 2 important points for further investiga-
tion. Firstly, small doses of LCn-3s had a positive effect on neural
tissue when combined with exercise. Secondly, LCn-3s alone did
not seem to change the neurological response of the participants
who had 60 days of lead-in supplementation. No differences were
seen at baseline for any variable; only when resistance training as
an additional anabolic stimulus was applied did the neural tissue
have greater responsiveness when compared with the control
groups. Considering that it is typically the higher force generating
type II fibres that are negatively affected in myopenia (Taaffe
2006), improving muscle protein synthetic and neurologic re-
sponses to training have useful implications in older and decon-
ditioned populations. Thus, future research determining the
LCn-3 benefits when in combination with progressive resistance
exercise is warranted.
Finally, Murphy et al. (2011a, 2011b) recently investigated the
effects of LCn-3s onmuscle quality in cancer survivor populations
undergoing chemotherapy. This group used CT images as part of
routine therapy to detail very accurate estimations of LBM, and in
addition, these images allow quantitative assessment of triglycer-
ide infiltration of the muscle tissue.
Initial observations in patients undergoing 10 weeks of chemo-
therapy for nonsmall cell lung cancer showed that patients clas-
sified as sarcopenic (low skeletal muscle mass values as assessed
McDonald et al. 465
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by CT scan; men, <55.4 cm2/m2 and women, <39.9 cm2/m2), or
those who experienced the greatest muscle loss (>–10% over
100 days) during treatment, had significantly lower content of
EPA, DHA, and total LCn-3s in their plasma phospholipids (Mur-
phy et al. 2010). Following this, in a similar population, supple-
mentation of 2.2 g EPA (choice of capsules or liquid was given) or
standard care (no EPA)were compared over 10weeks of treatment.
When compared with standard care, those consuming EPA expe-
rienced significantly better mass retention (–2.3 ± 2.6 kg vs. +0.5 ±
1 kg, p < 0.05, respectively) and muscle mass rate of change (–6.8% ±
2.6% per 100 days vs. +0.1% ± 1.6% per 100 days, respectively). Of
note, the rate of change of intramuscular triglycerides was signif-
icantly more favourable in the group supplemented with LCn-3
when comparedwith standard care (–16.4% ± 13.9% per 100 days vs.
+9.5% ± 5.2% per 100 days, respectively). Taken together, LCn-3s
were positively associated withmuscle quality over the treatment
period, as measured by intramyocellular triglycerides. While no
specific measures of muscle strength were assessed, a partially
overlapping population studied by the same group indicated
LCn-3 supplementation was correlated with a 2-fold improvement
in treatment response and improved treatment completion rates
(Murphy et al. 2011a, 2011b).
Discussion
The current literature does not support a clinically meaningful
effect from LCn-3s alone for change in LBM alone or in conjunc-
tion with energy restriction using doses up to 1.3 g EPA/day and
2.9 g DHA/day over 6 months. In addition, a high dose of DHA
LCn-3 (1.56 g/day) seems to have no effect on LBM in conjunction
with aerobic training after 12 weeks.
Theminimumdose of LCn-3s required to elicit change in LBM is
currently unknown; however, available evidence indicates that
trials may need to use at least 1.4 g EPA and 1.12 g DHA for at least
1 month to establish a high tissue saturation of LCn-3s. Until these
studies are conducted, definitive conclusions cannot be made.
Higher daily doses result in higher and more rapid tissue satu-
ration; however, it is not currently known which tissue or com-
partment is most relevant to LBM change. Studies investigating
anabolic response to exercise after LCn-3 supplementation did not
correlate muscle phospholipid content of LCn-3 to changes in
muscle physiology. In addition, neither dose–response nor dura-
tion have been assessed for muscle phospholipid content. How-
ever, a significant change in LBM physiology was seen after
8 weeks of LCn-3 supplementation.
In healthy young and older populations, the current evidence
indicates that LCn-3s may enhance muscle protein synthesis
and neural responses when combined with an anabolic stimu-
lus, hyperaminoacidaemic–hyperinsulinaemic clamp, and re-
sistance training, respectively. Furthermore, preliminary evidence
indicates that LCn-3s alone do not seem to improve LBM function in
healthy populations, rather they may have a more permissive role,
allowing muscle tissue to better respond to an anabolic stimulus. In
contrast, in typically catabolic populations, i.e., individuals undergo-
ing chemotherapy, LCn-3s may reduce LBM loss and intramyocellu-
lar triglyceride infiltration, while this may improve chemotherapy
response innonsmall cell lung cancer, it is not knownwhether these
improvements are related to better physical function.
It is recognised thatWestern diets have considerably lower LCn-
6:LCn-3 ratios than is considered optimal (15–20:1 compared with
1–4:1) (Calder 2009). The data reviewed above indicates a change in
muscle function or quality after supplementation; however, it is
unknownwhether the initial and poorer state of themuscle was a
result of LCn-3 deficiency, and that supplementation acted only to
restore optimal concentration, as opposed to the suggestion that
LCn-3s have a truly therapeutic effect comparable with that of
drugs. In populations experiencing significant catabolism, signif-
icant doses of LCn-3s have been shown to have a therapeutic ef-Ta
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fect. However, in healthier populations, a relatively low dose of
LCn-3s has elicited change in LBM function. Thus, LCn-3’s true
therapeutic value may be reserved for populations with signifi-
cant myopenia, while in contrast, healthy populations may be
assisted by establishing optimal LCn-3 levels. While future studies
should aim to tease these differences out, supplementation with
LCn-3s is safe, and is an important consideration in a number of
populations.
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 &
2.5.1 Summary of findings from Published Manuscript #2 
This review compiled the latest studies describing the effects of LCn-3 on LBM. From the 
literature, if LCn-3s to have an effect on LBM in non-cancer populations, it seems they need to be 
taken in conjunction with an anabolic stimulus. LCn-3 supplementation had no effect on LBM 
when combined with diet alone. However when combined with an acute anabolic stimulation 
through hormonal change or physical work (fed state amino acids and insulin or resistance training, 
respectively) changes in LBM and LBM function were observed. Indeed, in terms of LBM, LCn-3s 
are seen to be permissive and synergistic of change in LBM and LBM function, as opposed to being 
a primary driver for the change. Of note, in the case of the experiments performed by Smith et al 
(2011), the change in muscle protein synthesis seen in the LCn-3 group was not related to change in 
inflammation, thus additional pathways need to be investigated. 
Findings from this manuscript emphasise the need for further research into the effects of combining 
exercise and diet therapies. Some benefit may be found, however, these studies indicate the most 
efficient improvement in LBM will be found when the synergies of these modalities are harnessed 
appropriately. 
Finally, the review of dosing strategies indicates that when using a tissue level of LCn-3 to measure 
adherence, the type of tissue, dose and length of supplementation time is critical. Erythrocyte fatty 
acid content presents as an excellent marker for short to mid-term supplementation and uptake. A 
dose suitable to maximise uptake into this tissue is very important for studies of eight to 24 weeks 
in length. 
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 2.6 Overview of literature review and rationale of study 
Breast cancer survivors experience adverse body composition changes following treatment. 
Absolute body weight gains of 2-5kg are still common after treatment, however this has improved 
in the last decade due to greater awareness and improved treatment. Weight gains often occur in 
conjunction with a concurrent loss of LBM and deposition of both visceral and subcutaneous fat 
mass.  The changes are most dramatic in premenopausal and perimenopausal breast cancer 
survivors, however postmenopausal women experience similar changes, albeit at a lower 
magnitude. In addition, the highest rate of body composition change occurs during or soon (6-
12months) after treatment has finished. Similar body composition changes in non-cancer 
populations are associated with increased risk of cardiovascular and metabolic syndrome related 
diseases. Cardio-metabolic disease related mortality is now higher than breast cancer-related 
mortality for those with a history of breast cancer, thus attention to the known risk factors of this 
group of diseases is a priority for this population.  
Currently, the understanding of the mechanisms underpinning LBM change is limited by a lack of 
research. At this stage, taking AIs may have a positive effect on LBM, and it may act 
synergistically with exercise. LBM loss may be a result of chronic inflammation that may be partly 
induced by chemotherapy related myotoxicity, and/or physical inactivity. However, neither of these 
theories have been rigorously investigated in a breast cancer population. Given the benefits of 
physical activity to LBM maintenance, measuring muscle function variables as markers of physical 
activity may provide insights into modifiable risk factors associated with LBM loss. 
Interventions evaluating the effects of exercise during or following breast cancer treatment have 
shown that LBM loss may be halted and reversed after exercise training. Dietary interventions, 
while successful in reducing body weight have been shown to lead to increasing incidence of 
myopenia and LBM loss. For a population already at risk of decreased muscle mass, further losses 
that are typical of dietary energy restriction may be contraindicated. However, regardless of 
changes in LBM, total weight loss was shown to reduce classical risk factors of cardiovascular 
disease, such as blood lipids, triglycerides and waist girth. 
Combining aerobic and resistance exercise have been shown to improve body weight, body fat% 
and waist girth loss with maintenance of LBM. However, these interventions have been limited by 
poor description of the exercise protocols.  
An area that has not been investigated in breast cancer populations is the addition of nutrients 
known to have anabolic synergies with exercise or dietary interventions. LCn-3s are linked to a 
decrease in muscle wasting in advanced cancer patients, and recent evidence indicates they may 
have synergistic effects with other anabolic agents such as resistance training, and elevated amino 
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 acid/insulin concentrations. Furthermore, LCn-3s alone and in conjunction with exercise have been 
shown to reduce fat mass and may do this while preventing LBM in non-cancer populations.  Of 
note, benefits for LBM seen in advanced cancer patients seemed to be linked to adequate EPA 
content in the plasma, while improvements in body fat% in non-cancer populations may be 
primarily derived from DHA LCn-3. Considering breast cancer survivors share medical 
interventions with cancer populations and metabolic outcomes of those with cardio-metabolic 
conditions, an adequate dose of 1.4g of EPA and 1.12g of DHA per day, may be effective in 
preventing adverse body composition changes in breast cancer survivors particularly when 
combined with structured exercise.  
With consideration to the current literature, a theoretical model (Figure 2.1) was developed to 
outline factors that influence body composition after a breast cancer diagnosis. The model includes 
established treatment and intermediary factors, and established and hypothesised interventions 
related to body composition change after a diagnosis for breast cancer. 
Currently, there is limited knowledge regarding the associations of objective measures of physical 
activity or erythrocyte fatty acids and how they could predict LBM after completion of breast 
cancer treatment.  
 
In addition, no studies have assessed the influence of LCn-3 and resistance training on LBM 
changes in any population. Recognising this gap, and understanding the potential benefits that LCn-
3s may confer for this large population of women, this study aims:  1. To&investigate&the&effectiveness&of&LCn)3&supplementation&alone&compared&to&a&nutrition&and&exercise&lifestyle&program,&and&to&determine&if&there&is&further&benefit&for&LBM&when&LCn)3s&are&combined&with&the&nutrition&and&exercise&lifestyle&program.&2. To&investigate&the&lifestyle&and&treatment&related&predictors&of&LBM&after&completion&of&therapy&for&breast&cancer.&This&will&be&done&to&further&elucidate&the&role&of&modifiable&risk&factors&for&adverse&body&composition&change&following&treatment&
Primary Hypothesis 
Breast cancer survivors participating in a specifically designed group based cognitive behaviour 
therapy nutrition and exercise program and supplementing with 3g LCn-3s will have greater 
attenuation of LBM loss after 12 weeks compared to participants taking a supplement of 3g LCn-3s 
alone. 
Secondary Hypotheses 
Breast cancer survivors participating in the group based cognitive behaviour therapy nutrition and 
exercise program taking a supplement of 3g LCn-3s will have improved quality of life after 12 and 
24 weeks compared to participants of either the specifically designed nutrition and exercise 
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 program or participants taking a supplement of 3g LCn-3s alone. 
Breast cancer survivors in the group based cognitive behaviour therapy nutrition and exercise 
program taking a supplement of 3g LCn-3s acids will have lower levels of inflammation after 12 
and 24 weeks compared to participants of either the specifically designed nutrition and exercise 
program or participants taking a supplement of 3g LCn-3s alone. 
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Figure 2.1 Theoretical model of factors influencing body composition change after treatment for breast cancer 
Treatment factors: After a diagnosis of breast cancer, treatment of the cancer (CTx: Chemotherapy; Sx: Surgery; RTx: Radiation therapy) results in a number of adverse behavioural and physiological 
changes, which negatively affect body composition in the three to four years following treatment (Demark-Wahnefried, Campbell, and Hayes 2012).Intermediary factors: Treatment with Aromatase 
Inhibitors are associated with increments in LBM over time (Francini et al. 2006, Montagnani, Gonnelli, et al. 2008). Studies in breast cancer populations indicated by a blue line ! (an arrow ! 
indicates agonistic effect; solid circle • indicates antagonistic effect) show a reduction in physical activity has been associated with increased adiposity(Irwin et al. 2005), while treatment related 
menopausal changes have been shown to adversely affect LBM, body fat and body weight (Goodwin et al. 1999, Demark-Wahnefried et al. 2001). Inflammation as measured by CRP has been 
associated with greater fat mass(Dee et al. 2012). A review of research in non-breast cancer populations (purple line !) indicates that increased inflammation is associated with LBM loss and increased 
fat mass (Mourtzakis and Bedbrook 2009). Evidence indicates these adverse changes are associated with poorer disease-free survival. Interventions: Exercise training has been shown to increase 
LBM(Schmitz, Ahmed, et al. 2005, Herrero et al. 2006), decrease adiposity(Irwin, Alvarez-Reeves, et al. 2009, Kim, Kang, and Park 2009), while dietary energy restriction has reduced total and fat 
mass(Thomson et al. 2010). However, dietary energy restriction alone has also been shown to adversely decrease LBM(Thomson et al. 2010).Omega-3 fatty acids (LCn-3) have been shown to prevent 
loss of LBM in NSCLC patients (Murphy, Mourtzakis, and Mazurak 2012).yet not in non-cancer populations; previous reports indicate reduced body weight and adiposity in LCn-3 supplemented 
groups(Kabir et al. 2007, Noreen et al. 2010, Couet et al. 1997, Hill et al. 2007). It is currently unknown in breast cancer survivors (red dashed line --) if LCn-3 supplementation can protect LBM alone, 
in conjunction with a diet and exercise program, and if it does, whether this is a) modified through a decrease in inflammation, and b) more effective than the diet and exercise program alone. (LBM: 
Lean body mass) 
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 Chapter(3(–(Methods(
3.1(Overview(
The primary aim of this study was to compare the effect of LCn-3 supplementation alone (N-3), a 
combination of a specialised exercise and nutrition lifestyle program plus LCn-3 (Ex+N-3), and the 
lifestyle program plus olive oil (EP+OO), on changes in LBM in women who had completed 
treatment for breast cancer in the last 12 months. Secondary outcomes included changes in QOL, 
inflammation, other components of body composition and LBM function variables. Subjects were 
randomly allocated to one of the three groups for six months following baseline assessment; they 
were then re-assessed at 12 and 24 weeks after baseline. 
The first section of this chapter is presented as a published manuscript. It describes the study 
protocol with a focus on the primary outcome measures and a small number of secondary outcome 
measures. The manuscript outlines the relevant literature for our study design, which is a condensed 
repeat of the previous chapter. The methods section of the manuscript describes the assessment 
procedure for the primary and secondary outcome measures. In addition, the manuscript provides a 
list of auxiliary measures, which are further described in the second section of the chapter. Finally, 
power calculations and statistical analyses are outlined in the manuscript 
The second section of the chapter provides more complete information on the justification and 
procedures for the auxiliary outcome measures. Considerations for the inclusion of outcome 
measures and accuracy are described in this.  
 
3.2 Published Manuscript #3:  
The Muscle mass, Omega-3, Diet, Exercise and Lifestyle (MODEL) study – a randomised 
controlled trial for women who have completed breast cancer treatment
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STUDY PROTOCOL Open Access
The muscle mass, omega-3, diet, exercise and
lifestyle (MODEL) study – a randomised controlled
trial for women who have completed breast
cancer treatment
Cameron McDonald1*, Judy Bauer1, Sandra Capra1 and Joseph Coll2
Abstract
Background: Loss of lean body mass (LBM) is a common occurrence after treatment for breast cancer and is
related to deleterious metabolic health outcomes [Clin Oncol, 22(4):281–288, 2010; Appl Physiol Nutr Metab, 34
(5):950–956, 2009]. The aim of this research is to determine the effectiveness of long chain omega-3 fatty acids
(LCn-3s) and exercise training alone, or in combination, in addressing LBM loss in breast cancer survivors.
Methods/design: A total of 153 women who have completed treatment for breast cancer in the last 12 months,
with a Body Mass Index (BMI) of 20 to 35 kg/m2, will be randomly assigned to one of 3 groups: 3g/d LCn-3s (N-3), a
12-week nutrition and exercise education program plus olive oil (P-LC) or the education program plus LCn-3s (EX+N-3).
Participants randomised to the education groups will be blinded to treatment, and will receive either olive oil placebo
(OO+N-3) or LCn-3 provision, while the N-3 group will be open label. The education program includes nine 60-75min
sessions over 12 weeks that will involve breast cancer specific healthy eating advice, plus a supervised exercise session
run as a resistance exercise circuit. They will also be advised to conduct the resistance training and aerobic training 5 to
7 days per week collectively. Outcome measures will be taken at baseline, 12-weeks and 24-weeks. The primary outcome
is % change in LBM as measured by the air displacement plethysmograhy. Secondary outcomes include quality of life
(FACT-B + 4) and inflammation (C-Reactive protein: CRP). Additional measures taken will be erythrocyte fatty acid
analysis, fatigue, physical activity, menopausal symptoms, dietary intake, joint pain and function indices.
Discussion: This research will provide the first insight into the efficacy of LCn-3s alone or in combination with exercise
in breast cancer survivors with regards to LBM and quality of life. In addition, this study is designed to improve
evidence-based dietetic practice, and how specific dietary prescription may link with appropriate exercise interventions.
Trials registration: ACTRN12610001005044; and World Health Organisation Universal trial number: U1111-1116-8520.
Keywords: Breast cancer, Omega-3 fatty acids, Body composition, Exercise, Lean body mass, Inflammation
Background
Breast cancer is the predominant cancer diagnosed in
women with 1.4 million new cases diagnosed worldwide
in 2008 [1]. Modern treatment protocols have resulted
in a 5-year survival rate of 85% to 90% in developed
countries, with Australia’s reported at 89.4% in 2012 [2].
Following treatment for breast cancer, a majority of women
experience significant body weight increases [3-5]. These
changes unfortunately, are comprised of simultaneous lean
body mass (LBM) loss and fat tissue gain [4-7]. Further-
more, LBM loss and fat mass gains have been shown to
occur in the absence of total body weight change [8]. Data
from breast cancer cohorts reveal that weight gain is most
strongly associated with premenopausal status at diagnosis
[4], those who experience menopause as a result of treat-
ment [4,9], lower weight at diagnosis, lower levels of phys-
ical activity [10], and longer chemotherapy treatment [5].
Evidence from pharmacological trials indicate that initial
use of [11], or switching to aromatase inhibitors from
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tamoxifen [12,13] increases LBM, possibly due to the alter-
ation in sex steroid balance. The complete aetiology of
general LBM loss in this population is unclear, however it
appears to be associated with poorer metabolic outcomes,
such as earlier onset of cardiovascular disease and meta-
bolic syndrome related diseases [14,15].
Currently, no definitive recommendations can be made
in regards to the ideal weight or weight change for women
who have completed treatment for breast cancer. Epi-
demiological studies using weight or BMI have indicated
that weight stability may confer benefits in terms of mor-
tality [16-18]. Currently there have been no trials assessing
mortality and the impact of body composition change
(LBM and fat tissue), however results from shorter
intervention trials indicate that intentional weight loss
and increased activity can improve biochemical markers
associated with cardiovascular disease [19-21] and con-
ditions related to metabolic syndrome [19,21], which
both account for significant morbidity and mortality in
this population.
Interventions to improve body composition in women
diagnosed with breast cancer
A number of studies have assessed the impact of diet,
exercise or combined therapies on body composition
during or following treatment reporting mixed effects.
From studies that have reported a high quality measure
of body composition assessment (i.e. Dual-Energy X-ray
Absorptiometry: DEXA; Air Displacement Plethysmog-
raphy: ADP; Computed Tomography: CT-scan; and
Magnetic Resonance Imaging: MRI) resistance training
is most likely to cause an increase in LBM [22,23], aer-
obic training overall has had mixed effects on LBM
[21,24-26], with most studies indicating no change. Two
studies that prescribed a combination of resistance and
aerobic training have shown an increase in LBM [27,28].
Considering that aerobic exercise has been associated with
improved disease-free survival in breast cancer popula-
tions [29,30], a combination of resistance and aerobic two
may promote LBM growth and survival benefits extending
beyond the study timeline. Some data indicate LBM in-
creases may be more likely in younger individuals, and
separately, those taking aromatase inhibitors (AIs) [21,31].
Dietary energy restriction alone has resulted in significant
body weight loss but also involves significant LBM loss
[19], while combining nutrition and exercise prescription
may help to preserve LBM during weight loss [32], and/or
ameliorate fat tissue gain during weight stability [33].
Exercise and nutrition trials during chemotherapy
Numerous uncontrolled and controlled trials have been
conducted assessing change in body weight and/or body
composition. Of these trials, 11 studies that have used
a high quality measure of body composition have
indicated mixed effects on lean body mass for different
modalities. Exercise only interventions conducted dur-
ing chemotherapy have indicated that resistance exer-
cise training is probably required to realise an increase
in LBM [22], while aerobic training alone has shown
little to no impact on LBM change [26]. When Courneya
et al (2007) confined their analysis to women with more
advanced breast cancer (Stage IIb & IIIa) significant im-
provements were seen in the intervention group com-
pared to control, these differences were not seen in those
women with earlier stage disease (Stage 0-IIa) [31]. Com-
paratively, combined exercise and nutrition interventions
during chemotherapy have typically shown no effect on
LBM change [33-35]. Lack of LBM gains may be a result
of the less intensive/structured exercise training compo-
nents prescribed in combined trials.
Exercise and nutrition trials after completion of
chemotherapy
A larger literature exists describing effects of exercise
and nutrition on LBM in women after they have com-
pleted treatment (up to 3 to 4 years post). Of the four
[21,23-25] studies reporting a high quality measure of
body composition after exercise alone, two aerobic exer-
cise studies (one controlled, one uncontrolled) reported
statistically non-significant trends in LBM change [24,25],
while separate aerobic [21] and resistance training [23] tri-
als indicated a significant increase in LBM compared to
control groups (+0.8 kg vs -0.8 kg, p = 0.047 & +0.88 kg
vs +0.02 kg, P = 0.008, respectively). After further analysis,
Irwin et al [36] found that exercisers aged <56 years
had greater LBM gains than women >56 years and non-
exercisers, and those taking AIs and exercising had
greater LBM increases than those not taking AIs.
One well-designed study investigated dietary energy
restriction alone on body composition and examined the
differing effects of a low energy and low fat intake or
low energy and low carbohydrate intake [19]. Both groups
lost a similar and significant amount of body weight
(6.1 kg + 4.8 kg) over 12 months, unfortunately this
body weight change occurred at the expense of fat tis-
sue and LBM. Incidence of sarcopenia, as defined by an
appendicular LBM of <5.67 kg/m2, increased from 10%
at baseline to 18% at the end of the trial [19,37].
Of the two studies that have assessed the effect of
exercise and nutrition combined on LBM, one study has
shown that LBM may be preserved by exercise during
dietary energy restriction [32], while the other indicated
a reduction in fat accumulation with no change to LBM
during dietary energy balance [32,33,38]. After a 2000-
4000kJ energy restriction plus a combined aerobic and
resistance training protocol, Mefferd et al (2007) noted
stable LBM in both intervention and wait-list control
groups, however compared to control, the intervention
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group had a significant reduction in total body weight
(-0.5 kg vs. -5.7 kg, p < 0.05) [32]. Preservation of LBM
during significant weight loss could be viewed as a posi-
tive outcome in this population as losses of LBM are
typical. In a later study that did not use an energy re-
striction, Demark-Wahnefried et al (2008) [33] assessed
the effects of calcium rich diet alone (1200-1500 mg/day),
combined with low load resistance training (30 min, 3/wk),
or combined with the exercise and a low-fat, high fruit and
vegetable intake. No change over time in LBM was seen
within or between groups, however when trunk fat was ex-
cluded from calculations, the third group experienced
less body fat % gain over the 6 month intervention than
the other two groups (Change in body fat%: Gp3: +0.2%
vs Gp1: +1.7% & Gp2: +1.1%, respectively, p < 0.05).
The lack of LBM change is most likely due to the low
frequency and low-load callisthenic type resistance train-
ing prescribed, which may not have been adequate for op-
timal stimulation of muscle protein synthesis.
Taken together, LBM loss is most likely prevented by
resistance training in women who have been or are be-
ing treated for breast cancer. Increases in LBM may be
confined to those women who adhere to more intensive
exercise protocols [21-23], or in specific sub-populations
related to younger age [21] or later stage disease [31].
Dietary energy restriction alone at this stage could be
considered contraindicated due to the heightened risk of
sarcopenia in this population, while the addition of exer-
cise to an energy restriction may ameliorate this risk
[32]. At this stage, no studies have aimed to combine
dietary prescription and exercise training to specifically
increase LBM. Amino acids and long chain omega-3
fatty acids (LCn-3 FAs) are two potential nutrients that
can be targeted to compliment resistance training, yet
data is lacking in breast cancer survivor populations.
Advances in nutritional supplementation and support
for exercise training in other populations indicate that
inclusion of specific nutrients, such as amino acids [39]
or possibly long chain omega-3 fatty acids (LCn-3s) [40],
may significantly enhance the response of LBM in con-
junction with exercise training. To date, studies using
dietary interventions in breast cancer have not utilised
either of these nutrients to improve LBM outcomes
for survivors.
Omega-3 and body composition change
LCn-3s have been extensively investigated for their abil-
ity to preserve LBM in other cancer populations [41,42].
However, the populations typically studied have been
those with metastatic or advanced cancer and cachexia.
Breast cancer survivors do not experience LBM losses
comparable to cachectic populaionts, they are much
more like a metabolic syndrome population who undergo
slower change often associated with fat gains [43].
Long chain omega-3 fatty acids have been considered
as potential body composition modulators with or with-
out dietary energy restriction [44]. However, due to sig-
nificant heterogeneity in population, body composition
measurement, length of trial and dose of LCn-3s some
trials have reported no effect [45-50], while others have
indicated some effect [51-54]. However, of the studies
reporting an improvement of one of more body compos-
ition parameters after increased LCn-3s intake, the clinical
significance of the changes in LBM seen are minimal [40].
In contrast, recently published data indicate that
LCn-3s may have clinical utility as an adjunct to an
anabolic stimulus like resistance training [55] or during
a hyperaminoacidaemic/hyperinsulinaemic clamp [56,57].
Preliminary evidence suggests that LCn-3s may have a
permissive effect on muscle protein synthesis, i.e. reducing
anabolic resistance [56,57], and may improve neural acti-
vation [55] such that skeletal muscle tissue exhibits a
greater response to a given anabolic stimulus. In addition,
LCn-3s were seen to improve the ‘anabolic resistance’
found in older populations [56].
The safety of LCn-3 supplementation for doses of up
to 4g of EPA & DHA/day has been established as low,
with the most common concerns arising in regards to
gastrointestinal upset and allergic reactions [58]. There
is a theoretical link to an increased risk of bleeding when
taken in conjunction with anti-coagulant medication,
however this is not considered to be a contraindication
in these populations [59].
To the authors’ knowledge, no studies have assessed
the effect of exercise training and LCn-3 supplementa-
tion alone or together, in women who have had breast
cancer. Therefore the current study is aimed at compar-
ing the effects of LCn-3FAs alone, an exercise and nutri-
tion program alone, or a combination of both, and how
they influence LBM, QOL and inflammation over 12
and 24 weeks in women who have recently completed
treatment for breast cancer. It is hypothesised that the
greatest relative LBM gains will occur in the combin-
ation group.
Methods/design
Primary hypothesis
Breast cancer survivors participating in a specifically de-
signed group based cognitive behaviour therapy nutri-
tion and exercise program and supplementing with 3g
LCn-3s will have greater attenuation of LBM after 12
weeks compared to participants taking a supplement of
3g LCn-3s alone.
Secondary hypotheses
Breast cancer survivors participating in the group based
cognitive behaviour therapy nutrition and exercise pro-
gram taking a supplement of 3g LCn-3s will have improved
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quality of life after 12 and 24 weeks compared to partici-
pants of either the specifically designed nutrition and exer-
cise program or participants taking a supplement of 3g
LCn-3s alone.
Breast cancer survivors in the group based cognitive
behaviour therapy nutrition and exercise program taking
a supplement of 3g LCn-3s acids will have lower levels
of inflammation after 12 and 24 weeks compared to par-
ticipants of either the specifically designed nutrition and
exercise program or participants taking a supplement of
3g LCn-3s alone.
Trial design
In order to determine the relative efficacy of each inter-
vention, the design of the study is a parallel 3-arm ran-
domised controlled trial. The intervention will occur at
one site, with recruitment occurring at multiple sites.
The primary investigators and the participants allocated
to the exercise and nutrition groups (+/- LCn-3s) will be
blinded, while the LCn-3 FAs alone group is open label.
Details of power calculation and sample size
The primary outcome measure is change in lean body
mass (LBM) at 12 weeks. Exercise interventions In breast
cancer populations have shown LBM increases of 0.7 kg
to 1 kg [21-23,27], however other exercise intervention
studies have reported attenuation of LBM loss rather than
increase [60-62]. Assuming that the minimum difference
in LBM across the comparison groups is a mean of 2%, 38
participants per group will be required to detect this
difference with 90% power and type 1 error of 5% or
less (two-tailed) A total of 114 participants are there-
fore required. Assuming 10% for attrition and allowing
15% for contingency, 51 subjects per group will need to
be recruited to obtain complete data on at least 38 for
each group.
The study is sufficiently powered to test the secondary
hypotheses. A Bonferroni correction to the Type I error
will accommodate the 3 pair-wise comparisons by 2
visits such that p < 0.008 will be considered statistically
significant in order to preserve the family-wise Type I
error rate of 5% for each secondary outcome.
Participant recruitment
Women will be recruited through breast cancer oncol-
ogy centres, radio advertising, social media and breast
cancer research registries in Brisbane, Australia. Oncolo-
gists, breast care nurses and allied health professionals
will inform potential participants of the study during or
shortly following treatment (surgery, radiotherapy and/
or chemotherapy). Participants will be asked to contact
the primary investigator to express official interest in the
study and have eligibility determined. Recruitment into
the trial will be over 10 to 15 groups of 5 to 15
participants per group. A range of group sizes has been
chosen to ensure the maximum number of participants
can be recruited as delaying the start of intervention
may result in some being excluded due to time elapse
since treatment. Within each of these groups, partici-
pants will be randomly allocated to one of 3 groups. A
record will be kept of the number of participants who
have expressed interest to the primary investigator, the
number of potential participants who are eligible, ineli-
gible and then finally randomised into the trial. Ethical
approval has been received from the participating hos-
pital (UCH HREC: #1034) as well as from the University
of Queensland (#2011000079). All participants will pro-
vide written informed consent.
Eligibility criteria
To be included in the study, the women must be >18
years of age; have been diagnosed with early stage breast
cancer (Stage 0-IIIa); have successfully completed surgery,
radiotherapy and/or chemotherapy more than 6 weeks
prior to allow for wound healing and/or shoulder re-
covery, but not more than12 months post completion
of treatment (participants can be currently receiving
endocrine and/or herceptin therapy); able to perform
moderate intensity physical activity, and have a BMI
of >20 and <35 kg/m2.
Participants will be excluded if: they have completed
their treatment more than 12 months ago; there is pres-
ence of metastatic growth or local/distal recurrence of
cancer; they have been diagnosed with cardiovascular
disease or diabetes; they currently consume, or have in
the last 3 months been consuming >1 g of eicosapenta-
noic acid (EPA) and docosahexanoic acid (DHA) LCn-3s
combined per day; or they refuse to be randomly allo-
cated to one of the 3 groups.
Those who are ineligible will be referred to their gen-
eral medical practitioner with encouragement to pursue
appropriate lifestyle recommendations.
Randomisation
The supplier of the capsules who has no direct contact
with the participants will use NQuery Version 7 mixed
block design to randomise group order. Participants will
be allocated to their group in the order in which they
complete baseline assessment. This trial has been regis-
tered with Australia New Zealand Clinical Trials Registry:
ACTRN12610001005044; and World Health Organisation:
Universal trial number is U1111-1116-8520.
Interventions
The 3 intervention arms include: Daily consumption of
LCn-3 FAs (N-3) for 24 weeks; Daily consumption of
LCn-3 FAs for 24 weeks plus a supervised 12-week exer-
cise and nutrition group education program (EX+N-3);
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Daily consumption of placebo oil for 24 weeks and the
12-week program (OO+N-3).
Long chain omega-3 fatty acid supplementation
Both N-3 and EX+N-3 groups will be prescribed 3 g (1.75 g
EPA and 1.25 g DHA) per day taken in five 1 g capsules each
containing 0.35 g and 0.25 g for EPA and DHA, respectively.
Participants will be recommended to take the dose with a
meal, either all at once or spaced throughout the day. Re-
frigeration of the capsules will be also recommended.
Placebo supplementation
The OO+N-3 group will be prescribed five 1 g capsules
containing olive oil. The placebo capsules are visually
identical to the LCn-3 capsules and created by the same
vendor.
All capsules were created in the same batch and were
sample tested to ensure they contained the indicated dose.
All Participants will be asked to avoid ongoing supple-
mentation of any source that contains additional LCn-3s.
Exercise and nutrition education program
EX+N-3 and OO+N-3 groups will be asked to attend 9
nutrition and exercise sessions over 12 weeks, starting 1
to 10 days after baseline assessment. To ensure adequate
group size, both EX+N-3 and OO+N-3 groups will partici-
pate in the same sessions. Both participants and primary in-
vestigator will be blinded to group allocations, while all
capsules will be given out separately to minimise product
comparison. The sessions will run for 60-75 minutes at the
Wesley Research Institute, Brisbane. The sessions will in-
clude 30 to 45 minutes of nutrition education, the remain-
der of the time is committed to resistance exercise training.
The sessions will be facilitated by the Primary Investigator
who is an Accredited Practising Dietitian and Accredited
Exercise physiologist with relevant clinical experience.
Semi-supervised exercise program
The supervised exercise sessions are designed as circuit
based training sessions. The sessions will be started with
active range of motion exercises as a warm up, exercises
will then performed and the session completed with spe-
cific stretches and flexibility exercises. The exercises in-
clude push ups, squats*, lunges, glute bridging, seated
row*, shoulder press*, bicep curls* and a series of pos-
tural and abdominal exercises (*Exercises marked indi-
cates the use of the Gymstick™). The resistance exercise
program is designed to be performed at home using
body weight and the Gymstick™, a specialised elastic re-
sistance stick, which has been used in a previous non-
cancer population of similarly aged participants [63].
During the supervised sessions feedback will be given
regarding technique, exercise progression and modifica-
tion, and management of injury/discomfort. Participants
will be prescribed to reach at least 3 resistance sessions
per week including the supervised session, and at least 3
aerobic training sessions each week at home. The partic-
ipants will be given access to specifically made video
material that details the appropriate technique for the
majority of the exercises performed in class. The pro-
gram will be progressed with the addition of new exer-
cises, increased difficulty of exercises by increasing the
tension of the Gymstick™, or exercise modification, and
through an increase in workload volume (repetitions and
sets). Typically, each exercise will be performed as many
times as possible in 30-second to one-minute bouts, or
until temporary fatigue. This type of workload has been
chosen as it is most applicable to home training using
body weight and elastic apparatus. In addition, research
indicates that reaching temporary fatigue through a low
load high-volume protocol results in a similar increase
in muscle protein synthesis when compared to a high
load protocol with less repetitions [64].
Nutrition and exercise education program
The nutrition education program was based on a previ-
ously validated cognitive behavioural program for weight
loss [65] and adapted to focus on healthy food choices
for breast cancer survivors. It should be noted that par-
ticipants will not be given additional advice regarding
weight loss or energy restriction throughout the trial.
The 9 sessions will include advice on general and breast
cancer specific healthy eating, benefits of exercise and
practicalities of incorporating healthy habits. Group dis-
cussion will be facilitated by the primary investigator to
increase practical content. All of the nutrition sessions
will be recorded on the Powerpoint slides and provided
to the group members via an online portal.
Side effects of treatment
All participants will be asked to report the appearance of
any adverse symptoms that may be related to the exer-
cise program or capsule consumption. If a participant is
diagnosed with a recurrence they will be excluded from
the data analysis. They will also be advised in how to ac-
cess ongoing lifestyle treatment in a private setting. If
participants report an exacerbation of lymphoedema
symptoms they will be referred to a breast cancer spe-
cialist physiotherapist for assessment, in addition, they
will be advised to cease their upper body resistance
training until medical clearance is given to continue as
per the ACSM guidelines [66]. For gastro-intestinal
upset, or unpredicted reactions that arise during the
study period, participants will be asked to cease capsule
consumption and advised to seek medical clearance be-
fore recommencing.
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Measures
All outcome measures will be performed at baseline, 12
and 24 week time points. The 24 week time point has
been included to better understand the practicality of the
intervention in terms of maintenance of lifestyle changes
after the supervised time. Each assessment period will in-
volve 2 visits to the WRI. Visit 1 measures will include
body composition, questionnaires and aerobic fitness test-
ing. Over the next 7 days participants will be asked to:
complete the Diet History Questionnaire; wear a uniaxial
accelerometer every day; and have a fasting blood sample.
At Visit 2, the primary investigator will review the diet his-
tory questionnaire, collect the accelerometer and conduct
the muscle endurance testing. The progression of partici-
pants through the study can be seen in Table 1, with
specific timing of outcome measures shown in Table 1.
Primary outcome measure
Body composition
Change over time in percentage lean body mass will
be measured using air displacement plethysmograhy
(ADP) (BODPOD, COSMED USA Inc). Before each
assessment day, the BODPOD scales and air chamber
is calibrated as per the manufacturer’s instructions
using known weights and volumes, respectively. Air
Displacement Plethysmography is considered a valid alter-
native to hydrodenitometry (or underwater weighing); it is
based on the two-compartment model which views the
body as two distinct chemical components composed of
FM and FFM [67]. ADP was validated against hydrostatic
weighting and generated similar result with good preci-
sions when tested repeatedly [67,68]. Amongst health
subjects, ADP has been shown to agree well with other
laboratory methods including DXA [69,70] and isotope
dilution [71]. All measures will be performed by a certified
BODPOD assessor.
Participants will be assessed in a non-fasted state. To
minimise daily weight variations, participants are measured
at a similar time of day (within 60 minutes of initial assess-
ment) at all 3 assessment points. Consumption related
weight variations will be controlled by a food and drink rec-
ord. At the 12 and 24 week assessments, participants will
be asked to repeat their intake from the initial assessment.
Participants will be provided a lycra suit and hair cap
designed for the BODPOD that must be worn during the
assessment. Weight is measured with the electronic scale
attached to the BODPOD system. Height is measured using
a wall mounted stadiometer. The predicted thoracic volume
generated by BODPOD software is used for all calculations.
Secondary outcome measures
Quality of life (QOL)
QOL will be measured using the Functional Assessment
of Cancer Therapy- Breast + 4 (FACT-B + 4) tool. This
tool has been validated for quality of life measurement in
cancer survivor populations [72], breast cancer treatment-
related arm morbidity [73], measuring QOL change fol-
lowing exercise training [74], and is one of the most
widely cited tools in breast cancer research [75] It is com-
prised of 2 separate tools, the 27-item FACT-G, and the
additional 14-item ‘B + 4’ that specifically relates to in-
dividuals who have been treated for breast cancer. A
five-point Likert scale is utilised (ranging from 0 = ‘not
at all’ to 4 = ‘very much’) and includes four subscales
(physical, social, emotional, and functional well-being).
Higher scores represent better well-being.
Table 1 Timings for baseline, 12 & 24 week assessments
Day 1 – Approx 2 hours Days 2-6 Day 7 – approx 15 mins
Baseline assessment - Consent form and eligibility assessed - Fasting CRP and EFA test - Hand in Accel
Week -1 to 0 - Accel
- LBM, - Squat
- Body fat%, Wt, Ht, Waist, Hip - Push up
- DHQ- QOL related questionnaires
- TMill
- Handgrip strength
- Demographical info
- Accel given
Mid intervention assessment As above except for consent form
+
Pill countsWeek 12-13
Post-intervention assessment Same as mid-intervention assessment
Week 25-26
LBM: Lean body mass; Wt: Weight & Ht: Height; Waist & Hip: Girths; QOL: Quality of Life; TMill: Treadmill Sub-max Vo2 test; Accel: 7-day accelerometer; DHQ: Diet-
ary Habits Questionnaire; CRP: Fasting high sensitivity C-reactive protein; LCn-3: Fasting erythrocyte fatty acid analysis; Push up: 60-second push up test; Squat: 60-
second squat test.
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C-reactive protein
A fasting high sensitivity-CRP will be measured using a
latex-enhanced immunoturbidimetric assay of blood serum.
Participants will be asked to attend a Healthscope Path-
ology lab between Day 1 and 7 of each respective assess-
ment period to have a fasted blood sample taken by a
qualified lab technician.
Body composition
Percentage and total body weight, adipose tissue content
will be measured using the BodPod as described above.
Measure of adherence to capsule intake
Long chain omega-3 fatty acid intake will be accounted
for in two ways: erythrocyte LCn-3 FA content, and
combination of pill count and diet history questionnaire.
Erythrocyte fatty acid analysis
Lipids from red cells are extracted with chloroform
methanol mixture. The fatty acids are trans-esterificated
to methyl esters with methylation reagent “Meth-Prep 2”.
The methylation extract is analysed by gas liquid chroma-
tography method with flame ionisation detection (gas
chromatograph Schimadzu G-2010-FID). The proportion
of fatty acids content of the erythrocytes expressed as % of
total fatty acids.
Pill count
All capsule bottles will be handed in at the end of each
12 weeks. All pills not consumed will be counted and
recorded over the 24 weeks.
Measure of adherence to exercise and dietary program
The Active Australia Survey [76], 7-day Uniaxial accel-
erometry and exercise log during the intervention will
be completed for all assessment points in order to deter-
mine changes to physical activity. In addition, changes in
push-ups and squats will be considered an indirect marker
of exercise adherence. Dietary intake will be assessed
by an Accredited Practising Dietitian using the Dietary
Habits Questionnaire [77]. Additionally, attendance at
sessions will be recorded for each group.
A number of other measures will be taken to capture
changes in sub-maximal aerobic fitness [78], upper body
strength-endurance [78], lower body strength-endurance
[78], handgrip strength [79], waist and hip girths [80],
fatigue [81], physical function [82,83] and menopausal
symptoms [84]. The tools to be used to measure the
above are shown in Table 2.
Data analysis
The primary analysis population is intention to treat.
The ITT population will include all randomised partici-
pants with at least one post-baseline assessment. Analysis
will also be performed on the per protocol (PP) popula-
tion. The PP population will include all participants who
were at least 75% compliant to the exercise and nutrition
program (as measured by the number of exercise sessions
attended) and 70% adherent to pill intake (as measured
by pill count returned/diet history questionnaire or by
erythrocyte LCn-3 FA).
Baseline demographic and disease related characteris-
tics will be summarised by group as count and percent
for categorical variables and number, mean and standard
deviation for continuous variables. To compare the three
treatment groups at baseline, a chi square test or Fishers
exact test will be used for categorical variables and a one
way analysis of variance (ANOVA) or Wilcoxon rank-
sum test for continuous variables. Baseline demographic
and disease-specific characteristics that differ among groups
will be considered for covariate adjustments in analysis of
all outcomes.
Measurements collected longitudinally will be sum-
marised by group as number, mean and standard devi-
ation, minimum and maximum at each visit (baseline,
12 week, 24 week). Absolute change from baseline will
be calculated by subtracting the baseline measurement
from the 12 week and 24 week measurements; percent
change from baseline will be calculated by dividing the
12 week and 24 week measurements by the baseline
measurement. Measurements include: body composition,
quality of life, C-Reactive Protein, physical activity and
sedentary time, aerobic fitness, muscular endurance, muscle
strength, dietary intake, waist and hip girth, joint pain and
physical function and menopausal symptoms. All outcome
data will be visually inspected for normality. Data with
a skewed distribution may be transformed (e.g. log
transformation).
Table 2 Additional measures taken at baseline, 12-weeks
& 24 weeks
Outcome Tool
Physical activity & sedentary time -7-day uniaxial accelerometery
-Active Australia Questionairre
-Training log book (Wk 12 & 24)
Changes in aerobic fitness -Sub-maximal treadmill test
(modified Balke)
Muscular endurance Upper body: 1-min-push up test
Lower body: 1-min sit-to-stand test
Muscle strength Grip strength
Dietary intake Diet history questionnaire
Waist and hip girth Metal tape measure
Joint pain and physical function Health Assessment Questionnaire –
Disease Index (HAQ-DI)
Menopausal symptoms Greene Climacteric Scale
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The primary outcome of percent change in lean body
mass at 12 weeks between the N-3 and EX+N-3 groups
will be tested using a contrast in a one-way ANOVA and
a p-value <0.05 will be considered statistically significant.
Secondary outcomes will be evaluated using mixed models
to accommodate the correlation of the repeated measure-
ments taken on an individual over time. For each of the
change from baseline outcomes, time (12 week vs 24
week), treatment (N-3, EX+N-3, OO+N-3), the time by
treatment interaction and the baseline value of the out-
come will be tested as fixed effects with a random subject
effect specified. Interactions with p < 0.10 will be retained
in the models. Contrasts will be constructed to compare
pair-wise differences among the three treatment groups at
each time point. Similar mixed models will be fit to evalu-
ate the effect of adjusting for covariates. In addition to the
fixed effects for time, treatment, time by treatment and
baseline value, covariates at baseline identified as statisti-
cally different among the three groups and covariates
known or hypothesised to be associated with the particu-
lar change from baseline outcome will be evaluated as
fixed effects.
Discussion
This study will further the evidence base in regards to
omega-3 and exercise synergies. These findings will be
applicable to breast cancer populations and may trans-
late to populations with other chronic diseases. The ces-
sation of LBM loss, fat mass gain and the associated
metabolic benefits are an important consideration for
women after breast cancer treatment. Thus, the applic-
ability of known and practical lifestyle measures is an
important consideration for ongoing management.
Abbreviation
ADP: Air displacement plethysmography; BMI: Body mass index; CT-scan:
Computed tomography; Demo: Demographics; DEXA: Dual-energy X-ray
absorptiometry; E-LC: Education program plus LCn-3s; FACT-B + 4: Functional
assessment cancer therapy – breast +4 items; Hs-CRP: High sensitivity C-reactive
protein; LBM: Lean body mass; LC: 3g/d LCn-3s alone; LCn-3 FAs: Long chain
omega-3 fatty acids; MRI: Magnetic resonance imaging; P-LC: 12-week nutrition
and exercise education program plus olive oil group; QOL: Quality of life.
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 &
3.2.1 Additional information relevant to the primary outcomes 
Assessment of Hs-CRP 
A full explanation of the analytical processes can be found in Appendix 6. Healthscope pathologies 
laboratory were used for all results. Coefficient Variations (CV) of the instrument used were 
documented at 2.3 to 3.7% (see Appendix 6).  
In breast cancer populations, an increased risk of cardiovascular disease has been associated with a 
CRP value of >3.9 (Pierce et al 2008) and risk increased in a dose dependent manner. Considering 
Hs-CRP is a marker of chronic inflammation, that loss of LBM and higher fat mass is related to an 
increase in CRP (Dee et al 2010), and its measurement is readily available through routine 
assessment, it was considered as an appropriate measure. Preliminary evidence also indicates that 
exercise participation (Fairey et al 2005) and LCn-3 (Tsitouras et al 2008) intake are negatively 
associated with hs-CRP.  
3.3(Ethics(Approval(
This study proposal was submitted to UnitingCare Health Human Research Ethics Committee 
(HREC) as well as the University of Queensland HREC. This study was granted ethical approval 
jointly from the UnitingCare Health HREC on the 27/10/2010 (Reference #: 1035), and the 
University of Queensland HREC on the 28/4/2011 (Ref: 2011000079; see Appendix 1). Nine 
variations were applied for and approved by the respective HREC’s since initial approval was 
granted. These variations reflected the need to modify the study design to account for practical 
issues that arose during the course of the study. The majority of these changes were related to the 
wording of the participant informed consent document; and to expand the recruitment criteria to the 
general public, as opposed to referrals only from select consultants in the Wesley Medical Centre. 
Copies of the final participant information and consent forms (inclusive of the approved variations) 
are provided in Appendix 3. 
3.4(Study(Design(
The study included three groups to compare efficacy of LCn-3 and lifestyle alone or in combination 
together. An olive oil only group was not included for a number of reasons: 1) The goal of the trial 
was to determine the efficacy of LCn-3 in comparison to the lifestyle program, compared to a 
combination of both. A ‘no treatment, olive oil only’ group was not needed to answer this question; 
2) Current evidence indicates that exercise is an important consideration for better outcomes after 
treatment for breast cancer (Ibrahim and Al-Homaidh 2010, Schmitz et al. 2010), hence inclusion of 
a ‘no treatment’ group was not considered ethical. The overall structure of the study including data 
collection points can be seen in Table 3.1.  
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 TABLE&3.1&OUTLINE&AND&DESCRIPTION&OF&INTERVENTION&&
3.4.1(( Development(of(dietary(and(exercise(interventions(
The lifestyle program was designed to improve knowledge and practice of physical activity and 
healthy dietary practices specific to breast cancer. Physical activity and function was addressed 
through formal range of motion, strength and endurance exercise training. Dietary habits and 
knowledge was improved through delivery of theory and practical information sessions via 
powerpoint presentations and facilitated group discussions. A summary of the sessions and is 
shown in Table 3.1. 
& Intervention groups 
Week 
number 
N-3 EP+OO EP+N-3 
-1 Baseline assessment and data collection 
0 Baseline assessment and data collection (cont’d) 
Start of capsule consumption – Capsule collection and randomisation 
1  
 
 
 
Participants were 
able to contact the 
primary 
investigator at any 
stage during this 
time period 
General healthy eating and benefits of exercise specific to 
breast cancer; Resistance training familiarisation 
2 Resistance training familiarisation + goal setting for 
aerobic training; Plant food consumption, practicalities 
and budget 
3 Maintaining a healthy weight/intake – appropriate 
portions/fats; Resistance training session 
4 Mindful eating and hunger; Resistance training circuit 
5 Meat, Salt, Supplements; Resistance training 
6 Alcohol & Socialising; Resistance training 
8 Label Reading; Resistance training 
10 Nutrition myths and breast cancer; Resistance training 
12 Discussion group regarding keeping the program going; 
Goal setting for future 12 weeks and beyond 
13-14 12 week assessment and data collection & capsule collection 
15-24 Ongoing capsule consumption and/or exercise and nutritional habits 
25 Post-intervention assessment and data collection   
Cessation of capsule provision 
N-3: LCn-3 supplementation only group; Ex+OO: Nutrition and exercise lifestyle program 
plus olive oil supplementation; Ex+N-3: Nutrition and exercise lifestyle program plus LCn-
3 supplementation. 
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 All sessions including educational and exercise activities were held in a conference room within the 
Wesley Research Institute. Parking for the participants were offered at no cost. 
Exercise prescription for the Lifestyle Program  
A combination of resistance and aerobic exercise training was prescribed in agreement with the 
ACSM(Schmitz et al. 2010) and ESSA (Hayes et al. 2009) best-practice exercise for cancer 
survivors position stands. Details of the exercise prescription are shown in Table 3.2.  
Participants were directed to perform aerobic exercise at home or in the gym to elicit an intensity 
that related to a rating of 11-14 on the Borg Scale (Appendix 4). Aerobic exercises recommended 
included but was not restricted to walking, running, cycling, 
rowing, dancing, gym classes and/or swimming.   
Resistance training was performed using a combination of body 
weight exercises and a GymStick® Figure 3.1. Exercises involved 
all major muscle groups starting with 4 exercises and building to 
eight to ten exercises by week eight (progression was prescribed 
individually during sessions by the primary investigator).  
Prescribed and resistance progressions can be seen in full in the 
MODEL Study manual (Appendix 4).  
 
Figure 3.1 Gymstick - resistance training apparatus 
Participants were requested to record their activity in a diary that was supplied (Appendix 4). The 
log was designed to capture daily exercise feedback on intensity, duration and type of training.  
Due to the resistance of the GymStick® and body weight exercises being considerably lower than 
that available when using conventional weight machines and free weights, participants were 
instructed to perform the exercises to temporary fatigue regardless of number of repetitions. Current 
resistance training guidelines high-load contractions (i.e. >70% of 1-RM) for optimal stimulation of 
muscle growth (American College of Sports 2009), however a recent study in young men has 
indicated that achieving temporary failure may be more critical for muscle protein synthesis (MPS) 
than the absolute weight lifted (Burd et al. 2010). The study revealed an equivocal MPS response 
for four sets of 90% 1-repetition max (1-RM) and 30%1-RM when both were performed to 
temporary failure. However, a third group that performed 30%1-RM to match the workload of the 
90%1-RM (volume of work was the focus rather than temporary failure), experienced significantly 
lower rates of MPS (Burd et al. 2010). Considering this, exercising to temporary failure was 
considered a reasonable approach to manage the limitations presented by a semi-supervised 
intervention that utilised lower tension resistance apparatus. Exercise prescription during the trial is 
outlined in Figure 3.2. 
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 Exercise, physical activity education and adverse events 
Information regarding exercise terminology, decreasing sedentary time and ensuring safe exercise 
practices were delivered during education sessions. During this time and the supervised exercise 
sessions, participants were encouraged to ask questions about activity and report any discomforts 
experienced at home or during supervision. 
Nutrition education  
The aims of the nutrition education sessions were to improve dietary quality, and inform 
participants of relevant nutrition topics to prevent misinterpretation of information from media. The 
content was based on the whole food approach focusing on general healthy eating recommendations 
suitable for breast cancer survivors including high intake of plant foods, consuming lean meats, low 
fat dairy, wholegrain breads and cereals, appropriate fat consumption and a reduction of high fat 
and high sugary foods (Robien, Demark-Wahnefried, and Rock 2011, Pierce et al. 2007, 
Chlebowski et al. 2006, Harris, Bergkvist, and Wolk 2012, Magee and Rowland 2012). The basic 
structure and delivery style of the program was adapted from a previous 6-week group healthy 
eating weight loss program, Fat Booters Incorporated (FBI), published previously (Ash et al. 2006). 
Notable changes to this program from the original FBI protocol included the exclusion of 
prescribed energy restriction, and the addition of sessions that covered mindful eating, cancer 
nutrition myths/media misinterpretation, alcohol and cancer, soy products and nutrient 
supplementation.  
No specific recommendations were given in regards to energy and protein intake. An increase of 
both has been shown to result in overall body weight and LBM increases of which is known to 
significantly influence LBM change, and have synergistic effects when combined with exercise 
training (Norgan and Durnin 1980, Breen and Phillips 2013).  
To minimise additional LCn-3 intake, participants were advised to not consume any LCn-3 
supplements, nor was there a significant focus on LCn-3 related intake throughout the program.  
Nutrition and exercise information for LCn-3 consumption alone 
Participants randomised to the N-3 group were advised to live and eat freely. Information available 
to the public in regards to exercise and nutrition were provided on request. However, all other 
advice was limited to what they received from their medical team. They were recommended to 
access publicly available information regarding exercise and nutrition for breast cancer survivors. 
No nutritional restrictions were placed on this group other than avoiding added consumption of 
LCn-3 containing supplements.  
Freedom to act was an important component of this trial, as part of the research aims to answer if 
LCn-3 supplementation alone is enough to influence the participants LBM. Currently, there is good 
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 awareness through media and other promotion, that nutrition and physical activity have a role in 
wellbeing after a diagnosis of breast cancer. Thus, testing if LCn-3 is adequate in influencing 
outcomes to the same extent as a structured lifestyle program requires those in the LCn-3 only 
group to live as they would. In this way we determine the necessity for structured education versus 
the true influences found outside the program. &&TABLE&3.2&AEROBIC&AND&RESISTANCE&TRAINING&PRESCRIPTION& &PROGRESSION&
 
3.4.2 Omega-3 and Placebo supplementation  
Further information about the oil capsules 
Placebo capsules consumed by those in Ex+OO contained 1g of light olive oil. The olive oil was 
treated to remove the majority of its antioxidants during manufacture. The dose of 3g (1.75g EPA 
and 1.25g DHA per day) of LCn-3 was chosen because LCn-3 absorption into tissue is likely to be 
maximized at this dose (Dosing was confirmed by Alpha Laboratories, NZ, with documentation 
provided by the manufacturer on request). Uptake into the tissue is negatively correlated with BMI 
(Hogg et al. 2006), however findings from our review indicate that in order to achieve maximal 
LCn-3 uptake into erythrocytes, 1.42g of EPA and 1.12g of DHA may be required (Yee et al. 2010, 
McDonald, Bauer, and Capra 2013). 
Participants were given a 12-week supply of capsules at baseline and 12weeks. It was requested that 
all bottles and unconsumed pills were returned to the primary investigator. Blackmores Pty Ltd 
supplied all capsules for the trial gratus. They were approached for provision of the capsules as they 
already had a high strength 1000mg omega-3 product that achieved appropriate dosing. The 
Blackmores’ liaison was only involved for the provision of capsules and generation of the 
randomised sequence. 
Training/Location Weeks 1-3 Weeks 4-6 Weeks 7 - 24 
Aerobic training 
Home or Gym Based 
2 x 30mins/wk 
RPE: 11-13  & 3 x 30mins/wk RPE: 12-14 & 3-5 x 30-45 mins/wk RPE: 12-14 &
Resistance training 
Home based using 
only the GymStick 
2 x 30 min/wk 
4 exercises;  
Repetitions to fatigue  
1-2 sets per exercise 
2 x 30min/wk 
6-8 exercises 
Repetitions to fatigue  
2 sets per exercise 
2-3 x 30min/wk 
8-10 exercises 
Repetitions to fatigue  
2-3 sets per exercise 
RPE: Relative perceived exertion; wk: week;  
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 3Blinding of capsules 
The N-3 groups capsules were open-label, while the Ex+OO and Ex+N-3 groups’ capsules were 
blinded to participants and the research team. The Blackmore’s representative who mediated the 
production & delivery of the capsules also performed the blinding sequence. The blind was not 
broken until all participants had completed the 24 week protocol and all data was entered and 
cleaned.  
3.4.4(( Further(information(on(Recruitment(
The period of recruitment took place between July 2011 and January 2013. Original projections of 
recruitment were an uptake of 8-12 participants per month for 14 months, however, due to this 
recruitment being significantly lower than expected, the recruitment window was expanded. The 
primary method for recruitment was via Brisbane based oncologists (medical, radiological and 
surgical) at the Wesley Hospital and the Mater Hospital. In addition, recruitment materials 
(Appendix 2) and presentations were given at breast care centres, outpatient chemotherapy units, 
local radio, via social media, local newspapers, national and local television news and relevant 
email lists. Individuals were asked to contact the primary investigator and a preliminary screening 
was carried out. If they met the criteria for the study they were sent a Participant Information and 
Informed Consent Form (Appendix 3) to read and further consider the study. If they wished to 
participate, they were informed of the next assessment day, allocated a time convenient to them, 
and on signing the consent form were eligible to begin the baseline assessments. 
Eligibility Screening 
Upon calling or emailing to express interest in participation, individuals were asked a series of 
questions relating to the eligibility criteria (Appendix 3). If they met the criteria they were offered a 
choice of times on the next assessment day. As eligibility was in part determined by body 
composition, final eligibility was determined as a result of weight and height measures (BMI) taken 
at the time of the baseline assessment. 
Women who had completed treatment for breast cancer within the last 12 months were chosen for 
the study as it has been shown that the rate of body composition change is greatest for the six to 12 
months following treatment (Makari-Judson et al 2007). Therefore, if the intervention had an effect 
it was expected that differences between groups would be more pronounced. Both pre- and 
postmenopausal women were included in our study, as a review of the studies to date have reported 
a general lack of premenopausal participation in lifestyle interventions. In addition, both 
populations were included to increase the potential pool of recruitment, and so that the effect of the 
intervention could be assessed in both populations. Women were excluded if their BMI was less 
than 20kg/m2 or greater than 35kg/m2. It has been noted that women who experience significant 
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 loss of weight are at a greater risk of mortality (Nichols et al 2009, Caan et al 2008). The research 
team determined from clinical experience that women who were underweight would require a more 
specialised dietary and exercise intervention to prevent further weight loss following treatment. For 
those with a BMI of greater than 35, it was determined a more specialised dietary intervention 
would be required. In addition, exercise physiology considerations differ for this population. It was 
determined a more individualised and intensive program was necessary to allow for individual 
disease and biomechanical risk. Those with a chronic disease such as diabetes and cardiovascular 
disease were excluded as best practice for these individuals is an individualised program to address 
their specific condition; as information relating to those diseases, effects of medications and 
contraindications to exercise were not covered in the program.  
3.4.5(Secondary(Outcome(Measures(
The following section contains the considerations for the selection of and the procedure for the 
secondary outcome measures chosen. It should be noted to the reader that if the methodology was 
comprehensively accounted for in the Methods Paper – Section 3.2, then they are not accounted for 
in the following text.  
Measures of adherence to the intervention 
Physical)activity)during)the)12)week)intervention)
Both groups who completed the lifestyle program (Ex+N-3 and Ex+OO) were asked to report their 
weekly exercise throughout the first 12 weeks. The information gathered included: the number of 
times resistance and aerobic exercise was performed, for resistance exercise, sets, reps and specific 
exercises were recorded. For aerobic, time and intensity (as rated on the Borg Scale) was recorded. 
Changes in activity levels were also accounted for in the Active Australia Survey and through use 
of the accelerometer. 
Physical)activity)during)follow)up:)weeks)13;24)
All participants were asked to record their level of physical activity after the 12wk assessment in a 
diary provided. Information collected included the same data as through the first 12 weeks.  
Waist girth 
Waist girth was measured as a marker of abdominal obesity and cardio-metabolic health, both of 
which are relevant to co-morbidities in general and breast cancer survivor populations (Healy et al. 
2010, Thomson et al. 2009). As change in body composition over time was of relevance to this 
study, the site defined in the International Standards for Anthropometric Assessment(Marfell-Jones 
et al. 2007) was used. The metal tape measure was positioned at ‘the narrowest point between the 
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 lower coastal (10th rib) border and top of the iliac crest, perpendicular to the long axis of the trunk’ 
on the skin (i.e. sports bra or swimwear). The participant was asked to relax and to exhale during 
measurement. The tape measure was snug, but not compressing the skin. 
Hip girth 
Hip girth was measured as an additional marker of fat tissue change. Current evidence does not 
indicate that there is an increased risk of co-morbidity associated with fat deposition around the 
gluteal, however it is an area that is sensitive to body composition change (Rocha et al. 2008). The 
measure was taken after participants were asked to stand in bike shorts or swim wear with heels 
together, and relaxed gluteal muscles. The tape was placed around the buttocks ‘at the level of their 
greatest posterior protuberance, perpendicular to the long axis of the body’ (Marfell-Jones et al. 
2007).  
Fatigue 
Fatigue is a common side effect after treatment for breast cancer (Meeske 2007). Fatigue was 
measured using the FACT-F tool, a stand-alone 13-item scale that has been used in a number of 
studies assessing cancer related fatigue. A validation study carried out in cancer populations (24% 
of whom had breast cancer) indicated a clinically important difference was a change in score of 3.0 
(Cella et al 2002).  In addition, physical fitness and activity has been shown to be negatively 
associated with perceived fatigue (McNeely et al. 2006). One controlled exercise trial in breast 
cancer survivors indicated statistically improved fatigue as measured by FACT-F (Courneya, 
Mackey, et al. 2003) which is calculated through the addition of the FACT-G to the fatigue specific 
13-item survey. Each item can be answered on a five-point scale. Scores can range between 0 and 
52 with lower scores indicating greater fatigue. When assessing cancer-related fatigue syndrome 
(CRFS), compared to the recognised standard or diagnostic interview and structured psychiatric 
interview, the FACT-F scale was reported to have a sensitivity of 80%, specificity of 71%, a 
positive predictive value of 55% and negative predictive value of 89% (Alexander, Minton, and 
Stone 2009). 
  
Dietary history using the Diet History Questionnaire  
The primary investigator (an accredited practicing dietitian) carried out a semi-structured diet 
history of the participants overall food intake using the Diet History Questionnaire (Smart Foods 
Centre, University of Wollongong – Appendix 3). On day 7 of the assessment period, participants 
were asked to complete the form to the best of their ability, at which point the clinician clarified 
portion sizes and helped the participant complete items left blank. This particular tool has been 
validated for overall energy intake and total LCn-3 intake (Martin 2004).  The diet history takes 
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 amount and frequency of consumption into consideration for average daily intake (kilojoules) over 
the previous month. Nutrient intake was analysed using Foodworks 7, Xyris Software.  
Objective physical activity  
Increased time spent in sedentary activity is related to increased risk of heart disease and diabetes in 
general populations (Dunstan et al. 2010), and breast cancer survivors are at heightened risk of 
these diseases following treatment (Demark!Wahnefried, Campbell, and Hayes 2012). Objective 
physical activity was measured using a uniaxial accelerometer (GT1-M, Actigraph, USA). 
Participants were asked to wear the accelerometer for all waking hours between Day one and Day 
seven of each assessment period. Participants were instructed to attach the accelerometer to their 
hip (belt line) and asked to maintain its consistency of placement for all wear-time. At least four full 
days (10 hours) of data was required for the data to be classified as valid (Dunstan et al 2010). 
Accelerometers calculate movement in counts/minute. Sedentary activity is measured as  <100 
counts/min; light activity as 100-1951 counts/min; moderate activity as 1952-5724 counts/min; and 
vigorous activity >5724 counts/min. Excessive scores of  >20,000 counts/min will be excluded. 
Non-wear time was defined as intervals of at least 60 consecutive minutes of zero counts, with 
allowance for up to 2 min of observations of less than 50 counts/min within the non-wear interval. 
These measures have been used to ensure homogeneity with other studies, and validation studies 
using the same apparatus (Dunstan et al. 2010).  
Self-reported Physical Activity  
Self reported physical activity was measured by the Active Australia questionnaire. The tool 
collects reported time spent in light, moderate and vigorous physical activity, it is a reliable and 
validated tool against accelerometry, and for assessing changes in daily physical activity as short as 
13 days apart (Brown et al. 2008). 
Physical fitness and muscle function tests 
All assessments were performed under the supervision of the primary investigator, an accredited 
exercise physiologist. A standardised script was used to maintain consistency in verbal instructions 
and encouragement.  
Sub-maximal exercise  
Higher aerobic fitness is strongly associated with lower risk of cardiovascular disease, diabetes, 
cancer related fatigue and improved overall mortality. Aerobic fitness was measured using the 
modified Balke protocol on a treadmill in the cardiovascular rehabilitation unit of the Wesley 
Hospital. Participants were asked to abstain from caffeinated beverages, vigorous exercise for 2 
days before the test, and continue all normal medications on the day of the test. Pre-test measures of 
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 blood pressure and heart were taken to ensure the participant was safe to complete exercise. 
Participants with high blood pressure (>180/110) were not allowed to complete the test, as per best 
practice guidelines (Sharman and Stowasser 2009) and referred to their oncologist for further 
cardiovascular screening. The modified Balke protocol is a graded exercise test that consists of 7 
stages, each of which is 3 minutes in duration (see Appendix 3). The protocol was designed to 
increase in intensity until a heart rate equal to 85% of estimated heart rate max (or 70% of heart rate 
reserve) was reached. The test was terminated when this heart rate was achieved, or when the 
participant chose to stop, whichever came first. In case of cardiac or injurious event, a ‘Code’ was 
to be called and the participant was to be referred to The Wesley Hospital Emergency Department. 
Safety of this test has been confirmed through numerous studies using the same population and is a 
recognised assessment for estimated VO2max (Jones et al. 2008). 
LBM function tests  
Upper and lower body muscular strength-endurance and handgrip strength were measured using the 
1-minute push up, 1-minute sit-to-stand and a handgrip dynamometer, respectively. These were 
included to measure the improvement elicited from any resistance training performed during the 
study period. The tests followed a standard protocol outlined in the ACSM’s Guidelines for 
Exercise Testing and Prescription (8th Edition) (American College of Sports Medicine 2010).  
The 1-minute push-up test involved the participants performing as many consecutive push-ups 
(knees on ground) as possible in one minute. Technique was monitored to ensure consistent 
measurement and to minimize risk of injury. Safety of this test has been demonstrated in other 
populations (Suni et al. 1998), while more advanced tests, e.g. bench press 1-RM has been 
performed in numerous breast cancer interventions with similar (Schmitz, Ahmed, et al. 2005), and 
more ‘at-risk’ populations (Schmitz et al. 2009, Courneya et al. 2007). Participants experiencing 
lymphoedema were asked to wear their custom garment during the exercise and given specific arm 
mobility exercises before permitted to complete the test. Participants with upper limb 
injuries/limitations were allowed to decline the test. 
The one-minute squat test involved the participant performing as many sit-stand movements from a 
chair (43cm height) as they could in one-minute (American College of Sports Medicine 2010). The 
count included full sit-stand movements only, and participants were encouraged to go as fast as they 
could. Lower body injuries precluded participants from completing this test. This type of 
assessment has been used safely in breast cancer interventions previously (Herrero et al. 2006). 
Handgrip strength was measured using a handgrip strength dynamometer (Baseline Smedley 
Spring). Participants were instructed to use their dominant hand, maintain their shoulder in an 
adducted and neutrally rotated position, with elbow flexed at 90 degrees, forearm in a neutral 
position, and the wrist between 0 and 30 degrees extension and between 0 and 15 degrees ulnar 
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 deviation (Innes 1999). Handgrip strength was chosen as it provides an indication of overall muscle 
strength, and has been shown to improve in previously studies cancer populations as a result of anti-
inflammatory supplementation (Cerchietti, Naviganteac, and Castroa 2007). 
Lymphoedema index using Bioelectrical Impedance Spectroscopy (BIS) 
Lymphoedema index (L-Dex) is a measure of the extra-cellular fluid (ECF) and subclinical changes 
of ECF of the upper limbs using a low frequency bio-impedance machine (Impedimed XC 
Scanner). Electrodes were placed at each end of the participants arm as per the Impedimed protocol. 
This device uses an ‘impedance ratio’ to assess unilateral lymphoedema of the arm. It has been 
shown to detect subclinical lymphoedema in breast cancer survivors, and served as an added safety 
measure for potential lymphoedema exacerbations during the program. Typically, lymphoedema is 
indicated if an individuals score is >10, or if intra-participant measures change >3 standard 
deviations between assessments, i.e. a score increase of >10; thus, if a participant records a negative 
number, e.g. -2.5 at baseline, a subsequent score of +7.5 (+10 difference) would indicate 
lymphoedema. A recent review indicated that BIS is as effective and potentially more clinically 
relevant than arm water displacement, perometry and arm girth for management of lymphoedema 
(Ward 2009).   
Measure of pain and function using the Health Assessment Questionnaire-Disease Index (HAQ-
DI)  
Breast cancer survivors are at increased risk of arthralgias after treatment. Incidence is higher in 
those who received hormonal therapy, and higher still in those who received aromatase inhibitors 
(Din et al. 2010). The HAQ-DI is composed of 20 items in 8 categories (Dressing and Grooming, 
Hygiene, Arising, Reach, Eating, Grip, Walking, Activities of Daily Living (ADL). Items were 
developed to be mutually exclusive and collectively exhaustive of activities related to physical 
functioning. Each category has at least two sub-category questions. Within each category, patients 
report the amount of difficulty they have in performing the specific sub-category items. There are 
four response options ranging from ‘No Difficulty’ to ‘Unable to Do’, scored 0-3. A recent review 
of measures to assess quality of life in relation to physical function and joint pain as a result of AIs 
has suggested that the HAQ-DI is currently a preferred tool (Din et al. 2010). However, specific 
validation within breast cancer populations have not been performed, which is mainly due to the 
lack of ‘Gold Standard’ assessment of AI related arthralgias. The HAQ-DI was originally validated 
for measurement of change in rheumatoid arthritis (Cardiel et al 1993). 
Measure of menopausal symptoms using the Greene Climacteric Scale (GCS) 
Menopausal symptoms are a frequent and troublesome side effect of breast cancer therapy in 
women of all ages. Hot ﬂashes, night sweats, sexual dysfunction, poor sleep and tiredness 
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 frequently occur following breast cancer treatment (Hickey et al. 2008). The GCS is a 21-item 
questionnaire that measures a variety of menopausal symptoms on a 4-point Likert scale (0 = “not 
at all” to 3 = “extremely). Three separate sub-scales measure vasomotor symptoms, somatic 
symptoms, psychological symptoms, and an additional probe related to sexual function. 
Psychological symptoms can be further sub-divided to measure anxiety and depression. The Scale 
has also been used to identify menopausal women who are severely and possibly clinically anxious 
and/or depressed (Greene 1998). 
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 TABLE&3.3&JUSTIFICATION&AND&ACCURACY&OF&OUTCOME&MEASURES& 
Inclusion of Hs-
CRP as a marker 
of inflammation  
Justification  
 -  Increased levels of CRP have been associated with all cause mortality in 
breast cancer populations (Pierce et al 2008).   
 -  Hs-CRP is a general marker for low-grade chronic inflammation and is 
commonly used in general practice (Libby et al 2002).   
- Previous studies indicate that inflammation is thought to drive LBM loss 
(Fearon et al 2006) and be related to fatigue in cancer survivors 
Accuracy  
-  All measures were performed by the same laboratory group –     
Healthscope.   
-  All blood was drawn in a fasting state, at the same time of day   
-  Acute illness within the previous 5 days was a reason for  exclusion or   
test delay.   
Inclusion of the 
FACT- B+4 tool 
for quality of life  
Justification  
 -  The FACT-B (+4) tool is one of the two most commonly used tools for 
assessing quality of life in populations with breast cancer (Lemieux et al 
2011).   
 -  Change in FACT-B score has been concurrently reported with 
improvements in cardiorespiratory fitness (McNeely et al 2006).   
Accuracy   
- Questionnaires were delivered before body composition results to reduce 
the effect of results to bias perceived wellness.   
- The official FACT-B+4 was delivered to ensure consistency with other 
studies (Cella et al 1997).   
 
Waist & Hip Girth 
Measurement  
  
Justification  
-  Waist-to-hip and Waist circumference are associated with risk of breast 
cancer (Harvie et al 2003, Connolly et al 2002).   
-  Waist circumference is associated with metabolic syndrome in women 
who have completed breast cancer (Healy et al 2010).  
 -  It provides information on distribution of fat (abdominal fat mass), 
whereas the BODPOD describes only total fat volume.   
 -  Abdominal obesity is related to markers of inflammation (Festa et al 
2001), thus measurement allows observation of this relationship. This is 
relevant to the effects of LCn-3 (Tsitouras et al 2008) and exercise (Fairey 
et al 2005) in relation to CRP.  
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 Accuracy  
 -  The research assistant was trained and tested for inter- rater reliability 
with an Accredited Level 1 ISAK anthropometrist.   
 -  Measure of waist and hip were taken in the same type of clothing (lycra 
swimmers)   
 -  Measurement was made in accordance with ISAK protocols for waist and 
hip girths   
Interviewer 
assisted Diet 
History 
Questionnaire 
(DHQ)  
  
Justification  
  -  Open ended diet history method allows detailed collection of portion 
size and variations in intake (Martin et al 2004). Which is likely to improve 
accuracy of energy intake.  
  -  As opposed to a multiple-pass 24 hour recall method, the DHQ had a 
lower time burden as it was conducted at the same time other testing, 
ensuring higher completion.   
  -  Accurate assessment of energy and protein intake is important for 
controlling dietary intake when assessing body composition change.   
Accuracy  
 -  The DHQ was conducted using the methodology outlined in the original 
validation study that indicates good sensitivity to change in dietary intake 
(Martin 2004)   ) - The same Accredited Practising Dietitian conducted every assessment at 
each time point   
- Known volumes and quantities were used in the same fashion for all 
participants  
Objective Physical 
Activity   
7-day uniaxial 
accelerometry  
Justification  
 -  Objective measurement of physical activity through accelerometry is 
positively associated with cardio-metabolic morbidity, inflammation 
(Healy et al 2011) and may be related to body composition changes after 
breast cancer treatment (Lynch et al 2009)   
 -  Sedentary time has been related to physiological changes that may be 
related to an increase in inflammation and subsequent LBM loss (Hamilton 
et al 2007)   
Accuracy  
 -  Participants maintained a written log of ‘wear time’ that was cross-
referenced at each time point.   
 -  Participants wore the unit on the same anatomical location at each 
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 measurement point   
 -  Participants that did not wear the unit for a minimum of 10 hours for 4 
days were not included in the data   
-  Activities like water-sports were accounted for via the 7-day physical 
activity record kept as part of their physical activity journal, and through 
the modified Active Australia Survey.   
 
Lymphoedema-
index using (BIS)  
  
Justification  ) -  Lymphoedema is an important clinical consideration for women treated 
for breast cancer, who have had lymph glands removed (DiSipio et al 
2013).   ) - Sub-clinical assessment of lymphedema is able to be conducted  using 
BIS (Rockson et al 2007). 
 
Accuracy  ) -  All assessments were carried out by the same trained research assistant 
with experience in measurement of BIS.   
-  Procedures closely followed manufacturer and clinical guidelines 
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 Muscle function 
tests: 1-min Push 
up; 1 min Squat 
test; Hand grip 
strength; Sub-
maximal VO2 
treadmill test  
  
Justification  
 
- Increased muscle strength are beneficial to overall health, quality of life 
and mortality (Newman et al 2006, Ruiz et al 2008). These changes can 
occur without changes in body composition (Schmitz et al 2009). Thus 
their measurement gives a greater insight into physiological response to the 
intervention.  
- Exercise tests are another tool to validate the adherence to the strength 
training prescribed; upper body and lower body strength training was a 
focus of the program. 
- Muscle strength is associated with LBM size, thus controlling for the 
change in LBM due to strength increases may allow a clearer observation 
of the effect of LCn-3 on LBM  
- Improvements in cardiorespiratory fitness are related to a improve quality 
of life in a breast cancer population (McNeely et al 2006). Participation in 
aerobic training designed to increase cardiorespiratory fitness has been 
shown to improve body composition (Irwin et al 2009) 
 - Grip strength has been shown to correlate positively with LCn-3 intake 
(Robinson et al 2008)  
Accuracy  
  -  The same accredited exercise physiologist conducted all assessments at 
all time points.   
  -  Tests were conducted in accordance with the American College of 
Sports Medicines Official Guidelines for Clinical Exercise Testing (ACSM 
2010).   
 -  Tests were conducted in the same order at each time point. I.e. Day 1: 
Grip strength and then treadmill; Day 7: Push ups and then squats. This was 
to ensure that fatigue from a previous test was not a factor in the results.   
 -  Proper technique was demonstrated and monitored at each time point.   
 -  Time to reach 85% of estimated max heart rate was recorded for the 
treadmill test. Many of the participants did not have three readings at 
>115bpm as per description in the protocol. This allowed generation of a 
continuous data point. This continuous data point was statistically similar 
to the stage reached (i.e. counting up in units of 1-minute). Thus stage 
completed was used for analysis.   
-  Grip strength was calculated as a maximal result over 3 tests on both 
hands, with posture and movement monitored at each time point.   Hs)CRP:&High&sensitivity)&C)reactive&protein,&LCn)3:&Long&chain&omega)3&fatty&acids;&FACT)B:&Funcational&Assessment&during&Cancer&Therapy&–&Breast;&ISAK:&International&Society&for&the&Advancement&of&Kinanthropometry;&LBM:&Lean&body&mass;&DHQ:&Diet&History&Questionnaire;&bpm:&Beats&per&minute;&BIS:&Bio)Impedance&Spectroscopy.& 
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 3.5(Data(Analysis(
3.5.1(Analysis(of(baseline(for(crossGsectional(study(
Baseline characteristics were compared between treatment types and stages of disease using 
independent samples t tests or ANOVA for normal data, and Mann Whitney-U tests or Kruskal 
Wallis for non-normal data, respectively. Spearman’s correlation coefficient was used to assess the 
strength of bivariate associations. Percentage (%) of time spent in moderate and vigorous activity 
were grouped together into one variable: ‘% time in ≥ moderate activity’. To assess the significance 
of age- and/or weight-adjusted associations between an outcome and a potential predictor, 
multivariable linear regression was used. Multivariable linear regression was used to model LBM as 
a function of various markers of fitness while also controlling for total body mass. Only those with 
full data sets were included in the models. The variables considered for inclusion in the model were 
those that were individually associated with LBM after adjusting for age and weight. Markers of 
fitness were added to the model sequentially, with the order determined by decreasing r-values. A 
predictor was only retained in the model if its coefficient was significantly different from zero at the 
0.05 level. Adjusted R-squared was used to compare nested models. Models were also fitted that 
included interaction terms that explored the respective LCn-3 indices combined with fitness 
markers on LBM.  
3.5.2(Analysis(of(baseline(post(randomisation(
Baseline demographic and disease related characteristics were summarised by group as count and 
percent for categorical variables and number, mean and standard deviation for continuous variables.  
To compare the three treatment groups at baseline, a chi square test or Fishers exact test was used 
for categorical variables and a one-way analysis of variance (ANOVA) or Wilcoxon rank-sum test 
for continuous variables.  Baseline demographic and disease-specific characteristics that differed 
among groups were considered for covariate adjustments in analysis of all outcomes. 
Measurements collected longitudinally will be summarised by group as number, mean and standard 
deviation, or standard error (baseline, 12wk, 24wk).  Absolute change from baseline will be 
calculated by subtracting the baseline measurement from the 12 week and 24 week measurements; 
percent change from baseline will be calculated by dividing the 12-week and 24-week 
measurements by the baseline measurement.  Measurements include:  body composition, quality of 
life, C-Reactive Protein, physical activity and sedentary time, aerobic fitness, muscular endurance, 
muscle strength, dietary intake, waist and hip girth, joint pain and physical function and menopausal 
symptoms.  All outcome data will be visually inspected for normality. In the case of the data being 
not normal non-parametric analyses will be used. 
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 3.5.2(Analysis(of(intervention(data(
Differences in demographic data between groups were assessed by ANOVA and Kruskal Wallis 
tests, for parametric and non-parametric data, respectively. The Friedman test and repeated 
measures ANOVA were used to determine within group differences over 3 time points, and 
Wilcoxon Signed Rank tests and paired t-tests with Bonferroni adjustment for multiple comparisons 
were used to determine change within-groups between two time points. The effects of treatment on 
the dependent measures were analysed by a 3 x 3 factorial repeated measures ANOVA with group 
treatment (N-3 vs EP+OO vs EP+N-3), exercise treatment (EP+OO & EP+N-3 or N-3), LCn-3 
treatment (N-3 & EP+N-3 or EP+OO) and synergy treatment (EP+N-3 or EP+OO & N-3) at three 
time points. Intention-to-treat was used for all analyses. Contrasts were constructed to compare 
pair-wise differences among the three treatment groups at each time point.  Similar mixed models 
will be fit to evaluate the effect of adjusting for covariates.  In addition to the fixed effects for time, 
treatment, time by treatment and baseline value, covariates at baseline identified as statistically 
different among the three groups and covariates known or hypothesised to be associated with the 
particular change from baseline outcome will be evaluated as fixed effects. 
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 Chapter 4 – Findings from the baseline cross-sectional study 
This chapter is divided into 2 sections: Section 1 is a published manuscript that reports overall 
findings from the baseline assessment before randomisation. This paper also explores cross 
sectional associations between LBM, demographical variables and lifestyle factors that were 
measured. Section 2 includes additional analyses that were not included in the published 
manuscript, but were relevant to our theoretical model.  
The major findings from the baseline cross-sectional analyses add new information to the 
observational evidence base for women who have completed breast cancer treatment. Measures of 
physical activity and LBM function were significantly positively associated with LBM after 
adjusting for weight and age. In addition, a threshold effect for physical function and LBM was 
present. With further exploration, recommendations for exercise volume and optimal body 
composition could be created to give more specific guidance to women who have been treated for 
breast cancer. 
Considering that previous studies have only indicated non-modifiable or treatment related factors to 
be associated with LBM change, our observations provide the first evidence for modifiable lifestyle 
factors to play an important role. This data agrees with intervention data from intervention trials 
that have noted improvements in LBM after exercise training. 
4.1 Published manuscript #4 
Muscle function and omega-3 fatty acids in the prediction of lean body mass after breast cancer 
treatment. Within this paper an abbreviated table of demographic information appears. This detail is 
covered comprehensively between Table M5-1 in published manuscript #5 – Section 5.1.1, with 
additional data reported in Table 5.2. 
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Muscle function and omega-3 fatty acids in the
prediction of lean body mass after breast cancer
treatment
Cameron McDonald*, Judy Bauer, Sandra Capra and Mary Waterhouse
Abstract
Background: Decreased lean body mass (LBM) is common in breast cancer survivors yet currently there is a lack of
information regarding the determinants of LBM after treatment, in particular, the effect of physical activity and
dietary factors, such as long-chain omega-3 fatty acids (LCn-3) on LBM and LBM function. This cross-sectional study
explored associations of LBM and function with LCn-3 intake, dietary intake, inflammation, quality of life (QOL) and
physical fitness in breast cancer survivors to improve clinical considerations when addressing body composition
change.
Methods: Forty-nine women who had completed treatment (surgery, radiation and/or chemotherapy) were assessed
for body composition (BODPOD), LCn-3 content of erythrocytes, C-reactive protein (CRP), QOL, dietary intake, objective
physical activity, 1-min push-ups, 1-min sit-stand, sub-maximal treadmill (TM) test, and handgrip strength.
Results: After adjustment for age, LBM was associated with push-ups (r = 0.343, p = 0.000), stage reached on treadmill
(StageTM) (r = 0.302, 0.001), % time spent ≥moderate activity (Mod + Vig) (r = 0.228, p = 0.024). No associations were
seen between anthropometric values and any treatment, diagnostic and demographical variables. Body mass,
push-ups and StageTM accounted for 76.4% of the variability in LBM (adjusted r-square: 0.764, p = 0.000). After
adjustment docosahexanoic acid (DHA) was positively associated with push-ups (β=0.399, p = 0.001), eicosapentanoic
acid (EPA) was negatively associated with squats (r = −0.268, p = 0.041), with no other significant interactions found
between LCn-3 and physical activity for LBM or LBM function.
Conclusion: This is the first investigation to report that a higher weight adjusted LBM is associated with higher
estimated aerobic fitness and ability to perform push-ups in breast cancer survivors. Potential LCn-3 and physical
activity interactions on LBM require further exploration.
Keywords: Breast cancer; Omega-3 fatty acids; Lean body mass; Fitness; Nutrition; Exercise
Introduction
Loss of lean body mass (LBM) and simultaneous gains
in fat mass are amongst the most common side effects
following treatment for breast cancer (Mcdonald et al.
2011). This pattern of body composition change is dis-
tressing for the survivors and it is related to higher levels
of chronic inflammation (Mourtzakis & Bedbrook 2009),
and a greater risk for metabolic syndrome (Healy et al.
2010) and its related diseases (Healy et al. 2010; Pierce
et al. 2009). A growing literature has established LBM,
and in particular skeletal muscle tissue, as an influential
organ in hormonal, immune and metabolic function
(Pedersen & Febbraio 2012). Lifestyle factors such as
physical activity and nutrient intake can enhance LBM
size (Irwin et al. 2009) and function, (Courneya et al.
2007; Schmitz et al. 2005) and have also been associated
with improved survival (Ibrahim & Al-Homaidh 2010)
and quality of life (Mcneely et al. 2006) after treatment
for breast cancer. Taken together, LBM is becoming an
important marker for women who have been diagnosed
with breast cancer.
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Findings from observational studies have indicated
that chemotherapy has been associated with declines of
LBM during and after treatment (Cheney et al. 1994;
Demark-Wahnefried et al. 1997; Demark-Wahnefried
et al. 2001; Gordon et al. 2011; Kutynec et al. 1999),
however not all trials have reported LBM loss after
chemotherapy (Campbell et al. 2007). In contrast, associ-
ations between higher LBM and aromatase inhibitor
hormonal therapy have been reported in three different
data sets (Francini et al. 2006; Montagnani et al. 2008;
Van Londen et al. 2011). Modifiable variables such as
dietary intake and physical activity have not been exten-
sively explored with regard to LBM change in breast
cancer populations. Some evidence exists for an associ-
ation between decreased physical activity and increased
adiposity (Irwin et al. 2005), while mixed results have
been reported in relation to dietary intake and adiposity,
(Sheean et al. 2012) however a deeper understanding of
physical activity, dietary factors and LBM change are
needed to better guide clinicians in the post-treatment
period.
Long chain omega-3 fatty acids (LCn-3) are estab-
lished as anti-inflammatory agents and have been shown
to protect LBM in cancer populations (Dewey et al.
2001; Murphy et al. 2012; Ries et al. 2012; Van Der Meij
et al. 2011). However, conclusions from reviews of inter-
vention studies in cancer populations investigating the
effect of LCn-3’s on LBM have been mixed (Murphy
et al. 2012; Ries et al. 2012). Typically, older studies have
shown a protective effect for LBM when the appropriate
dose of LCn-3 is consumed (Fearon et al. 2006; Fearon
et al. 2003). More recent studies investigating 2 g of EPA
LCn-3 supplementation in individuals undergoing chemo-
therapy for non-small cell lung cancer (NSCLC) have
shown significantly greater attenuation of LBM and im-
proved levels of intra-muscular triglyceride (IMTG), com-
pared to those not supplementing. (Murphy et al. 2010;
Murphy et al. 2011). In non-cancer populations the ef-
fect of LCn-3 on LBM has been minimal, with the ma-
jority of controlled trials indicating limited clinical
effect (Mcdonald et al. 2013b).
Recent research has indicated that a greater effect may
be seen when LCn-3 s are combined with an anabolic
stimulus (Mcdonald et al. 2013b; Rodacki et al. 2012;
Smith et al. 2011a; Smith et al. 2011b). Three small, well
controlled studies combined LCn-3 supplementation
with exposure to an anabolic stimulus, i.e. hyperinsuli-
naemic/hyperaminoacidaemic clamp or resistance train-
ing. Two reported an increased muscle protein synthetic
(MPS) response to for young healthy (Smith et al.
2011b), and elderly participants (Smith et al. 2011a), yet
LCn-3 alone made no difference to basal MPS. The third
study that used resistance training reported increased
peak torque development for the supplemented group
above that of the group who received the resistance
training program only (Rodacki et al. 2012). Considering
LBM function, measured by strength or power develop-
ment, may be more important to health outcomes than
absolute values of LBM, (Newman et al. 2006; Ruiz et al.
2008) further investigations are required.
Therefore, the objectives of this cross-sectional study
was to explore associations of LBM and LBM function
in the context of LCn-3 intake, dietary energy and pro-
tein intake, inflammation, quality of life (QOL) and pa-
rameters of physical fitness and activity in women who
had completed breast cancer treatment. A secondary
goal was to determine the effect of interactions between
tissue content of LCn-3 and markers of physical fitness
on LBM after treatment for breast cancer.
Methods
Study design
All participants provided written informed consent. The
data presented here was collected as the baseline assess-
ment for a 6-month 3-arm randomized controlled trial
(RCT) investigating LBM in women who have com-
pleted treatment for breast cancer. Detailed rationale
study protocol for the full trial has been published previ-
ously (Mcdonald et al. 2013a). The study was approved by
the Uniting Care (UCH HREC: #1034) and the University
of Queensland (#2011000079).
Participants
Participants were invited to participate through hospital
breast cancer oncology centres, radio advertising, social
media and breast cancer research registries in Brisbane,
Australia. Baseline assessment occurred over one week,
which included two visits 7 days apart.
Eligibility
Women ≥18 years of age; had been diagnosed with early
stage breast cancer (Stage 0-IIIa as determined by the
American Joint Committee on Cancer Care); had suc-
cessfully completed surgery, radiation and/or chemo-
therapy in the last 12 months (participants could be
currently receiving endocrine and/or herceptin therapy);
were able to perform moderate intensity physical activity,
and have a BMI of >20 and <35 kg/m2 were eligible for
enrolment. Participants were excluded if they had pres-
ence of metastatic growth or local/distal recurrence of
cancer; a diagnosis of cardiovascular disease or diabetes;
or, consumed >1 g of eicosapentanoic acid (EPA) and doc-
osahexanoic acid (DHA) LCn-3 s combined per day.
Measures
Anthropometric variables
Height was measured to the nearest 0.5 cm using a sta-
diometer (Seca). Weight to the nearest 0.1 kg, LBM and
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fat mass were measured using the BODPOD digital
scales and air displacement plethysmography (ADP) pod
(BODPOD, COSMED USA Inc), respectively. Before
each assessment day, the BODPOD scales and air cham-
ber were calibrated as per the manufacturer’s instructions
using known weights and volumes. All measures were per-
formed by a certified BODPOD assessor. Results were
expressed as percentage LBM and body fat of total weight,
then absolute LBM was calculated giving a value in kilo-
grams of LBM.
Quality of Life (QOL)
QOL was measured using the Functional Assessment of
Cancer Therapy- Breast + 4 (FACT-B + 4) tool (Cella et al.
1993). That FACT-F subset of questions was also added to
capture participant fatigue. Higher scores are representa-
tive of better well-being.
Diet history
Dietary intake was measured by the practitioner assisted
Diet History Questionnaire (Martin 2004). Participants
were asked to complete the questionnaire based on their
intake over the last month. An accredited practicing
dietitian reviewed the questionnaire with the participant
to clarify portion sizes and other relevant details. Nutri-
ent analysis was carried out using Foodworks 7 (Xyris
Software).
Blood analyses
Fasting high sensitivity-C Reactive Protein (CRP) was
measured using a latex-enhanced immunoturbidimetric
assay of blood serum. The 8.5 ml sample of whole blood
was collected and analysed for CRP, then frozen at −20°C
for transport to Victoria, Australia for fatty acid testing.
Lipids from red cells were extracted with chloroform
methanol mixture. The fatty acids were trans-esterificated
to methyl esters with methylation reagent “Meth-Prep 2”.
The methylation extract was then analysed by gas liquid
chromatography method with flame ionisation detection
(gas chromatograph Schimadzu G-2010-FID). The pro-
portion of fatty acids content of the erythrocytes expressed
as % of total fatty acids.
Muscle function and fitness tests
Grip strength was performed on both arms, with the
maximum of 3 attempts recorded. Participants were
seated with feet flat on floor, shoulder in neutral position
with elbow bent at 90 degrees. Upper body muscular
strength-endurance was measured using a 1-minute
push-up test. Participants were asked to perform as
many push-ups (knees on ground) as possible in 1 mi-
nute (American College of Sports Medicine 2010).
Lower body muscular endurance was measured using
a 1-minute sit-stand test. The participant was asked to
perform as many sit-stand movements as possible in
1 minute. Chair height was standardised at 43 cm height
(American College of Sports Medicine 2010).
Sub-maximal aerobic capacity was measured using the
modified Balke sub-maximal treadmill test. Seated blood
pressure was measured before each assessment to ensure
safety of exercise (Sharman & Stowasserb 2009). The
test being completed when the individual had reached
85% of their estimated maximum heart rate (max HR)
(est. maxHR = 220-age).
Statistical analysis
Baseline characteristics were compared between treat-
ment types and stages of disease using independent sam-
ples t tests or ANOVA. Spearman’s correlation coefficient
was used assess the strength of bivariate associations, %
time in moderate and vigorous activity were grouped to-
gether into one variable: % time in ≥moderate activity. To
assess the significance of age- and/or weight-adjusted as-
sociations between an outcome and a potential predictor,
multivariable linear regression was used. Multivariable lin-
ear regression was used to model LBM as a function of
various markers of fitness while also controlling for total
body mass. For missing data, only those with full data sets
were included in the models. The variables considered for
inclusion in the model were those that were individually
associated with LBM after adjusting for age and weight.
Markers of fitness were added to the model sequentially,
with the order determined by decreasing r-values. A pre-
dictor was only retained in the model if its coefficient was
significantly different from zero at the 0.05 level. Adjusted
R-squared was used to compare nested models. Models
were also fitted that included interaction terms that ex-
plored the respective LCn-3 indices combined with fitness
markers on LBM.
Results
Participants were recruited over a 15-month period (Oct
2011 – Jan 2013). A total of 135 women were initially
screened for inclusion criteria. The major reasons for ex-
clusion were >12 months post treatment completion and
daily consumption of >1000 mg EPA and DHA com-
bined. Forty-nine participants were eligible for the study
and completed baseline assessment. Descriptive statistics
of the population are shown in Table 1.
Age
Age was positively correlated with improved breast can-
cer related QOL (r = 0.379, p = 0.007), fatigue (r = 0.311,
p = 0.30) and EPA (r = 0.339, p = 0.026), and negatively
correlated with % of time in vigorous activity (r = −0.342,
p = 0.022) and number of squats performed in 1-minute
(r = −0.363, p = 0.011).
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Associations of diagnostic and treatment related variables
Compared to those diagnosed with earlier stage disease
(0-IIa), those with later stage disease (IIb-IIIa) re-
ported poorer results for BrCa related QOL (89.2 ±9.3
vs 79.3 ±15.7; p = 0.009), fatigue (130.5 ± 15.3 vs 113.3 ±
24.7; p = 0.006), total score for Greene climacteric scale
(11.8 ± 6.8 vs. 17.5 ± 10.2; F = 5.308, p = 0.026), with specif-
ically worse symptom scores reported for psychological,
anxiety, depression and somatic fields (all p < 0.05). Stage
of disease was not associated with any indices of body
composition, LCn-3 or physical function.
Compared to those who did not have radiation ther-
apy, DHA values (t = 2.904; p = 0.016) and LCn-3: LCn-6
(t = 3.06; p = 0.004) ratios were higher for those who
underwent radiation therapy. Otherwise, radiation ther-
apy was not associated with markers of body compos-
ition, QOL, dietary intake, LBM function, endurance or
physical activity. Individuals taking tamoxifen tended to
have lower EPA content compared to those taking AIs
or no hormonal therapy (0.78% vs. 1.16% & 1.23%; F =
3.153, p = 0.054), however, there was no evidence to sup-
port an association between hormonal treatment and
other markers of body composition, QOL, dietary intake,
LBM function or physical activity.
Associations between LBM and dietary intake,
inflammation, physical activity, markers of fitness and
quality of life
LBM was positively correlated with daily intake of total
energy (r = 0.301, p = 0.036) and protein (r = 0.464, p =
0.001), and negatively correlated with higher squat test
results (r = −0.39, p = 0.006) (Table 2). However, after
adjusting for weight and age, the only significant associa-
tions with LBM were % time spent in ≥moderate inten-
sity activity (ß: 0.228, p = 0.024), number of push-ups
performed (ß: 0.343, p = 0.000) and treadmill stage com-
pleted (ß: 0.302, p = 0.001) (Table 2). CRP was positively
correlated with body fat %, waist and hip however, these
associations were no longer significant after controlling
for total body weight (data not shown).
Associations between LCn-3 and anthropometric indices,
inflammation & quality of life after breast cancer
treatment
No significant correlations were identified between abso-
lute LBM or % LBM for total RBC n-3, ratio of AA: EPA
or % RBC content of EPA or DHA (Table 3). No signifi-
cant relationships were found between any other an-
thropometric variables and n-3 related values.
No significant correlations were identified between
CRP and erythrocyte LCn-3. No markers of body com-
position, CRP or indices of LCn-3 intake were signifi-
cantly correlated with either measure of QOL.
Predictors of LBM in women soon after breast cancer
Number of push-ups, StageTM, and mod + vig activity
were considered for inclusion in a weight-adjusted linear
regression model for LBM (Table 2). Table 4 shows coef-
ficients for the variables included in the final model.
Table 4 also shows the value of adjusted R-squared ob-
tained as each variable was successively added to the
model. Mod + vig was not retained in the final model be-
cause the coefficient was not significantly different from
zero (β=0.115, p = 0.177) in the presence of the other
predictors. The model including weight, push ups and
Table 1 Characteristics of participants
Characteristic (n = 49) Value
Age in years (mean; SD) 48.6 ± 9.5
Race (n, %)
—Caucasian 44(88)
—Asian 3(6)
—African 1(2)
—Asian Pacific Islander 1(2)
Anthropometric (mean; SD)
Height (m) 1.65 ± 0.07
BMI (kgm-2) 26.6 ± 4
Body mass (kg) 73.1 ± 13.8
LBM (kg) 43.6 ± 5.6
Body fat % 39.5 ± 6.9
Waist (cm) 85.4 ± 11.1
Hip Girth (cm) 106.3 ± 9.2
CRP (n = 45; med; range)* (0.1–10.1)
Total % RBC n-3 (n = 43)* 5.9 ± 1.6
% EPA 1.1 ± 0.5
% DHA 2.9 ± 0.9
Charaterstic of Disease (n; %)
0-I 13 (26)
IIa 19 (28)
IIb-IIIa 17 (34)
Estrogen receptor + ve 39 (78)
HER-2 receptor + ve 12 (24)
Treatment variables (n; %)
Had Chemotherapy 41 (92)
Taxane – Yes 37 (74)
Radiation therapy
Tamoxifen 13 (26)
AI 20 (40)
None 16 (32)
Time since completion Rx 165 ± 107
AI–Aromatase inhibitors.
*Missing data.
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StageTM explained 76.4% of the variation in absolute
LBM (Table 4).
Interactions of physical activity and indices of LCn-3
intake on markers of LBM function
The number of push-ups performed was positively cor-
related with time spent in ≥moderate intensity activity
(r = 0.467; p = 0.001), total n-3 levels (r = 0.385; p =
0.012) and DHA levels (r = 0.517, p = 0.000) (Table 5).
The correlation with total n-3 levels was no longer sta-
tistically significant after adjusting for DHA. DHA main-
tained a significant association after adjusting for age,
weight, LBM and % time >mod activity (β=0.399, p =
0.001) % ≥. Mod activity remained a significant predictor
(F-Test: 8.95, p = 0.005) of the number of push-ups per-
formed in one minute after adjusting for DHA, age,
weight and LBM. There were no significant interactions
between RBC LCn-3 and time spent in any intensity of
activity for any of the regression models of physical
function (data not shown).
Discussion
This paper reports a positive relationship between LBM (ad-
justed for total weight) and physical function represented by
Table 2 Associations between markers of absolute LBM and markers of LCn‐3 intake, dietary intake, physical activity
and fitness adjusted for weight & age n value
Lean body mass (kg) Body fat %
Unadjusted Adjusted Unadjusted Adjusted
R p-value Standardise d B-coefficient p-value R p-value Standardise d B-coefficient p-value
Total daily kJ intake 0.301 0.036 0.135 0.132 −0.82 0.576 −0.192 0.065
Total daily protein
intake 0.464 0.001 0.144 0.121 0.04 0.787 −0.197 0.068
CRP* 0.258 0.083 −0.128 0.238 0.597 0 0.123 0.343
% time in sedentary
activity* 0.167 0.273 0.053 0.579 0.23 0.88 −0.058 −0.524
% time in light activity* −0.149 0.329 −0.104 0.272 0.156 0.305 0.125 0.258
% time in >moderate
activity* −0.041 0.787 0.228 0.024 −0.466 0.001 −0.275 0.015
Push up (in 1-min)* −0.045 0.760 0.343 0.000 −0.671 0 −0.457 0
Squats (in 1-min)* −0.39 0.006 0.044 0.71 −0.454 0.001 −0.098 0.439
Stage of treadmill
completed −0.047 0.746 0.302 0.001 −0.575 0 −0.39 0
FACT-B + 4 −0.13 0.373 0.038 0.699 −0.146 0.316 −0.009 0.936
FACT-F −0.128 0.381 0.023 0.813 −0.133 0.362 −0.002 0.982
% time in activity: Accelerometry; % time in >moderate activity: moderate and vigorous activity grouped together; Stage of treadmill completed: at which 85% of
estimated HRmax was reached; *Reduced data: CRP: n = 46; Accelerometer data: n = 45; Push-ups: n = 48; Squats: n = 48.
Table 3 Univariate associations between indices of erththrocyte LCn-3 s and markers of body composition, inflammation
and quality of life (n = 43)
Total n‐3 EPA DHA AA/EPA
r p-value r p-value r p-value r p-value
Weight (kg) 0.083 0.595 0.249 0.107 −0.088 0.576 −0.232 0.134
LBM (kg) 0.093 0.554 0.156 0.319 −0.27 0.864 −0.159 0.309
Body fat % 0.037 0.816 0.222 0.153 −0.107 0.493 −0.181 0.245
Waist (cm) 0.123 0.431 0.280 0.069 −0.061 0.697 −0.167 0.284
Hip (cm) 0.055 0.728 0.280 0.069 −0.141 0.366 −0.313 0.041
CRP (mmol/L) 0.035 0.822 0.183 0.241 −0.42 0.791 −0.224 0.149
FACT-B + 4 −0.063 0.689 0.039 0.804 −0.064 0.683 −0.007 0.962
FACT-F −0.129 0.411 0.040 0.797 −0.137 0.382 −0.026 0.868
LBM: Lean Body mass; CRP: C-reactive protein; EPA: eicosapentanoic acid; DHA: docosahexanoic acid; FACT-B + 4: Quality of life with breast related items;
FACT-F: Fatigue.
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the % time spent in ≥moderate intensity physical activity,
stage achieved on sub-maximal treadmill test and number
of push-ups completed. To the authors’ knowledge, this is
the first study to determine associations between physical
function and body composition in women who have com-
pleted treatment for breast cancer.
Our results agree with previous cross-sectional and
prospective cohort studies, which have shown that de-
creasing physical activity levels are associated with
greater adverse body composition change,(Irwin et al.
2003; Irwin et al. 2005) while dietary measures(Demark-
Wahnefried et al. 2001) have been less predictive of
these changes. The findings relating to the influence of
chemotherapy on LBM agree with two previous studies
(Campbell et al. 2007; Winters-Stone et al. 2009) but are
in contrast to five studies that have shown a greater de-
crease in LBM after chemotherapy (Cheney et al. 1994;
Demark-Wahnefried et al. 1997; Demark-Wahnefried
et al. 2001; Gordon et al. 2011; Kutynec et al. 1999). In
addition, Prado et al. reported that individuals with
chemotherapy toxicity had a greater risk of sarcopenia
(Prado et al. 2009). Differences in our results may be
due to the cross-sectional nature of the study. Previously
published data sets indicating LBM change after chemo-
therapy and hormonal therapies were prospective in na-
ture (Cheney et al. 1994; Demark-Wahnefried et al.
1997; Demark-Wahnefried et al. 2001; Gordon et al.
2011; Kutynec et al. 1999) and were able to see trends
over time.
No associations were found between erythrocyte LCn-3
and markers of body composition. Recent studies in popu-
lations during and post-chemotherapy treatment have in-
dicated a positive relationship between skeletal muscle
mass and plasma phospholipid LCn-3 content (Murphy
et al. 2010; Murphy et al. 2011), however these partici-
pants experienced significant and rapid muscle loss during
treatment. After early stage breast cancer treatment, the
rate and magnitude of muscle loss experienced is not typ-
ically as high as when compared to more advanced staged
cancers (Mcdonald et al. 2011; Murphy et al. 2010). As a
result, our results are comparable to metabolic/obese pop-
ulations undergoing similar body composition change
(Krebs et al. 2006; Noreen et al. 2010; Storlien et al. 2001).
Total body mass, push-ups performed in one-minute,
and stage completed on treadmill remained in the final
model accounting for 76% of the variation in LBM.
These results are of interest as they indicate an associ-
ation with physical function and healthier body com-
position. Specifically, the strength of association with
number of push-ups/minute as opposed to squats may
indicate the importance of whole body resistance train-
ing to maintain or achieve a higher LBM and lower fat
mass. A decrease in sports/recreational exercise has
been previously associated with an increase in adipos-
ity however, LBM change was not reported (Irwin et al.
2005). It is possible that those who performed more
push-ups due to an increase in relevant exercise train-
ing may also be more conscientious in regards to diet-
ary intake, however no association was found in this
study.
Both erythrocyte DHA and EPA content were associ-
ated with markers of physical function, surprisingly in
positive and negative directions, respectively. DHA was
strongly and independently associated with the ability to
perform push-ups, while erythrocyte EPA content was
negatively associated with squats performed. In addition,
assessing predictive models for push-up performance,
when%time ≥moderate physical activity was added to the
DHA model, a greater effect was seen. In contrast, EPA
content remained significantly negatively associated with
squats performed. Previous studies have indicated an in-
crease in muscle protein synthesis (Smith et al. 2011a;
Table 4 Best predictors of LBM post‐treatment using
hierarchical regression
Predictor Regression coefficient*
(95% CI)
p-value** Adjusted R2t
Weight 0.948 0.000 0.634
Stage Tmill
completed
0.225 0.007 0.713
No. push
ups (1 min)
0.275 0.002 0.764
*Regression coefficients taken from final model including: body mass, number
push‐ups performed, treadmill stage reached.
**Significance of the individual predictor within the final model.
tDenotes value reported as each variable was added into the model in the
order: body mass, stage tmill completed then no. push ups
CI = confidence interval.
Table 5 Correlations between measures of physical function and LCn-3 content of erythrocytes
Physical function* % time>mod EPA EPA adj** DHA DHA adj.**
r p-value r p-value β p-value r pcs-value β p-value
Push ups 0.467 0.001 0.072 0.648 0.212 0.118 0.517 0.000 0.399 0.001
Squats 0.110 0.479 −0.338 0.029 -0.268 0.041 0.153 0.333 -0.37 0.776
Handgrip -0.068 0.663 0.083 0.603 -0.144 0.340 0.109 0.492 0.099 0.482
Treadmill 0.224 0.138 -0.11 0.493 0.13 0.929 0.267 0.083 0.147 0.277
*Push ups: performed in one-minute; Squats: performed in one-minute; Stage of treadmill completed: at which 85% of estimated HRmax was reached.
% time >mod: moderate & vigorous data combined; EPA: eicosapentanoic acid; DHA: docosahexanoic acid.
**Fully adjusted model included: weight, age, % time >mod activity & LBM. Correlation coefficient (β)
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Smith et al. 2011b) and peak torque development (Rodacki
et al. 2012) after supplementation of LCn-3 s was combined
with an anabolic stimulus. In advanced cancer populations,
EPA LCn-3 supplementation (often in conjunction with a
protein-rich supplement) has been associated with improve-
ments in physical function (Moses et al. 2004) and strength
(Fearon et al. 2006), while EPA and DHA LCn-3 +NSAIDs
have been shown to improve handgrip strength (Cerchietti
et al. 2007). Our results both agree and disagree with the
previous literature base with no clear reason for the oppos-
ing directions for the associations between physical function,
DHA and EPA. Further investigation into LCn-3 and phys-
ical activity interactions are required.
Our population compared favourably with larger co-
horts for body composition, (Chlebowski et al. 2002; Irwin
et al. 2005) education level, (Irwin et al. 2005) however the
exclusion of those with a diagnosed chronic disease
(T2DM or CVD) and those who could not participate in
moderate physical activity, may have led to our partici-
pants being younger and more physically active than the
general breast cancer population.
Conclusion
This is the first study to report that higher weight adjusted
LBM is associated with greater upper body strength-
endurance and aerobic fitness in women after completion
of treatment for breast cancer. Further research is re-
quired to elucidate LCn-3-exercise interactions.
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 4.2 Results 
From the theoretical model, we hypothesized that treatment (Sx, RTx and CTx) was associated with 
increased inflammation, early menopause and decreased physical activity. In turn, these factors are 
hypothesized to be associated with greater loss of LBM, and increases in body fat% and/or body 
weight. In contrast, previous research has indicated the positive association between AI usage and 
LBM gains. The results below are included to compare relevant data to the existing evidence 
substantiating our theoretical model (Figure 4.2). 
4.2.1 Associations between proposed outcomes and breast cancer treatment.  
Forty-one (92%) of participants underwent chemotherapy, while 33 (67%) had radiotherapy. 
Compared to those who did not receive chemo, there were no differences in any marker of body 
composition, inflammation, markers of physical function or time spent in >moderate intensity 
activity (all p>0.05). At baseline, quality of life scores tended to be greater for those who had not 
undergone chemotherapy, compared to those who had (113.6+8.5 vs. 106.22+16.4, p=0.077). 
No additional significant relationships were noted when comparing those who underwent 
radiotherapy with those who had no radiotherapy. 
Further analyses investigating treatment type and stage of disease revealed that those who were 
diagnosed with later stage disease (Stage IIB & IIIA) were more likely to undergo chemotherapy 
than those with earlier stage disease (Stage 0 to IIA) (Chi-square: 100% vs 75.0%, Fisher’s Exact: 
p=0.038). In the published manuscript we reported an increase in fatigue and decreased quality of 
life for those with later stage disease. However, stage of disease was not associated with any 
measure of body composition, physical function, or CRP (all P>0.05). 
4.2.2 Associations between intermediary outcomes and body composition measures 
Aromatase Inhibitors and body composition 
No significant differences were observed in body composition when comparing those on aromatase 
inhibitors and those on tamoxifen or no hormonal treatment (data not shown, all p<0.05). In 
addition, no association between hormonal treatment and CRP or FACT-B scores (all p>0.05, data 
not shown) were noted.  
Physical activity and body composition  
Physical activity measured objectively through 7-day accelerometry and indirectly through tests of 
physical function, (1-min push up, squat, treadmill test) were strongly associated to higher LBM 
after adjustment for weight and age. Body fat% was significantly associated physical activity 
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 (reported in the manuscript). Furthering this, we observed an inverse association between physical 
activity and: waist girth (β: -1.157, p=0.001) and hip girth (β: -0.857, p=0.021).  
When assessed as tertiles of physical activity variables: time spent in >moderate intensity activity, 
number of push-ups performed and stage reached in the treadmill test, all three variables had a 
significant linear relationship with LBM.  Such that more physical activity or greater physical 
function was related to greater adjusted LBM (all p<0.05). However, both 2nd (3.4+0.59%) and 3rd 
(6.2+2.2%) tertiles of %time spent in >moderate intensity activity had significantly greater adjusted 
LBM than the first (1.2+0.6%) tertile (absolute values of LBM (kg): 44.9+0.7kg & 44.3kg+0.7 vs. 
42.03+0.7kg vs, respectively) (Figure 4.1). For push-ups (1st: 0.4+0.79, 2nd: 5.6+2.7, 3rd: 
20.5+9.0) and StageTM (1st: 9.6+1.4 2nd: 12.0+0.00, 3rd: 13.8+0.9), the highest tertile of each had 
significantly greater adjusted LBM than the 1st or 2nd tertiles (Figure 4.1). For body fat%, the 
relationships were equivalent and significant albeit in the inverse direction (data not shown). 
CRP and body composition 
While our main results indicated no effect for CRP on LBM we investigated associations with 
tertiles of CRP. There was an overall trend for higher CRP values being associated with lower LBM 
(F=2.89, p=0.067) and higher body fat% (F=3.5, p=0.038) after adjusting for weight and age. In 
addition, compared to the first tertile, the third tertile had significantly lower adjusted LBM 
(45.26+0.96kg vs. 41.71+0.98kg, p=0.021) and greater body fat% (36.5+1.4% vs. 42. 1+1.4kg, 
X-values indicate tertile grouping. Covariates included in the model: body weight, height and age. Estimated Marginal 
Means of LBM indicated on Y-Axis. 
Full line (—):tertiles&of&%time&spent&in&>moderate&intensity&activity&(ModVig);&Dashed&line&()))):&tertiles&of&Stage&reached&on&Treadmill&(StageTM);&Dotted&line&(•••):&tertiles&of&push&ups&performed&in&1)min&(Push&ups)&*Significantly&different&from&1st&tertile&of&ModVig,&p<0.05&§Significantly&different&from&1st&and&2nd&tertiles&of&StageTM,&p<0.05&‡Significantly&different&from&1st&and&2nd&&tertiles&of&Push&ups,&p<0.05&
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Figure 4.1 LBM for tertiles of time spent in >moderate intensity activity, push-ups performed and stage of treadmill 
completed (n=49) 
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 p=0.011). However, after adjustment for height, linear (p for trend=0.244 & 0.197) relationships 
were no longer significant for LBM or body fat%, respectively. No significant relationships for 
CRP were noted for waist and hip girths. 
Menopausal status in body composition, inflammation and QOL 
Of the 49 women, 24 (46.9%) were classified as post-menopausal. No associations for menopausal 
status (pre-, peri- and postmenopausal) were found for LBM, body fat%, waist or hip girths. When 
menopausal states were compared for CRP, no differences were noted for pre- (n=6) peri- (n=13) or 
postmenopausal (n=21) women (median: 1.5mg/L 95%CI: 0.98 to 6.7; 0.7mg/L 95%CI: 0.22 to 3.2 
& 0.9mg/L, 95%CI: 0.9 to 2.5, respectively, all p>0.2). In contrast, no differences were noted for 
quality of life scores or erythrocyte content of EPA or DHA (all P<0.05 for linear trend and 
between groups). However, due to the small number of premenopausal women, these results should 
be interpreted with caution.  
Erythrocyte LCn-3 and associations with body composition, inflammation and QOL 
Associations between EPA, DHA and LBM presented as contrasting, albeit non-significant patterns 
(Table 4.1). Numerically the tertiles indicated a negative and positive association with LBM for 
EPA and DHA, respectively. However, the small magnitude of difference was not clinically 
significant.  
Furthermore for tertiles of EPA, no significant associations were found for body fat%, waist, hip, 
CRP or FACT-B scores (Table 4.1). For DHA, a non-significant trend was observed for hip 
circumference, such that a lower hip girth tended to be associated with a greater % of DHA in the 
erythrocytes (p=0.062). Post-hoc analyses revealed that compared to the tertile 1, the 2nd tertile of 
DHA intake had a significantly lower hip girth (p=0.022), while the highest tertile was only 
numerically lower and not statistically significant.  
4.2.3 Discussion of additional baseline findings 
The influence of breast cancer diagnosis and treatment variables on intermediary and body 
composition outcomes 
There was no effect for time since diagnosis or treatment completion on any marker of body 
composition. In addition, we found that neither chemotherapy nor radiotherapy had an influence on 
performance of physical activity, quality of life or markers of inflammation in a population of 
women who had completed treatment for breast cancer in the last 12 months. Similarly, stage of 
disease did not influence any of these measures except for quality of life and fatigue. Chemotherapy 
has been associated with reduced physical activity previously (Demark-Wahnefried et al. 1997) and 
a combination of decreased activity and chemotherapy being conducive to greater body weight gain 
compared to those who maintain their activity (Irwin et al. 2005) 
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 TABLE&4.1&THE&EFFECT&OF&ERYTHROCYTE&LCN)3&CONTENT&(TERTILES)&AND&CROSS&SECTIONAL&ASSOCIATIONS&OF&BODY&COMPOSITION,&INFLAMMATION&AND&QUALITY&OF&LIFE.&
  %EPA in RBC %DHA in RBC 
  
Tertile  
1 
Tertile 
2 
Tertile 
3 
P 
trend* 
Tertile 
1 
Tertile 
2 
Tertile 
3 P trend* 
%EPA/DH
A1 
0.68 
(0.17) 
0.99 
(0.07) 
1.6 
(0.45) 0.000 
1.96 
(0.6) 
2.9 
(0.18) 
3.7 
(0.5) 0.000 
LBM (kg) 44.1 
(0.7) 
43.7 
(0.7) 
42.8 
(0.7) 0.439 
42.9 
(0.7) 
44.3 
(0.7) 
44.6 
(0.8) 0.247 
Body fat% 38.4 
(1.0) 
39.3 
(1.1) 
40.1 
(1.1) 0.526 
40.7b 
(1.1) 
39.0 
(1.1) 
38.1b 
(1.1) 0.241 
Waist (cm) 85.5 
(0.8) 
85.0 
(0.9) 
84.5 
(0.9) 0.726 
84.8 
(0.9) 
86.3 
(0.9) 
84.8 
(0.9) 0.374 
Hip (cm) 105.7 
(0.78) 
106.0 
(0.9) 
108.9 
(0.8) 0.594 
108.3a 
(0.8) 
105.5a 
(0.8) 
106.5 
(0.8) 0.062 
CRP 
(mg/L) 
1.59 
(0.47) 
1.2 
(0.5) 
2.2 
(0.5) 0.453 
2.1 
(0.5) 
0.8b 
(0.5) 
2.1b 
(0.5) 0.143 
FACT-B 110.2 
(3.5) 
102.4 
(3.8) 
111.7 
(3.7) 0.183 
110.8 
(3.9) 
106.8 
(4.0) 
109.5 
(4.0) 0.765 
1For %EPA tertiles, value for EPA is shown, for %DHA tertiles, value for DHA is shown. 
*Indicates linear trend for tertiles univariate analysis of covariance. All values are estimated 
marginal means, covariates included: weight, age, height. 
a: indicates significantly different to Tertile 1, p=0.022. b: Indicates a non-significant trend for 
difference compared to Tertile 1, p<0.1. 
 
However, our results agree with a recent long term follow up of breast cancer survivors that 
indicated no difference in quality of life for those who were treated with chemotherapy or not (Hsu 
et al. 2013). 
 
Chemotherapy (Aslani et al. 1999, Prado et al. 2009) and radiotherapy (Bower et al. 2009) have 
previously been associated with increases in markers of inflammation in those with cancer. Bower 
et al (2009) noted that radiation induced elevations in CRP and IL-6 were related to increases in 
fatigue in breast and prostate cancer survivors (Bower et al. 2009). These previous findings may 
explain our observation that those with later stage disease all underwent chemotherapy had 
increased fatigue and poorer quality of life. However, we found no difference between groups for 
concentration of high sensitivity (hs)-CRP. 
 
. 
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 Further analysis of physical function and effect on body composition 
A threshold association was noted for cross-sectional body composition and markers of physical 
activity and function. Those who achieved 20.4 (95%CI: 15 to 25) push ups in 1-minute, reached 
stage 13.8 (95%CI: 13.4 to 14.5) or spent more than 3.5% (95%CI: 3.1 to 7.5) of their time 
performing >moderate intensity activity were more likely to have a greater weight, age and height 
adjusted LBM. Previous studies in breast cancer have not assessed the relationship between 
physical function and LBM outcomes. However, a number of exercise interventions have shown 
that increasing strength and cardiorespiratory fitness through training can result in LBM increase 
(Schmitz, Ahmed, et al. 2005, Herrero et al. 2006, Fernández-Lao et al. 2013, Irwin, Alvarez-
Reeves, et al. 2009), but not in all cases (Schmitz et al. 2009, Demark-Wahnefried et al. 2008, 
DeNysschen et al. 2011). In a general female population (N=1443), physical activity participation 
was associated with increased muscle strength, and in turn, increased strength was associated with 
increased absolute LBM (Rolland et al. 2004). Thus, our data agree with the well-established links 
between participation in physical activity and increased LBM. 
 Effect of early menopause on breast cancer outcomes 
 
Lean%Body%Mass%
Loss 
Inflammation 
Treatment(for(
breast'cancer (CTx,%
Sx,$RTx) 
Increased)fat)
mass 
Physical)Inactivity 
Breast'Cancer'
Diagnosis 
Early&menopause 
Increased)body)
weight 
Omega.3"fatty"acids 
     Treatment factors            Intermediary factors          Body composition 
   Figure 4.2 Theoretical framework for body composition change after treatment for breast cancer. 
Connecting lines indicate an association established in previous observational studies. Solid line (-): Research 
conducted in breast cancer populations; Dotted line (……): Research conducted in non-breast cancer populations; 
Arrow: Agonistic relationship; Solid circle: Antagonistic relationship. Dashed line (---): Proposed relationship under 
investigation. 
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 We found no significant relationships between menopausal state and intermediary or body 
composition outcomes. Previous prospective research has indicated that women who experience 
early onset of menopause as a result of treatment are likely to gain more weight (Goodwin et al. 
1999, Niraula et al. 2012). A previous review of age, menopausal status and quality of life indicates 
that younger women typically experience lower quality of life after treatment (Howard-Anderson et 
al. 2012). One of the suggested drivers of this relationship is the onset of early menopause and 
fertility concerns (Howard-Anderson et al. 2012), however there is a dearth of research explaining 
quality of life and physical function differences between menopausal states. Our preliminary data 
indicates that menopausal status has little influence, although the study limited by it’s cross 
sectional nature. 
 
Effect of erythrocyte EPA and DHA concentrations 
Tertiles of neither EPA nor DHA were related to inflammation in our population. Previous 
epidemiological research has been inconsistent when describing the relationship between 
incorporation of LCn-3 into plasma tissue, and its association with lower concentrations of 
inflammatory markers (Calder 2012, Pischon et al. 2003). Observational research in breast cancer 
survivors reported that increased CRP was associated with higher fatigue and lower concentrations 
of LCn-3 compared to LCn-6 ratios (Alfano et al. 2012). Further analysis of our data did not show a 
significant association with CRP for ratios of LCn-3 to LCn-6. It is possible that these results were 
limited by our relatively low sample size. On the other hand we observed a generally low CRP 
value in our participants (1.6 +2.2mg/L) compared to the study by Alfano et al (4.4+8.6) (Alfano et 
al. 2012), thus a larger range in CRP may have made it’s effect more pronounced. 
We noted that increasing %DHA in the erythrocytes tended to be associated with decreased hip 
girth, with the 2nd tertile of %DHA had a significantly lower hip girth than the lowest tertile. DHA 
has been reported previously to be associated with changes in measures of body fat% (Munro and 
Garg 2012). Munro et al reported a significant correlation between DHA and body weight and body 
fat loss (Munro and Garg 2012), while a number of other studies have shown that LCn-3 
supplementation is related to greater loss in fat mass (Couet et al. 1997, Kabir et al. 2007, Noreen et 
al. 2010). However, we did not observe any other significant results for different markers of 
adiposity. 
 
Limitations 
Originally, a recruitment rate of two to three participants per week was estimated given clinical data 
from the oncologists referring participants to the trial. After 19 months of recruitment, only ~30% 
of the proposed sample size was initiated. Efforts were made to contact local chemotherapy units in 
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 Brisbane based hospitals, a larger list of oncologists, breast cancer and women’s centres, social 
media, public radio advertising and national research recruitment centres. Despite these strategies, 
our greatest limitation to recruiting participants were geographical barriers (women living >60 
minutes drive away from the Wesley Research Institute), and that many women were excluded as 
they had completed treatment more than 12 months prior to recruitment. These criteria were 
considered necessary, however the lower than projected number of participants is likely to have 
reduced the ability to identify relationships both at baseline and as a result of the intervention.   
 
4.3 Summary of findings at baseline 
In a population of women who have been recently treated for breast cancer, LBM is predominantly 
predicted by a combination of body weight, estimated cardiorespiratory fitness and upper, but not 
lower body strength-endurance. Physical activity measured objectively was related to LBM after 
adjustment for weight and age, however was not significant when controlling for cardiorespiratory 
fitness and upper body strength-endurance. Furthermore, a threshold effect of performance over 
those three measures in relation to weight adjusted LBM. In essence, LBM is likely to be greater in 
women who engage in physical activity that enhances or maintains a higher level of endurance and 
upper body strength-endurance. The fact that the relationship of LBM and upper body strength-
endurance differs from lower body strength-endurance may indicate two things: 1) that whole body 
strength training is necessary for maintenance of greater LBM, and/or 2) those who engage in 
exercise training that elicits greater upper body strength are a population who are likely to have 
greater LBM. 
 
We did not see a significant effect for LCn-3 on any marker of body composition, quality of life or 
inflammation. This data differs from that found in people with cancer undergoing more intense 
treatment for later stage disease, however it matches the mixed findings from healthy or chronically 
diseased populations. Since women who have completed breast cancer treatment are metabolically 
more similar to those chronically diseased, our findings are not surprising. 
 
These findings are limited by their cross-sectional nature and the shortfall in recruitment that we 
experienced.  Chapter 5 will describe findings from our intervention that investigates the effect of 
manipulating physical activity and LCn-3 consumption in this population of women who have 
completed treatment for breast cancer. 
 
120
 Chapter 5 – Intervention Results 
Section 1 is a submitted manuscript that reports the primary and secondary findings of the thesis at 
12 and 24 weeks. The intervention indicated the LCn-3 supplementation and a 12-week lifestyle 
program have a synergistic effect in the reduction of body weight and body fat, when compared to 
the lifestyle program or LCn-3 supplementation alone. The total body weight lost relates to a 
clinically significant amount of weight loss, and was shown to continue after the initial 12-week 
intervention. These changes were noted while LBM was consistent and unchanged for the three 
intervention groups. 
Furthermore, LCn-3, the lifestyle program nor both combined significantly influenced measures of 
inflammation or quality of life. It is likely that the lack of change in inflammation was due to the 
overall lower baseline value of CRP in this population. Similarly, quality of life was shown to 
improve for all groups and time from treatment is likely to have influenced this most profoundly. 
An interesting finding of the trial was the LCn-3 mediated improvement in grip strength and 
physical function from week 12 to 24, independent of exercise. This will need further validation 
from more detailed assessment, but agrees with previous literature that reported a positive effect for 
LCn-3 on grip strength and gait function. 
Section 2 reports on potential confounding factors not fully explored in the published manuscript. 
These analyses indicated that there were no significant changes between groups for dietary energy 
and protein intake. In addition, no significant differences in LBM change were observed when 
assessing protein intake relative to body weight over time. 
Finally, differences between the groups were not noted for markers of Lymphoedema risk or 
menospausal symptoms. &
5.1 Manuscript #5 – Submitted for Publication 
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 3 
Abstract 32 
Background 33 
Long chain omega-3 fatty acids (LCn-3s) may enhance the effect of an anabolic stimulus on LBM. This has not 34 
been investigated in women after treatment for breast cancer who are at risk of LBM loss. Our aim was to compare 35 
change in LBM, QOL and inflammation after LCn-3 supplementation alone (N-3), a nutrition and exercise (aerobic 36 
(AET) and resistance (RET) training) lifestyle  program plus olive oil (EP+OO), or the lifestyle program plus LCn-3 37 
(EP+n-3).  38 
Methods 39 
Forty-nine women who had completed treatment for breast cancer (48.9 + 1.4 years) were randomly assigned to 3 40 
groups. One consumed 5g of LCn-3s (N-3; open-label); two groups participated in a 12-week exercise and nutrition 41 
lifestyle program. In a double blind fashion, one consumed 5g/d of olive oil (EP+OO), while the other had 5g/d of 42 
LCn-3s (EP+N-3). Measures of body composition, CRP, QOL and physical function were taken at baseline, 12 and 43 
24 weeks.  44 
Results 45 
No change was noted in LBM or CRP after 24 weeks, QOL improved for all groups equally. EP+N-3 experienced 46 
greater reductions in body weight, waist and hip girth. Exercise prescription improved upper body strength-47 
endurance and LCn-3 supplementation attenuated decreases in handgrip strength. LCn-3 did not augment the LBM 48 
or CRP response to a lifestyle program, however combining LCn-3 with the lifestyle program may improve markers 49 
of adiposity relevant to breast-cancer specific outcomes.  50 
Conclusions 51 
LCn-3 may also enhance maintenance of grip strength over time. A larger trial using exercise and LCn-3 with a 52 
focus on cardio-metabolic and physical function outcomes is warranted. 53 
Key Words – Breast cancer; Nutrition; Omega-3 fatty acids; Exercise; RCT 54 55 
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 4 
INTRODUCTION  56 
After treatment for breast cancer, women typically experience a decrease in lean body mass (LBM) with a 57 
concurrent increase in measures of adiposity (subcutaneous, waist, visceral) with or without body weight change.[1] 58 
These changes are associated with a higher risk of metabolic syndrome related diseases after treatment.[2] 59 
Chemotherapy, younger age, and physical inactivity have been associated with increases in adiposity.[3] In contrast, 60 
mechanisms underpinning LBM change in breast cancer survivors are not fully known. Chemotherapy may 61 
contribute to LBM loss through the associated myotoxicity.[4] while decreased physical activity and chronic 62 
inflammation have been hypothesized as potential causes of LBM loss.[4] On the other hand, prospective LBM 63 
increases have been associated with treatment with aromatase inhibitors (AIs),[3] while cross-sectional push up 64 
performance,[5] and cardiorespiratory fitness have been positively associated with greater weight and age adjusted 65 
LBM.[5] 66 
Some,[6, 7] but not all[8] exercise interventions have reported an increase in LBM (0.7 to 1kg) compared to control; 67 
with positive results coming from aerobic (AET)[9] and resistance training (RET) alone[7] or combined.[10] No 68 
effect for exercise has been seen on total body weight, however, reductions in BF%and waist girth relevant to 69 
metabolic syndrome have been reported.[3]  Dietary energy restriction alone has been shown to decrease body 70 
weight and BF%, however it may be at the expense of LBM and an added risk of sarcopenia.[11] Thus trials 71 
reporting maintenance of LBM and a reduction in adiposity[8, 12] through diet and exercise prescription present as 72 
the most effective option for cardio-metabolic risk factor reduction.     73 
Long chain omega-3 fatty acids (LCn-3) have shown benefit in LBM maintenance for cancer populations.[13] while 74 
supplementation alone has had little effect in non-cancer populations.[14] Our recent review of the evidence has 75 
indicated a potentially synergistic relationship between RET and LCn-3.[14] Compared to controls, LCn-3 76 
supplementation resulted in improved neuromuscular function and power development, muscle protein synthetic 77 
response in the fed state,[14] and greater gait speed in postmenopausal women.[15] In addition, LCn-3 may help to 78 
reduce adiposity,[16] and theoretically this may be enhanced by AET.[16] Considering the established anti-79 
inflammatory properties of LCn-3s they present as a potential nutriceutical after treatment for breast cancer, yet 80 
have not been tested in this population. 81 
The aim of this study was to compare change in LBM, QOL and inflammation after LCn-3 supplementation alone 82 
(N-3), a nutrition and exercise (AET and RET combined) lifestyle  program plus olive oil (EP+OO), or the lifestyle 83 
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 5 
program plus LCn-3 (EP+n-3). We hypothesized that the additive effect of LCn-3 and the lifestyle program would 84 
be superior to both LCn-3 alone and lifestyle program alone.  85 
MATERIALS AND METHODS 86 
Participants were invited to participate through hospital breast cancer oncology centres, radio advertising, social 87 
media and breast cancer research registries in Brisbane, Australia. Eligible women as determined by telephone 88 
interview were those >18 years of age, with stage (Stage 0-IIIa) breast cancer; had successfully completed surgery, 89 
radiation and/or chemotherapy in the last 12 months; were able to perform moderate intensity physical activity, and 90 
BMI of >20 and <35kg/m.2 Exclusion criteria: a previous diagnosis with cardiovascular disease or diabetes; or, 91 
consumption of >1g/day of EPA and DHA LCn-3s combined. After baseline assessment, all measures were repeated 92 
at 12 and 24 weeks. Detailed rationale, study protocol for the full trial has been published previously. The study 93 
received ethical approval by the Uniting Care Health (UCH HREC #1034) and the University of Queensland (UQ 94 
HREC #2011000079) ethics committees.  95 
The study was a prospective, three-armed, randomized controlled trial. Allocation of entry to N-3, EP+OO, or 96 
EP+N-3 was determined with the use of the NQuery Version 7 (Statistical Solutions Ltd, Ireland) mixed block 97 
design to randomise group order in a ratio 1:1:1, and applied to the capsule bottles at the point of production. The 98 
randomisation was concealed from the primary investigator and applied to supplement bottle by the manufacturer 99 
who had no contact with any participants. EP+N-3 and N-3 consumed 5g of marine-triglcyeride/d (Omega Daily, 100 
Blackmores Ltd, Australia), which provided a total of 1.75g EPA and 1.25g DHA per day. The EP+OO group 101 
consumed 5g of olive oil. All groups consumed capsules for the whole study period of 24 weeks. All capsules were 102 
identical in colour and shape, and with the exception of the open-label N-3 group, EP+OO and EP+N-3 were 103 
assigned such that participants and the primary investigator were blinded. Batch testing of the capsules indicated 104 
that the capsules contained the stated amount and proportion of LCn-3s (testing carried out by Alpha Laboratories, 105 
NZ). 106 
Exercise and Nutrition Education Program 107 
EP+N-3 and EP+OO groups attended 9 nutrition and exercise sessions (60-75min each) over the first 12 weeks. 108 
Exercise prescription progressed from one set of six exercises (10 to 20 reps) for 2wks, to two to three sets of nine 109 
exercises (10 to 20 reps) at 6 weeks. Home exercises (same as during session) were prescribed with the aim of 110 
achieving three RET and three >30 minute AET sessions per week. RET included push-ups, squats*, lunges, glute 111 
bridging, seated row*, shoulder press*, bicep curls* and a series of postural and abdominal exercises (*Exercises 112 
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 6 
marked indicates the use of the Gymstick™). The Gymstick™, a specialised elastic resistance stick, which has been 113 
used in a previous non-cancer population of similarly aged participants was used for some of the exercises.[17] AET 114 
was prescribed at an RPE level of 11 to 13 for weeks one to three, and then 12 to 14 for the remainder of the 115 
intervention. Participants were able to select their preferred mode of AET. A handbook and narrated powerpoint 116 
slides were made available to those in the lifestyle program for reviewing at home. Attendance was noted for each 117 
session, and exercise diaries were completed by the women to capture weekly exercise completed. The Primary 118 
Investigator who was an Accredited Practising Dietitian and Accredited Exercise physiologist with relevant clinical 119 
experience facilitated the sessions. After 12 weeks, EP+OO and EP+N-3 participants were encouraged to continue 120 
the exercise program; all three groups recorded their exercise during this time. The N-3 group were encouraged to 121 
exercise and eat as they wished, and were offered the program after the intervention.  122 
Side effects of treatment 123 
All participants were asked to report the appearance of any adverse symptoms that may be related to the exercise 124 
program or capsule consumption. In cases of both exacerbation of lymphedema or severe gastro-intestinal upset, 125 
exercises and supplements were ceased, respectively, until symptoms had abated and cause determined by a medical 126 
professional. 127 
Anthropometric Variables – Primary outcome 128 
Height without shoes was measured to the nearest 0.5cm using a stadiometer (Seca). Weight to the nearest 0.1kg, 129 
LBM and fat mass were measured using the BODPOD digital scales and air displacement plethysmography (ADP) 130 
(BODPOD, COSMED USA Inc), respectively. Before each assessment day, the BODPOD scales and air chamber 131 
were calibrated as per the manufacturer’s instructions using known weights and volumes. All measures were 132 
performed by a certified BODPOD assessor. Results were expressed as percentage LBM and body fat of total 133 
weight, from which absolute LBM (kg) was then calculated. 134 
Quality of Life (QOL) – Secondary outcome 135 
QOL was measured using the Functional Assessment of Cancer Therapy- Breast + 4 (FACT-B+4)tool completed at 136 
baseline, 12wk and 24wk time-points.[18] Fatigue was measured using the additional 13-item FACT-F tool.[19] 137 
Blood analyses – Secondary outcome 138 
Inflammation 139 
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 7 
Fasting high sensitivity-C Reactive Protein (CRP) was measured using a latex-enhanced immunoturbidimetric assay 140 
of blood serum. The 8.5ml sample of fasting whole blood was collected and analysed for CRP on the day of 141 
collection.  142 
Fatty acid testing 143 
The sample was frozen at -20oC, and transported to Healthscope Pathology, Victoria. Lipids from red cells were 144 
extracted with chloroform methanol mixture. The fatty acids were trans-esterificated to methyl esters with 145 
methylation reagent "Meth-Prep 2". The methylation extract was then analysed by gas liquid chromatography 146 
method with flame ionisation detection (gas chromatograph Schimadzu G-2010-FID). The proportion of fatty acids 147 
content of the erythrocytes expressed as % of total fatty acids. 148 
Pill count 149 
Participants were asked to return all bottles, both empty and partially consumed and a pill count was carried out at 150 
the 12 and 24 week time points. 151 
Muscle function and fitness tests 152 
Upper body strength-endurance was determined by performing the maximum number of push-ups (knees on ground) 153 
in 1 minute.[20] Lower body muscular endurance was measured using a 1-minute sit-stand test. Chair height was 154 
standardised at 43cm[20]. Hand grip strength was performed on both arms, with the maximum of 3 attempts 155 
recorded.  156 
Sub-maximal aerobic capacity was measured using the modified Balke sub-maximal treadmill test. Seated blood 157 
pressure was measured before each assessment to ensure safety of exercise. The test being completed when the 158 
individual had reached 85% of their estimated maximum heart rate (max HR) (est. maxHR = 220-age). The Health 159 
Assessment Questionnaire-Disease Index (HAQ-DI) was completed to determine physical functional ability 160 
represented by the sum of scores generated from the eight subscales. A lower score indicates greater functional 161 
ability. 162 
Physical activity 163 
Daily physical activity was objectively measured using GT1M accelerometers (Actigraph, USA). Participants were 164 
asked to wear the device for at least 10 hours per day for one week at each time point. Activity counts were divided 165 
into % time spent in: sedendary, light and > moderate intensity activity. The participants also completed the Active 166 
Australia Survey[21], and EP+N-3 and EP+OO recorded all prescribed exercises performed throughout the 24 week 167 
period in a study-specific exercise diary. 168 
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 8 
Diet history 169 
Dietary intake was measured by the practitioner assisted Diet History Questionnaire.[22] The primary investigator 170 
reviewed the questionnaire with the participant to clarify portion sizes and ensure completion of the form. Nutrient 171 
intake analysis was carried out using Foodworks 7 (Xyris Software) and converted to daily intake. 172 
Lymphoedema Index 173 
Extra-cellular fluid in the upper limb was measured by BIS L-dex XCA™ (Bio-Impedimed, Queensland).[23] 174 
Electrodes were placed at anatomical landmarks at the wrist of each arm and right ankle by a trained research 175 
assistant. An increase in extra-cellular fluid is paralleled by a decrease in impedance and the result recorded as a 176 
ratio to the non-affected arm, taking into consideration arm dominance.[24]  177 
Statistical analysis and sample size calculation 178 
Differences in demographic data between groups were assessed by ANOVA and Kruskal Wallis tests, for parametric 179 
and non-parametric data, respectively. The Friedman test and repeated measures ANOVA were used to determine 180 
within group differences over 3 time points, and Wilcoxon Signed Rank tests and paired t-tests with Bonferroni 181 
adjustment for multiple comparisons were used to determine change within-groups between two time points. The 182 
effects of treatment on the dependent measures were analysed by a 3 x 3 factorial repeated measures ANOVA with 183 
group treatment (N-3 vs EP+OO vs EP+N-3), exercise treatment (EP+OO & EP+N-3 or N-3), LCn-3 treatment (N-3 184 
& EP+N-3 or EP+OO) and additive treatment (EP+N-3 or EP+OO & N-3). Intention-to-treat was used for all 185 
analyses. To optimise the analysis of differences between treatments, when appropriate, a nested ANOVA design 186 
was used to examine changes in dependent variables from baseline nested in time. The primary outcome measure is 187 
change in lean body mass (LBM) at 24 weeks. A mean change in lean body mass over 12 weeks of 0.8kg[9, 25] has 188 
been observed in group previous exercise and nutrition trials in breast cancer populations. Assuming that the 189 
minimum difference in LBM across the comparison groups is a mean of 1kg, 38 participants per group will be 190 
required to detect this difference with 90% power and type 1 error of 5% or less (two-tailed).  A total of 114 191 
participants was therefore required.  Assuming 10% for attrition and allowing 15% for contingency, 51 subjects per 192 
group will need to be recruited to obtain complete data on at least 38 for each group 193 
Results 194 
Participants were recruited over a 15-month period (Oct 2011 – Jan 2013) (Fig 1). A total of 135 women were 195 
initially screened for inclusion criteria, recruitment was stopped due to time constraints. The major reasons for 196 
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exclusion were >12 months post treatment completion, and daily consumption of  >1000mg EPA and DHA 197 
combined. Forty-nine participants were eligible for the study and completed baseline assessment. Forty-three 198 
(87.8%) participants returned at 12-wks, and 42 (85.7%) at 24-wks time-points. Forty-nine participants were 199 
included in the primary analyses. Descriptive statistics of the population are shown in Table 1. No significant 200 
differences were found between group for any demographic, treatment or body composition parameters. 201 
The EP+OO and EP+N-3 groups attended a mean of 7.06+2.4 and 6.6+2.09 out of 9 sessions, respectively. Of the 202 
participants allocated to EP+OO and EP+N-3 groups that submitted their exercise log (70%), they performed 67% 203 
and 72.3% of the prescribed RET, and 130.2% and 117.3% of the prescribed AET volume. In addition, from 12 to 204 
24 week time points, all three groups performed equal amounts of physical activity as measured by exercise diary 205 
and accelerometry (data not shown). One participant was excluded from CRP analyses at 12wks as her CRP was 206 
measured as 26.2mg/L, which was taken during an upper respiratory tract infection 207 
LCn-3 concentration within erythrocytes (RBC) 208 
Total n-3 fatty acids increased by 65%, 10% and 88% for N-3, EP+OO and EP+N-3, respectively. For N-3 and 209 
EP+N-3, 80% of the change was due to an equal 40% increase in both EPA and DHA (Figure 2), which resulted in a 210 
significant LCn-3 x time interaction for total n-3 (p=0.018), EPA (p<0.000), but not DHA (p=0.113). EP+N-3 211 
experienced a significantly greater increase in DHA at 24 weeks than EP+OO (+1.9% vs. +0.54%, p=0.023, 212 
respectively); N-3 displayed a within-group trend for increased DHA, but not compared to EP+OO (change at 24 213 
weeks: +1.54%; within: p=0.076, between: p=0.979). EP+OO did not experience any significant increases in EPA, 214 
DPA or DHA at 12 or 24 weeks (p<0.05).  215 
Accounting for all those who returned all capsule bottles (n=41), N-3, EP+OO and EP+N-3 consumed 84.6+21.6%, 216 
81.8+33.4% and 83.4+24.6% of the allocated capsules. Controlling for baseline levels of LCn-3s, capsule 217 
consumption tended to be correlated with erythrocyte levels of EPA, with no significant correlation seen for 218 
concentration of DHA. 219 
Changes in measures of body composition 220 
A significant treatment x time was found for change in LBM (F=2.6, p=0.04) Figure 3. Pairwise comparisons 221 
revealed that after 12 weeks, EP+OO had a significantly greater increase in LBM than N-3 (+0.6kg+1.4 vs. -222 
0.64kg+1.3; F=7.3, p=0.011. After 24 weeks, differences in change from baseline disappeared (N-3: -0.13kg+1.4 vs. 223 
EP+OO: +0.42kg+1.5; F=2.78, p=0.106). Change in LBM for EP+N-3 (12wk: -0.07kg+0.8 & 24wk: -0.38kg+1.3) 224 
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was not significantly different to either N-3 (F=2.65, p=0.113, respectively) or EP+OO (F=2.83, p=0.103, 225 
respectively) at either time point. A significant LCn-3 x time interaction was found, which indicated that EP+OO 226 
experienced greater gains in LBM after 12 weeks compared to those consuming LCn-3 (-0.34kg+1.0 vs. 227 
+0.6kg+1.4, respectively; F=7.0, p=0.011). However at 24 weeks, there was no difference between the groups (-228 
0.09kg+1.4 vs. +0.42kg+1.5, respectively, F=2.5, p=0.115). 229 
For total body weight, only the EP+N-3 group experienced a significant decrease at 12 and 24 wks (change from 230 
baseline: -1.3+1.3kg and -2.3+1.9kg, respectively). No statistically significant change was noted for EP+OO (-231 
0.36+1.6kg and -0.86+2.4kg) or N-3 (-.3+2.5kg and -0.83+2.0kg). No significant time x treatment interaction was 232 
observed for body weight, BF%, waist girth or hip girth (Figure 4A-D). Significant additive x time interactions were 233 
observed for body weight (p=0.042), while waist (p=0.143) and hip (p=0.07) approached statistical significance. No 234 
effect was observed for body fat% (p=0.509). Nested analyses indicated that compared to N-3 & EP+OO combined, 235 
the EP+N-3 (additive) group experienced a significantly greater reduction in body weight (-0.84kg+2.9 vs. -236 
2.27kg+1.9, p=0.028) and hip girth (-0.87cm+2.33 vs. -2.26cm+1.8, p=0.038) at 24 weeks. In addition, compared to 237 
N-3 & EP+OO, EP+N-3 had a greater reduction in waist girth at 12 weeks (-0.23cm+1.9 vs. -1.4cm+1.8, p=0.045), 238 
which was clinically meaningful, yet statistically non-significant at 24 weeks (-0.84cm+2.9 vs. -2.3cm+2.5; 239 
F=3.028, p=0.088).  240 
Change in CRP  241 
No significant interaction for time x treatment was noted for CRP at 12 or 24 week time points (p=0.319) Table 2. 242 
No significant exercise x time, LCn-3 x time or additive x time interactions were found (P>0.05). Pairwise 243 
comparisons indicated that EP+OO experienced a greater decrease in CRP than EP+N-3 at 12 weeks (-0.65+1.5 vs. 244 
+0.24+0.65, p=0.036), which was attenuated at 24 weeks (-0.77+1.5 vs. +0.1+1.0, p=0.07). No other significant 245 
differences were reported at either time point. Within group analyses indicated that both N-3 and EP+OO groups 246 
experienced non-significant decreases in CRP from baseline to 24 weeks (N-3: -0.39, p=0.133; EP+OO: -0.77, 247 
p=0.081), while the EP+N-3 experienced no change (+0.1, p=0.698). 248 
Change in measures of quality of life and fatigue 249 
No significant time x treatment interaction was found for FACT-B+4 (p=0.745) Table 2. Nor were there any 250 
significant exercise x time, LCn-3 x time or additive x time interactions (p>0.05). Within group analyses indicated 251 
that only EP+OO experienced a significant increase in FACT-B+4 after 12 weeks (+6.4+9.5, p=0.049), while 252 
changes for EP+N-3 (+6.8+12.0, p=0.094) and N-3 groups (+5.6+8.9, p=0.072) did not reach statistical significance. 253 
Numerical, but non-significant increases in FACT-B+4 score were seen for all groups. However, a main effect for 254 
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time was found corresponding with an increase in FACT-B+4 for all groups combined at 12 and 24wks (p=0.000 for 255 
both).  256 
No significant interactions were noted for FACT-F. In addition, no significant change was noted within groups at 257 
either time  258 
Changes in parameters of physical function 259 
All groups improved in number of push-ups performed over time (Table 3). A significant exercise x time interaction 260 
was found (p=0.004); compared to N-3, those who participated in the lifestyle program experienced greater 261 
improvement after 12 weeks (change in push ups performed: 0+11.1 vs. ‘exercise’ = 8.3+7.6, p=0.003). From 12 to 262 
24 weeks, both groups (N-3 and lifestyle program) experienced similar improvement (4.1+10.8 and 1.49+5.3, 263 
respectively, p=0.244), yet change from baseline remained significantly different at 24wk (N-3: 4.18+5.3 and 264 
lifestyle group: 9.8+8.7; p=0.022). 265 
No significant time x treatment interaction was found for squats performed (p=0.766), which was maintained when 266 
exercise groups were combined (F=0.939, p=0.398). There was a significant main effect for time (p=0.000). Within 267 
groups, compared to baseline, all 3 treatment groups significantly improved the number of squats performed 268 
(p<0.05) (Table 3).  269 
No significant time x treatment interaction, or main effect for time was found for time to 85% predicted HR in the 270 
sub-max treadmill test (p=0.267 & p=0.555, respectively).  271 
No significant time x interaction was found for handgrip strength (F=1.9, p=0.1) (Table 3). No exercise x time, LCn-272 
3 x time, or additive x time interactions were indicated at 12 weeks (F=0.54, p=0.588). However, while no 273 
difference was noted at 12wks (p<0.05), from 12 to 24wks a significant LCn-3 x time interaction was observed 274 
(p=0.013). This indicated a maintenance in grip strength for the LCn-3 supplemented groups compared to decrease 275 
in strength for the EP+OO group (0.05kg+0.37 and -0.94kg+2.12, respectively). These results were similar 276 
regardless of whether dominant or non-dominant, or treatment affected or unaffected arm were used.  277 
A non-significant treatment x time interaction was observed for HAQ-DI scores (p=0.092). The Ex+N-3 group 278 
experienced a significant decrease from baseline to 24 wks (-1.67+0.69, p=0.035), while no significant reductions 279 
were seen at 24 wks for the LCn-3 (-0.57, p=0.422) or Ex+OO (-0.067+0.6, p=0.809). Pairwise comparisons 280 
revealed no differences in change from baseline to 12 wks (p>0.05). However, a significant LCn-3 x time interaction 281 
from 12wks to 24wks (p=0.046) was observed (Figure 3). This indicated that those who consumed LCn-3 282 
experienced greater improvements in physical function compared to those who did not consume LCn-3 (Mean 283 
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change: LCn-3 group= -0.83+1.62 vs 0.26+1.75).  No significant hormonal therapy x time interaction was observed, 284 
which indicated there was no between-group effect of hormonal treatment on change in HAQ-DI. 285 
Covariates for LBM and body composition change 286 
No differences were noted between any group at either time point for overall energy and protein intake, nor for 287 
objective (accelerometry and treadmill test) or subjective physical activity measures (data not shown).  288 
 289 
Discussion 290 
The combination of LCn-3 and an exercise and nutrition lifestyle program has no advantage over either intervention 291 
alone for change in LBM, QOL or inflammation. However, greater reductions in body weight and measures of 292 
adiposity were observed in those exposed to the lifestyle program and LCn-3 supplementation. The magnitude of 293 
body weight and waist decrease was clinically significant to post-treatment mortality and morbidity. All groups 294 
experienced equal and significant improvements in QOL.  295 
Our observations of LBM are similar to previous interventions combining exercise and nutrition.[8] However, 296 
longer and supervised trials have reported LBM gain over 6 to 12 months of 0.7kg to 1kg.[7]  The EP+OO group 297 
experienced a significantly greater increase in LBM at 12wks; however, this was not maintained at 24 weeks. The 298 
exercise diaries indicate lifestyle program participants achieved ~70% adherence to prescribed RET while ~130% of 299 
prescribed AET; this shift to AET with the increased activity seen in the N-3 group may explain the lack of 300 
difference between groups, and no absolute gains in LBM and muscle strength generally. 301 
Apart from LBM, moderate total body weight loss is becoming a target to reduce all-cause mortality ,with a 2.7kg 302 
been shown to improve survival over 6 years of follow up.[2] Thus, the combination of LCn-3 and the lifestyle 303 
program elicited a clinically significant and greater reduction in waist girth at 12 weeks and body weight and hip 304 
girth at 24 weeks compared to the other two groups. This finding is of considerable relevance to both health 305 
practitioners and individuals. Body image due to the muscle and fat changes after treatment is a psychological 306 
stressor for survivors, and reduction of visceral fat (waist circumference) is of benefit to mortality and morbidity. 307 
Previous trials using LCn-3 with or without energy restriction have shown reductions in total fat mass and adipocyte 308 
diameter[16] however AET and LCn-3 in combination has not elicited greater reductions in fat mass previously.[26] 309 
In vitro and animal studies have repeatedly indicated an up regulation of fatty acid oxidation due to alterations in 310 
fatty acid transport to and metabolism within the mitochondria, reviewed in detail here[16]. AET is known to 311 
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similarly enhance mitochondrial density and enzyme concentration, thus this research provides a theoretical basis to 312 
explain the greater body weight and adiposity reduction observed in our study.   313 
Consumption of LCn-3 supplements resulted in an increase in erythrocyte concentration of EPA and DHA when 314 
compared to olive oil, however both N-3 did not experience statistically significant increases over EP+OO. We did 315 
notice an accumulation effect where %DHA content was significant at 24 weeks but not 12, which is likely to be 316 
due to the gradual incorporation of DHA into cells over time.5 However, pill counts reflected equal adherence 317 
between the three groups.  318 
Compared to lifestyle plus LCn-3, lifestyle program plus olive oil experienced a greater decrease in CRP at 12 319 
weeks, but this disappeared at 24 weeks. Our results match findings from previous exercise trials studies that 320 
reported no change in CRP after exercise in breast cancer[27] and healthy populations. Greater concentration of 321 
CRP has been associated with cross-sectional weight in our group at baseline[5] and other studies, however, changes 322 
in weight and CRP have not been shown to correlate in breast cancer and other populations.[12]  323 
Our data indicate that all interventions equally improved QOL in this breast cancer population. Previous exercise 324 
and/or nutrition interventions with a measure of quality of life have reported mixed findings. Overall quality of 325 
life,[28] physical function,[6] and psychosocial[28] subscales have been shown to improve after exercise only 326 
interventions. In contrast, similar to our study previous exercise and diet combined trials have not shown significant 327 
between group improvements.[8, 12] To explain this, exercise diaries indicated that the N-3 group performed as 328 
much AET as those in the lifestyle program from 12 and 24wk assessments. Previously, increased quality of life 329 
scores have been associated with greater aerobic fitness, and for all survivors, QOL has been observed to improve 330 
over time without intervention.[29] Thus we are unable to disentangle the effects of LCn-3, lifestyle program 331 
participation, or time since the end of treatment. However, it is a positive result that the population as a whole 332 
improved regardless of the intervention type. 333 
It was expected that the lifestyle program would elicit an increase in muscle strength, however no differences were 334 
found between the groups for lower body strength-endurance. While there was an effect for the lifestyle group and 335 
push up performance, the lack of difference between the olive oil and LCn-3 groups indicates LCn-3 had no 336 
influence on strength development over time. Participation in aerobic exercise was higher than prescribed in the 337 
intervention for all groups, however this was not reflected in fitness levels, as there was no change noted for any 338 
group in the treadmill test. Accelerometer data also indicated no change in moderate/vigorous physical activity. A 339 
few reasons may explain this disparity. Firstly, it is possible that participants over-calculated their weekly physical 340 
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activity; accelerometers were needed to be removed for water based activities, thus would have not accounted for 341 
swimming of which was common; or the aerobic activity may not have been performed at a high enough intensity to 342 
improve VO2max. Prior research has indicated that an intervention utilizing supervised and objectively measured 343 
exercise may be the most effective in augmenting body composition and fitness levels, which may partly explain our 344 
results.[9]  345 
Adherence to resistance training of ~70% may have been insufficient to promote significant LBM or strength 346 
change. Verbal feedback from participants indicated that motivation to perform the resistance training was the major 347 
factor for the adherence noted. Previous studies that have employed more frequent supervision in gym-based 348 
programs have recorded significantly greater increases in strength,[7, 30] thus the potential for home based elastic-349 
resistance exercises may only be sufficient to maintain LBM.  350 
Both HAQ-DI and handgrip strength were enhanced and better maintained for those consuming LCn-3 independent 351 
of exercise. Previously, compared to lower body RET alone, Rodacki et al (2012) observed a significant 352 
improvement after LCn-3 supplementation plus RET in muscle power generation via improved electromechanical 353 
delay in middle aged women.[31] Since our participants were tested for muscle strength-endurance, improved 354 
neuromuscular function may not have provided any advantage to LCn-3 supplemented individuals. However, 355 
handgrip strength and physical function (measured by HAQ-DI) was maintained in the LCn-3 supplemented groups, 356 
while lifestyle plus olive oil group experienced a decrease in both parameters from 12 to 24 weeks. It is plausible 357 
that similar to Rodacki et al,[31] LCn-3 may have improved neuromuscular activation leading to a better 358 
maintenance of force generation in the LCn-3 groups. Furthering this, Robinson et al previously reported that every 359 
additional serve of fatty fish was associated with 0.43kg and 0.48kg increase in handgrip strength for older (59 to 73 360 
years) men and women, respectively.[32] Additionally, Murphy et al, found that compared to a standard care 361 
control, the LCn-3 group experienced significantly lower chemotherapy induced infiltration of intra-muscular 362 
triglyceride (IMTG).[13] Where greater IMTG was related to a lower plasma concentration of EPA,[13] and 363 
previously has been associated with poorer physical function and strength in older populations.[33] It is 364 
acknowledged that the magnitude of change in handgrip strength is not large, such that a longer duration of follow 365 
up would be required to confirm the trends noted. With regard to physical function measured by the HAQ-DI, one 366 
previous study by Hutchins-Wiese et al[15] reported a significant improvement in gait speed after LCn-3 367 
supplementation, however HAQ-DI was not measured in this trial limiting a direct comparison. In regards to 368 
hormone treatment derived joint pain, we did not observe any differences in physical function between AIs and 369 
other hormonal treatments. In addition, HAQ-DI scores were not related to erythrocyte LCn-3 or HS-CRP levels. 370 
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However while oestrogen is associated with pro-inflammatory cytokine levels, these have not been consistently 371 
shown to affect AI-joint related pain.[34] 372 
Caution should be taken in interpretation of the results as our study was limited by a small sample size due to 373 
recruitment difficulties. Of those participants who were eligible there was good uptake into the trial, thus the 374 
narrowness of our selection criteria is likely to be the critical element of our reduced sample. We calculated that 135 375 
participants would be required in order to achieve sufficient power. In addition, to better determine the effects of 376 
LCn-3 on LBM and function, higher intensity of RET is recommended, as the previous studies indicating an effect 377 
of LCn-3 on muscle strength-power have used weights of greater specificity to LBM gains (machine and free 378 
weights).[7] On the other hand, our results are similar to those with studies that included a larger population with 379 
equivalent intervention protocols.[8, 12] Finally, our attrition rate of 16% (41/49) reflects that the intervention was 380 
well tolerated and similar to other lifestyle interventions in this population.[7, 30] 381 
The present trial is the first to evaluate the combined effect of LCn-3 supplementation and a lifestyle program 382 
compared to either intervention alone on body composition, inflammation and quality of life outcomes in a breast 383 
cancer survivor population. No significant effect on LBM or CRP was observed for any intervention group, while all 384 
groups experienced an improvement in QOL. The additive effect of LCn-3s and the lifestyle program was related to 385 
clinically relevant and greater reductions in body weight and adiposity compared to either intervention alone.  Those 386 
consuming LCn-3 supplements experienced better maintenance of grip strength and improvement in physical 387 
function compared to those consuming olive oil. Caution in the interpretation of these results is needed due to 388 
sample size. Further research involving a larger population assessing long-term cardio-metabolic and functional 389 
capacity outcomes is recommended.  390 
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N-3: Fish oil alone; EP+OO: Lifestyle program plus olive oil; EP+N-3: Fish oil plus lifestyle program. BMI: Body mass index; LBM: 
Lean body mass; Dx: Diagnosis; Rx: Treatment; AI: Aromatase Inhibitors; CRP: C-Reactive protein; %RBC: % of erythrocyte fatty 
acid composition; EPA: Eicosapentanoic acid; DHA: Docosahexanoic acid. *Kruskal Wallis test **Pearson’s Chi-Square test used
Table 1. Demographical parameters of participants at baseline 
 Overall 
(n=49) 
N-3 (n=16) EP+OO (n=16) EP+N-3 (n=17)  
Variable  P-value 
Age (mean;SD) 48.9 (1.39) 50 (11.4) 48.9 (7.99) 47.12 (9.16) 0.687 
Body Weight (kg) 73.1 (2.03) 76.4 (16.2) 73.4 (14.4) 69.7 (10.1) 0.387 
BMI (Median; SD) 26.3 () 27.9 (4.9) 26.2 (4.3) 26.1 (2.5) 0.806* 
LBM (kg) 
Mean;SD 
43.6 (0.8) 44.9 (6.9) 44.0 (4.9) 41.9 (4.7) 0.285 
BF% 29.7 (1.46) 40.4 (5.8) 38.8 (8.7) 39.3 (6.2) 0.828 
Days since Dx 
(Med;Range) 
344 
(150 - 961 
364 
(155 – 120) 
338 
(161-961) 
295 
(150-576) 0.958* 
Days Since Rx 
Finish (Med; 
Range) 
130 
(17 – 385) 
210 
(32 – 203) 
129.5 
(37-385) 
130 
(17-381) 0.985 
 No. % No. % No. % No. %  
Postmenopausal 23 46.9 9 56.3 7 43.8 7 41.2 0.81.3 
Disease stage         
0.514** 
I 13 26.5 5 31.3 4 25 4 23.5 
IIa 19 38.8 7 43.8 4 25 8 47.1 
IIb 9 18.4 1 6.3 4 25 4 23.5 
IIIa 8 16.3 3 18.8 4 25 1 5.9 
Surgical protocol 
0.693** 
Breast 
conservation 
23 46.9 6 37.5 7 43.2 10 58.8 
Mastectomy 25 51.1 9 46.3 9 56.3 7 41.2 
Unknown 1 2 1 6.3 0 0 0 0 
Adjunctive Rx          
Chemotherapy 41 83.7 13 81.3 14 87.5 14 82.4 0.877** 
Radiotherapy 33 67 8 50 12 75 13 76.4 0.298** 
Taxane 37 52.9 3 18.8 11 68.8 3 17.6 0.666** 
Tumour type          
HER2+ 12 24.5 4 25 6 37.5 2 11.8 0.550** 
Estrogen + 39 83 10 71.4 13 81.3 16 94.1 0.736** 
Hormone therapy 
0.351** Tamoxifen 13 26.5 2 12.5 4 25 7 41.2 AI 20 40.8 7 43.8 8 50 5 29.4 
None 16 32.7 7 43.8 4 25 5 29.4 
CRP (n=46) 
Median; Range 
0.8  (0.1-
10.1) 
1.45 (0.1-10.1) 1.9 (0.1-8.5) 0.7 (0.1-4.3) 0.523* 
% RBC Fatty Acids (n=43; Median; Range)    
EPA  1 (0.3-3.0) 0.8 (0.5-3.0) 1.15 (0.3-1.9) 0.9 (0.6-1.5) 0.496* 
DHA 2.9 (0.5-5.1) 2.7 (0.7-4.2) 2.95 (0.5-5.1) 2.95 (1.6-3.6) 0.736* 
Tables
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Table 2. Change in Hs-CRP and FACT-B+4 scores at 12 and 24 weeks 
 
Bline 
 
12wk  24wk 
 
p-value* p-value** 
CRP 
(mg/L) Mean SE Mean SE Mean SE 
  
N-3 1.96 0.72 1.87 0.53 1.57 0.56  
0.319 
 
0.099 
EP+OO 1.94 0.65 1.29a 0.54 1.47 0.37 
EP+N-3 1.22 0.32 1.47a 0.38 1.32 0.38 
FACT-B+4  
     
  
N-3  107.4 3.7 113 3.9 115 3.5  
0.745 
 
0.000 
EP+OO  108 2.8 114.7b 3.4 112.1 3.6 
EP+N-3  107.7 4.9 114.5 4.1 113.7 3.7 
N-3: Fish oil only; EP+OO: Placebo plus exercise and nutrition intervention; 
EP+N-3: Fish oil plus exercise and nutrition intervention. CRP: C-Reactive 
protein; FACT-B+4: Functional Assessment of Cancer Therapy – Breast + 4 
items (quality of life). No significant interaction was seen for treatment x time; 
no significant difference was noted with groups for change in LBM.  
asignificantly greater reduction from baseline for EP+OO, p<0.05 
bsignificant within group increase from baseline, p=0<0.05;  
*interaction for treatment x time at 24 weeks;  
**effect for time at 24 weeks (all groups combined)  
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Table 3. Data for measures of physical function at 12 and 24wks 
Measure Baseline 12 wks  24wks 
 
Mean SE Mean SE Mean SE 
Push Ups 
      N-3 7.5 2.6 7.5a,b 2.1 11.9a,b 2.8 
EP+OO 11.4 2.7 20.8a 3.6 20.8a 3.5 
EP+N-3 8.5 2.5 15.8b 3.5 18.7b 3.4 
Squats 
      N-3 31.6 3.8 37.1 4.4 39 4.6 
EP+OO 33.1 2 41.8 3.1 41.5 3.5 
EP+N-3 36.3 2 42.9 2.6 43.6 2.7 
Handgrip 
      N-3 29.8 1.8 32.1 1.7 32.1 1.7 
EP+OO 29.5 1.3 31.2 1.2 30.3 1.3 
EP+N-3 29.2 1.1 30.4 1.1 30.4 1.1 
Stage TMill 
      N-3 10.9 0.6 12.1 0.5 12 0.4 
EP+OO 12.1 0.5 12.2 0.5 11.2 0.9 
EP+N-3 11.9 0.5 12.2 0.4 12.5 0.5 
N-3: Fish oil only; EP+OO: Olive oil plus lifestyle program; EP+N-3: Fish oil plus lifestyle 
program. Push ups: number performed in 1-minute; Squats: number performed in 1-minute; 
Handgrip: Maximum value with dominant hand from 3 trials. A significant lifestyle program 
x time interaction indicated that those who participated in the lifestyle program had greater 
increases in push ups at 12 and 24 wks compared to fish oil only (p<0.05 for both). A 
significant oil x time interaction indicated that those who consumed fish oil maintained 
handgrip strength from 12 to 24wks, compared to a loss in strength in the EP+OO group.  
a,b change in measure of strength from baseline is significantly different between groups 
with corresponding letters with, p<0.05 
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Figure'1.'CONSORT'diagram'for'participant'flow'through'the'intervention'!
150!breast!cancer!survivors!who!had!completed!treatment!were!screened!for!eligibility!
101'Breast'cancer'survivors'were'not'
included'
75'were'excluded'53!had!completed!treatment!>12!months!previous!!12!had!a!BMI!>35;!!7!had!known!Dx!of!CVD!or!Diabetes;!!3!had!metastases!
26'declined'to'participate'15!did!not!respond!after!initial!screening;!!7!found!the!distance!too!far;!!4!declined!to!continue!after!initial!screening;!!!
49!women!who!had!completed!breast!cancer!treatment!were!randomly!assigned!(included!in!final!analysis:!
16!assigned!to!NM3! 16!assigned!to!Ex+OO!group! 17!assigned!to!Ex+NM3!group!
14!returned!for!assessment!at!12!wk!(16)!
2"declined"allocation"to"
LCn.3"only"group"
15!returned!for!assessment!at!12!wk!(16)!
"
14!returned!for!assessment!at!12!wk!(17)!
13!returned!for!assessment!at!24!wk! 14!returned!for!assessment!at!24!wk!(16)! 15!returned!for!assessment!at!24!wk!(17)!
N-3: Fish oil only; EP+OO: Placebo plus exercise and nutrition intervention; EP+N-3: Fish oil plus 
exercise and nutrition intervention. Numbers in ( ) indicate the number of participants included in 
the analysis !s!
             
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3. LBM for each treatment group at baseline, 12 and 24wks (n=49).   
N-3: Fish oil only; EP+OO: Placebo plus exercise and nutrition intervention; EP+N-3: Fish 
oil plus exercise and nutrition intervention. LBM: Lean body mass. No significant interaction 
was seen for treatment x time; no significant difference was noted with groups for change in 
LBM. *EP+OO experienced a greater increase in LBM compared to LC, p<0.05 
 
 
39 40 
41 42 
43 44 
45 46 
Baseline  12 weeks  24 weeks N-3  EP+OO  EP+N-3 Ch
ange in
 LBM (k
g) 
* 
Figure 2. A significant oil x time interaction was observed (p<0.05), which 
indicated an increase in EPA for the fish oil supplemented groups.  
Significant within group changes from baseline identified numerically: 
1=EPA, 2=DPA, 3=DHA, all p<0.05. Significant between-group changes 
from baseline in comparison to olive oil supplemented (EP+OO) group at the 
equivalent time point. a=EPA, b=DPA, c=DHA. 
 
a a,1 
a,b,c 1,2,3 
a,1 
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Figure 4. Mean (+SEM) of Health Assessment Questionnaire – Disease 
Index (HAQ-DI) (A) score and maximum handgrip strength of dominant hand 
(B) in those taking LCn-3(Dashed line ---; n=32) compared to those taking 
olive oil (Solid line ; n=16). N-3: Fish oil only; EP+OO: Placebo plus 
exercise and nutrition intervention; EP+N-3: Fish oil plus exercise and 
nutrition intervention. No overall interaction was observed for either measure 
over time. *A significant LCn-3 x time interaction was observed indicating a 
significantly different change between groups from 12 to 24 wk time points.   
HAQ-D
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 – Sum
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Figure 5. Change in body weight and measures of adiposity from baseline.  N-3: LCn-3 supplements alone; EP+OO: Olive oil and lifestyle program; EP+N-3: LCn-3 and program combined Graph A:. *: significant additive x time interaction (p<0.05), at 24 weeks, EP+N-3 experienced greater reductions in body weight compared to EP+OO and LC combined. B: A significant effect for time (p=0.000), no significant change in body fat% within or between groups. C: *significant additive x time interaction (p>0.05), EP+N-3 experienced greater reductions in waist girth at 12 weeks compared to EP+OO and LC combined; no significant difference at 24 weeks (p=0.088). D: *significant additive x time interaction (p<0.05), at 24 weeks, EP+N-3 experienced greater reductions in hip girth compared to EP+OO and LC combined.   
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5.2 Additional results and discussion  
Results from measures that were not included in the manuscript but were included in the methods 
chapter are the dietary energy and protein intake, Greene Climacteric Scale, and Lymphoedema 
Index (L-Dex).  
These measures were included as they are relevant outcomes to both LBM and body composition 
change, and quality of life after treatment for breast cancer. 
5.2.1 Baseline associations 
Change in energy and protein intake 
No significant treatment x time, LCn-3 x time or exercise x time interactions were observed for 
energy intake (all p>0.05). There were no significant differences within or between groups for 
energy intake at any time point (Table 5.1). A non-significant treatment x time interaction was 
observed for protein intake, indicating a significantly greater increase in protein for the N-3 group 
compared to EP+OO and EP+N-3. However, when one outlier was removed from 24wk data (233g 
of protein/day), this relationship was no longer significant. Univariate ANOVA revealed that after 
excluding the outlier in the N-3 group, at 24 weeks, N-3 had a greater energy adjusted protein 
intake than EP+N-3 (96.9+5.5g vs. 78.2+4.9, p=0.016), with no differences present for EP+OO 
(89.0+5.1g, p>0.1 for both).  
Relative protein intake and body composition change 
Relative daily protein intakes were used to generate categories of protein intake (Figure 5.1). Cut-
points of 0.8g and 1.0g/kg body weight (BW) were used, such that individuals who consumed 
above the threshold at baseline, 12wk and 24wks (‘high’) were compared to those who consumed 
less than the threshold on at least one occasion (‘low’). For 0.8g/kg BW, there was no significant 
group x time interaction (p=0.185). However, pairwise comparisons noted that from 12 to 24wk 
time points, the low group tended to experience a greater reduction in LBM compared to the high 
group (-0.64kg vs. 0.19kg, p=0.09). No significant interactions were noted at any time-point, or for 
any pairwise comparisons. 
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Figure 5.1 – Mean (+SEM) lean body mass at baseline, 12wk and 24wks (n=42).   
A: Groups classified by daily consumption of protein of more or less than 0.8g/kg body weight; B: Classification by 
daily consumption of more or less than 1g/kg body weight. Dashed (---) represents group with at least one reported 
intake below classification threshold; Solid line represents group that reported intake above threshold at all time points. 
No significant interaction for group x time.  *Non-significant trend for a greater decrease in LBM for those who 
consumed less than 0.8g/kg at least once compared to those who consumed more than 0.8g/kg at all time points.  
 
Change in Greene Climacteric Scale (GCS) scores  
No significant treatment x time interactions were observed for total GCS score, or any of the 
subscales (all p>0.05; Table 5.2). No change in association was observed when controlling for 
hormonal therapy (p=0.398) or menopausal status (p=0.081). However, with the exception of the 
Anxiety and Vasomotor subscales (p=0.131 and 0.09, respectively), a significant effect for time was 
observed for total GCS score and psychological, depression, somatic and vasomotor subscales (all 
p<0.015), such that all interventions improved symptoms of menopause. When defining groups as 
pre-, peri- or postmenopausal at baseline, or by hormonal therapy given (AIs, tamoxifen or no 
treatment), a significant effect for time was seen, with no differences in change between groups 
(p>0.05). 
  Baseline 12wk 24wk p-value* p-value** 
Energy Intake 
(kJ/day) Mean SEM Mean SEM Mean SEM & &
N-3 6457 433 6486 609 6912 730 0.947 0.412 
Ex+OO 6216 466 6396 524 6639 481 0.783 0.172 
Ex+LCn-3 6837 380 6550 353 6523 344 0.246 0.414 
Protein (g/day) & & & & & & & &
N-3 84.1 4.7 79.8 4.0 94.9 5.7 0.946 0.566 
Ex+OO 85.9 5.7 88.9 7.2 90.7 7.3 0.679 0.448 
Ex+LCn-3 83.6 5.5 84 5 79.5 6.3 0.495 0.095 
N-3: Fish oil only; EP+OO: Exercise and nutrition program plus olive oil; EP+N-3: Lifestyle program plus 
fish oil. No significant treatment x time interactions observed. *Within group change from baseline to 12wk 
time-point. **Within group change from baseline to 24wk time-point. Dietary intakes determined by a 
Dietitian led diet history questionnaire based on the previous months’ food intake. 
40&41&
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46&
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 Change in L-Dex and incidence of lymphoedema 
There were no significant treatment x time, LCn-3 x time or exercise x time interactions observed 
for L-Dex scores or incidence of lymphedema as determined by more than 10 (all p>0.05).  In 
addition, there were no within group changes at 12 week or 24 week time points. Clinically 
significant L-Dex scores were indicated by a score of more than +10, or a change of +10 between 
assessments. At baseline, two individuals recorded a score of >10 (one each from EP+OO and 
EP+N-3 groups) with no differences in incidence between groups (chi-square: (p=0.602). Including 
those two, five participants experienced lymphedema at any point throughout the trial determined 
by an absolute score of >10, or a change of >10 from a previous time-point; one from EP+N-3, and 
two each from EP+OO and N-3 groups (chi-square: 0.459, p=0.795). 
Compared to those who had an L-Dex score of more than +10 at baseline (n=2), there was no 
statistically significant differences for LBM for those with a score of less than 10 (44.8+1.3kg 
versus 43.5+5.7kg) or body fat% (43.9+7.9% versus 39.3+6.8%). Similarly, there were no 
significant differences in LBM or body fat% measurements when grouping participants into those 
who experienced an L-Dex score increase of 10 or more. Nor was there a significant correlation 
between L-Dex score and body fat% values at 12 or 24 weeks (p=0.923 and p=0.878, respectively). 
 
5.2.2 Discussion of additional results  
Overall energy and protein intake were consistent amongst groups at all three time points and both 
of these factors had no impact on body composition change over time. Previous studies have 
observed that energy intake is not associated with weight change after treatment for breast cancer 
(Demark-Wahnefried et al. 2001, Harvie et al. 2004). However, trials that have prescribed an 
energy deficit have consistently elicited body weight loss in breast cancer survivors (Thomson et al. 
2010, Shaw, Mortimer, and Judd 2007a, Shaw, Mortimer, and Judd 2007b, Mefferd et al. 2007). 
Furthermore, a number of dietary interventions have shown that prescribing various models of 
healthy eating without energy restriction often creates smaller but clinically significant body weight 
loss (Chlebowski et al. 2006, Villarini et al. 2012, Hebert et al. 2001). However, Villarini et al 
noted that the healthy dietary changes resulted in an incidental decrease in energy intake that may 
explain weight lost (Villarini et al. 2012). 
Epidemiological and clinical data indicate that LBM is influenced by protein intake, and that an 
adequate amount of protein may be required to maintain LBM over time (Bauer et al. 2013). In 
healthy populations, 0.8g/kg BW has been suggested as the recommended daily intake to maintain 
LBM status (Bauer et al. 2013). However recent evidence has indicated that this amount may be 1 
to 1.3g/kg BW for older populations aiming for optimal LBM outcomes (Robinson et al. 2013, 
Bauer et al. 2013, Daly et al. 2012). At a lower threshold of relative protein intake (0.8g/kg body 
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 weight), there was a trend for the low-intake group to experience a decline in LBM relative to those 
who consumed >0.8g/kg at all time points. However, no trends were noted when classifying groups 
by 1.0g/kg BW. To this point, no published data describes protein requirements for LBM 
maintenance in a breast cancer population and further research is needed to determine if there are 
significantly different requirements compared to a non-breast cancer population. 
Overall, baseline and subsequent change in measures of menopausal symptoms, and risk of 
lymphedema were similar between groups.  
 
All groups whether they were defined by treatment, menopausal states and hormonal therapy 
improved on Psychological, Somatic and Depression subscales of the GCS. No change over time 
was noted for Anxiety and Vasomotor scales, and no significant interactions were noted between 
groups. Biglia et al reported that in premenopausal breast cancer survivors, all subscales of GCS 
significantly worsened over 1-year of follow up (Biglia et al. 2010). Previous exercise and Yoga 
interventions have reported mixed findings in regards to perimenopausal symptoms. Two pilot 
Yoga studies (Waelde, Thompson, and Gallagher-Thompson 2004, Woolery et al. 2004) and one 
RCT (Chattha et al. 2008) have indicated improvement in perimenopausal symptoms and 
depression. However, Hayes et al (Hayes et al. 2013) reported no statistically or clinically 
significant change after an exercise intervention comparing face to face or telephone counseling.  
 
Our population closely matched the norms of the GCS measured in a North Brisbane, Australia 
catchment (n=500) (Travers et al. 2005); such that the highest scores were noted in women aged 20 
to 59 years, compared to the lower score for those 60 years and older. Thus, our population reported 
similar scores to that of perimenopausal women who have not been affected by breast cancer. 
Considering the normal decline in GCS related subscales, the significant effect for time for the 
overall population, and that all groups improved numerically in the majority of GCS subscales, 
indicates a positive effect for all interventions.  
 
L-Dex scores were shown to be stable over the 24 week time period for all groups. The 
accumulative incidence of lymphoedema was 5 (10%), with only three individuals experiencing a 
score indicating clinically significant lymphoedema after baseline assessment. A large landmark 
safety study (Schmitz et al. 2009), which has since been confirmed by another (Cormie et al. 2013), 
reported that resistance training is safe for those with pre-existing lymphoedema and may reduce 
exacerbations compared to those who do not perform it, for both high and low load exercise 
(Cormie et al. 2013). Our results reflect that no increased risk was experienced for any group, yet 
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 follow up may be too short to determine the true risk, as lymphoedema may occur years after 
treatment (Hayes et al 2009). 
 
L-Dex measures had no significant impact on body fat% as measured by ADP. Body density can be 
affected such that a higher body fat% can be reported after consumption of more than 1000ml in the 
hour prior to measurement (Vukovich and Peeters 2003). For our study, compared to those with a 
‘normal’ L-Dex score, i.e. <10), those who scored >10 at baseline had a significantly greater body 
fat%. However, the same magnitudes of difference were noted in hip and waist girths. Since, these 
measures are independent of upper arm swelling, it is likely that those with an L-Dex score of >10 
had generally greater fat mass. Also, without data on absolute volume change, it could be 
speculated that the fluid accumulation in the arm did not significantly change body density due to it 
being less than 1000ml. These results are limited by sample size and should be confirmed in larger 
populations with individuals of varying severity of lymphoedema. 
5.3 Summary of intervention findings 
After 6 months, there was no change in LBM for any group, nor differences between them. Of 
interest though, only the group that were exposed to both the lifestyle program and the LCn-3 
supplementation experienced significant decreases in body weight and markers of body fat. This is 
an important finding as body fat, particularly that found at the abdomen increases the risk of 
metabolic syndrome. Furthermore, the magnitude of body weight lost for the synergy group was 
similar that which was related to better survival in the WINS study (Chlebowski et al. 2006).  
LCn-3 was not found to influence LBM, cardiorespiratory fitness or strength-endurance. However, 
it was seen to better maintain physical function and strength as measured by the HAQ-DI and grip 
strength, respectively. These findings match up with a small number of studies that indicate 
physical functional improvements with LCn-3 intake (Hutchins-Wiese et al. 2013) and tissue levels 
of LCn-3 (Robinson et al. 2008).  
 
Quality of life improved for all groups, however CRP was not significantly influenced by either 
LCn-3 intake or the lifestyle program. However, these findings did agree with previous research 
These findings are important for women who have been treated for breast cancer. While our sample 
was relatively small, this study provides the first evidence of specific nutrients being used in 
conjunction with exercise and nutrition advice to improve outcomes for breast cancer.  
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 TABLE&5.2.&INTERACTIONS&FOR&GREENE&CLIMACTERIC&SCALE,&HAQ)DI&AND&L)DEX&AT&BASELINE,&12&AND&24WKS&(N=49)&
 Baseline 12wk 24wk   
GCS-Total Score SD Score SD Score SD  p-value* p-value** 
N-3 13.19 7.5 8.86 4.5 7.13 4.7 
NS 0.000 Ex+OO 13.38 5.8 11.53 6.5 9.19 7.6 
Ex+LCn-3 14.88 11.4 12.07 8.3 10.00 8.6 
GCS-Psych               
N-3 5.44 4.4 6.07 4.6 2.75 2.7 
0.942 0.000 Ex+OO 6.13 3.3 8.07 5.6 3.38 3.4 
Ex+LCn-3 7.47 5.8 9.73 7.2 5.00 4.7 
GCS-Anxiety               
N-3 2.81 2.3 2.00 1.0 1.69 2.0 
0.841 0.131 Ex+OO 3.25 2.0 2.67 2.0 1.88 2.0 
Ex+LCn-3 4.10 2.8 3.50 3.0 3.20 2.7 
GCS-Depression             
N-3 2.63 2.5 1.86 1.7 1.06 1.1 
0.919 0.004 Ex+OO 2.88 1.7 2.53 2.2 1.50 1.8 
Ex+LCn-3 3.41 3.3 3.33 2.5 1.82 2.4 
GCS-Somatic             
LCn-3 3.94 3.4 2.21 2.0 1.63 1.7 
0.421 0.015 Ex+OO 3.19 1.8 2.93 2.0 2.31 2.2 
Ex+LCn-3 4.24 4.0 2.60 2.1 2.24 2.0 
GCS-Vasomotor             
LCn-3 2.38 2.2 1.93 2.1 1.75 2.1 
0.708 0.09 Ex+OO 2.50 1.9 2.27 2.0 2.56 2.5 
Ex+LCn-3 2.24 1.9 1.40 1.5 1.94 2.0 
L-Dex               
LCn-3 0.34 3.96 -1.91 7.49 1.02 11.22 
0.753 0.383 Ex+OO 2.43 6.42 2.81 9.44 3.82 9.30 
Ex+LCn-3 1.31 7.04 0.46 5.87 0.43 6.42 
N-3: Fish oil only; EP+OO: Exercise and nutrition program plus olive oil; EP+N-3: Lifestyle 
program plus fish oil; GCS: Greene Climacteric Scale; L-Dex: Lymphoedema index - <-10 or 
>10 is indicative of lymphoedema. P-value*: interaction for treatment x time; **: effect for 
time (overall change of population). No significant interactions found between groups. 
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 Chapter(6(–(Discussion,(Future(Direction(and(Conclusion(
This chapter provides a full discussion and conclusion for the thesis as a whole. In order to interpret 
our results in the context of an Australian population, the generalisability of our sample to the larger 
population has been discussed. Furthermore, the limitations and strengths of our study are presented 
in order to validate the strength of the conclusions made and to aid in suggesting pathways for more 
research in this area. 
6.1(Generalisability(of(the(intervention(study(
Overall, our sample was representative of a young Caucasian Australian population. Women who 
were eventually included in the study were younger than those typically diagnosed with breast 
cancer in Australia (Australian Institute of Health and Welfare & Cancer Australia 2012, Statistics 
2013). Compared to large representative US breast cancer interventions (Chlebowski et al. 2006, 
Pierce et al. 2002) and observational cohorts (Caan et al. 2012, Lynch et al. 2010), socioeconomic 
status (Australian Institute of Health and Welfare & Cancer Australia 2012), treatment, diagnostic, 
body composition and physical activity related characteristics of our sample were similar. 
Furthermore, the randomisation of our group was adequate with no significant differences at 
baseline amongst all primary, secondary and demographical variables. 
6.1.1(Comparability(of(sample(to(general(breast(cancer(population(
The sample recruited into the MODEL study was younger (mean age: 48.9+ 1.39yrs) than the 
overall Australian average diagnosed with breast cancer in 2013 (Australian Institute of Health and 
Welfare & Cancer Australia 2012), and those included in an international prospective cohort study 
(n=12 915; mean age: 57+10.5yrs) (Caan et al. 2012). Australian breast cancer statistics indicated 
that 6%, 69% and 25% of breast cancers were diagnosed in those of ages <40yrs, 50-69yrs and 
>70yrs, respectively. Participants in the current intervention were distributed as 14.3%, 83.7% and 
2%, respectively. Previous epidemiological research has shown that younger populations are more 
likely to perform higher levels of physical activity (Irwin et al. 2004), yet also have a higher risk of 
weight gain after treatment (Sheean, Hoskins, and Stolley 2012). The risk of greater weight gain 
noted in younger individuals may have been advantageous for the study. In a population that is 
more likely to experience adverse changes in body composition (Demark-Wahnefried et al. 2002, 
Demark-Wahnefried et al. 2001) a greater effect of a successful intervention may be noted.  
The majority of our recruitment resources were directed through the Wesley Medical Centre, a 
private hospital in Brisbane. We observed that 63% of our participants self-reported an annual 
household income of >$80 000 and 59.2% had completed a University degree. According to the 
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 Index of Relative Socioeconomic Disadvantage, these two factors are associated with more 
advantaged socioeconomic status (Statistics 2013). Australian data indicate breast cancer risk is 
increased in those in higher socioeconomic status, thus making our sample relevant to the local 
population (Australian Institute of Health and Welfare & Cancer Australia 2012). Our participants 
did have a higher University completion rate than those in the International pooling project made up 
of a North American population (Caan et al. 2012). From non-breast cancer populations, higher 
levels of education have been associated with higher levels of physical activity (Pan et al. 2009, 
Chad et al. 2005). However, despite the mixed findings with regard to education, objectively 
measured %time spent in sedentary and light intensity activity was closely matched with 
observational data of older breast cancer survivors (mean age: 69+13yrs) reported from the 
NHANES data (Lynch et al. 2010). 
 
Of those included, 45% of the participants were employed full time, 87.8% were employed in some 
capacity and all were able to achieve 80% attendance. This suggests that the intervention may be 
transferable to working or non-working populations. 
Our sample, of which 85% were diagnosed with Stage I and II breast cancer, had similar diagnostic 
characteristics to two large (n=2437; 94%(Chlebowski et al. 2006) & n=3088; 90% (Pierce et al. 
2002)) intervention and cohorts and those included in the US category of the international pooling 
project (87.6%) (Caan et al. 2012). In addition, oestrogen receptor status, treatment rates of 
chemotherapy and radiation therapy were comparable to results reported by Chlebowski et al (2006) 
(Chlebowski et al. 2006), however, slightly higher rates of radiation therapy than those reported by 
Pierce et al (2002)(Pierce et al. 2002) (67% vs 48.4%, respectively). 
6.1.2(Adequacy(of(randomisation(
Across the three intervention groups, there were no differences between any of the primary or 
demographical variables. Even though the sample size was smaller than planned, the randomisation 
was sufficient to appropriately allocate participants evenly. 
 
Overall, while our sample was younger than those typically diagnosed with breast cancer in 
Australia, these differences did not have seem to have an effect on physical activity, treatment and 
diagnostic variables compared to previous intervention and observational trials. In addition, the 
randomisation appropriately allocated an even distribution of demographical attributes. Taken 
together, results from our population are generalisable to a predominantly Caucasian population of 
women diagnosed with breast cancer
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 6.2(Limitations(&(Strengths(of(the(study((
6.2.1(Limitations(
It is acknowledged that our study may have been limited by not including a placebo-only control 
group. While this may have allowed a comparison of the effect of LCn-3 alone versus no 
intervention, the Uniting Care Health HREC did not approve the study design with this group. In 
addition, this study was designed to test the efficacy of LCn-3 compared to a lifestyle intervention 
or a combination of change in LBM. It has been previously established that exercise maintains and, 
in some cases, increases LBM. Thus to answer our hypothesis, the study only required the 
comparison of best practice nutrition and exercise prescription from current guidelines, and best 
practice prescription in combination with LCn-3, and did not require a placebo only group. The 
LCn-3 only group was added to determine if tailored exercise prescription is needed to influence 
body composition change, or if this occurs due to the increased awareness physical activity benefits 
after diagnosis. 
Due to slower than expected recruitment, we were unable to reach projected participant numbers. 
The lower than expected recruitment rate was likely due to there being a number of other trials 
concurrently recruiting participants with similar demographic attributes, and that our eligibility 
criteria were too narrow. In addition, our main recruiting consultants from the Wesley Medical 
Centre unfortunately experienced a significant decrease in eligible patients at the time of 
recruitment. A number of other recruitment strategies were added, such as via advertising through 
radio, social media, additional hospitals, and this may have introduced a more representative sample 
than if all participants were recruited from the one private medical facility. On the other hand, the 
clinically and statistically significant effects of LCn-3 on body composition (Munro and Garg 2012) 
and muscle function (Smith et al. 2011b, Rodacki et al. 2012) have been reported within similarly 
sized samples. The lack of effect for LBM seen between groups in our study may be a result of the 
lower power, however, our results are similar to those with studies that included a larger population 
with equivalent intervention protocols (Demark-Wahnefried et al. 2008, Mefferd et al. 2007, Djuric 
2011, Matthews et al. 2007, Schmitz et al. 2009, DeNysschen et al. 2011). Alternatively, it is 
possible that the results reflect the true effect of the intervention, which supports LBM maintenance 
after all interventions, and an improvement in adiposity for participants exposed to both LCn-3 and 
the lifestyle program. 
 
To improve recruitment for future studies it is suggested that researchers form strong associations 
with a large number of oncologists and oncology teams. The most direct and effective method of 
recruitment was through local clinicians, and developing a strong network of these professionals 
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 would make recruitment more consistent and timely. Social media, research networks and breast 
cancer groups were less effective, albeit these avenues should be explored to maximise the 
recruitment potential. 
 
Prescription of home-based resistance training using body weight and elastic resistance equipment 
may have been inadequate to elicit an appropriate anabolic response. The one study that has 
reported significant functional improvements due to LCn-3 and exercise used specifically 
prescribed lower leg resistance training using a gym facility (Rodacki et al. 2012). It is possible that 
even though our participants were asked to perform the exercise until temporary fatigue, this 
training prescription may not have been performed adequately when participants were 
unsupervised.  Since Rodacki et al (2012) (Rodacki et al. 2012) did not measure LBM change, it is 
possible that LCn-3 is only effective in enhancing LBM power in conjunction with resistance 
training, and may not have significant effects on LBM accretion. A previous study in healthy young 
males indicated that exercising to temporary fatigue elicited the same response in MPS regardless 
of the load (Burd et al. 2010). Again, this study was conducted under supervision on weight 
machines, but only over one bout of exercise. Prolonged exercise prescription encouraging this type 
of exercise may not be sustainable, or fully adhered to over longer periods of time. 
6.2.2(Strengths(
Our study is strengthened by the double blind randomised control design, high quality objective and 
validated measures, intention to treat analyses and long term follow up to determine adherence to 
lifestyle changes after active support has ceased. 
Intervention and study design 
The double blind randomised controlled trial design is considered the ‘Gold Standard’ for assessing 
the difference in efficacy of two or more treatment protocols. In addition, our study design was 
pragmatic for two reasons: it could be replicated in general practice at low cost; and, the 
participants in the third intervention arm that prescribed LCn-3 supplementation alone allowed 
participants to exercise and diet freely, as opposed to restricting their behaviour. These two points 
allow us to report on the feasibility and efficacy of interventions, and to determine which protocol 
will be most beneficial to practitioners in aiding breast cancer survivors in body composition 
change. We found that those who did not receive specific exercise prescription finished the 
intervention performing similar amounts of aerobic physical activity as those who were prescribed 
resistance and aerobic exercise. This suggests that general awareness of physical activity after 
breast cancer may be sufficient to motivate individuals to increase aerobic exercise without specific 
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 advice. Or, the nature of the trial attracted individuals who were already willing and wanting to 
exercise. 
The diet (Robien, Demark-Wahnefried, and Rock 2011) and exercise (Schmitz et al. 2010, Hayes et 
al. 2009) intervention were based on best evidence for breast cancer survivors, and the content was 
delivered by a dual qualified Accredited Exercise Physiologist and Accredited Practising Dietitian 
(Primary Investigator – CM). 
The dose of LCn-3 supplementation prescribed was one that has previously produced the highest 
uptake into erythrocytes over a 2 to 6 month period (Yee et al. 2010) regardless of BMI. BMI has 
been negatively associated with erythrocyte concentration of LCn-3 after supplementation in 
children (Hogg et al. 2006). Furthermore, the LCn-3 supplements used can be found commercially 
adding to the pragmatic design. 
Follow up to six months after baseline allowed the long-term adherence and subsequent changes in 
body composition to be measured. Detraining in previous studies has led to a decrease in strength, 
fitness and quality of life (Herrero et al. 2007). Our results show that strength was maintained 
through 6 months, and there was an overall trend for improved body composition in all groups . 
Outcome measures 
Our primary outcome of body composition was analysed using the BOPOD (CosMed, USA), which 
has been previously validated against under-water weighing (Lukaski 2009). To compliment this 
measure, waist and hip girths were also measured and responded comparably to changes in weight 
and body composition measured by the BODPOD. In addition, the presence of lymphedema did not 
seem to alter body composition results, however validation studies in breast cancer populations with 
varying severity of lymphoedema need to be conducted to confirm these results.  
Measurement of erythrocyte LCn-3 content is a reliable marker of long term (2 to 6 month) LCn-3 
supplementation and is able to determine differences in dosage (Yee et al. 2010). In addition, blood 
analysis is removed from estimation errors inherent in intake calculations derived from diet history 
questionnaires (Martin 2004). 
Similarly, serum hs-CRP is an established marker for chronic inflammation, which we hypothesised 
as a potential mechanism for LBM wasting.  
 
Major potential confounders of body composition are dietary intake and physical activity. The 
interviewer administered Diet History Questionnaire has been previously validated and incorporates 
a one-on-one investigation with an Accredited Practising Dietitian (Martin 2004). This method of 
determining dietary intake has been shown to be less disruptive to normal eating patterns than 
weighed food records, and when assessing food intake of more than 7-days, is appropriate for 
assessing individual and group changes in eating patterns (Rutishauser 2005). 
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 Physical activity was measured in three different ways: objective monitoring with uniaxial 
accelerometry, and subjective reporting via the Active Australia Questionnaire and physical activity 
diary provided as part of the intervention. The findings from the literature review indicate that 
women who have been treated for breast cancer experience significant adverse changes in their 
body composition. Our observational study indicates that muscle function, as measured by upper 
body strength-endurance and cardiorespiratory fitness, are strongly associated with measures of 
body composition after treatment. The randomised controlled trial indicated that consumption of 
LCn-3, a 12-week exercise and nutrition lifestyle program, and LCn-3 plus the lifestyle program all 
promote LBM maintenance, have minimal effects on CRP, and promote better quality of life over 
time. The combination of LCn-3 plus the lifestyle program may be more effective in reducing body 
weight and markers of adiposity compared to either intervention alone. In regards to muscle 
function, structured semi-supervised training improves upper body muscular strength-endurance, 
while LCn-3 consumption may promote better maintenance of grip strength and physical function 
independent of structured exercise. These results warrant further research using a larger population 
over a time period relevant to post-treatment cardio-metabolic outcomes and physical function 
outcomes. 
6.3(Body(composition(change(after(breast(cancer(
6.3.1(Body(composition(changes(after(treatment:(patterns(and(mechanisms(
The published and unpublished sections of Chapter 2 composing the literature review of this thesis 
were used to create our theoretical model. The current evidence indicates that body weight gain in 
conjunction with a reduction in LBM is common after treatment for breast cancer (McDonald, 
Bauer, and Capra 2011). Furthermore, body weight and adiposity increases are more likely to occur 
after chemotherapy, as a result of lower physical activity, in those of younger age and/or in those 
who are premenopausal at diagnosis (Sheean, Hoskins, and Stolley 2012). In breast cancer 
survivors, loss of LBM is potentially related to chemotherapy treatment (Mourtzakis and Bedbrook 
2009), yet there is far less direct evidence of this compared to changes in body weight and body 
fat%. On the other hand, Murphy et al observed a significant LBM wasting effect of chemotherapy 
in non-small cell lunch cancer (NSCLC) patients (Murphy et al. 2011). They reported that 
prevalence of myopenia at baseline and chemotherapy and cancer related LBM wasting were 
correlated with the concentration of plasma EPA. In contrast, strong prospective evidence has 
linked Aromatase Inhibitor use with an increase in LBM over time (van Londen et al. 2011, 
Montagnani, Nuti, et al. 2008). 
The results from our cross sectional analysis indicates that increasing levels of moderate intensity 
physical activity, greater upper body strength and greater cardiorespiratory fitness are strong 
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 independent predictors of weight and age adjusted LBM. This is the first study to report that 
markers of LBM function are attributed to LBM status after treatment, and that a threshold effect 
may exist for each measure in relation to adjusted LBM. No data in breast cancer populations is 
currently available to compare these findings, and without follow up it is difficult to know if these 
thresholds are clinically relevant to obesity-breast cancer related disease risk. However, a 
substantial literature base indicates that improved longevity and quality of life are related to greater 
cardiorespiratory fitness (Gau et al. 2010, Lee, Blair, and Jackson 1999), and LBM function 
(Newman et al. 2006, Ruiz et al. 2008), respectively. Thus, this is a finding worth further 
investigation. 
We did not see a significant effect of LCn-3 on measures of body composition at baseline. Our data 
indicated non-significant, yet opposite effects of EPA and DHA on measures of physical function, 
which cannot be fully explained by further analyses and may be Type II error. It is possible these 
results are spurious as the results pertaining to EPA are in direct contrast to a large body of 
evidence that report a benefit for this nutrient. 
 
Clinically, decreases in LBM and increases in adiposity, particularly visceral adiposity (Cheney, 
Mahloch, and Freeny 1994) with or without total body weight increase, is a negative outcome for 
women after breast cancer treatment. Higher body fat% is associated with increased circulating 
inflammatory molecules (Dee 2010), which is predictive of greater non-breast cancer and overall 
mortality (Pierce, Ballard-Barbash, et al. 2009). Furthermore, due to improvements in treatment, 
cardiovascular mortality is more common than breast-cancer related deaths in survivor populations 
(Hanrahan et al. 2007). Hence, the close relationship of body composition change to cardio-
metabolic risk in this population exposes the importance of addressing healthy body weight change 
in this population. 
In terms of non-modifiable risk factors, we did not find significant effects on LBM for differing 
types of treatment (chemotherapy/radiotherapy or aromatase inhibitors), or menopausal status. 
Thus, with regards to our theoretical model, our results are in contrast to hypothesized (Mourtzakis 
and Bedbrook 2009).and previously observed findings (Demark-Wahnefried, Campbell, and Hayes 
2012, Goodwin et al. 1999) that have suggested a modifying effect of menopausal state and 
treatment. A difference and limitation of our study was that our cross-sectional analyses would not 
be sensitive to longitudinal change where these relationships were previously identified (Harvie 
2010, Montagnani, Gonnelli, et al. 2008, Francini et al. 2006). On the other hand, our observed 
relationships between markers of physical activity and body composition agree with previous 
research. Irwin et al (Irwin et al. 2005) reported an inverse association between time spent 
performing sports/recreational activity and body fat%, however the authors made no comment of 
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 longitudinal change in LBM. In practice, these results will strengthen the case for exercise training 
in the post-treatment period.  
After a diagnosis of breast cancer, current guidelines recommend regular physical activity to 
optimise outcomes in relation to survival, ameliorating treatment related side effects, quality of life 
and risk of co-morbidity (Schmitz et al. 2010). Early in the post-treatment period is thought to be 
the most teachable time for promoting behaviour change in relation to dietary and exercise habits 
associated with reduced risk of ongoing disease risk (Rabin 2009). Our results further confirm that 
physical activity was shown to enhance cardiovascular fitness, and with upper body strength was  
important to a greater LBM and lower fat mass. LBM is an important consideration for ongoing 
health in the general population (Pedersen and Febbraio 2012). Furthermore, LBM function, i.e. 
muscle strength and cardiovascular fitness, may be a more important indicator of survival (Newman 
et al. 2006, Ruiz et al. 2008). LBM function is more closely related to falls risk, the ability to 
perform activities of daily living and participation in exercise than LBM alone. This paper aids in 
connecting LBM function and body composition in a breast cancer population.
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Figure 6.1 Theoretical model for body composition change after treatment for 
breast cancer 
Studies in breast cancer populations indicated by a blue line ! (arrow ! indicates agonistic 
effect; solid circle • indicates antagonistic effect. Research in non-breast cancer populations 
(purple line !). Hypothetical relationships being explored (red dashed line --). Numbers related 
to hypotheses: 1: The combination of LCn-3 and exercise training promotes greater LBM accretion than either intervention alone; 2: LCn-3 will reduce inflammation (C-reactive protein), which will be 
related to a reduction in loss of LBM; 3: Improved body composition as a result of LCn-3 and exercise training will improve quality of life.
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 6.4$Primary$and$Secondary$Hypotheses$
6.4.1$Primary$Hypothesis$$
Our primary hypothesis (1 - Figure 6.1)- was that the individuals randomised to the group, which 
combined LCn-3 and nutrition and exercise program would experience significantly greater 
increases in LBM than those exposed to LCn-3 or the program alone. This hypothesis was not 
accepted. Our results indicate that LBM change was equivocal for all groups, with all intervention 
groups experiencing LBM maintenance. 
LBM change in breast cancer related trials 
Our results agree with the majority of exercise and exercise plus nutrition interventions that show 
no increase in LBM over time (Matthews et al. 2007, DeNysschen et al. 2011, Battaglini et al. 2007, 
MacVicar, Winningham, and Nickel 1989, Burnham and Wilcox 2002, Guinan et al. 2013, Schmitz 
et al. 2009, Mefferd et al. 2007, Djuric 2011). However, those that have reported LBM growth have 
typically been conducted in a gym, and exercise programming was supervised at least twice per 
week (Irwin, Alvarez-Reeves, et al. 2009, Schmitz, Ahmed, et al. 2005, Herrero et al. 2006, 
Fernández-Lao et al. 2013). Prescription of semi-supervised moderate intensity aerobic activity with 
elastic band resistance exercises may not have been adequate to elicit an appropriate anabolic 
response in our population. These findings mirror those of previous trials using the same type of 
resistance training equipment (Demark-Wahnefried et al. 2008). However, given the predisposition 
of breast cancer survivors to experience loss of LBM due to treatment and activity related factors 
(Sheean, Hoskins, and Stolley 2012, Mourtzakis and Bedbrook 2009), any level of aerobic or 
resistance training intensity that enables maintenance of LBM in conjunction with total weight loss 
or stability may be considered a good outcome. 
In regards to LCn-3, our results agree with those of trials in non-cancer populations that have shown 
no effect on LBM change after LCn-3 supplementation with or without dietary energy restriction 
(Couet et al. 1997, Noreen et al. 2010, Crochemore et al. 2012, Munro and Garg 2012, Storlien et 
al. 2001, Hlavaty et al. 2008, Krebs et al. 2006, Abete et al. 2008), or in conjunction with aerobic 
exercise training (Hill et al. 2007). In contrast, for individuals experiencing cancer related loss of 
LBM, higher plasma LCn-3 levels and LCn-3 supplementation during treatment, has resulted in the 
attenuation of LBM loss, while non-supplemented control groups have continued to rapidly lose 
body weight and LBM (Murphy et al. 2011, Fearon et al. 2003, Fearon et al. 2006). Given these 
contrasting findings between populations, the effect of LCn-3 may only be clinically evident in 
populations experiencing extreme LBM and significant reductions in tissue LCn-3 content. Breast 
cancer survivors seem to have a metabolic health profile that is more similar to those with cardio-
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 metabolic chronic disease populations (Healy et al. 2010, Thomson et al. 2005, Pierce, Neuhouser, 
et al. 2009), with clinically significant yet slower loss of LBM (<2kg per year(Harvie et al. 2004)) 
than those with advanced cancer.  
Similar to Denysschen et al (2011), the group randomised to capsule only (N-3) performed a similar 
amount of exercise as those who participated in the lifestyle intervention. The increase in physical 
activity may have prevented loss of LBM in this group thus decreased our ability to observe 
between group differences. Physical activity after treatment for breast cancer is becoming more 
widely supported by both the medical community and media, with specific exercise and breast 
cancer awareness initiatives being run in the community (National Breast Cancer Foundation 2012). 
This may place positive pressure on women who have completed treatment to continue or 
commence physical activity. Secondly, it is possible that participants volunteering for an exercise 
and nutrition this trial may have already been more inclined than the general population to engage 
in healthy eating and physical activity. Or finally, knowledge of their participation in an exercise 
and nutrition trial measuring physical function and body composition markers may have provided 
additional motivation for them to improve their current habits. In essence, our findings suggest that 
due to baseline physical activity levels of a younger Australian breast cancer cohort, tailored 
exercise prescription resulted in equivocal volume of exercise as control group who were given no 
restrictions on activity levels. Furthermore, exercise was similar across groups at the end of follow 
up, yet significant differences were found for erythrocyte LCn-3. Thus, in our study LBM change is 
likely to be most related to exercise training rather than an interaction of the LCn-3 and exercise 
training. 
6.4.2$Secondary$hypothesis$–$Quality$of$life$
Our secondary hypotheses, that the combined intervention group would experience greater 
improvements in quality of life and inflammation (2- Figure 6.1), were not accepted. Compared to 
baseline, after 12 and 24 weeks, QOL improved in all groups with no difference between them. 
Furthermore, no association was noted between erythrocyte LCn-3 content and change in QOL 
score.  
Quality of life after breast cancer trials 
Overall quality of life (Ohira et al. 2006, Herrero et al. 2006) and physical function (Courneya et al. 
2007), breast (Fernández-Lao et al. 2013), and psychosocial (Ohira et al. 2006, Matthews et al. 
2007) subscales have been shown to improve after exercise-only interventions. In opposition to this, 
previous exercise and diet combined studies of similar methodology to ours have not shown 
significant between group improvements in QOL (Demark-Wahnefried et al. 2008, Djuric 2011). 
Herrero et al (2007) reported that QOL improvements seen after an eight-week combined aerobic 
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 and resistance training intervention returned to baseline after a subsequent 8 weeks of detraining. 
Additionally, suggestions from Hebert et al (2001) who reported findings from a diet-only 
intervention in breast cancer survivors may be applicable to our results. They suggested that initial 
improvements in lifestyle habits during the 12-week nutrition and exercise program may have 
contributed to those participants setting a higher standard of behaviour for themselves. After regular 
meetings were ceased during the 12 to 24 week interval, and a partial return to their original pre-
intervention habits occurred, it may have caused personal disappointment, and thus a decrease in 
subjective QOL. This phenomenon would not have impacted the LCn-3 alone group as no 
expectations were placed on their activity levels at any point. Furthermore, Hsu et al (2013) 
examined a prospective cohort for QOL of life changes. They reported that 1 year after breast 
cancer diagnosis, women in general experienced 5.6% improvements in their QOL without 
intervention (Hsu et al. 2013). Previously, a meta-analysis revealed that cardiorespiratory fitness 
was positively associated with QOL as measured by FACT-B (McNeely et al. 2006). Participants in 
the LCn-3 only group did not experience a significant increase in cardiorespiratory fitness, however 
they did show improvements in upper and lower body strength, which corroborated with increases 
in reported participation in physical activity. Therefore, their improvement in physical function in 
the absence of expectations and standards that were placed on the tailored exercise and nutrition 
groups, may have contributed to the LCn-3 only group realising a continued increase in QOL over 
24 weeks. Unstructured anecdotal feedback from the participants of the nutrition and exercise 
program matched these results in that the intervention was well received; the lack of accountability 
in weeks 12 to 24 reduced their motivation to perform the full list of exercises. 
In summary, overall and physical function measures of QOL may improve after exercise training 
compared to non-exercising controls, however increasing time from diagnosis also seems to 
increase markers of QOL. LCn-3 did not enhance QOL overall, however continued follow up 
through phone or group support is an important consideration for future trials aiming to maintain 
and continue improvements in QOL. 
6.4.3$Secondary$hypothesis$–$Chronic$Inflammation$
We hypothesised that LCn-3 supplementation in conjunction with a tailored exercise and nutrition 
program would promote greater reductions in CRP compared to those who received LCn-3 
supplementation or the program alone (3 – Figure 6.1). This hypothesis was no accepted. All 
intervention groups experienced no change in CRP after 24 weeks. While the lifestyle program plus 
olive oil group experienced a greater reduction in CRP than lifestyle plus LCn-3, this was not 
maintained long term. Our hypothesis was based on the premise that chronic inflammation 
contributes to LBM wasting in breast cancer populations (Mourtzakis and Bedbrook 2009). We 
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 postulated that a combination of exercise and LCn-3 might reduce LBM wasting better than either 
in isolation, due to both having previously been shown to be anti-inflammatory. 
6.4.3.1 Exercise and LCn-3 and change in CRP 
In general, studies examining the effect of aerobic exercise on CRP in breast and non-breast cancer 
populations have typically reported significant benefit within exercise groups (Fairey et al. 2005, 
Guinan et al. 2013), but not between exercisers and controls. One trial in breast cancer survivors 
indicated a non-significant reduction in CRP after diet-induced weight loss (Fairey et al. 2005). The 
majority of research examining CRP change and LCn-3 indicates a strong cross sectional 
association with little to no effect for LCn-3 on CRP after supplementation. However, there is 
consistent suggestion in all three areas that significant benefit of intervention exists for those with 
higher levels of CRP at baseline. 
Exercise and CRP 
Smith et al (1999) conducted an uncontrolled six month aerobic exercise trial for those at risk of 
CVD and reported CRP was reduced by 35% overall, with 50% reductions for those in the highest 
quartile of CRP at baseline (Smith et al. 1999). Findings for change in CRP in breast cancer 
populations have shown similar effects for aerobic exercise on CRP. Two aerobic exercise trials of 
15 (Fairey et al. 2005) and 12(Guinan et al. 2013) weeks, respectively, in breast cancer populations 
reported within group decreases in CRP. However, only a trend between exercise and control 
groups was reported for both studies (Fairey et al. 2005, Guinan et al. 2013). Fairey et al (2005) and 
Guinan et al (2013) reported a change in CRP of -1.39mg/L and -0.65mg/L, for exercise groups 
respectively, and stability for control, +0.01mg/L and -0.01mg/L, respectively.  
Diet and CRP 
In a dietary study, body weight loss of 6kg from energy restriction alone accompanied a non-
significant decrease in CRP for breast cancer survivors (Thomson et al. 2010). In contrast, weight 
loss in non-breast cancer populations has been associated with significant decreases in CRP 
(Belalcazar et al. 2013, Yatsuya et al. 2011, Haffner et al. 2005, Tamakoshi et al. 2003, Kopp et al. 
2003, Esposito et al. 2003). However, these studies have been conducted in individuals with higher 
baseline BMI, and have reported greater weight loss (>10% of baseline body weight) resulting from 
the intervention than the 7.5% reduction in body weight reported by Thomson et al (2010). In a 
population of breast cancer survivors, compared to those with a body fat% of less than 35%, those 
with a body fat% higher than 35% had significantly greater CRP values (Dee 2010). Considering 
increased adiposity is related to greater CRP through an increased release of inflammatory 
adipokines (Lee et al. 2009), significant effects therefore, may be more readily elicited for those 
with excessive adiposity. This has been confirmed when comparing greater CRP reductions for 
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 overweight/obese populations and no changed for healthy weight populations after dietary 
manipulation (Neuhouser et al. 2012). 
Finally, in confirmation of previous findings, after a 12-month diet and exercise intervention in 
breast cancer survivors, CRP was only reduced in the group with the higher baseline CRP (3.6mg/L 
vs 1.8mg/L). However, a caveat in this finding is that differences between groups was not analysed 
due to inadequate power.  
LCn-3 and CRP 
Despite strong cross sectional association of CRP and LCn-3 intake, trials prescribing LCn-3 
supplementation have mixed effects on change in CRP over time (Smith et al. 2011a, Muhammad et 
al. 2011, Chan et al. 2002, Munro and Garg 2012, Madsen et al. 2003, Tsitouras et al. 2008, 
Micallef and Garg 2009). 
Studies have shown that a CRP has an inverse relationship with markers of medium (Poudel-
Tandukar et al. 2009) and LCn-3 intake (Kalogeropoulos et al. 2010, Micallef, Munro, and Garg 
2009, Farzaneh-Far et al. 2009, Niu et al. 2006). However, five intervention studies (Smith et al. 
2011a, Muhammad et al. 2011, Chan et al. 2002, Munro and Garg 2012) including a dose response 
investigation (Madsen et al. 2003) have reported no effect for LCn-3 on CRP levels. Similar to 
exercise and diet intervention literature, Tsitouras et al (2008) noted that a reduction in CRP was 
only found in those with higher baseline CRP levels (>3mg/L) (Tsitouras et al. 2008). Furthermore, 
Micallef et al (Micallef and Garg 2009) noted 39% (p=0.009) reductions in CRP after a blinded 
cross-over trial in men and women with hyperlipidaemia, relatively low BMI (mean: 26.6kg/m2), 
and moderate CRP levels (2.9 to 3.2mg/L).  
This is the first study to investigate the effects of LCn-3 on CRP in a breast cancer population to 
date. CRP has been correlated to increased incidence of cardiovascular disease and decreased 
survival in breast cancer survivors (Pierce, Ballard-Barbash, et al. 2009). Aerobic exercise (Fairey 
et al. 2005, Guinan et al. 2013), diet-induced weight loss (Thomson et al. 2010), and a healthy 
dietary advice plus exercise intervention (Djuric 2011) have resulted in statistically non-significant 
trends for a reduction in CRP. Similar to non-breast cancer populations, in our population, LCn-3 
supplementation did not affect group based CRP values over the course of the intervention. In 
contrast, all groups significantly increased physical activity, subsequent markers of upper and lower 
body strength, and as a whole experienced a statistically significant decrease in CRP from baseline 
to 24 weeks. It is important to note that our sample was of lower BMI and had lower CRP levels at 
baseline than those studies that reported benefit for those with higher BMI and CRP levels. 
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 Summary of CRP 
Our population had a relatively low baseline CRP (mean: 1.75mg/L), BMI (mean: 26.3kg/m2) and 
body fat% (29.7%). Therefore, considering previous data in weight loss and CRP, noting no 
significant change in CRP was not unexpected.  
6.4.4 Change in body weight, fat%, waist and hip girths 
The combination of LCn-3 and the lifestyle program was more effective in reducing body weight, 
waist and hip girths than either intervention alone. Change in body fat% was not significant 
between or within groups. In breast cancer survivors, high body fat% (Protani, Coory, and Martin 
2010) and increased waist girth (Protani, Coory, and Martin 2010) at diagnosis is thought to be 
central to breast cancer and non-breast cancer morbidity (Demark-Wahnefried, Campbell, and 
Hayes 2012). This is currently being investigated further in a large ongoing trial (Rock et al. 2013). 
Adipocyte aromatase enzymes convert androgens to oestrogen derivatives, and when over 
expressed in the case of those with a higher number and larger adipocytes, may contribute to the 
proliferation of hormone sensitive cancers (Simpson et al. 1994, van Londen et al. 2011). However, 
it is not yet known if a reduction in adipose tissue creates a clinically significant decrease in 
aromatase enzymes to influence breast cancer outcomes. On the other hand, cardio-metabolic 
disease and subsequent mortality poses an equal or greater risk for survivors of breast cancer (Rock 
and Demark-Wahnefried 2002, Nichols et al. 2009). Furthermore, an increased waist girth and CRP 
are important risk factors in the development of metabolic syndrome in breast cancer survivors 
(Thomson et al. 2005, Healy et al. 2010). 
 
LBM maintenance or increase in conjunction with moderate weight loss (1 to 3kg) is a clinically 
relevant outcome for women who have completed treatment for breast cancer (Ligibel and Goodwin 
2012, Chlebowski et al. 2006). Our literature review summarised exercise, diet and combined 
modality interventions for during or after treatment for breast cancer. The synthesis of this 
information indicated that the best method to prevent loss of LBM and create a concurrent reduction 
in body fat is through combining structured exercise training and dietary prescription.  
 
The magnitude of body weight loss experienced in the Ex+N-3 (2.27+1.9kg) is equal to that which 
was found to reduce breast cancer mortality over long term follow up (Chlebowski et al. 2006). A 
number of exercise interventions in breast cancer populations have produced decreases in waist 
girth (Guinan et al. 2013, Fernández-Lao et al. 2013). However, others have shown no effect for 
exercise (Irwin, Alvarez-Reeves, et al. 2009, Schmitz, Ahmed, et al. 2005) regardless of aerobic or 
resistance training prescription. In addition, energy restricted diets with (Harris et al. 2012, Scott et 
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 al. 2013, Djuric 2011) or without (Thomson et al. 2010, Villarini et al. 2012) exercise prescription 
have induced waist reductions in breast cancer survivors.  
 
LCn-3 supplementation has previously been associated with reductions in body weight (Kabir et al. 
2007, Hill et al. 2007) and body fat% (Couet et al. 1997, Noreen et al. 2010, Munro and Garg 2012) 
in non-breast cancer populations. In contrast, no effect has been reported in other studies (Storlien 
et al. 2001, Kunesová et al. 2006, Krebs et al. 2006, Tierney et al. 2010, DeFina et al. 2011). 
 
Mechanistic studies indicate that fatty oxidation may increase after both exercise and LCn-3 
supplementation. Aerobic exercise has been shown to induce proliferation of mitochondria and up-
regulation of β-oxidation enzymes (Holloway et al. 2006). While LCn-3 augment function of 
uncoupling protein-3 (Jaburek et al. 1999, Hun Cha et al. 2001) and fuel utilisation through the lipid 
catabolizing effects of peroxisome proliferator activated receptor (PPAR)-gamma (Flachs et al. 
2009). This combination of factors give a theoretical basis on which to predict greater fatty acid 
oxidation in those exposed to both concurrently. Previously, Hill et al (2007) reported the effects on 
aerobic training with or without LCn-3 supplementation compared to sunflower oil placebo groups. 
An interaction of LCn-3 and exercise was not reported for body fat, however both LCn-3 and 
exercise were independently associated with decreases in body fat%. 
Kabir et al (Kabir et al. 2007) noted that body fat mass and subcutaneous adipocyte diameter was 
decreased in the supplemented group compared to placebo, and Munro et al (2012) reported that 
body fat% change was associated with plasma DHA concentration. In addition, a large study 
examining the effects of high lean and fatty fish indicated a reduction in waist girth for men only, 
compared to a low seafood intake (Thorsdottir et al. 2007). In cancer populations undergoing 
chemotherapy, LCn-3 has been shown to reverse intramuscular triglyceride deposition over the 
course of treatment (Murphy et al. 2011). 
 
In summary of finding relating to adiposty, our trial confirms evidence from in vitro and previous 
human studies that LCn-3 supplementation in combination with an exercise and nutrition program 
is associated with greater reductions in adiposity. No reductions in body weight, hip or waist girth 
were seen in either the LCn-3 supplementation or lifestyle program plus olive oil, indicating a 
potential synergistic effect for the combination of the two groups. Reduction of body fat% and 
waist circumference is an important consideration for breast cancer survivors who are at an 
increased risk of cardio-metabolic conditions. It is important to interpret these findings with 
caution, as body fat% and waist were not primary outcomes of the trial, however, our findings are 
relevant to practice.  
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 A large intervention trial is currently under way to determine the effect of exercise and nutrition on 
long term breast cancer related outcomes, (Rock et al. 2013). While this study is not testing the 
effect of LCn-3, it may provide insight into the value of waist and body fat% reductions from a 
lifestyle program in a representative breast cancer population. 
6.4.5$Muscle$function$and$LBM$change$
Upper body strength increased significantly for the groups in the lifestyle program, while aerobic 
exercise and lower body strength was not changed at 24wks. LCn-3 was not observed to have an 
effect on strength-endurance or upper or lower body, nor on aerobic fitness. All groups improved 
handgrip strength and physical function (HAQ-DI) from baseline to 12wks. However, LCn-3 
supplementation better maintained these improvements than those consuming olive oil.  
 
Previous exercise intervention studies have reported improvements in cardiovascular fitness, muscle 
strength (Schmitz et al. 2009, Schmitz, Ahmed, et al. 2005) or both (Courneya et al. 2007, Herrero 
et al. 2006) regardless of change in body composition. Typically, strength increases of 20 to 65% 
(Schmitz et al. 2009, Schmitz, Ahmed, et al. 2005, Herrero et al. 2006) are noted after resistance 
training interventions, while increases in aerobic fitness have been consistently noted after aerobic 
exercise interventions (Schmitz et al. 2010). We noted significant increases in upper and lower 
body strength-endurance; upper body was only improved in those who participated in the lifestyle 
program. The push up test is a marker of upper body strength-endurance (American College of 
Sports Medicine 2010) and has been shown to increase when upper body resistance training is 
performed regularly (William et al. 2004). This improvement in push-ups performed is most likely 
due to the specificity of the training in the lifestyle program, i.e. push-ups were part of every 
supervised training session. This type of training may not be undertaken as commonly without 
prescription and supervision, such as in those who were given LCn-3 supplements only. Therefore, 
this may explain the comparatively lower improvement in the LCn-3 only group.  
 
In terms of the effect of LCn-3 on muscle function, previous synergistic effects of LCn-3 and 
exercise training have been observed in middle-aged women (via reduced electromechanical delay) 
(Rodacki et al. 2012). The effect of LCn-3 on strength-endurance (i.e. number of push ups/squats in 
1-minute) has not been tested previously. Thus, the understanding that LCn-3 may act through 
neural as opposed to through mechanical pathways may justify the lack of effect we noted for 
strength-endurance. However, we did observe better maintenance of maximum handgrip strength 
from 12 to 24wks for the LCn-3 supplemented groups independent of lifestyle program 
participation. Efficient neural activation is an important component of maximal force development 
(Fimland et al. 2009). In addition to this, evidence from dosing studies indicate that tissue 
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 accumulation of LCn-3 occurs over two to six months (Yee et al. 2010). Thus it is plausible to 
hypothesise that a greater concentration of LCn-3 made available to the neural system by 
supplementation over 3 months, which in turn may have better maintained the ability to produce 
maximum force. Furthermore, these results agree with observations of a community dwelling 
population indicating a higher handgrip with fish consumption (Robinson et al. 2008), and 
compliment our finding that overall physical function followed the same pattern as handgrip 
strength. 
 
Evidence from general populations indicate that function of LBM measured as muscle strength 
(Newman et al. 2006, Ruiz et al. 2008) or cardiorespiratory fitness (Lee, Blair, and Jackson 1999) is 
more predictive of mortality than LBM alone. Though, for the same fitness levels, greater total 
body weight is still associated with higher mortality (Hu et al. 2004). Similarly for breast cancer 
populations, stability or moderate decreases in weight are related to better survival (Caan et al. 
2012, Caan et al. 2006, Kroenke et al. 2005, Chen et al. 2010). However, increasing physical 
activity to three or more hours per week of brisk walking is associated with 30-50% reductions in 
breast cancer mortality (Irwin et al. 2011, Ibrahim and Al-Homaidh 2010), and smaller but 
significant reductions in recurrence (Ibrahim and Al-Homaidh 2010). In other words, the function 
of the muscle, i.e. how it is being used, may be a predictor of outcomes for breast cancer survivors 
that is equally important to simple body weight, or body composition change.  
6.5 Validity and feasibility of the intervention 
First and foremost, our intervention was safe with there being no serious adverse events reported as 
result of the trial. The format of the lifestyle program was successfully carried out even though it 
faced similar challenges as would be faced in clinical practice, i.e. timing of sessions and 
availability of individuals within groups, and inconsistent group size due to changing rate of 
recruitment. In addition, as the groups progressed through the program, greater discussion, sharing 
of perspective and inter-participant motivation increased significantly. This component of the 
education sessions became as relevant and motivating as the pre-organised materials. The primary 
investigator noted that group cohesion made a difference to the overall atmosphere of the sessions 
(increased story sharing, humour, comrardery), and is an important consideration for future 
programs in practice.  
 
The intervention could be replicated in a clinical setting at relatively low cost. Without including 
the cost of the clinician providing the services, all exercise equipment, stationery and blood results, 
was calculated at ~$300 per person. Of this, 75% was spent on blood analyses of LCn-3 (which 
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 would not be necessary in practice) and exercise equipment (which was kept by each participant 
after the trial).   
 
The home-based style exercise program was effective in that changes in strength were documented, 
however even with annotated video explanations of the exercises available to the participants, a 
significant amount of time was spent on technique correction during the supervised sessions. This 
reduced the intensity of these sessions, which formed 50% of the resistance training volume 
completed by the participants. Furthermore, motivation to complete the full exercise program at 
home was low, and this was reflected by a ~70% adherence to those exercises. As a suggestion, 
basing interventions of this type in a gym, and/or aligning with gyms and exercise physiologists in 
multiple locations is recommended. This would allow more supervised sessions to be conducted, 
and is also recommended to enhance safety and progression of the program. 
 
In contrast, aerobic exercise increased significantly for all groups and was the preferred mode of 
exercise indicated by the above 100% adherence. Considering that mortality and recurrence rates 
are decreased by an increase in brisk walking (Ibrahim et al 2010), aerobic participation is a 
relevant outcome. However, it is noteworthy that both lifestyle program and supplementation only 
groups increased their physical activity.  
 
Due to similar change in participation, dietary intake, and LBM, it is possible that just assessing 
body composition and providing basic information on physical activity and nutrition may be 
adequate to promote change in this population as a whole. As mentioned previously, our population 
may have been more inclined to participate in exercise as they expressed an interest in the trial 
initially. Thus, our participants may be more motivated than the general breast cancer population, 
from an activity/sedentary time perspective. However, considering the extensive assessment and 
follow-up treatment load placed on this population, recommending an intensive intervention may be 
over-burdening participants, and is contrary to a recent movement in ‘minimally disruptive care’ 
(Bohlen et al 2012). In contrast, certain individuals within the intervention thrived on the consistent 
follow-up, feedback and structured prescription offered by the weekly lifestyle program. Thus, 
rather than attempting to find the ‘optimal’ intervention, it may be more effective to offer a number 
of programs with varying intensity and involvement, then triaging patients on their preference, 
requirements and means. 
 
 LCn-3 and the lifestyle program combined were found to be more effective together than alone 
across a number of parameters, thus further research exploring diet-exercise-treatment synergies are 
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 still important. Therefore, balancing the further research of program intensity and adherence, with 
synergistic interventions is needed to provide clinical programs a greater reach and impact. 
 
 
176
 Conclusions 
Consumption of LCn-3s in combination with an exercise and nutrition program had a synergistic 
effect in reducing total body weight, waist girth and hip girth, while LBM was maintained. These 
findings agree with hypotheses generated from experimental evidence that LCn-3 and exercise lead 
to influence fat metabolism, and do so in a complementary manner. This is the first study to have 
reported this synergistic effect in humans, and the first trial to combine specific nutrients and 
exercise training in a population of women who have been diagnosed and treated for breast cancer. 
We found that motivation levels were sufficient to increase aerobic activity with or without 
structured prescription. However, only the addition of LCn-3 was associated with clinically 
significant weight loss, and body fat reductions, that have been associated with decreased mortality 
and decreased risk of metabolic disease in larger and longer trials. 
 
Despite the recent evidence that LCn-3 may augment the response of LBM to exercise training, our 
study indicated that LCn-3, a 12-week exercise and nutrition lifestyle program, and a combination 
of the two all promote LBM maintenance without differences between interventions. This is most 
likely due to the fact that the LCn-3 only group significantly increased their level of activity in line 
with the lifestyle program groups. In addition, similar to the majority of research that reported little 
the effect of LCn-3 or exercise on CRP, we did not see a significant change for any group. Quality 
of life improved for all groups over the intervention period. This mirrors findings that quality of life 
improves generally in the year following treatment, which may also be related to the increased 
physical activity in all groups.  
  
As expected from a wealth of prior research, structured and specific semi-supervised training 
improves upper body muscular strength-endurance. In contrast improvements in lower body 
strength-endurance were common to all groups independent of prescribed exercise. This is most 
likely due to the fact that the control group significantly increased their exercise volume from 12 to 
24 weeks. In turn, this may indicate that current awareness of the importance of physical activity 
after breast cancer is adequate to motivate this population to engage in aerobic exercise. However, a 
similar engagement in resistance training was not seen in the LCn-3 only group.  
Of interest, LCn-3 consumption was seen to promote better maintenance of grip strength, which 
was matched by an improved measure of daily physical function independent of structured exercise 
during the 12 to 24 week period. This agrees with the previous literature describing that increased 
tissue levels of LCn-3 are associated with greater grip strength and muscle function. Also, in 
agreement with our review, the delayed effect of LCn-3 supplementation on muscle function may 
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 be due to the gradual accumulation of LCn-3 in the tissue over two to three months. Thus, 
prolonged supplementation may be key to elicit a significant change. 
In all, these results indicate that LCn-3 is a useful nutrient in the prescription of nutrition for women 
who have completed treatment for breast cancer. Further research combining LCn-3 and exercise 
over a time period relevant to post-treatment cardio-metabolic outcomes is recommended to 
determine if these body composition changes convert to positive health outcomes. 
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 Clinical implications 
With increasing incidence of breast cancer diagnoses, and therefore an increased number of 
survivors at risk of recurrence and cardio metabolic conditions, efficacious interventions that 
positively affect body composition and post-treatment disease risk are of high importance.  
Recommending high dose (3g/day of EPA plus DHA) LCn-3 in conjunction with a lifestyle 
program may clinically improve adiposity over and above that of LCn-3 or the lifestyle program in 
isolation. 
Regular aerobic exercise is effective in preventing LBM loss after treatment for breast cancer. The 
addition of LCn-3 is likely to have little effect on this. 
Prescription of an ad libitum healthy eating pattern, without specific energy restriction, is adequate 
to allow body weight and adiposity reductions without LBM decrease when paired with exercise 
and LCn-3 supplementation. 
Prescription of high dose LCn-3 may improve physical function and maintain greater grip strength 
independently of exercise training. 
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 Future Recommendations 
Future recommendations for research in this area need to include outcomes that relate to disease-
free survival, body composition with a focus on lean body mass and quality of life. This study has 
indicated that there is benefit for the combination of LCn-3 and exercise. Both interventions have 
been shown to have positive effects on long term health in breast cancer and non-breast cancer 
populations. 
Enhancing disease-free life after breast cancer 
The synergistic effects of exercise and nutrition prescription with LCn-3 supplementation on body 
weight, and waist and hip girths should be followed for a longer time period, such that changes in 
risk factors for cardio-metabolic disease and breast cancer related outcomes can be measured. Do 
the changes in body fat due to the dual intervention have a preventive effect for future disease? 
Increasing LBM after breast cancer 
In future studies aiming to increase LBM after treatment, a supervised and fully objectively 
monitored gym-based resistance and aerobic training program should be prescribed to enhance the 
intervention’s effect on both muscular hypertrophy and adiposity reductions. At a higher intensity 
of training, conducted in a more accountable manner, dose of exercise in conjunction with LCn-3 
may be elucidated.  
To further assess the proposed effect of LCn-3 on LBM growth, it is suggested that it is combined 
with resistance training as described above, and validated through the measurement of 
intramuscular triglyceride (IMTG) concentration (MRI or CT scans). IMTG deposition in inactive 
individuals has been associated with insulin resistance and greater inflammation, and is increased 
after chemotherapy. Understanding the effects of LCn-3 on IMTG in conjunction with exercise 
training may provide a better understanding of metabolic pathways involved in the synergy. 
Additional, and potentially greater LBM growth may be possible through appropriate protein 
supplements in conjunction with structured supervised resistance training. Combining LCn-3, 
which seems to be permissive of LBM growth, with appropriately timed and sized protein meals 
may be more synergistic than the combination used in this study.  
Quality of life after breast cancer 
Measures of physical function (strength, cardiorespiratory fitness, performance of activities of daily 
living) should be included in future trials determining general outcomes for breast cancer survivors. 
If further evidence proves that measures of physical function are related to clinically relevant 
endpoints, it will allow exercise and nutrition prescription to target risk factors directly. Promoting 
behaviours to increase physical function rather than body composition may be more positive and 
may reduce the angst associated with increased adiposity. 
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Approved(Clinic(flyers(
Version 2.0: 08/03/2011
Do FISH OIL and EXERCISE  help with BODY WEIGHT & COMPOSITION after 
TREATMENT FOR BREAST CANCER? 
We are seeking women who have completed treatment for breast cancer to be part of this exciting new study. 
All study related medical care will be at no cost to participants 
If you would like to participate or interested in knowing more about the study please contact: 
Contact:  Mr. Cameron McDonald Phone:  0411380566 Email:  UQbreastcancerstudy@gmail.com  Version(3(–(5/06/12(
!!!Do!FISH%OIL!and!EXERCISE!!help!with!BODY%WEIGHT%&%
COMPOSITION!after!!
TREATMENT%FOR%BREAST%
CANCER?!!We!are!seeking!women!who!have!completed!treatment!for!breast!cancer!to!be!part!of!this!exciting!new!study.!$$$!
All%study%related%medical%care%will%
be%at%no%cost%to%participants%If!you!would!like!to!participate!or!interested!in!knowing!more!about!the!study!please!contact:!Contact:!! Mr.!Cameron!McDonald!Phone:!! 0411380566!Email:!!UQbreastcancerstudy@gmail.com!!
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Appendix!3!
A>3.1!Participant!information!and!data!collection!tools!
Telephone(Initial(Screening(Tool(
Version Date: 20101119
Telephone Screening Tool 
PROTOCOL: The MODEL Study 
TRIAL SUMMARY:  
i.e. aim of trial, healthy, disease specific, length of involvement and 3 key points of selection criteria 
1. Assess changes in body composition
2. Breast cancer survivors finishing treatment in the last 12 months
3. Involvement for 6 months, Minimum number of visits = 9 over 6 months (maximum 12)
PARTICIPANT’S DETAILS GP DETAILS: 
Name: 
Sex: 
Female DOB: Age 
Contact details: Preferred time to be contacted: 
Mobile: Home phone: 
Email address: SPECIALIST: 
Postal address: 
How did you hear about the study? 
Advertising source? 
Screening conducted by: Date:  Time: 
SELECTION CRITERIA: 
Inclusion Criteria: If response falls within the grey area please exclude participant  
Diagnosis and Rx of Breast cancer No Yes
Completed treatment successfully in last 12 months No Yes
Age older than 18yrs No Yes
Appropriate BMI No Yes
Willing to be randomized No Yes
No diagnosis of diabetes or cardiovascular disease No Yes
Not pregnant No Yes
No Yes
Exclusion Criteria: If response falls within the grey area please exclude participant  
Did the cancer spread to any other parts of your body? No Yes
Has the doctor indicated you currently have a cancer? No Yes
Use of cardiac or diabetic medications No Yes
Planning to have a child in next 9 months No Yes
No Yes
No Yes
No Yes
Eligibility 
Not eligible but consent for database No  Yes Consent form sent N/A No Yes
Eligible according to this phone screen No  Yes Would like to be contacted No Yes
PICF sent No Yes
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Approved(participant(information(and(informed(consent(
Participant!Information!and!Consent!Form!
Protocol!Title:!The!Muscle!Mass,!Omega#3,!Diet,!Exercise!&!Lifestyle!(MODEL)!Study:!a!nutrition!program!for!women!after!breast!cancer!treatment!
Investigators:! Associate!Professor!Judy!Bauer,!Professor!Sandra!Capra,!Dr.!Geoffrey!Beadle,!Dr.!Nicole!McCarthy,!Cameron!McDonald!
Site:!! ! The!Wesley!Research!Institute!
Co>ordinating!centre:! The!Wesley!Research!Institute!&!University!of!Queensland!
Funding!agency:! The!Wesley!Research!Institute!
Dear%Participant,%
This%form%has%2%sections:%
1. Participant%Information%(to%share%information%about%the%study%with%you)
2. Consent%Form%(for%signatures%if%you%agree%to%take%part).
You%will%be%provided%with%a%copy%of%the%signed%full%Participant%Information%and%Consent%Form%
to%keep%as%a%record.%Introduction!
You%have%been%invited%to%take%part%in%this%study%as%you%have%completed%treatment%for%breast%
cancer% in% the% last% 12%months.% A% healthy% lifestyle% after% treatment% is% important% for% ongoing%
good%health.%The%purpose%of%this%study%is%to%compare%the%effects%of%fish%oil%(omegaG3)%when%
delivered%alone,%or%in%combination%with%a%nutrition%and%exercise%program,%and%to%see%if%this%
affects%markers%of%health.%
Before%agreeing%to%participate%in%the%study,%it%is%important%that%you%read%and%understand%the%
information%on%this%form.%It%explains%all%the%procedures%involved.%It%also%tells%you%what%your%
rights%are%including%the%right%to%withdraw%from%the%study%at%anytime.%Please%ask%your%study%
doctor% or% other% research% staff% to% explain% anything% that% you% do% not% understand.% Take% your%
time,%and%if%you%wish,%discuss%the%study%with%your%family,%doctor,%friends%and%relatives.%
How!many!women!will!be!in!the!study!and!how!long!will!it!last?!There!will!be!30#35!women!in!3!groups!(90#115!altogether)!taking!part!in!the!study.!The!study!will!compare!results!of!the!3!groups!over!6!months.!If!you!agree!to!participate!in!the!study!you!will!be!allocated!to!one!of!3!groups.!Which!group!you!go!into!is!purely!a!matter!of!chance!(random!allocation)!and!out!of!the!study!staff’s!control.!
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!If!you!are!allocated!to!Group!1,!you!will!attend!a!12#week!nutrition!and!exercise!group#based!program!specifically!developed!for!women!who!have!completed!treatment!for!breast!cancer;!If!you!are!allocated!to!Group!2,!you!will!receive!a!specific!daily!dose!of!fish!oil;!If!you!are!allocated!to!Group!3!you!will!attend!the!nutrition!and!exercise!program!plus!receive!the!daily!dose!of!fish!oil.!!
What!will!happen!during!the!study?!
General!timing!This!study!will!be!conducted!over!6!months.!The!initial!3!months!will!require!weekly!or!fortnightly!visits!to!The!Wesley!Research!Institute.!After!this!period!you!will!be!contacted!monthly!to!monitor!your!progress!and!update!your!details!as!necessary.!
Study!Assessments!All!participants!will!be!asked!to!complete!a!number!of!questionnaires,!physical!tests!and!a!dietary!report!at!three!time!points!–!before!you!start!the!nutrition!program!and!at!3!and!6!months!.!It!is!estimated!that!the!study!assessments!will!require!two!hours!to!complete.!Week!1!–Location:)The)Wesley)Research)Institute)and)The)Wesley)Hospital)
Rehabilitation)Gym)
• Questionnaires!will!be!completed!while!you!wait!for!availability!of!theother!tests.!There!are!5!questionnaires!in!total!and!will!take!30#40minutes!to!complete.!These!questionnaires!will!gather!informationregarding!quality!of!life,!joint!pain!and!soreness!and!levels!of!fatigue.
• Basic!body!measures:!Your!weight,!height,!waist!and!hip!circumferencewill!be!measured!using!a!simple!set!of!scales!and!standard!measuringtape!and!stand.
• Lymphoedema!Index:!will!be!measured!using!a!specialised!instrument,that!passes!a!very!small!electric!current!through!your!body.!It!determinesthe!amount!of!fluid!in!your!arm.!You!will!not!feel!any!discomfort!duringthe!measurement
• Body!composition!will!be!measured!using!the!BodPod.!This!is!a!specialpiece!of!equipment!in!which!you!sit!for!4!minutes!while!the!measurementis!being!taken.!It!will!provide!you!with!a!very!accurate!reading!of!totalbody!fat%!and!muscle!mass!%.Personal!Interview!
• Your!Diet!history!will!be!gathered!through!an!initial!questionnaire!andthen!followed!up!with!an!!interview!from!an!Accredited!PracticingDietitian.!You!will!be!asked!a!series!of!questions!relating!to!your!regulardaily!food!intake.!Amounts!and!frequency!of!foods!will!be!requested!andreference!cups,!bowls!and!plates!will!be!used!to!help!you!accuratelyidentify!your!typical!food!portions.!This!stage!will!take!around!20!minutesto!complete.
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• Cardio#respiratory!fitness:!!If!your!Oncologist!considers!this!safe!andappropriate!for!you,!you!will!be!asked!to!perform!what!is!called!a!sub#maximal!exercise!test.!This!involves!walking!on!a!treadmill!for!6#12minutes,!the!incline!and!speed!is!gradually!increased!until!you!reach!apredetermined!heart!rate!(85%!of!your!maximum!heart!rate),!or!whenyou!decide!to!end!the!test!yourself.!The!speed!of!the!treadmill!will!besimilar!to!a!slow!walk!up!a!hill,!and!will!build!over!time.!Blood!pressure,heart!rate!and!blood!oxygen!levels!will!be!recorded!throughout!the!test.The!highest!workload!will!only!continue!for!3!minutes!(normally!less)and!is!not!expected!to!unduly!stress!your!body.!See!additionalinformation!sheet!attached!for!full!details.
• Physical!Activity:!You!will!be!asked!to!wear!a!device!called!anaccelerometer.!This!device!measures!your!pattern!of!movement!throughthe!day!and!the!intensity!at!which!you!perform!these!activities.!You!willbe!asked!to!wear!the!device!for!7!days!during!waking!hours!except!fortimes!when!you!are!showering,!bathing,!swimming!or!performing!otheractivities!that!may!wet!the!device.!The!device!is!similar!in!size!to!a!box!ofmatches!and!is!attached!at!hip!height!with!a!special!belt.!This!will!behanded!in!at!your!attendance!the!following!week.
• A!Blood!sample!will!be!taken!from!your!arm.!If!you!do!not!wish!to!give!ablood!sample!you!will!still!be!considered!for!participation!in!the!study.You!will!have!around!2!teaspoons!of!blood!taken!per!sample.!Theprocedure!will!be!carried!out!by!a!specialised!technician!(phlebotomist)to!ensure!accuracy!and!safety.
Week!2!–Muscular!endurance:!These!tests!indicate!the!strength!and!endurance!of!different!groups!of!muscles!–!upper!body,!lower!body!and!abdominal!strength!
o Push!up!test:!Is!measured!by!the!number!of!push#ups!you!canperform!consecutively!without!stopping.!Technique!will!bemonitored!for!safety.!If!you!require!a!garment!for!lymphoedema(swelling)!in!your!arm!it!is!essential!that!this!garment!is!wornduring!the!test.
o Abdominal!crunch!test:!Measured!by!the!most!crunches!you!canperform!in!one!minute.!A!set!distance!is!marked!to!maintainconsistency.
o 30!second!sit#stand!test:!Measures!how!many!times!you!can!movefrom!a!sitting!position!to!a!standing!position!from!a!standard!chairin!30!seconds.All!movements!will!be!demonstrated!before!you!perform!them,!and!you!may!stop!the!test!at!any!time.!
12!Week!Nutrition!and!Exercise!Program!If!you!are!allocated!to!Group!1!or!3,!you!will!be!asked!to!attend!the!12!week!nutrition!and!exercise!program.!The!commitment!includes!9!sessions!over!12!weeks,!and!information!presented!will!be!relevant!to!nutrition!and!exercise!considerations!for!optimising!health!after!treatment!for!breast!cancer.!Sessions!will!involve!group!discussions,!nutrition!and!exercise!presentations!and!active!
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exercise.!The!program!will!be!run!based!on!cognitive!behavioural!therapy!which!is!a!technique!that!encourages!goal#setting,!taking!steps!to!achieve!those!goals,!and!addresses!appropriate!management!of!barriers!to!these!goals.!
Visiting!Schedule!Below!is!an!outline!of!the!study!and!your!commitments!if!you!choose!to!participate.!
Groups%1%&%3% Group%2%
Week%1G%
Day%1%testing%
Initial%introduction%and%measurements%as%described%above%for%Day%1%
Week%1G2% Wear%accelerometer%for%7%days%during%waking%hours.%
Week%2% Hand%in%Accelerometer%and%complete%a%questionnaire%regarding%your%
physical%activity%for%the%previous%week.%
Week%2G13% Attend%9%weekly%60%minute%
sessions.%Wks%2,%3,%4,%5,%6,%7,%9,%11,%
13.%
Attend%fortnightly%meetings%to%pick%
up%supply%of%fish%oil%capsules%and%
check%in%with%research%team%(30%
min)%
Attendance%required:%Week%2,%3%
(exercise%testing),%5,%7,%9,%11,%13%%
Week%2,3%&%
13%
Muscular%endurance%tests%will%be%carried%out%in%week%2,%3%&%13%during%
the%sessions%
Week%14%
Day%1%testing%
Measurements%as%described%for%Day%1%
Week%14G26% GMaintain%prescribed%capsule%intake%and%nutrition%and%exercise%habits.%
GReceive%ongoing%support%for%progress%via%email%and%internet%blog%for%
your%study%group.%
Week%26%&%27% Repeat%of%initial%assessments%performed%at%Week%1/2%&%14/15.%
Capsule(consumption(Groups!1!&!3!will!complete!the!12#week!nutrition!and!exercise!program!together.!However,!those!who!are!randomly!allocated!to!Group!1!will!receive!placebo!(fake)!fish!oil!capsules,!while!Group!3!will!receive!genuine!fish!oil!capsules.!Both!instructors!and!participants!will!not!know!who!has!been!allocated!to!Group!1!or!Group!3!until!after!the!study!is!completed.!Group!2,!who!will!not!be!participating!in!the!nutrition!and!exercise!program!&!will!be!taking!genuine!fish!oil!capsules.!All!participants!will!be!strongly!discouraged!from!taking!any!additional!fish!oil!capsules!for!the!duration!of!the!study.!!
Are(there(any(benefits(to(me?(You!may!or!may!not!receive!any!direct!benefit!from!taking!part!in!this!study.!You!may!receive!additional!information!about!your!health!and!the!information!learnt!in!this!study!may!help!others!in!future.!
What(are(the(risks?(You!may!not!have!any!problems!with!the!fish!oil!doses!or!exercise!testing!and!training.!However,!others!have!reported:!Fish!oil:!gastrointestinal!upset,!‘fishy’!aftertaste!and!a!longer!bleeding!time.!Taking!more!than!the!prescribed!dose!of!fish!oil!may!have!adverse!effects!in!
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some!cases.!It!is!strongly!advised!you!do!not!take!more!than!the!dose!given!to!you!and!discuss!any!issues!with!CI!McDonald!or!your!Oncologist.!Exercise!testing:!dizziness,!light#headedness,!fatigue,!muscle!soreness,!joint!ache!or!pain!Any!adverse!effects!related!to!the!study!will!be!addressed!immediately!so!that!the!issue!can!be!resolved!as!quickly!as!possible!with!the!help!of!the!study!doctor!and!research!team.!
Will(I(have(to(pay(anything(to(be(part(of(the(study?(You!will!not!be!paid!to!take!part!in!the!study.!The!fish!oil!capsules!and!education!program!will!be!offered!at!no!charge.!After!6!months!you!will!need!to!purchase!your!own!fish!oil!capsules!if!you!wish!to!continue!with!the!dose!after!the!study.!The!funding!body!will!provide!remuneration!for!parking!fees!to!attend!the!sessions.!Your!study!doctor!is!not!being!paid!to!conduct!this!study.!Details!of!any!financial!or!other!relevant!declarations!of!interest!of!researchers!of!institutions!can!be!provided!to!you!by!your!study!doctor!if!you!wish.!
Will(my(information(be(kept(private?(Any!information!obtained!during!this!study!that!can!identify!you!will!remain!confidential!and!will!only!be!used!for!the!purpose!of!the!study.!Your!personal!information!will!only!be!disclosed!with!your!permission,!except!where!required!by!law.!We!plan!to!present!information!and!results!from!the!study!at!meetings!or!publish!it!in!journals.!Your!name,!and!other!personal!information!that!can!easily!be!traced!back!to!you,!will!not!be!included!in!presentations!and!publications.!Your!health!records!and!any!information!obtained!during!the!study!are!subject!to!inspection!(for!the!purpose!of!verifying!the!procedures!and!data)!by!regulatory!authorities!such!as!the!Australian!Government’s!Therapeutic!Goods!Administration!(TGA)!and!authorised!representatives!of!the!funding!body,!and!its!representatives,!ethics!committee,!or!as!required!by!law.!By!signing!the!attached!Consent!Form,!you!authorise!release!of,!or!access!to,!this!confidential!information!to!the!relevant!study!personnel!and!regulatory!authorities!as!noted!above.!The!handling,!storage,!transfer!and!destruction!of!your!data!will!comply!with!the!
Australian)Privacy)Act)1988)(Cth)!and!any!other!legislation,!code!or!guideline!which!applies!in!the!jurisdiction!in!which!the!study!site!is!located!and!which!related!to!the!protection!of!personal!information.!All!your!data!will!also!be!securely!stored!at!the!Wesley!Research!Institute!and!the!University!of!Queensland!and!eventually!archived!for!at!least!15!years.!After!this!time!it!will!be!disposed!of!appropriately.!
Do(I(have(to(take(part(in(this(study?(You!do!not!have!to!take!part!in!this!study!if!you!do!not!wish!to!do!so.!You!may!stop!participating!in!the!study!at!any!time!by!telling!the!study!doctor!or!research!staff!that!you!do!not!want!to!continue.!You!do!not!have!to!give!a!reason.!Your!decision!whether!to!take!part!or!not!to!take!part,!or!take!part!and!then!withdraw,!will!not!affect!your!routine!treatment!or!your!relationship!with!those!treating!you.!If!you!decide!to!stop!the!study,!no!more!information!will!be!collected!about!you!for!the!study.!All!the!information!you!gave!us!before!you!decided!to!stop!the!study!will!be!used!for!the!study.!
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Can(I(be(taken(out(of(the(study?(The!study!doctor!may!at!any!time!decide!to!stop!the!study!or!take!you!out!of!the!study!for!several!reasons!such!as:!
• The!required!number!of!study!participants!has!been!met.
• You!have!not!followed!the!study!instructions!given!to!you.
• It!is!better!for!your!health.
• Any!other!reasons.
Results(of(the(study(We!aim!to!publish!the!results!of!this!study!so!that!other!interested!people!may!have!access!to!the!information.!The!information!will!be!shared!with!you!before!it!is!made!widely!available!to!the!public.!You!should!feel!free!to!ask!your!doctor!about!this.!A!plain!English!summary!of!the!study!results!will!be!made!available!to!you!if!you!wish.!
New(information(arising(during(the(project(During!this!study,!new!information!about!the!risks!and!benefits!of!the!project!may!become!known!to!the!study!staff.!If!this!occurs,!you!will!be!told!about!this!new!information.!This!new!information!may!mean!that!you!can!no!longer!participate!in!this!research.!If!this!occurs,!the!person(s)!supervising!the!research!will!stop!your!participation.!In!all!cases,!you!will!be!offered!all!available!care!to!suit!your!needs!and!medical!condition.!
Further(information(for(any(problems(If!you!require!further!information!or!if!you!have!any!problems!concerning!the!study!you!can!contact!the!investigators:!The!Study!Co#ordinator:!Cameron!McDonald!(0411380566)!or!!Assoc!Professor!Judy!Bauer!(3232!7918),!Professor!Sandra!Capra!(334 67703)!or!Dr.!Geoffrey!Beadle!(3870!4255).!If!you!have!any!complaints!about!any!aspects!of!the!project,!the!way!it!is!being!conducted!or!any!questions!about!your!rights!as!a!study!participant,!then!you!may!contact:!The!UnitingCare!Health!Human!Research!Ethics!Committee:!07!3232!7500!
Ethical(Guidelines(The!study!will!be!carried!out!according!to!the!National!Statement!on!Ethical!Conduct!in!Research!Involving!Humans!(2007)!produced!by!the!National!Health!and!Medical!Research!Council!of!Australia.!This!statement!has!been!developed!to!protect!the!interests!of!people!who!agree!to!participate!in!human!research!studies.!This!consent!form!and!ethical!aspects!of!this!research!have!been!approved!by!the!Human!Ethics!Committee!of!The!Wesley!Hospital.!This!study!adheres!to!the!Guidelines!of!the!ethical!review!process!of!The!University!of!Queensland.!Whilst!you!are!free!to!discuss!your!participation!in!this!study!with!project!staff!(Cameron!McDonald!#!0411380566),!if!you!would!like!to!speak!to!an!officer!of!the!University!not!involved!in!the!study,!you!may!contact!the!Ethics!Officer!on!3365!3924!
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A>3.2!Consent!Form!
Protocol!Title:%The%Breast%Cancer%Muscle%mass,%OmegaG3,%Diet,%Exercise%&%Lifestyle%
(MODEL)%Study:%a!nutrition!program!for!women!after!breast!cancer!treatment!
• I!have!read!and!understand!the!information!in!this!ParticipantInformation!and!Consent!Form
• I!have!read!and!understand!the!information!in!the!Preparation!forPerformance!of!Sub#maximal!exercise!test
• I!have!been!well!informed!about!the!study
• I!have!had!the!chance!to!ask!questions!and!my!questions!have!beenanswered
• I!understand!that!any!new!information!that!may!affect!my!decision!to!beon!the!study!will!be!made!available!to!me
• I!understand!that!I!may!ask!questions!at!any!time!and!that!I!am!free!towithdraw!from!this!study!at!any!time!without!affecting!my!medicaltreatment!or!relationship!with!my!doctors
• I!understand!that!my!participation!in!this!study!may!be!ended!by!theinvestigator!or!by!the!funding!body!for!reasons!that!would!be!explained
• I!agree!that!the!study!sponsors!affiliates!and/or!related!companies,authorised!representatives!of!HREC!or!appropriate!regulatory!agencies,will!be!granted!access!to!original!medical!records!for!verification!ofclinical!trial!procedures!and/or!data!without!violating!my!confidentiality
• I!consent!to!my!information,!provided!that!I!cannot!be!identified!by!it,being!passed!to!other!bodies!working!with!the!funding!body!and!Iunderstand!this!may!include!other!countries
• I!agree!that!data!gathered!from!the!results!of!the!study!may!be!published,provided!that!I!cannot!be!identified
• I!agree!to!follow!all!study!procedures!as!outlined!in!this!ParticipantInformation!and!Consent!Fro
• I!understand!that!I!do!not!give!up!any!of!my!legal!rights!by!signing!thisform
• I!agree!that!my!consent!is!voluntary
• A!copy!of!this!signed!Consent!Form!will!be!given!to!meBy!signing!this!consent!form!you!are!saying!that!you!understand!the!information!and!that!you!give!your!consent!to!take!part!in!the!study.!Participant’s!Name:!!!!________________________________________________________!Participant’s!Signature:! _______________________________!!!Date:!__________________!I!have!given!a!verbal!explanation!of!this!study,!its!procedures!and!risks!believe!that!the!participant!understood!the!explanation.!Investigator’s!Name:!! _______________________________!Investigator’s!Signature:!! _______________________________!!!Date:!____________________!
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A>3.3!Participant!Completed!Data!Collection!Sheets!
Contact!details!and!Coding!
FORM%–%1%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%Participant%#:%
Assessment%code:%
%
The%M.O.D.E.L.%Study%
! For!women!who!have!completed!Breast!Cancer!treatment%%
Version%1.%08/03/2011%
%
%
Contact%details%
Full%name:%_______________________________________________________%
D.O.B:__________________________________________________________%
Address:_________________________________________________________%
%
_________________________________________________________________%
%
Preferred%email%address:%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%__%
Preferred%phone%number:%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%_%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
Secondary%phone%number:%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%
Emergency%contact%(name%&%relationship%to%you):%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%_%
% Preferred%phone%#:%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%%_%
GP/Specialist%Details:%%
%
%
Change%to%Details%(if%needed):%%
Full%Name:%___________________________________%
Address:%___________________________________________________%
______________________Suburb:%%%%%%%%%%%%%%%%%%%%%%%%%%%Postcode:%_________%
%
%
xv 
Demographical!data!collection!sheet!
FO
RM
 – 3  
   Participant #: 
Assessm
ent: 
Please answ
er ALL of the follow
ing questions. Please ask one of the research team
 if you w
ould like 
further clarification for any of the item
s below
. 
1. 
W
hat is your age in years? 
2. 
W
hat is your current m
arital status?    (Please circle) 
Single, N
ever m
arried 
  Defacto        M
arried  
  Separated 
   Divorced  
  W
idow
ed   
3. 
Do you have any children? (Please circle)
  YES-go to Q
4   
 N
O
 –go to Q
5 
4. 
How
 m
any children do you have? 
5. 
W
hat is highest level of education you have com
pleted? (Please circle) 
x Less than high school 
x High school 
x Som
e U
niversity 
x U
niversity (please specify level of achievem
ent) 
Bachelor   
M
asters 
Doctorate 
x Som
e TAFE or post-schooling education 
x TAFE course 
x Graduate Certificate/Diplom
a 
x O
ther (please  specify)…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
…
. 
6. 
W
hat best describes your current em
ploym
ent status?
Full tim
e 
Part tim
e 
Casual 
  Contractor      U
nem
ployed 
7. 
For how
 m
any hours on average do you w
ork each w
eek?
FO
RM
 – 3  
   Participant #: 
Assessm
ent: 
8. 
W
hat is your race? (Please circle) 
  Asian (specify region)............................... 
Aboriginal or Torres Strait Islander 
Caucasian 
African-Am
erican 
Asian-Pacific Islander 
Hispanic  
9. 
Please indicate your total household annual incom
e?
Less than $10,000 
$10,000 - $19,999 
$20,000-29,999 
$30,000-$39,999 
$40,000-$49,999 
$50,000-$59,999 
$60,000-$69,999 
$70,000-$79,999 
$80,000-$89,999 
$90,000-$99,999 
$100,000-$149,999 
+$150,000 
10. Please indicate if there is any history of the follow
ing conditions in your first degree relatives 
(father, m
other, siblings). Tick the box that applies to you. 
Condition 
N
o history 
Father 
M
other 
Sibling 
Heart disease, heart attack, heart 
failure, heart surgery 
Diabetes (Type 2) 
High blood pressure 
High cholesterol 
Breast cancer 
O
ther cancer (describe): 
11. Current sm
oking habits 
a. 
Current sm
oker – How
 m
any cigarettes per day?................................
b. 
Past sm
oker – How
 long since your last cigarette?.............................
c. 
N
ever sm
oked 
12. Current alcohol usage 
a. 
Som
e alcohol consum
ed each w
eek
b. 
N
o alcohol consum
ed 
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!!
Medical!information!collection!sheet!
!!!
FORM%&4&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&&Participant&#:&
Assessment&code:&&
& &
Please&fill&in&your&answer&in&the&far&right&hand&box&for&each&question.&
& & Answer&Here&
1.&Date&of&Diagnosis&(approximate)& (mm/yy)& &
2.&Date&of&surgery& Add&all&dates&if&you&have&
had&>1&surgery&
(mm/yy)&
&
&
&
3.&Description&of&tumour&
Stage&of&cancer&&
PLEASE&PROVIDE&
DIAGNOSTIC&INFO&FROM&
YOUR&ONCOLOGIST&
Stage&0,&Stage&I&&&Stage&IIA;&&
Stage&IIB,&&Stage&IIIA&
Size&of&tumour&(mm):&&
4.&When&did&you&complete&surgery,&
chemo&and/or&radiotherapy&
Please&be&specific&with&
date&(dd/mm/yy)&
&
5.&Type&of&breast&cancer& Please&circle&one&or&more&
of&the&options&
Oestrogen&Positive&&
Oestrogen&Negative&
HER2&+ve&
&6.&Type&of&Surgery&&
&
&If&yes,&please&circle&the&
type&(s)&of&surgery&you&
have&had&to&date.&
Mastectomy&
Double&Mastectomy&
Breast&Reconstruction&
Breast&Conservation&
7.&Did&you&have&lymph&nodes&
removed?&&
&
Please&indicate,&‘YES’&or&
‘NO’&&&the&total&number&
of&lymph&nodes&removed&
Yes&–&nodes&were&removed&
............nodes&were&removed&
No&–&nodes&weren’t&removed&
8.&Did&you&have&Chemotherapy&?& Please&indicate&‘Yes&or&
No’&&&the&type&of&
chemotherapy&agent(s)&
used&
YES&&&&&&&&NO&
&
Type........................................&
................................................&
9.&Did&you&have&Taxane&
chemotherapy&
E.g.&Taxol,&Paclitaxel,&
Onxal&
YES&&&&&&&NO&
&
10.&Menstrual&cycle&
Date&of&your&last&
menstrual&cycle:&&
&
Date:_______________&
&
And&circle&one&of&the&
options&that&best&relates&
to&your&menstrual&cycle&at&
this&time.&
Still&having&regular&menstrual&
cycles&
&
Having&intermittent&menstrual&
cycles&–&less&than&6&months&
apart&
&
Last&menstrual&cycle&was&6%12&
months&ago&
&
Last&menstrual&cycle&was&more&
than&12&months&ago&
11.&Had&you&experienced&
menopause&before&treatment&for&
breast&cancer?&
Please&answer&YES&or&NO& &
Yes&&&&&&&&&&&&&&&&&&&&&&&&&&&&&No&
12.&Did&you&experience&menopause&
during&treatment?&
Did&you&have&your&last&
menstrual&cycle&during&
chemotherapy?&
&
Yes&&&&&&&&&&&&&&&&&&&&&&&&&&&&&No&
13.&Are&you&currently&on&hormonal&
therapy&
Please&circle&one& NONE&&&&&&&&&&&&&&&&FEMARA&&&&&
ARIMIDEX&&&&&&&&&TAMOXIFEN&&&&
OTHER...............&
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Body!composition!and!Physical!Function!Collection!Sheet!
FO
RM
%8'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
Code'#:'
'
Tim
e'of'assessm
ent:'
Page2&
!
H
eight!
(m
)!
W
eight!
(kg)!
FFM
!
(kg)!
FFM
!!%
!
BFM
!
(kg)!
BFM
!%
!
W
aist!
(cm
)!
N
arrow
/'
M
idpoint!
H
ip!(cm
)!
!
M
easure!
1!
!
!
!
!
!
!
!
!
M
easure!
2!
!
!
!
!
!
!
!
!
M
easure!
3!
!
!
!
!
!
!
!
!
LTD
EX!
Trial!
1!
2!
3!
Average!
Affected!
arm
!(R/L)!
LTD
EX!–!!
N
orm
al/!
N
ot!
R:!Affected!
Xc:!
Affected!
R:!
U
naffected!
Xc:!
U
naffected!
!!!
!
!
!
!
!
!
Feelings!of!Energy!out!of!10:!!
G
rip!Strength!
R/L!D
om
inant!
Trial!1!
Trial!2!
Trial!3!
Average!
D
om
inant!arm
!
!
!
!
!
!
N
onTD
om
inant!arm
!
!
!
!
!
!
RH
R!
Blood!pressure!sitting!
Blood!pressure!standing!!
!
M
easure!
!!!
!
!
Treadm
ill!test!
!
Age!
M
ax!H
R!
85%
!M
ax!
!
Stage!&
!
start!
tim
e!
Speed!
G
rade!(%
)!
RPE!!
(last'5s'each'm
in)'
H
eart!Rate!
(last'5s'each'm
in)'
Signs!and!
Sym
ptom
s'
Final!
tim
e '
1'(0m
in)'
2.7!
0!
!
!
!
!
!
!
!
2!(3m
in)'
2.7!
5!
!
!
!
!
!
!
!
3(6m
in)'
2.7!
10!
!
!
!
!
!
!
!
4!(9m
in)'
4!
12!
!
!
!
!
!
!
!
5(12m
in)'
5.4!
14!
!
!
!
!
!
!
!
6(15m
in)'
6.7!
16!
!
!
!
!
!
!
!
!Assessm
ent!2!
! !
!
Com
m
ents!
PushTup!test!
!
!
SitTtoTstand!
!
!
FO
RM
%8'''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''''
Code'#:'
'
Tim
e'of'assessm
ent:'
Page1&
!Follow
!up!assessm
ents!
Caffeine!consum
ption!today:!!!!!!
!
YES!!
!
!!!!!!N
O
!
Feeling!(energy)!out!of!10:!!!!
!
!!!!!!!!!!1!!!2!!!3!!!4!!!5!!!6!!!7!!!8!!!9!!!10!
D
ate!of!last!illness:!
!
!
!!!!!!!!!!!!!!!!!!!!!!!!!!!/!!!!!!!!/!!!!!!!!!or!approx:!
!Food!and!drink!log!
M
eal!
Food!
Am
ount!
(w
eight,'cup,'
volum
e)'
Fluid!intake!(including'
m
ilk'on'cereal,'w
ater,'
tea,'N
O
'CO
FFEE/TEA)!
!!
Breakfast!
!!!!!
'
'
''''''''''
!!
M
orning!
tea!
!!!!
'
'
'
!
!
!
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!!!
QOL!Questionnaires!–!FACT>B+4!&!FACT>F!subscale!!
!!!!
FU
N
C
T
IO
N
A
L
 A
SSE
SSM
E
N
T
 of C
A
N
C
E
R
 T
H
E
R
A
PY
 
 
English (U
niversal) 
 
C
opyright  1987, 1997
 
 
Page 3 of 4 
Participant: 
A
x C
ode:  
 Please circle or m
ark one num
ber per line to indicate your response as it applies to the past 7 
days. 
   
A
D
D
IT
IO
N
A
L
 C
O
N
C
E
R
N
S 
N
ot at 
all 
A
 little 
bit 
Som
e-
w
hat 
Q
uite 
a bit 
V
ery 
m
uch 
 B1 
I have been short of breath ...................................................  
0 
1 
2 
3 
4 
B
2 
I am
 self-conscious about the w
ay I dress ............................  
0 
1 
2 
3 
4 
B
3 
O
ne or both of m
y arm
s are sw
ollen or tender .....................  
0 
1 
2 
3 
4 
B
4 
I feel sexually attractive .......................................................  
0 
1 
2 
3 
4 
B
5 
I am
 bothered by hair loss ....................................................  
0 
1 
2 
3 
4 
B
6 
I w
orry that other m
em
bers of m
y fam
ily m
ight 
som
eday get the sam
e illness I have ....................................  
 0 
 1 
 2 
 3 
 4 
B
7 
I w
orry about the effect of stress on m
y illness ...................  
0 
1 
2 
3 
4 
B
8 
I am
 bothered by a change in w
eight ...................................  
0 
1 
2 
3 
4 
B
9 
I am
 able to feel like a w
om
an .............................................  
0 
1 
2 
3 
4 
P2 
I have certain parts of m
y body w
here I experience pain .....  
0 
1 
2 
3 
4 
Q
6 
O
n w
hich side w
as your breast operation? 
 
Left 
R
ight 
(please circle one) 
B
10 
M
ovem
ent of m
y arm
 on this side is painful ...........................  0 
1 
2 
3 
4 
B
11 
I have a poor range of arm
 m
ovem
ents on this side ................  0 
1 
2 
3 
4 
B
12 
M
y arm
 on this side feels num
b ..............................................  0 
1 
2 
3 
4 
B
13 
I have stiffness of m
y arm
 on this side ....................................  0 
1 
2 
3 
4 
  
FO
R
M
 - 5  
FU
N
C
T
IO
N
A
L
 A
SSE
SSM
E
N
T
 of C
A
N
C
E
R
 T
H
E
R
A
PY
 
 
English (U
niversal) 
 
C
opyright  1987, 1997
 
 
Page 2 of 4 
Participant: 
A
x C
ode:  
Please circle or m
ark one num
ber per line to indicate your response as it applies to the past 7 
days. 
   
E
M
O
T
IO
N
A
L
 W
E
L
L
-B
E
IN
G
 
N
ot 
at all 
A
 little 
bit 
Som
e-
w
hat 
Q
uite
a bit 
V
ery 
m
uch 
 G
E1 
I feel sad ........................................................................................  
0 
1 
2 
3 
4 
G
E2 
I am
 satisfied w
ith how
 I am
 coping w
ith m
y illness ....................  
0 
1 
2 
3 
4 
G
E3 
I am
 losing hope in the fight against m
y illness ............................  
0 
1 
2 
3 
4 
G
E4 
I feel nervous .................................................................................  
0 
1 
2 
3 
4 
G
E5 
I w
orry about dying .......................................................................  
0 
1 
2 
3 
4 
G
E6 
I w
orry that m
y condition w
ill get w
orse ......................................  
0 
1 
2 
3 
4 
    
FU
N
C
T
IO
N
A
L
 W
E
L
L
-B
E
IN
G
 
 
N
ot 
at all 
A
 little 
bit 
Som
e-
w
hat 
Q
uite
a bit 
V
ery 
m
uch 
 G
F1 
I am
 able to w
ork (include w
ork at hom
e) ....................................  
0 
1 
2 
3 
4 
G
F2 
M
y w
ork (include w
ork at hom
e) is fulfilling ...............................  
0 
1 
2 
3 
4 
G
F3 
I am
 able to enjoy life ....................................................................  
0 
1 
2 
3 
4 
G
F4 
I have accepted m
y illness .............................................................  
0 
1 
2 
3 
4 
G
F5 
I am
 sleeping w
ell .........................................................................  
0 
1 
2 
3 
4 
G
F6 
I am
 enjoying the things I usually do for fun ................................  
0 
1 
2 
3 
4 
G
F7 
I am
 content w
ith the quality of m
y life right now
 ........................  
0 
1 
2 
3 
4 
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N
C
T
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N
A
L
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E
N
T
 of C
A
N
C
E
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A
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English (U
niversal)
C
opyright  1987, 1997
Page
1
of4
Participant: 
A
x C
ode:  
B
elow
 is a list of statem
ents that other people w
ith your illness have said are im
portant. Please circle 
or m
ark one num
ber per line to indicate your response as it applies to the past 7 days. 
PH
Y
SIC
A
L
 W
E
L
L
-B
E
IN
G
 
N
ot 
at all 
A
 little 
bit 
Som
e-
w
hat 
Q
uite
a bit 
V
ery 
m
uch 
G
P1 
I have a lack of energy ..................................................................
0 
1 
2 
3 
4 
G
P2 
I have nausea .................................................................................
0 
1 
2 
3 
4 
G
P3 
B
ecause of m
y physical condition, I have trouble 
m
eeting the needs of m
y fam
ily ....................................................
0 
1 
2 
3 
4 
G
P4 
I have pain .....................................................................................
0 
1 
2 
3 
4 
G
P5 
I am
 bothered by side effects of treatm
ent ....................................
0 
1 
2 
3 
4 
G
P6 
I feel ill ..........................................................................................
0 
1 
2 
3 
4 
G
P7 
I am
 forced to spend tim
e in bed ...................................................
0 
1 
2 
3 
4 
SO
C
IA
L
/FA
M
IL
Y
 W
E
L
L
-B
E
IN
G
 
N
ot 
at all 
A
 little 
bit 
Som
e-
w
hat 
Q
uite
a bit 
V
ery 
m
uch 
G
S1 
I feel close to m
y friends ...............................................................
0 
1 
2 
3 
4 
G
S2 
I get em
otional support from
 m
y fam
ily .......................................
0 
1 
2 
3 
4 
G
S3 
I get support from
 m
y friends .......................................................
0 
1 
2 
3 
4 
G
S4 
M
y fam
ily has accepted m
y illness ...............................................
0 
1 
2 
3 
4 
G
S5 
I am
 satisfied w
ith fam
ily com
m
unication about m
y 
illness ............................................................................................
0 
1 
2 
3 
4 
G
S6 
I feel close to m
y partner (or the person w
ho is m
y m
ain 
support) .........................................................................................
0 
1 
2 
3 
4 
Q
1 
Regardless of your current level of sexual activity, please 
answ
er the follow
ing question. If you prefer not to answ
er it, 
please m
ark this box           and go to the next section. 
G
S7 
I am
 satisfied w
ith m
y sex life ......................................................
0 
1 
2 
3 
4 
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Participant: 
A
x C
ode:  
Please circle or m
ark one num
ber per line to indicate your response as it applies to the past 7 
days. 
A
D
D
IT
IO
N
A
L
 C
O
N
C
E
R
N
S 
N
ot 
at all 
A
 little 
bit 
Som
e-
w
hat 
Q
uite 
a bit 
V
ery 
m
uch 
H
I7 
I feel fatigued .......................................................................
0 
1 
2 
3 
4 
H
I12 
I feel w
eak all over ...............................................................
0 
1 
2 
3 
4 
A
n1 
I feel listless (“w
ashed out”) ................................................
0 
1 
2 
3 
4 
A
n2 
I feel tired .............................................................................
0 
1 
2 
3 
4 
A
n3 
I have trouble starting things because I am
 tired ..................
0 
1 
2 
3 
4 
A
n4 
I have trouble finishing things because I am
 tired ...............
0 
1 
2 
3 
4 
A
n5 
I have energy ........................................................................
0 
1 
2 
3 
4 
A
n7 
I am
 able to do m
y usual activities .......................................
0 
1 
2 
3 
4 
A
n8 
I need to sleep during the day ..............................................
0 
1 
2 
3 
4 
A
n12 
I am
 too tired to eat ..............................................................
0 
1 
2 
3 
4 
A
n14 
I need help doing m
y usual activities ...................................
0 
1 
2 
3 
4 
A
n15 
I am
 frustrated by being too tired to do the things I w
ant 
to do ......................................................................................
0 
1 
2 
3 
4 
A
n16 
I have to lim
it m
y social activity because I am
 tired ............
0 
1 
2 
3 
4 
---------------------------------------------------------------End of Q
uestionnaire--------------------------------------------------------------- 
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Health!Assessment!Questionnaire!–!Disease!Index!(HAQ>DI)!!
!
HEALTH ASSESSM
ENT QUESTIONNAIRE (HAQ-DI)© 
  
N
am
e: ____________________________________________ 
 
D
ate:  ____________________ 
  Please place an “x” in the box which best describes your abilities OVER THE PAST W
EEK: 
  
W
ITH
O
U
T
 A
N
Y
 
W
ITH
 S
O
M
E
 
W
ITH
 M
U
C
H
 
U
N
A
B
LE
 
 
  D
IFFIC
U
LTY
 
D
IFFIC
U
LTY
 
D
IFFIC
U
LTY
 
  TO
 D
O
 
DRESSING & GROOM
ING 
 Are you able to: 
   D
ress yourself, including shoelaces and buttons? 
 
   S
ham
poo your hair? 
 ARISING 
 Are you able to: 
   S
tand up from
 a straight chair? 
 
 
 
   G
et in and out of bed? 
 
 
 
 EATING 
 Are you able to: 
   C
ut your ow
n m
eat? 
 
 
 
   Lift a full cup or glass to your m
outh? 
 
 
 
   O
pen a new
 m
ilk carton? 
 
 
 
 W
ALKING 
 Are you able to: 
   W
alk outdoors on flat ground? 
 
 
 
   C
lim
b up five steps? 
 
 
 
  Please check any AIDS OR DEVICES that you usually use for any of the above activities: 
       D
evices used for D
ressing 
B
uilt up or special utensils 
C
rutches 
      (button hook, zipper pull, etc.) 
 
 
C
ane 
 
W
heelchair 
  
S
pecial or built up chair 
W
alker 
 
 
 Please check any categories for which you usually need HELP FROM
 ANOTHER PERSON: 
  
D
ressing and groom
ing 
A
rising 
E
ating 
W
alking 
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Please place an “x” in the box which best describes your abilities OVER THE PAST W
EEK: 
   
W
ITH
O
U
T
 A
N
Y
 
W
ITH
 S
O
M
E
 
W
ITH
 M
U
C
H
 
U
N
A
B
LE
 
 
  D
IFFIC
U
LTY
 
D
IFFIC
U
LTY
 
D
IFFIC
U
LTY
 
  TO
 D
O
 
HYGIENE 
 Are you able to: 
   W
ash and dry your body? 
 
 
 
   Take a tub bath? 
 
 
 
   G
et on and off the toilet? 
 
 
 
 REACH 
 Are you able to: 
   R
each and get dow
n a 5 pound object (such as 
  a bag of  sugar) from
 above your head? 
 
 
 
   B
end dow
n to pick up clothing from
 the floor? 
 
 
 
 GRIP 
 Are you able to: 
   O
pen car doors? 
 
 
 
   O
pen previously opened jars? 
 
 
 
   Turn faucets on and off? 
 
 
 
 ACTIVITIES 
 Are you able to: 
   R
un errands and shop? 
 
 
 
   G
et in and out of a car? 
 
 
 
   D
o chores such as vacuum
ing or yard w
ork? 
  Please check any AIDS OR DEVICES that you usually use for any of the above activities: 
       R
aised toilet seat 
B
athtub bar 
Long-handled appliances for reach 
  
B
athtub seat 
Long-handled appliances 
Jar opener (for jars previously opened) 
 
 
in bathroom
 
 
 
 
 
 Please check any categories for which you usually need HELP FROM
 ANOTHER PERSON: 
  
H
ygiene 
R
each 
G
ripping and opening things 
E
rrands and chores 
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Greene!Climacteric!Scale!Questionnaire!
Your ACTIVITIES
:  To w
hat extent are you able to carry out your everyday physical activities such as w
alking, 
clim
bing stairs, carrying groceries, or m
oving a chair? 
C
O
M
P
LE
TE
LY
 
M
O
S
TLY
 
M
O
D
E
R
A
TE
LY
 
A
 LITTLE
 
N
O
T A
T A
LL 
Your PAIN
:  H
ow
 m
uch pain have you had IN
 TH
E
 P
A
S
T W
E
E
K
?   
O
n a scale of 0 to 100 (w
here zero represents “no pain” and 100 represents “severe pain”), please record the 
num
ber below
. 
Your HEALTH
:  P
lease rate how
 w
ell you are doing on a scale of 0 to 100 (0 represents “very w
ell” and 100 
represents “very poor” health), please record the num
ber below
. 
- 3 -  
The M
.O.D
.E
.L. Study    
The G
reene C
lim
acteric Scale 
 Please indicate the extent to w
hich you are bothered at the m
om
ent by any of these 
sym
ptom
s by placing a tick in the appropriate box. 
(Tick one box for each item
) 
Not at all 
A little 
Quite a bit 
Extrem
ely 
a 
H
eart beating quickly or strongly 
b  Feeling tense or nervous 
c 
D
ifficulty in sleeping 
d 
Excitable 
e 
Attacks of panic 
f 
D
ifficulty in concentrating 
g 
Feeling tired or lacking in energy 
h Loss of interest in m
ost things 
i 
Feeling unhappy or depressed 
j 
Crying spells 
k 
Irritability  
l 
Feeling dizzy or faint 
m
 Pressure or tightness in head or body 
n Parts of body feel num
b or tingling 
o 
H
eadaches
p 
M
uscle and joint pains 
q 
Loss of feeling hands or feet 
r 
Breathing difficulties 
s 
H
ot flushes 
t 
Sw
eating at night 
u Loss of interest in sex 
G
reen, J. G
., Constructing a standard clim
acteric scale. M
auritas, 1998. 29:p. 25-31. 
Participant #
: 
Ax Code #
:  
FO
RM
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Active!Australia!Survey!!!
!
The$M
.O.D
.E
.L.$Study$
!!!T
h
e!A
ctive!A
u
stralia!Su
rvey!
$Physical A
ctivity Q
uestionnaire 
 These questions are designed to determ
ine how
 m
uch physical activity you have 
perform
ed in the last w
eek. 
 - A
nsw
er all questions in relation to the last w
eek (7 days) 
        The A
ctive A
ustralia Survey  
T
h
e n
ext q
u
estion
s are ab
ou
t an
y p
h
ysical activities th
at you
 m
ay h
ave d
on
e in
 th
e 
last w
eek
:  
 1. In the last w
eek, how
 m
any tim
es have you w
alked continuously, for at least 10 
m
inutes, for recreation, exercise or to get to or from
 places?  
  
Tim
es 
  2. W
hat do you estim
ate w
as the total tim
e that you spent w
alking in this w
ay in the 
last w
eek?  
 
In
 h
ou
rs an
d
/or m
in
u
tes  
 
m
inutes  
 
hours  
   3. In the last w
eek, how
 m
any tim
es did you do any vigorous gardening or heavy w
ork 
around the yard, w
hich m
ade you breathe harder or puff and pant?  
  
tim
es 
 
Initials:$
Code$#:$$
FORM$8$13$$
3
4. 
W
hat do you estim
ate w
as the total tim
e that you spent doing vigorous gardening or
heavy w
ork around the yard in the last w
eek?
In hours and/or m
inutes
m
inutes
hours
The next questions exclude household chores, gardening or yardw
ork:
5. 
In the last w
eek, how
 m
any tim
es did you do any vigorous physical activity w
hich m
ade
you breathe harder or puff and pant? (e.g. jogging, cycling, aerobics, com
petitive tennis)
tim
es
6. 
W
hat do you estim
ate w
as the total tim
e that you spent doing this vigorous physical
activity in the last w
eek?
In hours and/or m
inutes
m
inutes
hours
7. 
In the last w
eek, how
 m
any tim
es did you do any other m
ore m
oderate physical
activities that you have not already m
entioned? (e.g. gentle sw
im
m
ing, social tennis,
golf)
tim
es
 xxiii 
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4
8. 
W
hat do you estim
ate w
as the total tim
e that you spent doing these activities in the last
w
eek?
In hours and/or m
inutes
m
inutes
hours
To w
hat extent do you agree or disagree w
ith the follow
ing statem
ents about physical
activity and health?
9(a) Taking the stairs at w
ork or generally being m
ore active for at least 30 m
inutes each day
is enough to im
prove your health.
strongly
disagree
disagree
neither agree
nor disagree
agree
strongly agree
9(b) H
alf an hour of brisk w
alking on m
ost days is enough to im
prove your health.
strongly
disagree
disagree
neither agree
nor disagree
agree
strongly agree
9(c) To im
prove your health it is essential for you to do vigorous exercise for at least
20 m
inutes each tim
e, three tim
es a w
eek.
strongly
disagree
disagree
neither agree
nor disagree
agree
strongly agree
9(d) Exercise doesn’t have to be done all at one tim
e—
blocks of 10 m
inutes are okay.
strongly
disagree
disagree
neither agree
nor disagree
agree
strongly agree
9(e) M
oderate exercise that increases your heart rate slightly can im
prove your health.
strongly
disagree
disagree
neither agree
nor disagree
agree
strongly agree
 xxiv 
Participant!Data!Collection!Package!–!Day!2!to!7!
Home!data!collection!instructions!
!
!
Thank!you!for!being!part!of!this!study,!
Congratulations!on!completing!the!first!day!of!your!baseline!measures!for!the!MODEL!study.!
Over!the!next!week!there!are!two!very!important!things!you!need!to!do!before!coming!back!for!the!
final!day!of!your!baseline!measures.!
1.#Wear#your#accelerometer#as#much#as#possible#during#the#waking#hours#of#the#
day#–#as#described#in#your#accelerometer#journal.#
2.#Plan#to#have#a#fasting#blood#sample#taken#at#your#nearest#Healthscope#Pathology#
branch#within#the#next#7#days#
3.#Please#complete#the#Diet#History#Questionnaire#in#one#sitting.#Fill#the#form#out#
whilst#thinking#about#your#food#intake#over#the#last#month#
Your%accelerometer%package%
Inside!your!initial!package,!you!will!find!the!accelerometer!journal!that!includes!instructions!
and!2!tables!to!fill!out!through!the!week.!
Table!1!is!used!to!record!when!you!wear!your!accelerometer;!Table!2!is!for!reporting!the!
amount!of!time!spent!performing!activities!labelled!in!the!boxes.!!
Taking%your%blood%sample%
Take!the!Healthscope!form!provided!in!this!package!to!the!closest!Sullivan!&!Nicolaides!
Pathology!lab.!
The!test!will!involve!collection!10M20ml!of!blood!that!is!similar!to!a!routine!blood!test.!
The!addresses!of!the!laboratories!are!listed!on!the!sheet!attached!
Please!ensure!that!for!the!test!you:!
M Have!not!eaten!prior!to!the!blood!being!taken!
M Take!a!snack!to!consume!after!the!blood!test!
M Do!not!perform!any!vigorous!exercise!the!morning!of!the!test!
M Are!not!planning!any!heavy!lifting!for!the!next!24!hours!
Next#week...#
You!will!be!performing!some!muscular!endurance!tests!and!we!will!go!through!your!diet!
history!form!M!that!will!take!around!30!minutes.!You!will!also!hand!in!your!accelerometer!
and!be!given!your!first!month’s!batch!of!capsules!to!start!consuming.!
See!you!then,!!
Cam!McDonald!!
0411380566!!
UQbreastcancerstudy@gmail.com!!
 xxv 
Healthscope!Pathology!Blood!Analysis!Request!Form!!
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Accelerometer!Manual!and!Wear!time!journal!
Instructions for Accelerometer Diary 
What your accelerometer is measuring. 
The accelerometer is designed to measure how much, and how intensely 
you move during the day. This information will give you an indication of 
how much energy you expend. 
Please wear the accelerometer as much as possible during waking hours. 
Do not wear it swimming, in the shower or where it may get wet! 
How to wear your 
accelerometer 
Using the strap provided, wear 
the accelerometer at the front of 
your right hip. Make sure the 
strap is tight enough to not fall, 
but not so tight that it is 
uncomfortable 
Below are further explanations for completing the accelerometer 
journal 
Wake Up Time: The time you get out of bed in the morning 
Accelerometer Attached: The time at which you attach the 
accelerometer to your waist 
Accelerometer removed: Time at which the accelerometer is removed 
Multiple attach and remove: If you take the accelerometer off through 
the day please indicate the time on and time off. 
Time in bed:  Time you get into bed for the night 
Accelerometer Instructions 
and Journal 
Cameron McDonald  
P: 0411380566   
E: UQbreastcancerstudy@gmail.com 
How to wear your accelerometer 
1. Aim for 10 hours per day as a minimum
2.  It’s  ok  if  you  miss  a  day! 
3. Make sure it is comfortable – options for placement: 1. Strapped on 
top of your belt (in line with the middle of your thigh); 2. At your 
waistline in the middle of your back (if option 1 is uncomfortable) 
i) The most important thing is to keep the position consistent.
4. You can wear it under or on top of your clothes
5. Try to wear it on at least one weekend day 
6.  If  you  are  going  out  at  night  and  don’t  want  to  wear  it,  thats  ok.  Aim  to
wear it for 10 hours before that time! 
7.  You  don’t  have  to  wear  it  to  bed.  But  keep  it  on  the  dresser!
Table 1 Accelerometer usage 
Day No. 1 2 3 4 5 6 7 
Actual Day 
E.g. Monday 
Hours of sleep 
(previous night) 
Wake Up Time 
Accelerometer 
attached 
Accelerometer 
removed 
Accelerometer 
attached 
Accelerometer 
removed 
Accelerometer 
attached 
Accelerometer 
removed 
Time in bed 
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How much exercise are you performing – use this chart to record your organised exercise each day
Day No. 
1 2 3 4 5 6 7 
Vigorous 
exercise (mins) 
e.g.  
Brisk walk – 25 
mins +  
heavy gardening- 
60 mins 
 
       
 
 
Moderate 
exercise (mins) 
e.g. slow walk – 
20mins  
       
 
 
Vigorous exercise: Physical activity that includes brisk walking, jogging, swimming, weight training, hard cycling, heavy 
gardening or housework that makes you breath harder and puff. 
 
Moderate exercise: More gentle activity that is not as intense as vigorous exercise, some examples but not limited to: 
E.g. slow walking, social tennis, gentle cycle or swimming, golf. 
 
 xxviii 
Diet%History%Questionnaire%
The MODEL Study                                             
 
Diet History Questionnaire  
Created by: Smart Foods Centre University of Wollongong   
 
 
Please complete the following pages while thinking about 
your average week of food over the last month. 
 
Try to complete the entire questionnaire in one or two sittings. Don’t spread entry out over the week. 
 
Work through the booklet one meal at a time, and anything that happens once a month or 
more frequent than that should be included. 
 Current'Medications:___________________________________________________________________________________________' ''Supplements:'_________________________________________________________________________________________________''Office'use:'Interviewer:'_________________''''Interview'number:'____________''''Date:'_____________''
Partici
pant'
#:' Ax'Cod
e:'
xxix 
Part'1:'Breakfast'How'often'do'you'eat'breakfast?'__________________________'
Breakfast%Cereals/Porridge'
Prompts% Type% Frequency%Corn'Wheat'Rice'Muesli'Oats'
Milk'Type:'____________________________________' Serving'size:'________________'mls/cups' Frequency:'___________'Sugar/Sweetener:'__________________________' ' Serving'size:'________________'tsp' Frequency:'___________'
Bread/Toast/Muffins%including%toppings'
Prompts% Type% Serving%size% Frequency%White'bread'Wholemeal'bread'Rye'bread'Soy'&'Linseed'bread'Raisin'bread'Muffins'Crumpets'
 xxx 
Prompts%% Type% Serving%size% Frequency%%White'bread' % ' 'Wholemeal'bread' ' ' 'Croissants'''''
' ' '
''
Hot/Cooked%Dishes'%
Prompts%% Type% Serving%size% Frequency%%Scrambled'eggs' % ' 'Fried'eggs' ' ' 'Poached'eggs' ' ' 'Boiled'eggs' ' ' 'Bacon' ' ' 'Baked'beans' ' ' 'Pancakes' ' ' 'Sausages' ' ' 'Hash'browns' ' ' '
% ' ' '
% ' ' '
% *****%SALT%*****' ' ''Type'of'oil/fat'used'in'cooking:'_______________________________' ' Serving'size:'________________________________''Tea,'coffee'and'other'drinks'(hot'chocolate,'fruit'juice,'smoothie)''
 xxxi 
Type:_______________________________________________________________________________' Frequency:_____________''' _________________________________________________________________________________________________________'Frequency:_____________''Other'Foods'
Prompts%% Type% Serving%size% Frequency%%Yoghurt' % ' 'Fruit'salad' ' ' 'Cereal'Bars' ' ' 'Protein'shakes' ' ' 'Protein'powder' ' ' '' ' ' '' ' ' '
% ' ' '
%
 xxxii 
Part%2:%Morning%Tea%
%
Prompts% Type% Serving%size% Frequency%%Tea'Coffee'Juice'Flavoured'milk'Yoghurt'
% ' '
Fruit' ' ' 'Biscuits' ' ' 'Cake' ' ' 'Cereal'bars' ' ' 'Muffins' ' ' 'Chocolate' ' ' ''''''
' ' '
' ' ' '' ' ' '' ' ' ''''''''
' ' '
xxxiii 
Prompts% Type% Serving%size% Frequency%Tea'Coffee'Juice'Flavoured'milk'Yoghurt'Fruit'
xxxiv 
Part%3:%Lunch''Sandwiches/Rolls'
Prompts% Type%of%Bread/Roll% Serving%size% Frequency%White'roll/bread'Wholemeal'roll/bread'Multigrain'bread'Rye'bread'Lebanese'bread'Pita'bread'Turkish'bread'
Fillings/Toppings'
Prompts% Type% Serving%size% Frequency%Meat/ham/chicken'Burger'meat'Cheese'Vegemite'Jam'Honey'Salad'Mayonnaise'
 xxxv 
Salads''
Prompts%% Type% Serving%size% Frequency%%Mixed'green' % ' 'Potato'salad' ' ' 'Coleslaw' ' ' 'Greek'salad' ' ' '
Caesar%salad% ' ' 'Bean'salad'' ' ' '
Tabouleh% ' ' 'Pasta'salad''''''
'' ' '
% ' ' '' *****%SALT%******' ' ''
Soups%'
Prompts%% Type% Serving%size% Frequency%%Minestrone'soup' % ' 'Pea'&'ham'soup' ' ' 'Potato'&'leek'soup' ' ' 'Chicken'soup' ' ' 'Cuppa'soup' ' ' 'Vegetable'soup' ' ' 'Pumpkin'soup' ' ' '' ' ' '
xxxvi 
Hot'Meals'(home'prepared)'
Prompts% Type% Serving%size% Frequency%Fish'Chicken'Meat'Spaghetti'Bolognaise'Pasta'
Takeaway'foods'Pies'Pizza''Hamburgers'
Hot%chips%
*****%SALT%******'
xxxvii 
Prompts% Type% Serving%size% Frequency%Fish'Chicken'
Tea,%coffee,%juice,%soft%drink,%cordial%etc'''Type:'_____________________________________________________________' Frequency:____________________________'Type:_____________________________________________________________' Frequency:____________________________'Other'Foods'
Type% Serving%size% Frequency%
xxxviii 
Part%4:%Afternoon%Tea%
Prompts% Type% Serving%Size% Frequency%Tea'Coffee'Juice'Flavoured'milk'Yoghurt'Fruit'Biscuits'Cake'Cereal'bars'Muffins'Chocolate'
xxxix 
Prompts% Type% Serving%Size% Frequency%Tea'Coffee'Juice'Flavoured'milk'Yoghurt'Fruit'
xl 
Part%5:%Dinner%
Prompts% Type%,%serving%size,%cooking%method% Frequency%Meat'(steak)'Chicken'Fish'Schnitzel'Pasta'Spaghetti'Bolognaise'Lasagne''Stir'fries'Casseroles'Stews'Soups'Risotto''Quiche'
Accompaniments'Potato'Vegetables%%Accompaniments'Potato'Vegetables%%Mash'Wedges'Rice'Cous'cous'Salads'
xli 
Prompts% Type%,%serving%size,%cooking%method% Frequency%Meat'(steak)'Chicken'
Tea,%coffee,%juice,%soft%drink,%cordial%etc'''Type:___________________________________________________________________' Frequency:______________________'Type:___________________________________________________________________' Frequency:______________________'Type:___________________________________________________________________' Frequency:_______________________'
xlii 
Desserts'
Prompts% Type% Serving%size% Frequency%Ice'cream'Fruit'Apple'pie'Crumbles'Cake'Pudding'Lamingtons'Cookies'Biscuits'
xliii 
%Part%6:%Evening%Snack%Foods%
Prompts% Type% Serving%size% Frequency%Tea'Coffee'Juice'Flavoured'milk'Yoghurt'Fruit'Biscuits'Cake'Cereal'bars'Muffins'Chocolate'
xliv 
Part%7:%Takeaway/Restaurant%Meals%
Prompts% Type% Serving%size% Frequency%
McDonald’s%'quarter'pounder'burger'fries'shake'Kentucky'Fried'Chicken'fried'chicken'roast'chicken'nuggets'fries'Pizza'pan'thin[based'toppings'soft'drink%Asian'food'Chinese'Japanese'Thai'Vietnamese%Fish'and'chips'battered'and'fried'grilled'potato'scallops'fries'Other''
 xlv 
Prompts%% Type% Serving%size% Frequency%%
McDonald’s% % ' ''quarter'pounder' ' ' 'soft'drink'Indian'food'Italian'food'Mexican'food'
%
' ' '
%
xlvi 
Part%8:%Food%Frequency%Checklist%(only%tick%required%if%accounted%for)%
Type%of%food% Serving%size% Frequency%Milk/Flavoured'Milk'Fruit'Fruit'juice'Softdrinks/cordials'Alcohol'Yoghurt'Cheese'Ice'creams'
Crispbreads/crackers%
Biscuits%
Cakes/Scones%
Chocolate%
Chips%
Lollies%
xlvii 
Omega[rich'foods'
Type%of%food% Serving%size% Frequency%
Walnuts%Pecans'
Mixed%Nuts%Omega'eggs'Gold’n'Canola'margarine'Salmon'Tuna'Canned'tuna/salmon'Mackerel'White'fish'varieties'Oysters'Other'fish'
Linseed%or%flaxseed%oil%
Red%clover%
Seeds%Soy[rich'foods''Soy'and'Linseed'Bread'and'Muffins'Soy'milk'Soy'beans'Flavoured'soy'drinks'Soy'enriched'cereals'
Tofu%
Tempeh%
Soy%sauce%
Soy%snacks%
Soy%yoghurt%Soy'meat'products'Soy'cheese'Soy'ice'cream'
xlviii 
Part%9:%Food%Preparation%Practices%
6.1%Butter/Margarine%____________________________________%%%_____________________________________________________%What'type'do'you'usually'use?'Butter' e) Margarine'['monounsaturated,'regular h) Canola'margarineDairy'Blend' f) Margarine'['monounsaturated,'reduced'fat i) Gold’n'CanolaMargarine'['polyunsaturated,'regular' g) Margarine'['polyunsaturated,'reduced'fat j) Soy'margarine6.2'Oil/Fat'in'Cooking___________________________________''''_____________________________________________________'What'type'of'oil/fat'do'you'use'in'cooking?'Butter' h) Olive'oilDairy'blend' i) Canola'oilMargarine'['polyunsaturated,'regular' j) Soybean'oilMargarine'['polyunsaturated,'reduced'fat' k) Gold’n'CanolaMargarine'['monounsaturated,'regular' l) Other'vegetable'oil' ____________________________________________Margarine'['monounsaturated,'reduced'fat' 'Lard'or'dripping'
6.3%Fat%on%Meats/Chicken________________________________%How'much'fat'is'trimmed'from'meat'before'cooking/eating?'None'25%'50%'75%'All'
_____________________________________________________'How'much'skin'do'you'eat'on'chicken?''None'25%'50%'75%'All'Other,'please'specify:'''______________________________'
6.4%Salt_______________________________________________%All'the'time'during'cooking'All'the'time'at'the'table'Some'of'the'time'during'cooking'Some'of'the'time'at'the'table'What'do'you'consider'to'be'a'serve'of'salt?''__________________'
_____________________________________________________'Never'during'cooking'Never'at'the'table'I'don’t'use'salt'at'all'
xlix
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!!
Thanks!for!participating!in!‘The!MODEL!Study’:!a!nutrition!and!exercise!program!for!women!after!
treatment!for!breast!cancer.!
We!greatly!appreciate!your!participation!in!this!trial!as!the!information!gathered!will!be!used!to!
further!the!health!of!breast!cancer!survivors!both!in!Australia!&!internationally.!!
You!have!been!allocated!into!the!following!group:!!
Daily!capsule!consumption!
You!will!be!required!to!consume!capsules!containing!omegaI3!fatty!acids!for!the!next!6!months.!!
Below!are!details!of!your!study!commitments!for!the!next!6!months!
!
PLEASE!RETURN!ALL!BOTTLES!WHEN!YOU!HAVE!FINISHED!THEM!(They!will!be!collected!at!12!and!24!
wk!assessments,!or!in!between!if!convenient)!
!
Ongoing!assessments!
12!&!24!weeks:! After!12!and!24!weeks,!you!are!asked!to!repeat!the!baseline!testing!that!you!
have!just!completed.!!
Important!dates:! 12!week!testing:!TBA;!24!week!testing:!TBA!!
Capsule!consumption!
Dose:! ! ! 5!capsules!per!day!
Method!of!intake:!! It!is!best!if!the!capsules!are!consumed!around!the!time!of!any!meal,!they!can!
be!divided!into!multiple!doses!throughout!the!day,!or!be!taken!all!at!one!
time.!! !
Storage!of!capsules:! Please!keep!the!capsules!in!a!cool,!dry,!and!dark!location.!It!is!appropriate!to!
keep!the!capsules!in!the!fridge.!!
Adverse!reactions:! If!there!are!any!severe!effects!like!swelling!in!the!throat,!rash,!hives!and!
others!please!contact!your!doctor!immediately.!In!addition,!please!notify!
research!staff!as!soon!as!it!is!convenient!for!you.!
Your!supply!of!capsules!
Pick!up:! You!will!be!required!to!pick!up!a!supply!of!capsules!every!month!over!the!
next!6!months.!Your!first!pick!up!has!occurred!already.!You!will!receive!
notice!about!when!to!come!and!pick!up!your!capsules.!
!
Location:! Level!8,!East!Wing,!The!Wesley!Hospital,!Auchenflower.!I.e.!Where!the!initial!
tests!were!carried!out!for!the!study.!Can!arrange!to!do!a!driveIby!pick!up.!
Miss!a!session:! If!you!know!you!cannot!make!it!in!time!to!refill!your!capsules!please!contact!
Cameron!as!soon!as!you!are!aware!of!this!and!other!arrangements!will!be!
made.!
If!you!have!any!queries!or!comments,!please!contact!the!study!coIordinator,!Cameron!McDonald,!
using!the!following!details:!
!
Ph:!0411380566;!Email:!UQbreastcancerstudy@gmail.com!!
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You$have$been$allocated$into$the$following$group:!$
Daily!capsule!consumption!and!participation!in!a!specialised!nutrition!and!exercise!
program!
Owing$to$the$nature$of$this$research$study,$both$you$and$those$people$guiding$you$through$this$
intervention$do$not$know$if$you$are$to$be$taking$the$omega<3$fatty$acid$capsules,$or$the$placebo$
(fake$omega<3)$oil.$This$will$be$revealed$only$after$all$participants$have$completed$the$study.$$
PLEASE!RETURN!ALL!BOTTLES!WHEN!YOU!HAVE!FINISHED!THEM!(They!will!be!collected!at!12!and!
24!wk!assessments,!or!in!between!if!convenient)!
Below$are$details$of$your$study$commitments$for$the$next$6$months$
Capsule!consumption!
Dose:$ $ $ 5$capsules$per$day$
Method$of$intake:$$ It$is$best$if$the$capsules$are$consumed$around$the$time$of$any$meal,$they$can$
be$divided$into$multiple$doses$throughout$the$day,$or$be$taken$all$at$one$
time.$$ $
Storage$of$capsules:$ Please$keep$the$capsules$in$a$cool,$dry,$and$dark$location.$It$is$appropriate$to$
keep$the$capsules$in$the$fridge.$$
Adverse$reactions:$ If$there$are$any$severe$effects$like$swelling$in$the$throat,$rash,$hives$and$
others$please$contact$your$doctor$immediately.$In$addition,$please$notify$
research$staff$as$soon$as$it$is$convenient$for$you.$
!
The!12Sweek!intervention!
Attendance:$ The$nutrition$and$exercise$program$will$have$9$education$and$exercise$
sessions$starting$next$week$continuing$over$the$next$12$weeks.$$
$
Duration:$$ Each$session$will$be$60<75min$in$duration$&$will$include$exercise.$
Clothing:$$ Wear$light,$comfortable$clothing$and$a$supportive$sports$shoe$
Location:$ Level$8,$East$Wing,$The$Wesley$Hospital,$Auchenflower.$I.e.$where$the$initial$
tests$were$carried$out$for$the$study.$
What$to$bring:$ Pen$or$pencil$and$notebook$if$you$would$like$to$make$additional$notes$
Parking:$ Will$be$covered$as$per$normal$
Miss$a$session:$ If$you$know$you$cannot$make$a$particular$session,$let$Cameron$know$as$
soon$as$possible,$and$other$arrangements$will$be$made.$It$is$hoped$you$can$
attend$every$session.$
If$you$have$any$queries$or$comments,$please$contact$the$study$co<ordinator,$Cameron$McDonald,$
using$the$following$details:$
Ph:$0411380566;$Email:$UQbreastcancerstudy@gmail.com$
$
$ $
Session$ 1$ 2$ 3$ 4$ 5$ 6$ 7$ 8$ 9$
Projected$
dates$
31/1/13$ TBA$ TBA$ TBA$ TBA$ TBA$ TBA$ TBA$ TBA$
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Introduction 
Healthy eating habits and exercise are vital components to an optimal recovery after 
treatment for breast cancer.  
The effects of the treatment and other factors place strain on your body, and these 
strains may be lessened through healthy lifestyle habits. 
A diet rich in nutrients, providing adequate energy for the working cells and regular 
physical activity improve the health of your heart, muscles, brain and immune system. In 
addition, these habits have been shown to reduce the feelings of fatigue, improve 
feelings of well-being and help you perform your daily functions. 
The MODEL program is one that is designed to improve the lifestyles of women who have 
completed treatment for breast cancer. 
The program is designed to educate you on how to include healthy foods in your diet and 
how to safely increase your fitness and strength through endurance and resistance 
exercise training. 
Areas of focus for the program 
Food and nutrition related 
- General healthy eating  
- Mindful eating 
- Inclusion of fruit and vegetables 
- Healthy meat choices 
- Identification of foods to reduce 
- Breast cancer related nutrition – the 
latest science on nutrients 
- Healthy cooking tips and meal fat 
reduction 
Exercise related content 
- Starting and progressing both 
endurance and strength training 
programs 
- Weekly supervised exercise sessions 
- Safety in exercising for risk of 
lymphoedema 
- Increasing physical activity throughout 
the day 
- Learning how to further your own 
program 
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How Breast Cancer and  it’s  Treatment  Affect  the  Body 
 
Both diagnosis and treatment of breast cancer take a serious toll on the body and the 
spirit. Sometimes knowing why your body is behaving the way it is gives you some relief 
in that, firstly, you are not the only ones experiencing what you are experiencing, 
secondly, there are things we can do to help! 
Below is just a small list of the issues that may affect you after treatment: 
 
 
 
Fatigue and Lethargy  
Chemotherapy and radiation therapy are known to be taxing on 
the body, and partially toxic to the muscles. 
When the muscles are damaged this can lead to a significant 
amount of fatigue. 
In addition, it may make you feel like doing less, and this lower 
level of activity increases the feeling of fatigue – it’s  a  vicious  
cycle. 
In particular, Taxane chemotherapies seem to cause significant 
muscle weakness and tiredness in the leg muscles. Currently, the 
only way to reduce this is through exercise. 
 
Reduced movement 
in the arms 
The treatment to your lymph nodes can cause what is called 
‘cording’,  where  it  feels  like  there  are  thick  bands  of  tissue  
limiting your movement. This is common, and a physio + regular 
movement can assist in improving this. 
 
 
Weight gain and loss 
of muscle tone 
Even when you have been active, and have been careful with 
your food weight gain is still very common. 
Currently, it is not completely understood why this weight gain 
occurs. 
After treatment for breast cancer, the majority of women put on 
weight even when being careful with their food intake. A 
combined approach of exercise and diet is key. 
 
Lasting effects on 
your metabolism 
Breast  cancer  and  it’s  treatments  can  cause  a  change  in  your  
body in regards to heart disease and diabetes. If these changes 
are left unchecked, it can result in a faster development time of 
these conditions. A healthy lifestyle is essential for reducing 
these changes, and therefore lowering your risk of those 
diseases. 
 
Participating in regular exercise, while it may seem difficult at the start, is one of the only 
ways we know that will reduce fatigue, prevent muscle loss, improve arm mobility, and 
improve your metabolism. Healthy eating is an important consideration in maximising 
the effects of exercise, and should be considered essential for a long post-treatment 
period. 
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Week 1 - Introduction to healthy eating, exercise & stretching 
The purpose of the first session is to help you understand the overarching principles of 
healthy eating and exercise. 
It is understood that a large number of people know the majority of this information, 
however we often do not put it into practice. 
There are certain nutrients that your body needs, and a certain amount of physical 
activity that will greatly improve your health. Just by increasing the consumption of these 
foods, and performing some exercise above what you are doing currently will improve 
your health. 
Use the following as a checklist of things, and try and achieve one or two more things 
each week 
Basic Healthy Food Choices Checklist 
x 2 pieces of Fruit per day
x 2 meals containing vegetables
x Wholegrain choices
x Handful of nuts
x Lower fat dairy options
x Lean meat choices with the
inclusion of meat alternatives
x Enjoy extra foods mindfully
x Alcohol in moderation
Exercise & Movement 
              
 
x Increased energy levels
x Maintenance of healthy weight
x Healthy blood pressure, sugar
levels, cholesterol
x Better recovery from exercise
x Muscle mass, strength, power
x Cardio-respiratory fitness
x Better sleep
x Physical activity levels
x Flexibility
x Improves your immune system
x Body image, self-esteem and mood
Tactics for moving more 
Active transport 
-Get off the bus a stop earlier  
-Take the stairs instead of the lift  
-Park the car further away at the 
supermarket  
Active Excuses 
-Throw away the TV remote control  
-Enjoy a walking lunch  
-Take the dog for a walk 
-Meet up for a walk and a coffee   
-Walk the children or grandchildren to 
school 
o 3 exercise sessions this week
o 2 Aerobic sessions
o At least 1 resistance session
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Week 1 Activity: Your food checklist 
 
Over the next week, start taking note of the choices you are making with your food. Use 
this practical activity as a starting point that will increase your awareness, and guide you 
as to which foods to include more of. 
Tick it off if you have feel you have reached the goal for each of the foods on the 
checklist. 
Your Exercise checklist 
 
Day 
Fruit     
2 piece 
Veg 
5 serve 
>75% 
Wholegrain 
Low fat 
dairy 
Lean 
meat 
Nuts Legumes 
1 
       
2 
       
3 
       
4 
       
5 
       
6 
       
7        
 
Day 1 2 3 4 5 6 7 
Walk      
 
 
 
 
GymStick 
training 
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Goal Setting 
Without  direction  or  a  destination,  we  don’t  know  where  we  are  going  and  we  don’t  know  
it when we get there! 
Any time you want to change your habits for the long term you have to have a very clear 
reason as to why you are wanting to change. We all know the what, i.e. to get fitter you 
need to exercise more, however, why is improved fitness important to you? 
If you can start to visualise how you will feel when you reach your goal, this is a really 
good way of building something to strive for. If you don’t have that vision or that emotion 
pulling you towards it like a big unstoppable magnet, then there’s a chance the change 
will seem too hard. 
Use the following exercise to combine both the What and the Why, and keep these 
things in the forefront of your mind when you are going through this program  
Be Specific, Measurable, Accountable, Realistic, Time oriented 
Goal 1 – Short term 
Push ups Perform at least 15 
in one go (all the 
way to the ground) 
Record all sets of 
push ups in my 
journal 
Achieve it by the 
end of January 
Where am I now? 
5 push ups. 
Why is this goal important? 
If I can improve my push ups it will give me the confidence to engage in more difficult activities that I have 
been wary of. In addition, I want to feel like I am in charge of my strength, and completing this will mean I 
have some control over my body. 
What does 
Goal 2 – Long term 
Improve my energy 
levels 
I want to feel like a 
8-10 out of 10 
when I wake up 
and start the day 
and have energy 
all day 
Record my energy 
levels through the 
day 
Achieve it within 
the next 6 months 
Where am I now? 
Feeling like a 5 or 
less 
Why is this goal important? 
My energy levels is one of the things that was reduced after treatment. When I get my energy levels back it 
will mean that I am able to work harder, take better care of the family and feel like my old self (or even 
better than that!). When I have better energy levels it will allow me to feel like I have some control of my 
body that was reduced during treatment. 
Just  some  examples...next,  it’s  your  turn.  Please  write  down  as  many  goals  as  you  like.  Paint  the  picture  of  
what it will be like when you achieve your goals. 
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Goal Setting - Practical 
Be Specific, Measurable, Accountable, Realistic, Time oriented 
Goal  
 
 
 
 
    
Why is this goal important? 
 
 
Goal  
 
 
 
 
 
    
Why is this goal important? 
 
 
Goal  
 
 
 
 
 
 
    
Why is this goal important? 
 
 
Goal  
 
 
 
 
 
 
    
Why is this goal important? 
 
 
6 
7 
Week 2 – Eating more plant food 
Fruits, vegetables, nuts, seeds and legumes are amongst the most important foods you 
can consume for overall health and well-being. Thinking about these foods as something 
that your body needs every day is very important.  
Use some of the tips below to use vegetables and fruit more commonly in your daily 
meals 
How can I eat more vegetables? 
 Try to ensure that half your dinner plate is vegetables or salad by serving 2-3 types of
vegetables with your main meal or serving vegetables and a side salad
 Whenever you see a dish that has a sauce component, i.e. mince, soups, stir-fry or
casserole – get into the habit of adding lots of vegetables to bulk it up. 
 Add extra salad to sandwiches and rolls or perhaps serve salad alongside a
sandwich
 Spend 30 minutes on the weekend to roast some vegetables, e.g. onion, sweet
potato, capsicum, carrot, swede, turnip, pumpkin – enjoy the change in flavour
 Use tinned/ fresh tomatoes as the base for a pasta or rice dish
 Serve crunchy raw vegetables (i.e. carrots, celery) as a snack
 Used chopped or puree vegetables to make a low fat sauce
 Add extra taste to cooked vegetables with low fat flavourings such as herbs, spices,
lemon or orange juice, pepper, garlic, chili or chopped fruit
How can I eat more fruit? 
 Try adding fresh, frozen or dried fruit to breakfast cereals
 Blend soft fruit like bananas and strawberries with skimmed or reduced fat milk or
plain low fat yoghurt for a smoothie.  You could also try freezing smoothies in ice
block moulds.
 Eat fruit as snacks between meals & keep fruit available in a fruit bowl
 Add fruit like apple, pears, peach and grapes to salads
 Top toast or muffins with slices of fruit e.g. bananas
 Choose fresh, canned (in natural juice) or stewed fruit for dessert
 Prepare stuffing for meat, fish and poultry dishes from fresh or dried fruit
 Try having a glass of unsweetened fruit juice (fruit juice should only count for one
serve of fruit/vegetables a day)
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Consuming more legumes 
Anything that has a sauce involved is perfect for the addition of legumes. They are 
cheap,  fibrous,  nutritious  and  don’t  really  affect  the  flavour  of  the  dish. 
- Add lentils or beans to bolognaise, lasagna or chili con carne 
- Add beans, lentils or chickpeas to a stir-fry 
- Add any or all to curries, soups, casseroles, stews 
- Home-made bean dishes: Diced tomatoes, five-bean mix, extra virgin olive oil, garlic, 
onion, mixed herbs, +/- a touch of chili and simmer for 5 minutes. 
If you like them: 
- Add them to a salad for a great colour and texture change! 
Making the most of shopping 
Meal Planning and Fruit & Vegetables 
Food Amount Options 
Fruit 2 pieces 
per day per 
person. 
Fresh fruit 
Frozen fruit: mango, berries etc 
Canned in juice 
Dried fruit and/or nuts 
Vegetables 6 types of 
vegetables 
per day 
Always lots of green: Broccoli, Spinach, Rocket, 
Celery, Lettuce etc. 
Then at least 3 other colours: purple cabbage, onion; 
yellow/orange capsicum, pumpkin, sweet potato 
carrots; red capsicum, tomatoes; & many others. 
Frozen vegetables are great for regular consumption 
or if you need a quick fix 
Legumes 75g per day 
per head 
Get a mixture of big and small cans for whole meals 
and individual meals alike. 
Canned is ok. Fresh are good and require soaking. 
- Cooking: normally 45-60 minutes on simmer, perfect 
for a curry/soup/casserole/stew that is cooking for a 
while. 
Nuts Handful 
each day 
Raw and unsalted is always best. 
If you love salt – add a salted nut to a mixture of 
unsalted nuts. 
Toasted nuts are ok. 
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Shopping Tips 
 
 
x Plan your menu in advance as much as possible 
x Buy fruit and vegetables in season 
x Plan your menu around the specials for that week (fresh produce that is on 
special is on average 35% cheaper than normal price) 
x Include more fruit and vegetables and less meat in the menu plan. Meat is almost 
always more expensive per kilogram than fruit and vegetables  
x Buy less pre-packaged items (for example chopping your own coleslaw 
ingredients rather than buying them pre-chopped) 
x Offering fruit and vegetable snacks for morning and afternoon snacks rather than 
expensive packaged snacks such as muesli bars and fruit rollups 
x Look at the cost for weight and compare value for money. For example a 250 gram 
pack of chopped mushrooms may only be $3.00, but if the cost of loose 
mushrooms is only $6.99/kg then the pack becomes very expensive by 
comparison (250g x 4 = $12.00 per kilogram) 
x Avoid shopping when hungry 
x Buy in bulk where available and practical. However, ensure that you have 
sufficient space to store the bulk items under the right conditions to prevent 
them from spoiling 
x Consider buying marked down fruit and vegetables if they are still in a reasonable 
condition. 
 
 
A budget consideration  
By replacing mince in recipes with vegetables or lentils you save a considerable amount 
of money per meal. Or you can use your original recipe and add the legumes to make the 
whole meal go further for cheaper! 
Mince: $10-$14/kg; Lentils and legumes: $3-$4/kg.  
By removing ¼ - 1/3  of the mince from a recipe you stand to save close to $3 per meal. 
Over the month that can be an extra $80 in the pocket + you are getting healthier. 
Great vegetables to grate and add to a mince dish or one with sauce: 
- Zucchini, carrot, pumpkin, swede, turnip, sweet potato 
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Week 3 – Healthy weight, Mindfulness and First Serve Portion 
Key points for managing a healthy weight… 
1. Always have breakfast, or food within a couple of hours of rising.
2. Choose nutritious foods to abate hunger – including snacks
3. Consume water before and during every meal – aim for 2L per day
4. Have at least 3 meals each day that contain some protein, healthy carbs, healthy fats
and plenty of fibre. 
Maintaining a healthy weight improves the health of your heart, enables you to better 
control blood sugar levels, takes strain of your joints, improves mobility and function. 
In addition, energy levels are normally better and self-esteem often improves. 
First plate portion 
A great way of ensuring you receive all your key nutrients in a portion that is suitable for 
your hunger levels and appetite. 
Fill Half the Plate with 
Vegetables or Salad 
Mix up the colours 
Aim for at least 4 
colours over the day! 
A portion of Meat or 
Meat alternative 
Choose lean 
Vary red & white 
meats
A portion of quality 
carbohydrates 
Wholegrain/Meal, 
Low GI, Minimally 
processed 
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MINDFUL EATING – Having what you want, when you feel like it. 
 
It’s  time  to  enjoy  the  foods  you  love without the guilt! 
Mindful eating is a process where you learn to maximally enjoy your foods. It will help 
you consume less high fat and high sugar foods, without letting you feel deprived of all 
the good things in life! 
The principles of mindful eating are very simple, firstly, it is important we are putting the 
right type and amount of nutrients in: 
 
1. Your body needs wholesome foods in order to operate 
2. When you are hungry, your body is asking for nutrients 
3. We eat when our body tells us we are hungry, we should listen to it!  
4. When  we  are  no  longer  hungry  the  body  doesn’t  need  more  food 
The great thing about mindful eating is that if you feel like a treat or some sweet/savoury 
foods, YOU CAN HAVE IT!  
‘But first  ask  yourself,  ‘Am  I  really  hungry  for  this  food?’ 
Often we have high fat or high sugar foods out of habit, plus there is an element of 
liberation and enjoyment that comes along with these foods. However, what are the 
purposes of these foods? We know that the wholesome foods listed above are filling our 
body with the nutrients we need for good daily function, so the only purpose of these 
treat foods are flavour!!! 
Once high fat and sugar foods have passed the tongue, there is no more purpose for it. 
Sooo, it’s  very  important  that  we  taste  these  delicious  foods  for  as  long  as  possible  
before swallowing. Follow this step-by-step guide to really getting the most out of your 
sweet foods. 
1. Remove distractions while you are eating – e.g. watching TV, driving, cleaning up 
etc are all ways to decrease your ability to taste.  
-Grab  a  chair  and  focus  on  the  wonderful  food  you’re  about  to  eat! 
2. Use all your senses – look at it, smell it, touch it before you taste it – this is a 
guaranteed way to make the memory of this food last for a lot longer. 
3. Take a small piece of the food and taste it for at least 2 minutes. Roll it round, 
break it down and try and pick the flavours – this will maximise your enjoyment of 
the food and make you aware of every flavour in it. 
4. Ask yourself after every bite – ‘Do  I  feel  like  more?’   
Often, after  only  a  few  bites  of  chocolate,  the  next  piece  doesn’t  add  to  your  
enjoyment  anymore.  It’s  at  this  time  that  you  might  consider  putting  the  rest  
away, knowing that you can have more if you feel like it later. 
These principles are about enjoying the foods that are designed to taste wonderful. 
Listen to your body – it does know when you need food! Feel liberated in having your 
favourite foods when you desire, and know that when you have them, you will enjoy 
them maximally. 
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          Eat before you feel 
 Neutral 
After your meal: Take 15-20 minutes and then decide if you want more! 
Making the most of mindfulness! 
What can help you maximize your mindfulness is to plan some treats into your 
week. Knowing that you can have them enables you to make an objective 
decision about whether or not you feel like it, AND allows you to have it without 
the guilt. 
List your favourite foods – the  ones  you  can’t  live  without, and plan them into 
your week. 
My  favourite  foods  are… Day & Time to have them 
E.g. Chocolate bar Monday morning tea 
You  may  discover  that  you  don’t  like  these  foods as much as you used 
to – in that case, it is ok to not eat them! 
Hunger Pangs 
Eat until you feel 
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Week 4 – Eating  the  ‘right  fats’ 
Lowering saturated fat intake 
Sources of Saturated Fats Lower fat substitutes 
Animal meats 
Fresh meats (white) 
Processed meats ++  
Dairy foods 
Double, thickened, pouring cream, Creme 
fraiche  
Sour cream, light sour cream 
Butter, Lard, Dripping 
Cheese  
Extra Foods 
Pastries 
Commercial cakes 
Deep fried foods 
Chocolate 
Chips 
Coconut cream 
- Trim the fat off the meat - Choose lean cuts (<5% fat) - Limit intake of processed meats 
- Evaporated milk (Carnation) 
Extra light sour cream, Natural yoghurt 
Ricotta, Cottage cheese - Margarine, lower fat butter, 
unsaturated cooking oil. - Small portion, cream cheese, low fat 
Limit intake of these foods through 
mindfulness and more nutritious snack 
selections 
- Evaporated milk + coconut essence 
Ways to increase Poly and Monounsaturated fat intake 
1. A daily serve of nuts (particularly walnuts, brazil and pine nuts)
2. Healthy cooking oils: Sunflower oil, rice bran oil, grapeseed oil
3. Healthy dressing oils: Extra virgin olive oil
3. Consume specific plant foods: Olives, Avocado, Seeds, Nuts & Olives.
4. Using a polyunsaturated margarine (Nuttelex, Meadow Lea)
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Healthy cooking methods 
Cooking Method It’s  advantages/Methods 
Grilling 
- Will allow fat to drain away - Fast, convenient and gives great flavour 
Be careful of: - Cooking at high temperatures and charring the 
meats 
Steam/ Microwaving 
- Fast, convenient - No problems with charring or burning - Best for fish or chicken 
o Use of herbs/spices is a good idea
Boiling 
- Removes most of the fat from the meat - Great way to achieve moist meat - Use stock/herbs/spices in the broth to add 
flavour 
o After boiling, throw into the grill or fryer
to give it a nice crusty edge.
Baking 
- Great way to give the same foods a different 
flavour: carrots, sweet potato, pumpkin  - Use a baking tray & water instead of oil. Brush 
the oil on to prevent drying of meat/vegetables 
Frying/BBQ 
- Use a pan that enables fat to drain away - Don’t  allow  food  to  char - Seal meats either side then turn them more 
frequently 
Additional Tips for healthy fat consumption 
Great foods to add in: 
Linseed, Sunflower & Almond meal – Cereal, smoothies, yoghurt 
Mixed seeds and grains – healthy section at supermarket (pepitas, sunflower, 
flaxseed/linsseds, chia seeds and others) 
Use marinades to maintain tenderness & protect the foods 
Use herbs and spices to increase flavour without the need for added fats 
Allow meat to rest for 5 minutes after cooking 
Place in a bowl covered in al-foil and put in oven @ 1000C for 5 minutes 
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Week 5 – Meat and salt intake 
Meat and Meat Alternatives 
Meats and alternatives are vital for adequate intake 
of protein, some fats, essential vitamins and trace 
minerals. You do not need large portions of these 
foods to maximize their benefit 
1. Aim for a variety of meats each week
2. Choose lean, unprocessed meats
3. Consume red meat in moderation
4. Reduce the charring from high cooking
temperatures, especially BBQ meats. 
5. Try vegetable based protein sources
- Legumes: chick peas, lentils, beans;
Soy based foods:  tofu, tempeh; &
Nuts and Seeds. 
Salt Consumption 
A high salt intake is not beneficial for health, and may be 
related to an increase risk of stomach cancer and high blood 
pressure. Most salt in our diet is within the foods we eat, while 
the rest is added salt during or after cooking. It is important to 
reduce salt intake and increase the consumption of foods that 
contain potassium, calcium and other minerals. 
1. Choose lower salt varieties of canned foods, stock
cubes 
2. Limit obviously salty foods
3. Use herbs and spices to cooking for flavour
4. Eat fresh foods, as opposed to processed foods
5. Allow 4 weeks for your taste buds to adjust to the
lower salt intake 
6. Compare labels for: biscuits, canned foods, chips,
sauces, and cereals. 
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Sedentary activity  
Record the time you spend sitting on an average day, and how long this sitting is 
uninterrupted 
Activity - How much of your day do you spend sitting? 
http://www.computerworld.com/s/article/9115340/Health_hazards_for_IT_workers_how_that_desk_job_wears_your_body_down 
Activity Total time sitting Sitting without a break 
Watching TV 
At work 
Transport 
Meal Times 
Coffee shops 
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Tactics to decrease your sedentary activity 
1. Know that sitting for longer than 30 minutes without a break has a negative impact on
your health – it reduces fat burning, decreases uptake of blood sugar, may add to fat 
stores around your abdomen and puts strain on your heart. 
2. Think of the times you are sitting still and think of how you may increase movement at
those times: 
Seated activity Options to reduce sitting time 
Watching TV 
- Use the ads as an excuse to move: Grab a glass of water, do 
a few sit to stands, do some cleaning, just stand up  
- Exercise  during  your  favourite  shows.  TV  doesn’t  often  
require a whole lot of your attention, so perform some of your 
GymStick or body weight exercises while you watch. 
- Reduce the amount of TV you watch.  
Sitting at work 
- Phone call/email rise: Stand up and squat whenever you 
get a phone call/email 
- Talk to people in person, as opposed to calling them 
- Put a box on your desk and work standing up! (Sometimes 
not practical) 
- Take a walking morning tea break with your drink or snack. 
Driving in the car 
Sitting on the bus 
- Practice your core/foundation exercises in the car: Shoulder 
blades back and down, core muscles on, chin tucked. 
- Flex your gluteus (bottom), legs, arms, shoulders and neck 
muscles as you drive – muscle activation counts! 
- Ride a bike or walk to work where possible 
- Take a stop off each end of the bus and walk further 
- Occupy a standing space on the bus 
Decreasing your sitting time is always going to be different when comparing different 
people. 
The essential component is that if you move, then your body wants you to hold onto the 
tissues that enable you to move, i.e. your muscles. 
If you know you have been sitting for a long time, then try standing up, moving around 
and see how different you feel afterwards. It should give you some energy back and 
reduce fatigue. 
It all starts with your awareness! 
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Full  – 5% 
1 std = 285ml 
Mid  – 3.5% 
1 std = 375ml 
Light – 2.7% 
1 std = 570ml 
High – 14% 
1 std = 90ml 
Normal – 12% 
1 std = 100ml 
Low – 9-10% 
1 std = 125ml 
Spirits – 40% 
1 std  = 30ml 
Fortified – 20% 
1 std = 40ml 
Liquers– 20% 
1 std = 40ml 
See above for strengths of different alcoholic beverages and the amount that relates 
to one standard drink 
Week 6 – Alcohol, Drinks and Socialising 
Appropriate Alcohol Consumption 
Is it good for you?
Often it is stated that 1-2 standard 
drinks can be beneficial for heart health. 
However, it is very important to note that 
while some benefits may exist for heart 
health, alcohol may be harmful to your 
breast cancer related health even at 
small levels of consumption. 
For women who have completed 
treatment for breast cancer, reducing 
alcohol consumption to the safe 
drinking levels is very important.  
Alcohol in moderation is still key, and 
no-one should increase their 
consumption to achieve health benefits. 
“The  safest  range  of alcoholic consumption is between 0 & 1.5 standard drinks per 
day.” 
Tips for reducing your alcohol  intake… 
1. Switch to standard sized drinks
(smaller) and sip slowly
2. Add ice
3. Enjoy a wine spritzer
4. Switch to light beer
5. Alternate alcohol with water
6. Don’t  refill  your  glass until
it is empty
7. Reduce the number of days you have a
drink
8. Apply mindfulness to your drinking
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Energy from Beverages 
Beverages including juices, soft drinks, flavoured milks and alcoholic beverages contain 
a considerable amount of energy (kilojoules). The problem is that these fluids will not 
often give us a feeling of fullness that matches the energy they are providing. 
Juices – as good as fruit? 
Fruit juices that contain often contain a number of beneficial nutrients, however they 
normally contain a higher concentration of carbohydrate that found in whole fruits. In 
addition, they contain very little fibre, which is one of the more beneficial components of 
fruit consumption. 
1. Always choose a piece of fresh fruit over its juice. Replace the juice with water.
2. When consuming juice, aim to have fresh juice as much as possible and add the pulp
back into the juice (good source of fibre) 
3. Avoid fruit drink – typically these have very little real fruit in them.
Soft drinks 
There are no benefits to be received from consuming soft drinks. Therefore, enjoy them 
mindfully and look for options like water, weak cordial or juices as preferred beverages. 
Regardless of full sugar or diet soft drinks, these beverages should be consumed on an 
occasional basis. If your current consumption is large, then switching to a diet variety 
while you try to reduce your intake is an option for you. 
Flavoured milks 
Flavoured milks typically are quite high in energy (300ml = 900kJ), and therefore going 
for a light version, or lower sugar option is beneficial. 
After exercise, particularly if you have been exercising intensely for over an hour, a 
flavoured milk is a fantastic recovery drink that has enough protein and carbohydrate to 
maximize your recovery. However, a normal nutritious meal will also allow you to 
recover as effectively. 
The drink ‘kilojoule-o-meter’ 
0kJ     50kJ     100kJ    200kJ     300kJ     400kJ     500kJ     600kJ     700kJ     800kJ     900kJ     1000kJ 
<100kJ 
Water 
Tea (+/- milk) 
Coffee (black) 
Diet drinks 
<400kJ 
Skim Coffee/Milk  
300ml Vegie Juice 
1 std drink: wine, 
lite/mid beer, nip 
spirits 
<700kJ 
250ml Whole milk  
400ml Juice - Natural 
1 Bottle full strength 
beer 
>700kJ 
Soft drink – 500ml 
Juice – 500ml 
Milk  (choc…)  – 300ml 
Alco-pops – bottle 
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Socialising with awareness 
It is part of our culture to enjoy foods with friends at social functions/gatherings. It is 
often at these times that we consume a considerable amount of food that although 
tastes great, has a high level of fat and/or sugar. Particularly during the festive season, 
and at other times when we are socialising regularly, the foods at these functions can 
contribute considerably to our intake. 
A couple of guidelines: 
1. If it is a one-off event and it is not happening regularly – DON’T  WORRY  ABOUT  IT!  If
you were to hinge your health goals on one night out, then we are blaming the mouse for 
sinking the boat! 
2. If it is a regular social function or you are looking to reduce your intake of these foods
(which never hurts), then read the tactics below for decreasing your consumption. 
For functions providing finger food 
x Have a full nutritious meal before you go to the function – abates hunger.
x Don’t  stand  next  to  the  food  platter  – this will reduce grazing.
x Drink plenty of water – keeps your mouth busy!
x Be selective about the foods you want to try – really focus on the food and
experience the flavour.
x Be mindful of how full you are – you can always have more if you feel hungry.
x Provide a platter of vegie sticks, healthy dips & fruit.
When attending a buffet 
x Employ the first portion rule – plenty of vegetables and salad, a serve of meat
and pasta/potato/rice
x Ask yourself – Do you really feel like it?  Or  are  you  just  feeling  like  you’re  hungry
because it is in-front of your eyes?
x Share a plate with a friend to get more variety while keeping the amount the same
x DON’T  RUSH:  Consume  it  slowly,  take  time  to  taste  it,  give  yourself  time  to  feel
full before rushing back and loading the plate up again
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Week 7 Handout – Food Labels 
The nutrition label reading should be used to assess the best food according to: fat, 
sodium, fibre and in some cases, sugar content. 
However, food groups will vary widely and types of food in specific products will have a 
large impact on the nutrition label. 
Per  100g Breads + 
Cereals 
Dairy Foods & 
Cream 
Snack foods Canned foods 
& sauces 
Energy N/A N/A 300-500kJ/ serve N/A 
Protein N/A 
Total fat Saturated <33% 
of Total Fat 
<3% for milk & 
yoghurt 
<7% for cream, 
sour cream, 
evaporated milk 
Cheese – portion 
size not fat 
content 
No limit 
Nuts could be 
60-90g fat per  
100g 
No limit 
-Saturated Fat Will always be 
60% saturated 
Saturated <33% 
of Total Fat 
Carbohydrates No Limit 
Will often be 50-
70% 
>10g per 100g 
indicates added 
sugar 
No Limit 
provided energy 
and type of fat is 
looked after 
No Limit 
-Simple sugars If cereals contain 
fruit: can be up 
to 20g per 100g 
Higher for: 
baked, toasted, 
added sugar. 
Oats contain 
<1g/100g 
<15g per 100g 
Better to have 
<10g/100g 
Canned tomato 
products often 
contain added 
sugar – check 
ingredients list 
Sodium Not vital 
Breads: <500mg 
Pasta: <120mg 
Cereals: <200mg 
All Bran = 650mg, 
ok as an addition 
N/A Compare for 
chips, savoury 
biscuits, dips. 
Use total energy 
as guide for how 
many you eat  
Aim for <120mg 
Or  
No added salt 
varieties 
Fibre  >7g per 100g 
Even >10g is a 
good aim 
N/A N/A N/A 
All fruits, vegetables and lean meats can be considered appropriate for consumption, 
and will not often contain a nutrition label. Processed meats and packaged fruits (two 
fruits etc) are worth comparing though 
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Foods are not defined by one bad nutrient 
Breads and cereals - Typically high in sodium compared to fruit and vegetables, however benefits come 
from fibre, vitamin, mineral and antioxidant content. - High sugar content may be due to fruit – this is still ok! 
Dairy foods - Always have a high percentage saturated fat of total fat. - High in protein, and vital vitamins and minerals. Milk normally has low absolute 
content of fat (<4%), and satisfies hunger well.  - For foods like cream, sour cream, thickened cream & butter, comparing fat content of 
their  ‘lite’  versions  can  greatly  reduce  your  fat  intake. 
Snack foods - Unless they are healthy options like fruit, vegetable sticks, glass milk & nuts, it is 
good to aim for around 300-500kJ per snack - To really optimize snacks, compare saturated fat, sodium & sugars, however the 
main aim is to reduce the energy of the snacks 
Canned foods and sauces - Typically high in salt – look at the sodium/100g as the main focus. - Some sauces have a large amount of added sugar – compare products within the 
same range. 
Understanding words on the ingredients list 
Sugar Fat Salt 
 Dextrose
 Disaccharides
 Fructose
 Glucose
 Golden Syrup
 Honey
 Lactose
 Malt, Maltose,
Maltitol
 Maple syrup
 Monosaccharides
 Sucrose
 Animal Fat/Oil
 Beef Fat
 Butter
 Chocolate
 Coconut, Coconut
Oil, Copha
 Cream, Sour Cream
 Mayonnaise
 Vegetable Oil/Fat
 Diglycerides
 Monoglycerides
 Dripping, Lard
 Milk Solids
 Oil, Palm Oil
 Shortening
 Baking Soda
 Boosters
 Celery Salt
 Garlic Salt
 Meat/Yeast Extract
 Monosodium
Glutamate (MSG)
 Onion Salt
 Vegetable Salt
 Sea Salt
 Rock Salt
 Sodium
 Sodium Ascorbate
 Sodium Bicarbonate
 Sodium Lactate
 Sodium
Nitrate/Nitrite
 Stock Cubes
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EXTRA MATERIALS 
Includes:  
Your training diary 
Healthy eating and exercise tips 
Safety during training 
Measuring your training
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Nutrition and Exercise – How they work together 
Consumption of specific nutrients around exercise can greatly influence how effective 
that exercise is for overall muscle health. 
Protein and carbohydrates are important nutrients in the hour following exercise. A 
protein shake is not completely necessary as adequate protein consumption can be 
achieved through foods like meat, eggs, milk, nuts and seeds. 
In the hour following exercise your muscles are primed for uptake of protein & 
carbohydrates, and if these two nutrients are provided, your recovery will be greatly 
improved. 
‘Bricks  don’t  lay  themselves’.  You  need  carbs  to  power the protein building process. Just 
like you need bricklayers to provide the power to the bricks (protein). 
Ideal snacks or meals following exercise 
Protein – 15 to 25g is required for maximal muscle recovery after exercise 
Carbohydrate  
- 30g of carbohydrate is needed to refuel muscles and power protein building. 
What foods have enough protein and carbohydrates for a good recovery? 
Protein: 15-25g Carbs: 30g Protein & Carbs 
-60-80g meat or Tofu 
-2-3 eggs 
-80g cheese (have 40g 
with some meat) 
-2 slices bread; 3-4 rice cakes 
-2 pieces of fruit or 1 big 
banana 
-1 cup pasta, cereal, potato 
-400ml Gatorade; 300ml 
juice; 
-Up & Go Energise (250ml) 
-Meat sandwich 
-Cereal and Milk/Yoghurt 
-Meat + potato/pasta/rice 
-Handful of nuts + Yoghurt  
OR Milk instead of yoghurt 
-A normal healthy main meal 
as previously discussed 
Plan your exercise to occur just before a main meal. 
You can see from the table above that normal meals will accommodate your 
requirements after exercise, provided it is a balanced meal. 
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Exercising Safely and Effectively 
Always Warm Up & Cool Down – aim for 2-3 minutes 
- Warming up prepares the body for exercise and helps to prevent injury and prolong 
your workout 
- Warming up increases blood flow through your muscles and other tissues gradually – 
cool down helps to help remove excess fluid from your active muscles after exercise. 
Both warm up and cool down are essential to help in preventing issues related to 
lymphoedema and fluid build up. 
- A warm-up incorporates both general movements – walking and dynamic stretching + 
more specific movements that relate to the exercise that follows. 
e.g. Before resistance training – walking and stretching the whole body for 90 
seconds  is  a  general  warm  up.  Performing  an  ‘easy’  or  ‘light’  set  of  chest  press  before 
you try for a harder weight is a specific warm-up to your activity. 
Measuring Intensity of your workout 
Perceived Exertion Measuring Heart Rate 
The Borg Scale – a rating from 6 to 20. 
It relates to how hard the exercise feels 
to you.  
Rate your perceived exertion on how 
you feel. 
Aim to keep it within 11-14 
6  No exertion at all 
7 
Extremely light 
8 
9  Very Light 
10 
11 Light 
12 
13 Somewhat hard 
14 
15 Hard Heavy 
16 
17 Very Hard 
18 
19 Extremely Hard 
20 Maximal Exertion 
Find your radial pulse as per the 
picture below. 
Count the number of beats in 15 
minutes. 
Multiply that number by 4 to calculate 
beats per minute (bpm). 
This is not considered the most 
accurate heart rate measure, however, 
it gives you some indication of your 
heart rate. 
Find out what your optimal heart rate is 
from your fitness results. 
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Resistance training safety and progression 
Safety 
- If you have a lymphoedema garment – WEAR IT at all times during warm up, exercise 
and cool down. 
- Always perform you specific limb warm up movements before any exercise. 
- Always perform shoulder mobility exercises before and after you do any exercise. 
- Technique before power – All exercises should be able to be completed with correct 
technique before any progression in weight occurs. 
- Core strength – before any exercise, think: CORE MUSCLES ON 
- Always continue breathing through the exercise 
+ Breath OUT when you are overcoming the resistance; breath IN during the 
opposite movement. 
- If in doubt about the technique– wait until you are supervised before attempting the 
movement. 
- INJURY – Please report the injury to Cam ASAP so we can arrange optimal treatment for 
you – and allow you to continue other exercises. 
- Make sure you complete all the exercises – they are designed to bring balance to your 
muscles – skipping a couple may create an imbalance 
Progressing your training 
- Once you have completed 10 repetitions for 2 full sets, in 2 consecutive sessions, your 
program can be advanced. 
- Aim for 8-12 repetitions 
- All program advancements will be directed by the exercise physiologist staff. 
- Progression that is too fast may result in injury or poor technique habits. 
- Monitoring your training: Always write down the number of full repetitions completed 
for each set, for each exercise – your goal is to maintain or improve this number each 
following set. 
Exercise/Date 11/09/2011 13/09/2011 
Load/Resistance Reps per set Load/Resistance Reps per set 
Chest Press 2 Wind-ups OR 
1 x 12 
1 x 10 
3 Wind ups 
1 x 8 
1 x 7 
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Aerobic Exercise - Safety and Progression 
Safety 
- Ensure you have comfortable clothes and supportive shoes. 
- Consume water before exercise – take a bottle with you if it is going to be longer than 
25 minutes. 
- Always start the first 3 minutes  with  an  easy  ‘warm-up’  pace, and finish with a couple of 
minutes of cool down. 
- You should be able to talk – but not sing, or stay within the 12-14 range on the Borg 
Scale. 
- It is good to let someone know when you will be going, or take a friend along with you. 
- Be sun-safe 
- Wear a hat in cold weather to reduce heat loss. 
- Monitor small niggling injuries – if they are getting worse over time – notify study staff 
ASAP for appropriate management. 
- Always think about you core muscles during exercise – protection of spine is crucial 
Progressing your training 
- Monitor the distance/time and the exertion of the exercise. 
- Measure the length of your walking track. 
- Always look to increase time OR intensity, not both together 
E.g. Your first walk went for 20 minutes and you ranked it as 11-12 on the Borg 
Scale. To progress your walk you have two options: 
1. Increase the time of the walk (+ 5 minutes) and continue at the same intensity
2. Increase the intensity (12-13 on the Borg Scale) and maintain the length of the walk.
DO NOT increase time and intensity together. 
After you have increased one component – you can then increase the other for further 
progression. 
Record your progress 
Exercise/Date 11/09/2011 13/09/2011 
Distance + Time 
Borg Rating or 
Heart Rate 
Distance + Time 
Borg Rating or 
Heart Rate 
3.3km  
25:25 minutes 
11-12 
110bpm 
3.3km in 24 
minutes 
13 
125bpm 
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Designed & created by Cameron McDonald 
PhD Candidate, 2011 
Resistance Training Guide 
Exercises and Instructions for Safe Strength 
See instructions on back page
Contact: 
Cam McDonald 
Ph: 0411380566 
E: UQbreastcancerstudy@gmail.com 
General Safety 
1. Don’t  perform  prolonged  stretches  before  resistance  training  Only dynamic stretches and
light exercises should be performed before training. 
2. Always perform your limb mobilising movements before and after any exercise
3. Core strength – before any exercise, think: CORE MUSCLES ON
4. Always continue breathing through the exercise
- Breath OUT when you are overcoming the resistance; 
- Breath IN during the opposite movement. 
5. Technique before power – All exercises should be able to be completed with correct
technique before any progression in weight occurs. 
- If in doubt about the technique– wait until you are supervised before attempting the 
movement. 
6. Complete all prescribed exercises – they are designed to bring balance to your muscles.
Lymphoedema related safety 
1. If you have a lymphoedema garment – WEAR IT at all times during warm up, exercise and
cool down. 
2. Always warm down – stretching and limb movements
3. Do not remove garment until completely cooled down
4. FLARE UP - Stop upper body training and alert study staff, oncologist and/or breast care
nurse. 
Safety when resistance training 
Serious injury – call the hospital or your medical practitioner immediately 
Minor Injury – Please report the injury to study staff ASAP so we can arrange optimal treatment 
for you – and allow you to continue other exercises. 
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To perform any exercise properly, there must be a strong foundation from which you are working. 
Your core muscles protect your lower back, spine, shoulders and neck. If they are not turned on 
when you lift, then you have a much higher chance of sustaining an injury which will delay your 
training. 
Using the core muscles when you perform your daily activities is essential for it to become a 
habit. 
The 3 essential exercises 
The Guidance The Picture 
1. Lie on the ground, knees bent
2. Place one hand on your lower stomach & one
hand in the small of your back 
3. While breathing out
i) Turn  on  your  1’s,  2’s  &  3’s
ii) Draw your belly button to your spine while
maintaining the position of your lower back. 
4. Breath normally & hold for 8 seconds
Abdominal activation 
This  is  called  ‘Neutral  Spine  position’  not  
pushed forward or back, but held firm in the 
middle 
1. Perform lying down or sitting up
2. Turn on your trunk muscles
3. During normal breathing
i) Roll your shoulders up, back & down
ii) Try to put your shoulder blades into your
back pockets 
iii) Ensure your shoulders are down and not
hitched up 
4. Breath normally & hold for 8 seconds
Scapula setting 
1. Perform lying or seated
2. Turn on trunk & shoulder muscles
3. While breathing through your nose
i) Place the tongue on the roof of your
mouth 
ii) Maintaining head position, gently nod
your chin down and feel a small pressure 
build at the front of your neck. 
4. Breath normally & hold for 8 seconds
Deep neck muscles 
YOUR CORE EXERCISES 
Every time you lift! 
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Breathing – Always BREATH OUT when pushing the surface or GymStick away from your body 
Level I
Wall Push Up 
1. Stand at arms length away from the wall
2. Place your hands on the wall below the level of your
shoulders, shoulder width apart – fingers pointing up 
3. Turn your CORE muscles on
4. Allow your arms to bend taking the strain in your chest
muscles. 
5. Maintain a straight body from shoulders to toes
6. Using your chest muscles, push back to the starting
position 
Level II 
Kneeling - Box push up 
1. On your knees, place your hands the surface shoulder
width apart. 
2. Core muscles on
3. Lower yourself down by bending your arms
4. Maintain a straight body from shoulders to knees
Level III
Kneeling Push Up 
1. On your knees, place your hands the surface shoulder
width apart. 
2. Core muscles on
3. Lower yourself down by bending your arms
4. Maintain a straight body from shoulders to knees
GymStick Chest Press 
Link the Gymstick straps around each foot & assume a 
kneeling position. 
1. Ensure you have all core muscles turned on
2. Maintain a steady trunk and head throughout movement.
3. Hold the Gymstick with hands outside the width of your
shoulders. 
4. Push the Gymstick up and away from your body.
5. Control the Gymstick while allowing it come back to the
starting position. 
LEVEL IV
Full Push-Up 
1. Assume a position on your hands and toes
2. Follow instructions similar to push ups on knees.
3. CORE ON – straight & firm body from shoulders to toes
4. DO NOT allow your shoulders to sink into the push up
Chest Strength Exercises
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Level I
Wall Angel 
1. Stand against wall with all core groups turned on.
2. Place slight bend in knees
3. Push your arms back against the wall and you raise them
above your head 
4. Focus on pushing your arms back while your trunk and
head do not move. 
5. Drag your arms down while you breathe out.
Level II 
Seated Row 
1. Place your feet in the long straps of the Gymstick
2. Assume a seated position with knees slightly bent and
your back is upright and straight. 
3. Turn core muscles on.
4. From a position of outstretched arms, keeping your upper
body still, pull the Gymstick towards you. 
5. Pull it in at the level just below your chest with arms by
your side. 
Bent Over Row- Warning (if core is not on your back will be 
exposed to injury) 
1. Straps around your feet. Knees slightly bent, and bending
forward at the waist. 
2. Turn core muscles on
3. Pull the Gymstick up in a straight line towards your
stomach – keep your arms by your side. 
4. Control your arms on the way down
Level III
Upright Row 
1. Standing with knees slightly bent, straps around your feet
2. Core muscles on
3. Start with your arms relaxed in front of you, holding the
stick shoulder width apart. 
4. Maintaining your shoulder blade position, pull the bar
straight up to the level of your collarbone. 
5. Control back down to start position
One armed bent over row 
1. Strap bar to both feet and assume a forward lunge
position. 
2. Use your non-lifting arm as support on your front knee
3. Turn on core muscles
4. Start with your hand in the middle of the Gymstick, arm
relaxed by your side. 
5. Pull the Gymstick straight up, keeping your arm next to
your body. 
6. Control the arm back down to the starting position
Back Exercises
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Level I
Ia) Sit to Stand 
1. Start in seated position in a chair.
2. Turn core muscles on.
3. Arms out in front (or you can use the arm supports)
4. Stand up from the chair as if you are being pulled from
the middle of the chest. 
5. Push your hips forward to engage the glut muscles.
6. When lowering yourself – push your hips back first and
control the movement with your glut muscles. 
7. Maintain core activation throughout.
Ib) Calf Raises (with or without GymStick) 
1. In a standing position, ensure you have a supporting wall
nearby in for safety and balance. 
2. Standing up straight with core muscles on
3. Lift up onto your toes and hold for 1 second.
4. Control the movement as you lower yourself down
If using the Gymstick 
5. Place it across your shoulders and the back of your neck –
DO NOT stick your neck forward. 
Ic) Double Glut Bridge 
1. Lie on the ground with feet shoulder width apart.
2. Squeeze your gluts together tightly
3. Use your gluts to push your hips up.
4. Slowly  lower  your  hips,  but  don’t  let  them  touch  the
ground between repetitions. 
5. Stop when you feel like your hamstrings (the muscles on
the back of the thigh are being used) 
TIP: Put your fingers on your glut muscles – it will help you 
turn them on. 
LEVEL II
IIa) Squats – Body Weight 
1. Feet shoulder width apart, standing up (can do it in front
of a chair/box) 
2. Core muscles on
3. Push your hips back - keeping your head upright and
shoulders back (as if you are sitting down) 
4. Go down as far as you feel comfortable for balance
5. When coming up – push hips forward and drive from your
glut muscles. 
IIb) Lunge – Body Weight 
1. Take a normal to large step forward
2. Turn on core muscles
3. Make sure your feet are pointing straight ahead
4. Lift the heel of the hind leg
5. Lower the back knee toward the ground until the front
thigh is parallel to the ground – keep your head up and 
shoulders back  
6. Use  your  leading  leg’s  glut muscles to push you up
Lower Body Exercises
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Leg Exercises - LEVEL  II  cont’d 
IIc) Leg Abduction – Lying 
1. Lie on your side with your legs in line with your upper
body and knees slightly bent behind you 
2. Roll and push hips slightly forward
3. Slowly lift and lower the top leg.
4. Toes face straight ahead
IId) Single Leg Calf Raise 
As above with double leg – standing on one leg, perform 
equal repetitions on both sides (start exercise without 
Gymstick) 
LEVEL III
GymStick Squat 
1. As per normal squat (Exercise IIa)
2. Core muscles on
3. Rest Gymstick on shoulders behind the neck.
4. Keep head up and shoulders back throughout
Single Leg Glut Bridge 
1. Set up as per double leg glut bridge (Exercise Ic)
2. Squeeze glut muscles together
3. Push hips up – keeping the hips even and horizontal to
the ground. 
4. Stop when the hamstring muscles are felt throughout the
movement. 
Dead Lift – Gymstick 
1. Strap feet into Gymstick
2. Core muscles on – maintain neutral spine throughout
3. Hands shoulder width apart
3. Start in standing position
4. Push hips back - keeping arms straight at all times.
5. Bend forward with control keeping the bar close to the
thighs and shins. 
6. Return to standing by pushing hips forward
Leg abduction – Gymstick 
1. Put the lower Gymstick loop on the moving leg.
2. Place Gymstick on the opposite side – 40-60cm away
from the stationary foot. 
3. Maintaining stable trunk and upper body – lift foot away
from the body. 
4. Control the movement back down to the starting position
5. DO NOT – sink into the stationary hip (see Cam for more
instructions) 
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Always place your tongue at the roof of your mouth when performing abdominal exercises 
LEVEL I
4 Point Exercise 
1. Start  on  all  4’s.  Activate  core  muscles  in  neutral  spine
position. 
2. Keeping hips and shoulder steady – raise one arm and
hold for 8s, relax for 15s, then repeat 
3. Repeat for each arm and leg individually
TIP: Use a tennis ball on the back to ensure stability 
throughout movement. 
Abdominal Obliques 
1. In lying position, press opposite hand and knee together.
2. Do not strain your neck
3. Hold for 8s, relax for 15s and repeat
Level II
Single Leg Raises 
1. Turn on trunk muscles
2. Slowly lift one leg off the ground
3. Maintain neutral spine at all times
4. Continue breathing normally throughout
Lateral Trunk Raises 
1. Strap GymStick to feet and place on shoulders at the back
of your neck. 
2. Turn on core muscles
3. Push hips forward to maintain straight posture
4. Bend from side to side – ensure it is only lateral
movement 
5. Maintain slow and controlled movements throughout
4 point Exercise (II) 
1. Start in same position as per Level I.
2. Maintaining level hips and shoulders – extend opposite
arm and leg and hold for 8 seconds, rest for 15s then repeat 
with the other arm and leg. 
3. Place a tennis ball or broomstick to test stability.
LEVEL III
Single leg lift – straight leg 
1. As single leg lift above – but straightening the leg
2. Extend leg and hold just above the floor.
3. Maintain neutral spine position – 8s on, 15s rest
4. If you feel it in your lower back, STOP & back off.
Side Bridge – Knees 
1. Lie on side, rest on your forearm directly below shoulder.
2. Lift your hips & push them forward slightly – hold 10s
3. Maintain strong shoulders throughout
Abdominal and Trunk Exercises 
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LEVEL I
Bicep Curl 
1. Stand with feet and hands shoulder width apart.
2. Slightly bent knees and core muscles on
3. Start with arms straight down holding the bar.
4. Keeping your shoulders still, fully bend your elbows.
5. Control the movement back down
6. Maintain steady frame at all times.
Front Raise  - Lying 
1. Strap Gymstick to your feet in lying position, knees
slightly bent. 
2. Stabilise shoulders and core
3. Keeping straight arms, lift the bar up to be in line with
your chin. 
4. Slowly lower the bar back down
LEVEL II
Dips – On Chair/Box 
1. Hands on bench (fingers facing forward or back)
2. Support body weight partially with feet on ground
3. Lower body until arms are parallel to the ground.
4. Ensure your back is as close to the bench as possible
TIP: The closer your feet are to your body, the easier it is 
LEVEL III
Shoulder Press – Standing 
1. Strap to feet and grip with hands outside shoulder width.
2. Slightly bend knees, turn on core muscles
3. Start with bar across the your collar bone.
4. Lift the bar up and just in front of your face.
5. DO NOT lean back into this exercise. Maintain strong core
muscles throughout movement. 
TIP: Easier to control when seated. 
If you feel any discomfort in your lower back, you are either: 
1) leaning back too far – bend your knees more;
2) Not turning your core muscles on – activate them before
each lift. 
Triceps Extension 
1. Set up the same as above exercise.
2. Start position as shown – bar at the back of your head
3. Elbows facing straight ahead.
4. Straighten your elbow until bar is directly above your
head. 
5. Always maintain the position of your upper arm. Only
allow the forearm to move. 
Arms and Shoulder Exercises 
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Record Sheet – Aerobic & Resistance training 
Exercise/ 
Date 
Example 
Warm up Walking + Stretches 
Load Reps per set Load 
Reps per 
set 
Load 
Reps per 
set 
Load Reps per set Load 
Reps per 
set 
Chest Press Wind x 2 
1 x 12 
1 x 10 
Squats BW 
1 x 15 
1 x 10 
Seated Row Wind x 1 
1 x 8 
1 x 8 
Walking 
3.3km 
25 min 
11-12 RPE 
120bpm 
Stretches completed: 
1 2 3 4 5 6 7 8 
Record Sheet – Walking or aerobic training 
Pain/Aches:  Shoulders Neck Lower back Hips Knees Ankles 
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Exercise/ 
Date 
Warm up 
Cool down 
Exercises 
performed 
Comments: 
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Siemens Healthcare Diagnostics Inc.
Wide Range C-Reactive Protein (wrCRP)
NOTE: For an explanation of the symbols in this document and associated products, 
refer to Understanding the Symbols located on the introductory page of the Methods 
Directory. 
Method Summary
System New Information
ADVIA® 1200 Update to Siemens Healthcare Diagnostics
ADVIA 1650/1800 Update to Siemens Healthcare Diagnostics
ADVIA 2400 Update to Siemens Healthcare Diagnostics
Item Description
Method Principle Latex enhanced immunoturbidimetric
Specimen Type Human serum and plasma (lithium heparin)
On-board Stability ADVIA 1200: 35 days
ADVIA 1650/1800: 35 days
ADVIA 2400: 21 days
Reagent Storage Temperature 2–8°C
Calibration Frequency ADVIA 1200: 21 days
ADVIA 1650/1800: 21 days
ADVIA 2400: 21 days
Reagent Blank (RBL) Frequency At time of method calibration
Reaction Type 2-point (EPA)
Measurement Wavelength 571 nm
Standardization IRMM Reference Material CRM 470
Wide Range C-Reactive Protein (wrCRP)
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Intended Use 1-4
For in vitro diagnostic use in the quantitative determination of the concentration of 
C-Reactive Protein in human serum and plasma on the ADVIA Chemistry systems. 
Such measurements are used in the detection and evaluation of infection, tissue injury, 
inflammatory disorders, and associated diseases. Increases in CRP values are 
non-specific for many disease processes and should not be interpreted without a 
complete clinical evaluation. 
This method is referred to as wide range CRP (wrCRP) because of the relatively wide 
analytical range that can be measured.
Summary and Explanation
The wrCRP method measures CRP in serum and plasma by a latex-enhanced 
immunoturbidimetric assay. It is based on the principle that the analyte concentration is 
a function of the intensity of scattered light caused by the latex aggregates. The latex 
particles coated with anti-CRP rapidly agglutinate in the presence of C-Reactive 
Protein-forming aggregates.
Principles of the Procedure
The wrCRP latex reagent is a suspension of uniform polystyrene latex particles coated 
with anti-CRP antibody. When serum or plasma containing CRP is mixed with the latex 
reagent, agglutination takes place resulting in an increase in the turbidity. This turbidity 
is measured at 571 nm. The CRP concentration in serum or plasma is determined from 
a calibration curve that is generated with the calibrators.
Analytical Range System Serum/Plasma*
ADVIA 1200 0.002–(15.6–16.4) mg/dL 
(0.02–[156–164] mg/L)
ADVIA 1650/1800 0.012–(15.6–16.4) mg/dL 
(0.12–[156–164] mg/L)
ADVIA 2400 0.003–(15.6–16.4) mg/dL 
(0.03–[156–164] mg/L)
*The wrCRP concentration in the ADVIA Wide Range 
C-Reactive Protein Calibrator Level 6, varies from 
15.6 16.4 mg/dL (156  164 mg/L).
Expected Values Adults: 0–0.5 mg/dL
(0–5.0 mg/L)
Newborns, cord 
blood: 
< 0.06 mg/dL 
(< 0.6 mg/L)
Infants,
4 days–1 month:
< 0.16 mg/dL 
(< 1.6 mg/L)
Reagent Code 74038
Calibrators ADVIA Chemistry Wide Range C-Reactive Protein 
Calibrators:
REF 00337402 (PN B03-4815-01)
Item Description
Wide Range C-Reactive Protein (wrCRP)
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Reagents
The reagents are packaged as listed below. Components of the package are available 
as a kit only. 
Components and Concentrations
CAUTION! This device contains material of animal origin and should be handled as a 
potential carrier and transmitter of disease.
NOTE: Sodium azide can react with copper and lead plumbing to form explosive metal 
azides. If disposal into a drain is in compliance with federal, state, and local 
requirements, flush reagents with a large amount of water to prevent the buildup of 
azides. 
For In Vitro Diagnostic Use. 
Reagent Preparation and Use
Reagents are ready to use. Before use, gently swirl the reagent to disrupt bubbles and 
assure homogeneity. If bubbles still exist or foam is present, using a clean transfer 
pipette, aspirate them from the reagent container prior to use.
REF (PN)
Container Size Symbol Contents Amount No. of Tests
03108390
(B01-4800-01)
Wide Range C-Reactive 
Protein Reagents
2 x 220
20-mL Reagent 1 2 x 13.0 mL
20-mL Reagent 2 2 x 13.0 mL
00829585 Wide Range C-Reactive 
Protein Reagents
7 x 315
20-mL Reagent 1 7 x 18 mL
20-mL Reagent 2 7 x 18 mL
Reagent Component Concentration
Reagent 1 Glycine
Sodium chloride
Sodium EDTA disodium salt dihydrate
Sodium azide
170 mmol/L
100 mmol/L
50 mmol/L
0.09% w/v
Reagent 2 antiCRP antibody (rabbit)  synthetic latex 
Sodium azide
Lot specific
0.09% w/v
Wide Range C-Reactive Protein (wrCRP)
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On-board Reagent Stability (OBS)
For all systems, unopened reagents are stable until the expiration date printed on the 
product label when stored at 2–8°C. Do not freeze reagents. 
For additional details, refer to the Methods Introduction section of the system-specific 
Operator’s Guide.
Sample Handling
Siemens Healthcare Diagnostics recommends using serum and plasma (lithium 
heparin) for this method. 
For additional details, refer to Sample Collection and Preparation in the Methods 
Introduction section of the system-specific Operator’s Guide.
For instructions on how to load reagents and run samples, refer to the Daily Operations 
section of the system-specific Operator’s Guide. 
Materials Required but not Provided
The following list contains the materials required, but not provided, to perform this 
method:
• sample containers
• system solutions
• calibrator (refer to the Method Summary section for the REFs)
• control materials
• reagent container adapters:
• 20-mL adapter (REF 02404085; PN 094-0159-01) for 40-mL slot 
(ADVIA 1200/1800)
• 20-mL adapter (REF 05249323; PN 073-0936-01) for 70-mL slot (ADVIA 1800) 
• 20-mL adapter (REF 00771668; PN 073-0345-02) for 70-mL slot 
(ADVIA 1650/2400)
For storage and stability information, refer to the package insert.
Calibration
Refer to the package insert supplied with the ADVIA Chemistry Wide Range 
C-Reactive Protein Calibrators (REF 00337402; PN B03-4815-01) for handling 
instructions and values. For setup and use instructions, refer to the Calibration 
Overview section of the system-specific Operator’s Guide.
System Stability
ADVIA 1200 35 days 
ADVIA 1650/1800 35 days
ADVIA 2400 21 days
Wide Range C-Reactive Protein (wrCRP)
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Calibration Frequency
Perform a calibration when this method is implemented on the system. You must 
recalibrate after the following events:
• when the reagent lot number changes
• after replacing critical optical or hydraulic components
• when indicated by quality control procedures
Siemens has validated the calibration stability for this method as shown in the following 
table:
Siemens recommends calibrating new reagent packs if the previous reagent pack was 
calibrated any time during its on-board stability, other than as a fresh pack.
Individual laboratory quality control programs and procedures may require more 
frequent calibration.
Reagent Blank (RBL) Frequency
The RBL is measured at the time of method calibration.
Quality Control
Siemens recommends the use of quality control material from Bio-Rad Laboratories 
with at least 2 levels (low and high). A satisfactory level of performance is achieved 
when the analyte values obtained are within the Acceptable Control Range for the 
system or within your range, as determined by an appropriate internal laboratory 
quality control scheme. 
The actual frequency of control in a laboratory is based on many factors, such as 
workflow, system experience, and government regulation. Each laboratory should 
evaluate the controls based on the frequency established by their laboratory 
guidelines. When the method is performed, analyze at least 2 levels of controls daily. 
Also, assay controls under the following conditions: 
• whenever you use a new reagent lot 
• following the performance of any system maintenance, cleaning, or troubleshooting 
procedure 
• after performing a new calibration 
For more information, refer to the Quality Control Overview section of the 
system-specific Operator’s Guide.
System
Minimum Calibration 
Stability* 
ADVIA 1200 21 days
ADVIA 1650/1800 21 days
ADVIA 2400 21 days
*or whenever indicated by quality control data
Wide Range C-Reactive Protein (wrCRP)
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Limitations of the Procedure 5
A number of substances cause physiological changes in serum or plasma analyte 
concentrations. A comprehensive discussion of possible interfering substances, their 
serum or plasma concentrations, and their possible physiological involvements is 
beyond the scope of this document. Consult listed reference for specific details on 
known potential interfering substances.5
As with any chemical reaction, you must be alert to the possible effect on results of 
unknown interferences from medications or endogenous substances. The laboratory 
and physician must evaluate all patient results in light of the total clinical status of the 
patient.
Interferences 
Siemens tested the following potential interferents and found the results shown below: 
ADVIA 1200
Interferent Interferent Level 
wrCRP Sample 
Concentration Interference*
Bilirubin 
(conjugated and 
unconjugated)
50
(855
mg/dL 
µmol/L)
1
(10
mg/dL
mg/L)
NSI
Hemolysis 
(hemoglobin)
1000
(10.0
mg/dL
g/L)
1
(10
mg/dL
mg/L)
NSI
Lipemia 
(from Intralipid)
750
(8.48
mg/dL
mmol/L)**
1
(10
mg/dL
mg/L)
NSI
Lipemia 
(from triglycerides 
concentrate)
1000
(11.30
mg/dL
mmol/L)**
1
(10
mg/dL
mg/L)
NSI
*NSI = No Significant Interference. A percentage effect t10% is considered a significant 
interference.
**as triolein
ADVIA 1650/1800
Interferent Interferent Level 
wrCRP Sample 
Concentration Interference*
Bilirubin 
(conjugated/unconjugated)
30
(513
mg/dL
µmol/L)
0.068
(0.68
mg/dL
mg/L)
NSI 
Hemolysis 
(hemoglobin)
694
(6.94
mg/dL
g/L)
0.068
(0.68
mg/dL
mg/L)
NSI 
Lipemia 
(from Intralipid)
 500
(5.65
1000
(11.30
mg/dL
mmol/L)**
mg/dL
mmol/L)**
0.068
(0.68
0.458
(4.58
mg/dL
mg/L)
mg/dL
mg/L)
NSI
NSI
*NSI = No Significant Interference. A percentage effect t10% is considered a significant 
interference.
**as triolein
Wide Range C-Reactive Protein (wrCRP)
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Performance Characteristics
Precision 6
Each sample was assayed 2 times per run, 2 runs per day, for at least 10 days. 
Precision estimates were computed according to CLSI document EP05-A2, Evaluation 
of Precision Performance of Quantitative Measurement Methods; Approved Guideline.6 
Data contained in this section represents typical performance for 
ADVIA Chemistry systems. Your laboratory data may differ from these values.
Conversion factor: mg/dL x 10 = mg/L 
ADVIA 2400
Interferent Interferent Level 
wrCRP Sample 
Concentration Interference*
Bilirubin 
(conjugated/unconjugated)
25
(428
mg/dL
µmol/L)
0.094
(0.94
mg/dL
mg/L)
NSI
Hemolysis 
(hemoglobin)
1000
(10.0
mg/dL 
g/L)
0.102
(1.02
mg/dL
mg/L)
NSI
Lipemia 
(from Intralipid)
800
(9.04
mg/dL
mmol/L)**
0.094
(0.94
mg/dL
mg/L)
NSI
*NSI = No Significant Interference. A percentage effect t10% is considered a significant 
interference.
**as triolein
ADVIA 1200
Within-Run Total
Specimen Type Level  SD CV (%) SD CV (%)
Common Units (mg/dL)
wrCRP Control 1 0.110 0.004 3.7 0.006 5.1
wrCRP Control 2 0.409 0.009 2.3 0.013 3.1
Control 1 2.636 0.022 0.8 0.030 1.1
Control 2 5.161 0.069 1.3 0.089 1.7
Control 3 8.030 0.171 2.1 0.183 2.3
SI Units (mg/L)
wrCRP Control 1 1.10 0.04 3.7 0.06 5.1
wrCRP Control 2 4.09 0.09 2.3 0.13 3.1
Control 1 26.36 0.22 0.8 0.30 1.1
Control 2 51.61 0.69 1.3 0.89 1.7
Control 3 80.30 1.71 2.1 1.83 2.3
Wide Range C-Reactive Protein (wrCRP)
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Analytical Range
This method measures the wrCRP concentration in serum and plasma ranging from 
the minimum detectable concentration (MDC) to the wrCRP concentration in the 
highest level of the calibrator according to the table shown below. MDC is an estimation 
based on two times the within-run standard deviation of the zero calibrator. 
Siemens has validated an automatic rerun condition for this method that extends the 
reportable ranges for serum and plasma to:
• 78.0 mg/dL (780 mg/L) for ADVIA 1200
• 62.4 mg/dL (624 mg/L) for ADVIA 1650, 1800, and 2400
ADVIA 1650/1800
Within-Run Total
Specimen Type Level  SD CV (%) SD CV (%)
Common Units (mg/dL)
wrCRP Control 1 0.079 0.003 3.3 0.003 3.5
wrCRP Control 2 0.406 0.007 1.8 0.008 1.9
SI Units (mg/L)
wrCRP Control 1 0.79 0.03 3.3 0.03 3.5
wrCRP Control 2 4.06 0.07 1.8 0.08 1.9
ADVIA 2400
Within-Run Total
Specimen Type Level  SD CV (%) SD CV (%)
Common Units (mg/dL)
wrCRP Control 1 0.225 0.007 3.2 0.011 4.9
wrCRP Control 2 1.035 0.017 1.7 0.022 2.1
Control 1 4.996 0.257 5.2 0.390 7.8
SI Units (mg/L)
wrCRP Control 1 2.25 0.07 3.2 0.11 4.9
wrCRP Control 2 10.35 0.17 1.7 0.22 2.1
Control 1 49.96 2.57 5.2 3.90 7.8
System Serum/Plasma*
ADVIA 1200 0.002–
(0.02–
(15.6–16.4) mg/dL 
[156–164] mg/L)
ADVIA 1650/1800 0.012–
(0.12–
(15.6–16.4) mg/dL 
[156–164] mg/L)
ADVIA 2400 0.003–
(0.03–
(15.6–16.4) mg/dL 
[156–164] mg/L)
*The wrCRP concentration in the ADVIA Wide Range C-Reactive 
Protein Calibrator Level 6 varies from 15.6 16.4 mg/dL 
(156  164 mg/L).
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Prozone Effect
A prozone effect has been observed to occur at concentrations greater than 
95 mg/dL (950 mg/L).
Expected Values 3,4
The following table lists the reference ranges for this method: 
Siemens provides this information for reference. Each laboratory should establish its 
own normal range. You can enter normal range values and abnormal range values at 
the Analytical Parameters (Chemistry) window.
System Correlation
The performance of the applicable method (y) was compared with the performance of 
the same method on the comparison system (x). 
Sample Type Reference Range
Adults 0–
(0–
0.5 mg/dL
5.0 mg/L)
Newborns, cord blood <
(<
0.06 mg/dL 
0.6 mg/L)
Infants from 4th day of life 
to 1 month
<
(<
0.16 mg/dL 
1.6 mg/L)
ADVIA 1200
Specimen Type Comparison System (x) N Regression Equation Sy.x r Sample Range 
Serum ADVIA 1650 98 y = 0.99x - 0.047
y = 0.99x - 0.47
0.129
1.29
0.996
0.996
0.99–
9.9–
5.99 mg/dL
59.9 mg/L
Plasma* ADVIA 1200 (serum) 49 y = 1.00x + 0.002
y = 1.00x + 0.02
0.075
0.75
0.998
0.998
0.62–
6.2–
4.75 mg/dL
47.5 mg/L
*lithium heparin
ADVIA 1650/1800
Specimen Type Comparison System (x) N Regression Equation Sy.x r Sample Range 
Serum Hitachi CRP 60 y = 0.96x - 0.037
y = 0.96x - 0.37
0.135
1.35
0.999
0.999
0–
0–
15.81 mg/dL
158.1 mg/L
Plasma* ADVIA 1650 (serum) 65 y = 0.99x - 0.004
y = 0.99x - 0.04
0.110
1.10
0.998
0.998
0.02–
0.20–
6.98 mg/dL
69.8 mg/L
*lithium heparin
Wide Range C-Reactive Protein (wrCRP)
04069518, Rev. D, 2008-10 10 - English
Standardization
The ADVIA wrCRP method is traceable to the IRMM reference material CRM 470 from 
IFCC (International Federation of Clinical Chemistry). Recovery averaged 105% for the 
ADVIA 1200, 95% for the ADVIA 1650/1800, and 99% for the ADVIA 2400, of the 
target concentration. Assigned values of ADVIA Chemistry Wide Range C-Reactive 
Protein Calibrators are traceable to this standardization.
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Technical Assistance
For customer support, please contact your local technical support provider or 
distributor.
www.siemens.com/diagnostics
Trademarks
ADVIA is a trademark of Siemens Healthcare Diagnostics.
Intralipid is a trademark of Fresenius Kabi AB.
ADVIA 2400
Specimen Type Comparison System (x) N Regression Equation Sy.x r Sample Range 
Serum ADVIA 1650 94 y = 1.03x + 0.023
y = 1.03x + 0.23
0.288
2.88
0.998
0.998
0.03–
0.30–
15.11 mg/dL
151.1 mg/L
Plasma* ADVIA 2400 (serum) 48 y = 1.00x - 0.00
y = 1.00x - 0.00
0.080
0.80
0.999
0.999
0.04–
0.40–
14.30 mg/dL
143.0 mg/L
*lithium heparin
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